US20030096951A1

US20030096951A1 - Secreted proteins and polynucleotides encoding them

Info

Publication number: US20030096951A1
Application number: US09/374,046
Authority: US
Inventors: Kenneth Jacobs; John McCoy; Edward LaVallie; Lisa Collins-Racie; David Merberg; Michael Agostino; Robert Steininger; Vikki Spaulding; Gordon Wong; Hilary Clark; Kim Fechtel; Cheryl Evans; Maurice Treacy
Original assignee: Genetics Institute LLC
Current assignee: Ono Pharmaceutical Co Ltd
Priority date: 1998-08-14
Filing date: 1999-08-13
Publication date: 2003-05-22
Also published as: US7344861B2; US20080139452A1; US20040038276A1; US20060177904A1

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

This application is a continuation-in-part of the following applications: [0001]
(1) provisional application Ser. No. 60/096,622 (GI 6075), filed Aug. 14, 1998; [0002]
(2) provisional application Ser. No. 60/096,815 (GI 6076), filed Aug. 17, 1998; [0003]
(3) provisional application Ser. No. 60/099,229 (GI 6077), filed Sep. 4, 1998; [0004]
(4) provisional application Ser. No. 60/105,368 (GI 6078), filed Oct. 23, 1998; [0005]
(5) provisional application Ser. No. 60/115,234 (GI 6079), filed Jan. 8, 1999; [0006]
(6) provisional application Ser. No. 60/119,931 (GI 6080), filed Feb. 12, 1999; [0007]
(7) provisional application Ser. No. 60/120,575 (GI 6081), filed Feb. 18, 1999; [0008]
(8) provisional application Ser. No. 60/132,020 (GI 6082), filed Apr. 30, 1999; [0009]
(9) provisional application Ser. No. ______ (GI 6083), filed Aug. 11, 1999; [0010]
all of which are incorporated by reference herein.[0011]

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques done novel polynucleotides “directly” in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent “indirect” cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone co62 _—12 deposited under accession number ATCC 98825;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone co62 _—12 deposited under accession number ATCC 98825;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone co62 _—12 deposited under accession number ATCC 98825;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone co62 _—12 deposited under accession number ATCC 98825;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:1.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625; the nucleotide sequence of the full-length protein coding sequence of clone co62_—12 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone co62_—12 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone co62_—12 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:1; and

(ab) the nucleotide sequence of the cDNA insert of clone co62 _—12 deposited under accession number ATCC 98825;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:1; and

(bb) the nucleotide sequence of the cDNA insert of clone co62 _—12 deposited under accession number ATCC 98825;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone co62 _—12 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone lo311 _—8 deposited under accession number ATCC 98825;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone lo311 _—8 deposited under accession number ATCC 98825;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone lo311 _—8 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone lo311 _—8 deposited under accession number ATCC 98825;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013; the nucleotide sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013; the nucleotide sequence of the full-length protein coding sequence of clone lo311 _—8 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone lo311_—8 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lo311_—8 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

(a) a process comprising the steps of:

(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:3; and

(ab) the nucleotide sequence of the cDNA insert of clone lo311 _—8 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:3; and

(bb) the nucleotide sequence of the cDNA insert of clone lo311 _—8 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013.

(a) the amino acid sequence of SEQ ID NO:4;

(b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and

(c) the amino acid sequence encoded by the cDNA insert of clone lo311 _—8 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino add sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of

clone ns197

_—1 deposited under accession number ATCC 98825;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of

clone ns197

_—1 deposited under accession number ATCC 98825;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of

clone ns197

_—1 deposited under accession number ATCC 98825;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ns197

_—1 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:5.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825; the nucleotide sequence of the full-length protein coding sequence of

clone ns197

_—1 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone ns197 _—1 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ns197 _—1 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thiy) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

(a) a process comprising the steps of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of

clone ns197

_—1 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of

clone ns197

_—1 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825.

(a) the amino acid sequence of SEQ ID NO:6;

(b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ns197

_—1 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pj193 _—5 deposited under accession number ATCC 98825;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pj193 _—5 deposited under accession number ATCC 98825;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pj193 _—5 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pj193 _—5 deposited under accession number ATCC 98825;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829; the nucleotide sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829; the nucleotide sequence of the full-length protein coding sequence of clone pj193 _—5 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pj193_—5 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj193_—5 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

(a) a process comprising the steps of:

(aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:7; and

(ab) the nucleotide sequence of the cDNA insert of clone pj193 _—5 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone pj193 _—5 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829.

(a) the amino acid sequence of SEQ ID NO:8;

(b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and

(c) the amino acid sequence encoded by the cDNA insert of clone pj193 _—5 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292;

clone pj317

_—2 deposited under accession number ATCC 98825;

clone pj317

_—2 deposited under accession number ATCC 98825;

clone pj317

_—2 deposited under accession number ATCC 98825;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone pj317

_—2 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:9.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292; the nucleotide sequence of the full-length protein coding sequence of

clone pj317

_—2 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pj317 _—2 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj317 _—2 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

(a) a process comprising the steps of:

(aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:9; and

(ab) the nucleotide sequence of the cDNA insert of done pj317 _—2 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:9; and

(bb) the nucleotide sequence of the cDNA insert of

clone pj317

_—2 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292.

(a) the amino acid sequence of SEQ ID NO:10;

(b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and

(c) the amino acid sequence encoded by the cDNA insert of

clone pj317

_—2 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of

clone pt332

_—1 deposited under accession number ATCC 98825;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of

clone pt332

_—1 deposited under accession number ATCC 98825;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of

clone pt332

_—1 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone pt332

_—1 deposited under accession number ATCC 98825;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517; the nucleotide sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517; the nucleotide sequence of the full-length protein coding sequence of done

pt332

_—1 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pt332 _—1 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pt332 _—1 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

(a) a process comprising the steps of:

(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:11; and

(ab) the nucleotide sequence of the cDNA insert of

clone pt332

_—1 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:11; and

(bb) the nucleotide sequence of the cDNA insert of

clone pt332

_—1 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:11, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517.

(a) the amino acid sequence of SEQ ID NO:12;

(b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and

(c) the amino acid sequence encoded by the cDNA insert of

clone pt332

_—1 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qc297 _—15 deposited under accession number ATCC 98825;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qc297 _—15 deposited under accession number ATCC 98825;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qc297 _—15 deposited under accession number ATCC 98825;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qc297 _—15 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:13.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257; the nucleotide sequence of the full-length protein coding sequence of clone qc297 _—15 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qc297_—15 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qc297_—15 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

(a) a process comprising the steps of:

(aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:13; and

(ab) the nucleotide sequence of the cDNA insert of clone qc297 _—15 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:13; and

(bb) the nucleotide sequence of the cDNA insert of clone qc297 _—15 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:13, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257.

(a) the amino acid sequence of SEQ ID NO:14;

(b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and

(c) the amino acid sequence encoded by the cDNA insert of clone qc297 _—15 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qg596 _—12 deposited under accession number ATCC 98825;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qg596 _—12 deposited under accession number ATCC 98825;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qg596 _—12 deposited under accession number ATCC 98825;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qg596 _—12 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432; the nucleotide sequence of the full-length protein coding sequence of clone qg596 _—12 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qg596_—12 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qg596_—12 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

(a) a process comprising the steps of:

(aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:15; and

(ab) the nucleotide sequence of the cDNA insert of clone qg596 _—12 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone qg596 _—12 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:15, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432.

(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and

(c) the amino acid sequence encoded by the cDNA insert of clone qg596 _—12 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rb649 _—3 deposited under accession number ATCC 98825;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rb649 _—3 deposited under accession number ATCC 98825;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rb649 _—3 deposited under accession number ATCC 98825;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rb649 _—3 deposited under accession number ATCC 98825;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105; the nucleotide sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105; the nucleotide sequence of the full-length protein coding sequence of clone rb649 _—3 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone rb649_—3 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done rb649_—3 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

(a) a process comprising the steps of:

(aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:17; and

(ab) the nucleotide sequence of the cDNA insert of clone rb649 _—3 deposited under accession number ATCC 98825;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:17; and

(bb) the nucleotide sequence of the cDNA insert of clone rb649 _—3 deposited under accession number ATCC 98825;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:17, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105.

(a) the amino acid sequence of SEQ ID NO:18;

(b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and

(c) the amino acid sequence encoded by the cDNA insert of clone rb649 _—3 deposited under accession number ATCC 98825;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ca106 _—19x deposited under accession number ATCC 98835;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ca106 _—19x deposited under accession number ATCC 98835;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ca106 _—19x deposited under accession number ATCC 98835;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ca106 _—19×deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:19.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467; the nucleotide sequence of the full-length protein coding sequence of clone ca106 _—19x deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone ca106_—19x deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ca106_—19x deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

(a) a process comprising the steps of:

(aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:19; and

(ab) the nucleotide sequence of the cDNA insert of clone ca106 _—19x deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:19; and

(bb) the nucleotide sequence of the cDNA insert of clone ca106 _—19x deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:19, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467.

(a) the amino acid sequence of SEQ ID NO:20;

(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and

(c) the amino acid sequence encoded by the cDNA insert of clone ca106 _—19x deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of done ci52 _—2 deposited under accession number ATCC 98835;

clone ci52

_—2 deposited under accession number ATCC 98835;

clone ci52

_—2 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ci52

_—2 deposited under accession number ATCC 98835;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:22;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802; the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802; the nucleotide sequence of the full-length protein coding sequence of

clone ci52

_—2 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone ci52 _—2 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ci52 _—2 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:21.

(a) a process comprising the steps of:

(aa) SEQ ID NO:21, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:21; and

(ab) the nucleotide sequence of the cDNA insert of done ci52 _—2 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:21, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:21; and

(bb) the nucleotide sequence of the cDNA insert of

clone ci52

_—2 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:21, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802.

(a) the amino acid sequence of SEQ ID NO:22;

(b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ci52

_—2 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:22. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone md124 _—16 deposited under accession number ATCC 98835;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone md124 _—16 deposited under accession number ATCC 98835;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone md124 _—16 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone md124 _—16 deposited under accession number ATCC 98835;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:23.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714; the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714; the nucleotide sequence of the full-length protein coding sequence of clone md124 _—16 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone md124_—16 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone md124_—16 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23.

(a) a process comprising the steps of:

(aa) SEQ ID NO:23, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:23; and

(ab) the nucleotide sequence of the cDNA insert of clone md124 _—16 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:23, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:23; and

(bb) the nucleotide sequence of the cDNA insert of clone md124 _—16 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:23, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714.

(a) the amino acid sequence of SEQ ID NO:24;

(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and

(c) the amino acid sequence encoded by the cDNA insert of clone md124 _—16 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk366 _—7 deposited under accession number ATCC 98835;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk366 _—7 deposited under accession number ATCC 98835;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pk366 _—7 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pk366 _—7 deposited under accession number ATCC 98835;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:25.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726; the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726; the nucleotide sequence of the full-length protein coding sequence of clone pk366 _—7 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pk366_—7 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pk366_—7 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino add 267 to amino acid 276 of SEQ ID NO:26.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.

(a) a process comprising the steps of:

(aa) SEQ ID NO:25, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:25; and

(ab) the nucleotide sequence of the cDNA insert of clone pk366 _—7 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:25, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:25; and

(bb) the nucleotide sequence of the cDNA insert of clone pk366 _—7 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:25, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726.

(a) the amino acid sequence of SEQ ID NO:26;

(b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and

(c) the amino acid sequence encoded by the cDNA insert of clone pk366 _—7 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 267 to amino acid 276 of SEQ ID NO:26.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pl741 _—5 deposited under accession number ATCC 98835;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pl741 _—5 deposited under accession number ATCC 98835;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pl741 _—5 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pl741 _—5 deposited under accession number ATCC 98835;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788; the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788; the nucleotide sequence of the full-length protein coding sequence of clone pl741 _—5 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pl741_—5 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pl741_—5 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.

(a) a process comprising the steps of:

(aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:27; and

(ab) the nucleotide sequence of the cDNA insert of clone pl741 _—5 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:27; and

(bb) the nucleotide sequence of the cDNA insert of clone pl741 _—5 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:27, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788.

(a) the amino acid sequence of SEQ ID NO:28;

(b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and

(c) the amino acid sequence encoded by the cDNA insert of clone pl741 _—5 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pp314 _—19 deposited under accession number ATCC 98835;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pp314 _—19 deposited under accession number ATCC 98835;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pp314 _—19 deposited under accession number ATCC 98835;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pp314 _—19 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:29.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338; the nucleotide sequence of the full-length protein coding sequence of clone pp314 _—19 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pp314_—19 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pp314_—19 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29.

(a) a process comprising the steps of:

(aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:29; and

(ab) the nucleotide sequence of the cDNA insert of clone pp314 _—19 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:29; and

(bb) the nucleotide sequence of the cDNA insert of done pp314 _—19 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:29, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338.

(a) the amino acid sequence of SEQ ID NO:30;

(b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and

(c) the amino acid sequence encoded by the cDNA insert of clone pp314 _—19 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102;

clone pv35

_—1 deposited under accession number ATCC 98835;

clone pv35

_—1 deposited under accession number ATCC 98835;

clone pv35

_—1 deposited under accession number ATCC 98835;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone pv35

_—1 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:31.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102; the nucleotide sequence of the full-length protein coding sequence of

clone pv35

_—1 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pv35 _—1 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv35 _—1 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:31.

(a) a process comprising the steps of:

(aa) SEQ ID NO:31, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:31; and

(ab) the nucleotide sequence of the cDNA insert of

clone pv35

_—1 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:31; and

(bb) the nucleotide sequence of the cDNA insert of

clone pv35

_—1 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:31, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102.

(a) the amino acid sequence of SEQ ID NO:32;

(b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and

(c) the amino acid sequence encoded by the cDNA insert of

clone pv35

_—1 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pw337 _—6 deposited under accession number ATCC 98835;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pw337 _—6 deposited under accession number ATCC 98835;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pw337 _—6 deposited under accession number ATCC 98835;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pw337 _—6 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:34;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:33.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733; the nucleotide sequence of the full-length protein coding sequence of clone pw337 _—6 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pw337_—6 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw337_—6 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:33.

(a) a process comprising the steps of:

(aa) SEQ ID NO:33, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:33; and

(ab) the nucleotide sequence of the cDNA insert of clone pw337 _—6 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:33; and

(bb) the nucleotide sequence of the cDNA insert of clone pw337 _—6 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:33, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733.

(a) the amino acid sequence of SEQ ID NO:34;

(b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and

(c) the amino acid sequence encoded by the cDNA insert of clone pw337 _—6 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:34. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938;

clone rd610

_—1 deposited under accession number ATCC 98835;

clone rd610

_—1 deposited under accession number ATCC 98835;

clone rd610

_—1 deposited under accession number ATCC 98835;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone rd610

_—1 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:35.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938; the nucleotide sequence of the full-length protein coding sequence of

clone rd610

_—1 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd610 _—1 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd610 _—1 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35.

(a) a process comprising the steps of:

(aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:35; and

(ab) the nucleotide sequence of the cDNA insert of

clone rd610

_—1 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:35, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:35; and

(bb) the nucleotide sequence of the cDNA insert of

clone rd610

_—1 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:35 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:35, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938.

(a) the amino acid sequence of SEQ ID NO:36;

(b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and

(c) the amino acid sequence encoded by the cDNA insert of

clone rd610

_—1 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd810 _—6 deposited under accession number ATCC 98835;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd810 _—6 deposited under accession number ATCC 98835;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd810 _—6 deposited under accession number ATCC 98835;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd810 _—6 deposited under accession number ATCC 98835;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:38;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:37.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494; the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494; the nucleotide sequence of the full-length protein coding sequence of clone rd810 _—6 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd810_—6 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd810_—6 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:37.

(a) a process comprising the steps of:

(aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:37; and

(ab) the nucleotide sequence of the cDNA insert of clone rd810 _—6 deposited under accession number ATCC 98835;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:37; and

(bb) the nucleotide sequence of the cDNA insert of clone rd810 _—6 deposited under accession number ATCC 98835;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:37, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494.

(a) the amino acid sequence of SEQ ID NO:38;

(b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and

(c) the amino acid sequence encoded by the cDNA insert of clone rd810 _—6 deposited under accession number ATCC 98835;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:38. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a protein comprising a fragment of the amino add sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080;

clone cf85

_—1 deposited under accession number ATCC 98850;

clone cf85

_—1 deposited under accession number ATCC 98850;

clone cf85

_—1 deposited under accession number ATCC 98850;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone cf85

_—1 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:39.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080; the nucleotide sequence of the full-length protein coding sequence of

clone cf85

_—1 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone cf85 _—1 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cf85 _—1 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39.

(a) a process comprising the steps of:

(aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:39; and

(ab) the nucleotide sequence of the cDNA insert of

clone cf85

_—1 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:39; and

(bb) the nucleotide sequence of the cDNA insert of

clone cf85

_—1 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:39, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080.

(a) the amino acid sequence of SEQ ID NO:40;

(b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and

(c) the amino acid sequence encoded by the cDNA insert of

clone cf85

_—1 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd504 _—18 deposited under accession number ATCC 98850;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd504 _—18 deposited under accession number ATCC 98850;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd504 _—18 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dd504 _—18 deposited under accession number ATCC 98850;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:41.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348; the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348; the nucleotide sequence of the full-length protein coding sequence of clone dd504 _—18 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone dd504_—18 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd504_—18 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

(a) a process comprising the steps of:

(aa) SEQ ID NO:41, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:41; and

(ab) the nucleotide sequence of the cDNA insert of clone dd504 _—18 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:41, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:41; and

(bb) the nucleotide sequence of the cDNA insert of clone dd504 _—18 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:41, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348.

(a) the amino acid sequence of SEQ ID NO:42;

(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and

(c) the amino acid sequence encoded by the cDNA insert of clone dd504 _—18 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np26 _—3 deposited under accession number ATCC 98850;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone np26 _—3 deposited under accession number ATCC 98850;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone np26 _—3 deposited under accession number ATCC 98850;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone np26 _—3 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:43.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386; the nucleotide sequence of the full-length protein coding sequence of clone np26 _—3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone np26_—3 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone np26_—3 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43.

(a) a process comprising the steps of:

(aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:43; and

(ab) the nucleotide sequence of the cDNA insert of done np26 _—3 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:43, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:43; and

(bb) the nucleotide sequence of the cDNA insert of clone np26 _—3 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:43, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386.

(a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and

(c) the amino acid sequence encoded by the cDNA insert of clone np26 _—3 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm412 _—12 deposited under accession number ATCC 98850;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm412 _—12 deposited under accession number ATCC 98850;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm412 _—12 deposited under accession number ATCC 98850;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm412 _—12 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:46;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:45.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515; the nucleotide sequence of the full-length protein coding sequence of clone pm412 _—12 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pm412_—12 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm412_—12 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:45.

(a) a process comprising the steps of:

(aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:45; and

(ab) the nucleotide sequence of the cDNA insert of clone pm412 _—12 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:45, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:45; and

(bb) the nucleotide sequence of the cDNA insert of clone pm412 _—12 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:45, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515.

(a) the amino acid sequence of SEQ ID NO:46;

(b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and

(c) the amino acid sequence encoded by the cDNA insert of clone pm412 _—12 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm421 _—3 deposited under accession number ATCC 98850;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm421 _—3 deposited under accession number ATCC 98850;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm421 _—3 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm421 _—3 deposited under accession number ATCC 98850;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:47.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780; the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780; the nucleotide sequence of the funll-length protein coding sequence of clone pm421 _—3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pm421_—3 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm421_—3 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:47.

(a) a process comprising the steps of:

(aa) SEQ ID NO:47, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:47; and

(ab) the nucleotide sequence of the cDNA insert of done pm421 _—3 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:47, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:47; and

(bb) the nucleotide sequence of the cDNA insert of clone pm421 _—3 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:47, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780.

(a) the amino acid sequence of SEQ ID NO:48;

(b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and

(c) the amino acid sequence encoded by the cDNA insert of clone pm421 _—3 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486;

clone pv6

_—1 deposited under accession number ATCC 98850;

clone pv6

_—1 deposited under accession number ATCC 98850;

clone pv6

_—1 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone pv6

_—1 deposited under accession number ATCC 98850;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:50;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:49.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486; the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486; the nucleotide sequence of the full-length protein coding sequence of

clone pv6

_—1 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pv6 _—1 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv6 _—1 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:49.

(a) a process comprising the steps of:

(aa) SEQ ID NO:49, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:49; and

(ab) the nucleotide sequence of the cDNA insert of

clone pv6

_—1 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:49, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:49; and

(bb) the nucleotide sequence of the cDNA insert of

clone pv6

_—1 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:49, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486.

(a) the amino acid sequence of SEQ ID NO:50;

(b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and

(c) the amino acid sequence encoded by the cDNA insert of

clone pv6

_—1 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:50. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qs14 _—3 deposited under accession number ATCC 98850;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qs14 _—3 deposited under accession number ATCC 98850;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of done qs14 _—3 deposited under accession number ATCC 98850;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qs14 _—3 deposited under accession number ATCC 98850;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:51.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783; the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783; the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938; the nucleotide sequence of the full-length protein coding sequence of clone qs14 _—3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone qs14_—3 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qs14_—3 deposited under accession number ATCC 98850. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:51.

(a) a process comprising the steps of:

(aa) SEQ ID NO:51, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:51; and

(ab) the nucleotide sequence of the cDNA insert of clone qs14 _—3 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:51, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:51; and

(bb) the nucleotide sequence of the cDNA insert of clone qs14 _—3 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:51 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:51, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938.

(a) the amino acid sequence of SEQ ID NO:52;

(b) the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135;

(c) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and

(d) the amino acid sequence encoded by the cDNA insert of clone qs14 _—3 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:52 or the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy338 _—9 deposited under accession number ATCC 98850;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy338 _—9 deposited under accession number ATCC 98850;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy338 _—9 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy338 _—9 deposited under accession number ATCC 98850;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:53.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843; the nucleotide sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843; the nucleotide sequence of the full-length protein coding sequence of clone qy338_—9 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone qy338_—9 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy338_—9 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:53.

(a) a process comprising the steps of:

(aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:53; and

(ab) the nucleotide sequence of the cDNA insert of clone qy338 _—9 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:53; and

(bb) the nucleotide sequence of the cDNA insert of clone qy338 _—9 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:53, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843.

(a) the amino acid sequence of SEQ ID NO:54;

(b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and

(c) the amino acid sequence encoded by the cDNA insert of clone qy338 _—9 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906;

clone rc58

_—1 deposited under accession number ATCC 98850;

clone rc58

_—1 deposited under accession number ATCC 98850;

clone rc58

_—1 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone rc58

_—1 deposited under accession number ATCC 98850;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906; the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906; the nucleotide sequence of the full-length protein coding sequence of

clone rc58

_—1 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rc58 _—1 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rc58 _—1 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55.

(a) a process comprising the steps of:

(aa) SEQ ID NO:55, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:55; and

(ab) the nucleotide sequence of the cDNA insert of done rc58 _—1 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and =(b) a process comprising the steps of:

(ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:55; and

(bb) the nucleotide sequence of the cDNA insert of

clone rc58

_—1 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:55, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906.

(a) the amino acid sequence of SEQ ID NO:56;

(b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and

(c) the amino acid sequence encoded by the cDNA insert of

clone rc58

_—1 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd232 _—5 deposited under accession number ATCC 98850;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd232 _—5 deposited under accession number ATCC 98850;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd232 _—5 deposited under accession number ATCC 98850;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd232 _—5 deposited under accession number ATCC 98850;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:58;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:57.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973; the nucleotide sequence of the full-length protein coding sequence of clone rd232 _—5 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rd232_—5 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done rd232_—5 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:57.

(a) a process comprising the steps of:

(aa) SEQ ID NO:57, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:57; and

(ab) the nucleotide sequence of the cDNA insert of clone rd232 _—5 deposited under accession number ATCC 98850;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:57, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:57; and

(bb) the nucleotide sequence of the cDNA insert of clone rd232 _—5 deposited under accession number ATCC 98850;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:57, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973.

(a) the amino acid sequence of SEQ ID NO:58;

(b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and

(c) the amino acid sequence encoded by the cDNA insert of clone rd232 _—5 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:58. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ck213 _—12 deposited under accession number ATCC 98918;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ck213 _—12 deposited under accession number ATCC 98918;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ck213 _—12 deposited under accession number ATCC 98918;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ck213 _—12 deposited under accession number ATCC 98918;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:60;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:59.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596; the nucleotide sequence of the full-length protein coding sequence of clone ck213 _—12 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone ck213_—12 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ck213_—12 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:59.

(a) a process comprising the steps of:

(aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:59; and

(ab) the nucleotide sequence of the cDNA insert of clone ck213 _—12 deposited under accession number ATCC 98918; 115 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:59; and

(bb) the nucleotide sequence of the cDNA insert of clone ck213 _—12 deposited under accession number ATCC 98918;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:59 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:59, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:59. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596.

(a) the amino acid sequence of SEQ ID NO:60;

(b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and

(c) the amino acid sequence encoded by the cDNA insert of clone ck213 _—12 deposited under accession number ATCC 98918;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750;

clone pg195

_—1 deposited under accession number ATCC 98918;

clone pg195

_—1 deposited under accession number ATCC 98918;

clone pg195

_—1 deposited under accession number ATCC 98918;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone pg195

_—1 deposited under accession number ATCC 98918;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:62;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:61.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750; the nucleotide sequence of the full-length protein coding sequence of

clone pg195

_—1 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pg195 _—1 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pg195 _—1 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:61.

(a) a process comprising the steps of:

(aa) SEQ ID NO:61, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:61; and

(ab) the nucleotide sequence of the cDNA insert of

clone pg195

_—1 deposited under accession number ATCC 98918;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:61, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:61; and

(bb) the nucleotide sequence of the cDNA insert of

clone pg195

_—1 deposited under accession number ATCC 98918;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:61, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750.

(a) the amino acid sequence of SEQ ID NO:62;

(b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and

(c) the amino acid sequence encoded by the cDNA insert of

clone pg195

_—1 deposited under accession number ATCC 98918;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:62. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pw460 _—5 deposited under accession number ATCC 98918;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pw460 _—5 deposited under accession number ATCC 98918;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pw460 _—5 deposited under accession number ATCC 98918;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pw460 _—5 deposited under accession number ATCC 98918;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:64;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:63.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440; the nucleotide sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440; the nucleotide sequence of the full-length protein coding sequence of clone pw460 _—5 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pw460_—5 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw460_—5 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:63.

(a) a process comprising the steps of:

(aa) SEQ ID NO:63, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:63; and

(ab) the nucleotide sequence of the cDNA insert of clone pw460 _—5 deposited under accession number ATCC 98918;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:63, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:63; and

(bb) the nucleotide sequence of the cDNA insert of clone pw460 _—5 deposited under accession number ATCC 98918;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:63, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:63. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440.

(a) the amino acid sequence of SEQ ID NO:64;

(b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and

(c) the amino acid sequence encoded by the cDNA insert of clone pw460 _—5 deposited under accession number ATCC 98918;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:64. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356;

clone qa136

_—1 deposited under accession number ATCC 98918;

clone qa136

_—1 deposited under accession number ATCC 98918;

clone qa136

_—1 deposited under accession number ATCC 98918;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone qa136

_—1 deposited under accession number ATCC 98918;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:66;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:65.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356; the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356; the nucleotide sequence of the full-length protein coding sequence of

clone qa136

_—1 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qa136 _—1 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qa136 _—1 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:65.

(a) a process comprising the steps of:

(aa) SEQ ID NO:65; and

(ab) the nucleotide sequence of the cDNA insert of

clone qa136

_—1 deposited under accession number ATCC 98918;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:65; and

(bb) the nucleotide sequence of the cDNA insert of

clone qa136

_—1 deposited under accession number ATCC 98918;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:65 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:65. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:66;

(b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and

(c) the amino acid sequence encoded by the cDNA insert of

clone qa136

_—1 deposited under accession number ATCC 98918;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:66. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624;

clone qy1261

_—2 deposited under accession number ATCC 98918;

clone qy1261

_—2 deposited under accession number ATCC 98918;

clone qy1261

_—2 deposited under accession number ATCC 98918;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone qy1261

_—2 deposited under accession number ATCC 98918;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:68;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:68;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:67.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624; the nucleotide sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624; the nucleotide sequence of the full-length protein coding sequence of

clone qy1261

_—2 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qy1261 _—2 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy1261 _—2 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:68, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:67.

(a) a process comprising the steps of:

(aa) SEQ ID NO:67, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:67; and

(ab) the nucleotide sequence of the cDNA insert of

clone qy1261

_—2 deposited under accession number ATCC 98918;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:67, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:67; and

(bb) the nucleotide sequence of the cDNA insert of

clone qy1261

_—2 deposited under accession number ATCC 98918;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:67 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:67, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624.

(a) the amino acid sequence of SEQ ID NO:68;

(b) a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; and

(c) the amino acid sequence encoded by the cDNA insert of

clone qy1261

_—2 deposited under accession number ATCC 98918;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:68. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd432 _—4 deposited under accession number ATCC 98918;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd432 _—4 deposited under accession number ATCC 98918;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd432 _—4 deposited under accession number ATCC 98918;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd432 _—4 deposited under accession number ATCC 98918;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:70;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:70;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:69.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817; the nucleotide sequence of the full-length protein coding sequence of clone rd432 _—4 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone rd432_—4 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd432_—4 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:69.

(a) a process comprising the steps of:

(aa) SEQ ID NO:69, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:69; and

(ab) the nucleotide sequence of the cDNA insert of clone rd432 _—4 deposited under accession number ATCC 98918;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:69, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:69; and

(bb) the nucleotide sequence of the cDNA insert of clone rd432 _—4 deposited under accession number ATCC 98918;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:69 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:69, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:69. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817.

(a) the amino acid sequence of SEQ ID NO:70;

(b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; and

(c) the amino acid sequence encoded by the cDNA insert of clone rd432 _—4 deposited under accession number ATCC 98918;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:70. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rb789 _—14 deposited under accession number ATCC 207004;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rb789 _—14 deposited under accession number ATCC 207004;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rb789 _—14 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rb789 _—14 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:72;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:72;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:71.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195; the nucleotide sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195; the nucleotide sequence of the full-length protein coding sequence of clone rb789 _—14 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone rb789_—14 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rb789_—14 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:72.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:71.

(a) a process comprising the steps of:

(aa) SEQ ID NO:71, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:71; and

(ab) the nucleotide sequence of the cDNA insert of clone rb789 _—14 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:71, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:71; and

(bb) the nucleotide sequence of the cDNA insert of clone rb789 _—14 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:71 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:71, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:71. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195.

(a) the amino acid sequence of SEQ ID NO:72;

(b) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and

(c) the amino acid sequence encoded by the cDNA insert of clone rb789 _—14 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:72. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:72.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374;

clone yd137

_—1 deposited under accession number ATCC 207004;

clone yd137

_—1 deposited under accession number ATCC 207004;

clone yd137

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone yd137

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:74;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:74;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:73.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374; the nucleotide sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374; the nucleotide sequence of the full-length protein coding sequence of

clone yd137

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yd137 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yd137 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:74.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:73.

(a) a process comprising the steps of:

(aa) SEQ ID NO:73, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:73; and

(ab) the nucleotide sequence of the cDNA insert of

clone yd137

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:73, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:73; and

(bb) the nucleotide sequence of the cDNA insert of

clone yd137

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:73 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:73, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:73. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374.

(a) the amino acid sequence of SEQ ID NO:74;

(b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and

(c) the amino acid sequence encoded by the cDNA insert of done yd137 _—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:74. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:74.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343;

clone yd218

_—1 deposited under accession number ATCC 207004;

clone yd218

_—1 deposited under accession number ATCC 207004;

clone yd218

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone yd218

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:75.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343; the nucleotide sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343; the nucleotide sequence of the full-length protein coding sequence of

clone yd218

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yd218 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yd218 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:76.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:75.

(a) a process comprising the steps of:

(aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:75; and

(ab) the nucleotide sequence of the cDNA insert of

clone yd218

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:75; and

(bb) the nucleotide sequence of the cDNA insert of

clone yd218

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:75 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:75, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343.

(a) the amino acid sequence of SEQ ID NO:76;

(b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and

(c) the amino acid sequence encoded by the cDNA insert of

clone yd218

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:76.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679;

clone ye11

_—1 deposited under accession number ATCC 207004;

clone ye11

_—1 deposited under accession number ATCC 207004;

clone ye11

_—1 deposited under accession number ATCC 207004;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ye11

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:77.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679; the nucleotide sequence of the full-length protein coding sequence of

clone ye11

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye11 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye11 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 261 to amino acid 270 of SEQ ID NO:78.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:77.

(a) a process comprising the steps of:

(aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:77; and

(ab) the nucleotide sequence of the cDNA insert of

clone ye11

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:77; and

(bb) the nucleotide sequence of the cDNA insert of

clone ye11

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:77 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:77, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679.

(a) the amino acid sequence of SEQ ID NO:78;

(b) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ye11

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 261 to amino acid 270 of SEQ ID NO:78.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646;

clone ye72

_—1 deposited under accession number ATCC 207004;

clone ye72

_—1 deposited under accession number ATCC 207004;

clone ye72

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ye72

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:80;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:79.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646; the nucleotide sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646; the nucleotide sequence of the full-length protein coding sequence of

clone ye72

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye72 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye72 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 257 to amino acid 266 of SEQ ID NO:80.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:79.

(a) a process comprising the steps of:

(aa) SEQ ID NO:79, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:79; and

(ab) the nucleotide sequence of the cDNA insert of

clone ye72

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:79, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:79; and

(bb) the nucleotide sequence of the cDNA insert of

clone ye72

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:79 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:79, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646.

(a) the amino acid sequence of SEQ ID NO:80;

(b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ye72

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 257 to amino acid 266 of SEQ ID NO:80.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423;

clone ye78

_—1 deposited under accession number ATCC 207004;

clone ye78

_—1 deposited under accession number ATCC 207004;

clone ye78

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ye78

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:82;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:82;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:81.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423; the nucleotide sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423; the nucleotide sequence of the full-length protein coding sequence of

clone ye78

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye78 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye78 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:82.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:81.

(a) a process comprising the steps of:

(aa) SEQ ID NO:81, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:81; and

(ab) the nucleotide sequence of the cDNA insert of

clone ye78

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:81, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:81; and

(bb) the nucleotide sequence of the cDNA insert of

clone ye78

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:81 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:81, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:81. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423.

(a) the amino acid sequence of SEQ ID NO:82;

(b) a fragment of the amino acid sequence of SEQ ID NO:82, the fragment comprising eight contiguous amino acids of SEQ ID NO:82; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ye78

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:82. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:82.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321;

clone ye90

_—1 deposited under accession number ATCC 207004;

clone ye90

_—1 deposited under accession number ATCC 207004;

clone ye90

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ye90

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:84;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:84;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:83.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321; the nucleotide sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321; the nucleotide sequence of the full-length protein coding sequence of

clone ye90

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye90 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye90 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 186 to amino acid 195 of SEQ ID NO:84.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:83.

(a) a process comprising the steps of:

(aa) SEQ ID NO:83, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:83; and

(ab) the nucleotide sequence of the cDNA insert of

clone ye90

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:83, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:83; and

(bb) the nucleotide sequence of the cDNA insert of

clone ye90

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:83 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:83, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:83. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321.

(a) the amino acid sequence of SEQ ID NO:84;

(b) a fragment of the amino acid sequence of SEQ ID NO:84, the fragment comprising eight contiguous amino acids of SEQ ID NO:84; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ye90

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:84. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 186 to amino acid 195 of SEQ ID NO:84.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605;

clone yi62

_—1 deposited under accession number ATCC 207004;

clone yi62

_—1 deposited under accession number ATCC 207004;

clone yi62

_—1 deposited under accession number ATCC 207004;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone yi62

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:86;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:86;

(j) a polynucleotide which encodes a spedes homologue of the protein of (g) or (h) above;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:85.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605; the nucleotide sequence of the full-length protein coding sequence of

clone yi62

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yi62 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yi62 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:86.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:85.

(a) a process comprising the steps of:

(aa) SEQ ID NO:85, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:85; and

(ab) the nucleotide sequence of the cDNA insert of

clone yi62

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:85, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:85; and

(bb) the nucleotide sequence of the cDNA insert of

clone yi62

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:85 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:85, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:85. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605.

(a) the amino acid sequence of SEQ ID NO:86;

(b) a fragment of the amino acid sequence of SEQ ID NO:86, the fragment comprising eight contiguous amino acids of SEQ ID NO:86; and

(c) the amino acid sequence encoded by the cDNA insert of

clone yi62

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:86. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:86.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798;

clone yk78

_—1 deposited under accession number ATCC 207004;

clone yk78

_—1 deposited under accession number ATCC 207004;

clone yk78

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone yk78

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:88;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:88;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:87.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798; the nucleotide sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798; the nucleotide sequence of the full-length protein coding sequence of

clone yk78

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yk78 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yk78 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:88.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:87.

(a) a process comprising the steps of:

(aa) SEQ ID NO:87, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:87; and

(ab) the nucleotide sequence of the cDNA insert of

clone yk78

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:87, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:87; and

(bb) the nucleotide sequence of the cDNA insert of

clone yk78

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:87 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:87, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:87. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798.

(a) the amino acid sequence of SEQ ID NO:88;

(b) a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; and

(c) the amino acid sequence encoded by the cDNA insert of

clone yk78

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:88. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:88.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942;

clone yk251

_—1 deposited under accession number ATCC 207004;

clone yk251

_—1 deposited under accession number ATCC 207004;

clone yk251

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone yk251

_—1 deposited under accession number ATCC 207004;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:90;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:90;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:89.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942; the nucleotide sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942; the nucleotide sequence of the full-length protein coding sequence of

clone yk251

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yk251 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yk251 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:90.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:89.

(a) a process comprising the steps of:

(aa) SEQ ID NO:89, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:89; and

(ab) the nucleotide sequence of the cDNA insert of

clone yk251

_—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:89, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:89; and

(bb) the nucleotide sequence of the cDNA insert of

clone yk251

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:89 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:89, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:89. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942.

(a) the amino acid sequence of SEQ ID NO:90;

(b) a fragment of the amino acid sequence of SEQ ID NO:90, the fragment comprising eight contiguous amino acids of SEQ ID NO:90; and

(c) the amino acid sequence encoded by the cDNA insert of

clone yk251

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:90. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:90.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784;

clone yt14

_—1 deposited under accession number ATCC 207004;

clone yt14

_—1 deposited under accession number ATCC 207004;

clone yt14

_—1 deposited under accession number ATCC 207004;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone yt14

_—1 deposited under accession number ATCC 207004;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:92;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:92;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:91.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784; the nucleotide sequence of the full-length protein coding sequence of

clone yt14

_—1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yt14 _—1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yt14 _—1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:92.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:91.

(a) a process comprising the steps of:

(aa) SEQ ID NO:91, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:91; and

(ab) the nucleotide sequence of the cDNA insert of done yt14 _—1 deposited under accession number ATCC 207004;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:91, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:91; and

(bb) the nucleotide sequence of the cDNA insert of

clone yt14

_—1 deposited under accession number ATCC 207004;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:91 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:91, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:91. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784.

(a) the amino acid sequence of SEQ ID NO:92;

(b) a fragment of the amino acid sequence of SEQ ID NO:92, the fragment comprising eight contiguous amino acids of SEQ ID NO:92; and

(c) the amino acid sequence encoded by the cDNA insert of

clone yt14

_—1 deposited under accession number ATCC 207004;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:92. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:92.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bf157 _—16 deposited under accession number ATCC 207088;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bf157 _—16 deposited under accession number ATCC 207088;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bf157 _—16 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bf157 _—16 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:94;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:93.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441; the nucleotide sequence of the full-length protein coding sequence of clone bf157 _—16 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone bf157_—16 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bf157_—16 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:94, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino add 220 to amino acid 229 of SEQ ID NO:94.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:93.

(a) a process comprising the steps of:

(aa) SEQ ID NO:93, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:93; and

(ab) the nucleotide sequence of the cDNA insert of clone bf157 _—16 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:93; and

(bb) the nucleotide sequence of the cDNA insert of clone bf157 _—16 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:93 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:93, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:93. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441.

(a) the amino acid sequence of SEQ ID NO:94;

(b) a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; and

(c) the amino acid sequence encoded by the cDNA insert of clone bf157 _—16 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:94. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 220 to amino acid 229 of SEQ ID NO:94.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629;

clone bk343

_—2 deposited under accession number ATCC 207088;

clone bk343

_—2 deposited under accession number ATCC 207088;

clone bk343

_—2 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone bk343

_—2 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:96;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:96;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:95.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629; the nucleotide sequence of the full-length protein coding sequence of

clone bk343

_—2 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone bk343 _—2 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bk343 _—2 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:96.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:95.

(a) a process comprising the steps of:

(aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:95; and

(ab) the nucleotide sequence of the cDNA insert of done bk343 _—2 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:95, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:95; and

(bb) the nucleotide sequence of the cDNA insert of

clone bk343

_—2 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:95 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:95, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:95. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629.

(a) the amino acid sequence of SEQ ID NO:96;

(b) a fragment of the amino acid sequence of SEQ ID NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; and

(c) the amino acid sequence encoded by the cDNA insert of

clone bk343

_—2 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:96. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:96.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of

clone cd205

_—2 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of

clone cd205

_—2 deposited under accession number ATCC 207088;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of

clone cd205

_—2 deposited under accession number ATCC 207088;

(h) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone cd205

_—2 deposited under accession number ATCC 207088;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:98;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:98;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or 0) above;

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:97.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951; the nucleotide sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951; the nucleotide sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295; the nucleotide sequence of the full-length protein coding sequence of

clone cd205

_—2 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cd205 _—2 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cd205 _—2 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:98.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:97.

(a) a process comprising the steps of:

(aa) SEQ ID NO:97, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:97; and

(ab) the nucleotide sequence of the cDNA insert of

clone cd205

_—2 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:97, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:97; and

(bb) the nucleotide sequence of the cDNA insert of

clone cd205

_—2 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:97, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:97. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295.

(a) the amino acid sequence of SEQ ID NO:98;

(b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; and

(c) the amino acid sequence encoded by the cDNA insert of

clone cd205

_—2 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:98.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw1292 _—8 deposited under accession number ATCC 207088;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw1292 _—8 deposited under accession number ATCC 207088;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cw1292 _—8 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cw1292 _—8 deposited under accession number ATCC 207088;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:100;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:100;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:99.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443; the nucleotide sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443; the nucleotide sequence of the full-length protein coding sequence of clone cw1292 _—8 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cw1292_—8 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cw1292_—8 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:100, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:100.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:99.

(a) a process comprising the steps of:

(aa) SEQ ID NO:99, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:99; and

(ab) the nucleotide sequence of the cDNA insert of clone cw1292 _—8 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:99, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:99; and

(bb) the nucleotide sequence of the cDNA insert of clone cw1292 _—8 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:99 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:99, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:99. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443.

(a) the amino acid sequence of SEQ ID NO:100;

(b) a fragment of the amino acid sequence of SEQ ID NO:100, the fragment comprising eight contiguous amino acids of SEQ ID NO:100; and

(c) the amino acid sequence encoded by the cDNA insert of clone cw1292 _—8 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:100. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:100, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:100.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447;

clone cw1475

_—2 deposited under accession number ATCC 207088;

clone cw1475

_—2 deposited under accession number ATCC 207088;

clone cw1475

_—2 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone cw1475

_—2 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:102;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:102;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:101.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447; the nucleotide sequence of the full-length protein coding sequence of

clone cw1475

_—2 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cw1475 _—2 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cw1475 _—2 deposited under accession number ATCC 207088.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:102.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:101.

(a) a process comprising the steps of:

(aa) SEQ ID NO:101, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:101; and

(ab) the nucleotide sequence of the cDNA insert of

clone cw1475

_—2 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:101, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:101; and

(bb) the nucleotide sequence of the cDNA insert of

clone cw1475

_—2 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:101 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:101, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447.

(a) the amino acid sequence of SEQ ID NO:102;

(b) a fragment of the amino acid sequence of SEQ ID NO:102, the fragment comprising eight contiguous amino acids of SEQ ID NO:102; and

(c) the amino acid sequence encoded by the cDNA insert of

clone cw1475

_—2 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:102. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:102.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd428 _—4 deposited under accession number ATCC 207088;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd428 _—4 deposited under accession number ATCC 207088;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd428 _—4 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dd428 _—4 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:104;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:104;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:103.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954; the nucleotide sequence of the full-length protein coding sequence of clone dd428 _—4 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dd428_—4 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd428_—4 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 102 to amino acid 111 of SEQ ID NO:104.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:103.

(a) a process comprising the steps of:

(aa) SEQ ID NO:103, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:103; and

(ab) the nucleotide sequence of the cDNA insert of clone dd428 _—4 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:103, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:103; and

(bb) the nucleotide sequence of the cDNA insert of clone dd428 _—4 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:103 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:103, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:103. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954.

(a) the amino acid sequence of SEQ ID NO:104;

(b) a fragment of the amino acid sequence of SEQ ID NO:104, the fragment comprising eight contiguous amino acids of SEQ ID NO:104; and

(c) the amino acid sequence encoded by the cDNA insert of clone dd428 _—4 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:104. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 102 to amino acid 111 of SEQ ID NO:104.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dh1073 _—12 deposited under accession number ATCC 207088;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dh1073 _—12 deposited under accession number ATCC 207088;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dh1073 _—12 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dh1073 _—12 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:106;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:106;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:105.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895; the nucleotide sequence of the full-length protein coding sequence of clone dh1073 _—12 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dh1073_—12 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dh1073_—12 deposited under accession number ATCC 207088.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:106.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:105.

(a) a process comprising the steps of:

(aa) SEQ ID NO:105, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:105; and

(ab) the nucleotide sequence of the cDNA insert of clone dh1073 _—12 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:105, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:105; and

(bb) the nucleotide sequence of the cDNA insert of clone dh1073 _—12 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:105 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:105, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895.

(a) the amino acid sequence of SEQ ID NO:106;

(b) a fragment of the amino acid sequence of SEQ ID NO:106, the fragment comprising eight contiguous amino acids of SEQ ID NO:106; and

(c) the amino acid sequence encoded by the cDNA insert of clone dh1073 _—12 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:106. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:106.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:107;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791;

clone dw78

_—1 deposited under accession number ATCC 207088;

clone dw78

_—1 deposited under accession number ATCC 207088;

clone dw78

_—1 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone dw78

_—1 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:108;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:108;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:107.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791; the nucleotide sequence of the full-length protein coding sequence of

clone dw78

_—1 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dw78 _—1 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dw78 _—1 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:108, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:108.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:107.

(a) a process comprising the steps of:

(aa) SEQ ID NO:107, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:107; and

(ab) the nucleotide sequence of the cDNA insert of

clone dw78

_—1 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:107, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:107; and

(bb) the nucleotide sequence of the cDNA insert of

clone dw78

_—1 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:107 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:107, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:107. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791.

(a) the amino acid sequence of SEQ ID NO:108;

(b) a fragment of the amino acid sequence of SEQ ID NO:108, the fragment comprising eight contiguous amino acids of SEQ ID NO:108; and

(c) the amino acid sequence encoded by the cDNA insert of

clone dw78

_—1 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:108. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:108, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:108.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:109;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fh116 _—11 deposited under accession number ATCC 207088;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fh116 _—11 deposited under accession number ATCC 207088;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fh116 _—11 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fh116 _—11 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:110;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:110;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:109.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944; the nucleotide sequence of the full-length protein coding sequence of clone fh116 _—11 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone fh116_—11 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fh116_—11 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:110, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising the amino acid sequence from amino acid 136 to amino acid 145 of SEQ ID NO:110.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:109.

(a) a process comprising the steps of:

(aa) SEQ ID NO:109, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:109; and

(ab) the nucleotide sequence of the cDNA insert of clone fh116 _—11 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:109, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:109; and

(bb) the nucleotide sequence of the cDNA insert of clone fh116 _—11 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:109 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:109, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:109. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944.

(a) the amino acid sequence of SEQ ID NO:110;

(b) a fragment of the amino acid sequence of SEQ ID NO:110, the fragment comprising eight contiguous amino acids of SEQ ID NO:110; and

(c) the amino acid sequence encoded by the cDNA insert of clone fh116 _—11 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:110. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:110, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising the amino acid sequence from amino acid 136 to amino acid 145 of SEQ ID NO:110.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fy356 _—14 deposited under accession number ATCC 207088;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fy356 _—14 deposited under accession number ATCC 207088;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fy356 _—14 deposited under accession number ATCC 207088;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fy356 _—14 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:112;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:112;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:111.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610; the nucleotide sequence of the full-length protein coding sequence of clone fy356 _—14 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone fy356_—14 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fy356_—14 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:112.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:111.

(a) a process comprising the steps of:

(aa) SEQ ID NO:111, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:111; and

(ab) the nucleotide sequence of the cDNA insert of clone fy356 _—14 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:111, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:111; and

(bb) the nucleotide sequence of the cDNA insert of clone fy356 _—14 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:111 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:111, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610.

(a) the amino acid sequence of SEQ ID NO:112;

(b) a fragment of the amino acid sequence of SEQ ID NO:112, the fragment comprising eight contiguous amino acids of SEQ ID NO:112; and

(c) the amino acid sequence encoded by the cDNA insert of clone fy356 _—14 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:112. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:112.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669;

clone iw66

_—1 deposited under accession number ATCC 207088;

clone iw66

_—1 deposited under accession number ATCC 207088;

clone iw66

_—1 deposited under accession number ATCC 207088;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone iw66

_—1 deposited under accession number ATCC 207088;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:114;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:114;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:113.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669; the nucleotide sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669; the nucleotide sequence of the full-length protein coding sequence of

clone iw66

_—1 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone iw66 _—1 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone iw66 _—1 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:114, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:114.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:113.

(a) a process comprising the steps of:

(aa) SEQ ID NO:113, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:113; and

(ab) the nucleotide sequence of the cDNA insert of

clone iw66

_—1 deposited under accession number ATCC 207088;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:113, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:113; and

(bb) the nucleotide sequence of the cDNA insert of

clone iw66

_—1 deposited under accession number ATCC 207088;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:113 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:113, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:113. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669.

(a) the amino acid sequence of SEQ ID NO:114;

(b) a fragment of the amino acid sequence of SEQ ID NO:114, the fragment comprising eight contiguous amino acids of SEQ ID NO:114; and

(c) the amino acid sequence encoded by the cDNA insert of

clone iw66

_—1 deposited under accession number ATCC 207088;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:114. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:114, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:114.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:115;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone kh13 _—4 deposited under accession number ATCC 207089;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone kh13 _—4 deposited under accession number ATCC 207089;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone kh13 _—4 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone kh13 _—4 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:116;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:116;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:115.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416; the nucleotide sequence of the full-length protein coding sequence of clone kh13 _—4 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone kh13_—4 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone kh13_—4 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:116, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:116.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:115.

(a) a process comprising the steps of:

(aa) SEQ ID NO:115, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:115; and

(ab) the nucleotide sequence of the cDNA insert of clone kh13 _—4 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:115, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:115; and

(bb) the nucleotide sequence of the cDNA insert of clone kh13 _—4 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:115 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:115, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:115. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416.

(a) the amino acid sequence of SEQ ID NO:116;

(b) a fragment of the amino acid sequence of SEQ ID NO:116, the fragment comprising eight contiguous amino acids of SEQ ID NO:116; and

(c) the amino acid sequence encoded by the cDNA insert of clone kh13 _—4 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:116. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:116, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:116.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:117;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ko258 _—4 deposited under accession number ATCC 207089;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ko258 _—4 deposited under accession number ATCC 207089;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ko258 _—4 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ko258 _—4 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:118;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:118;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:117.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602; the nucleotide sequence of the full-length protein coding sequence of clone ko258 _—4 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone ko258_—4 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ko258_—4 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:118, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:118.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:117.

(a) a process comprising the steps of:

(aa) SEQ ID NO:117, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:117; and

(ab) the nucleotide sequence of the cDNA insert of clone ko258 _—4 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:117, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:117; and

(bb) the nucleotide sequence of the cDNA insert of clone ko258 _—4 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:117 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:117, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:117. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602.

(a) the amino acid sequence of SEQ ID NO:118;

(b) a fragment of the amino acid sequence of SEQ ID NO:118, the fragment comprising eight contiguous amino acids of SEQ ID NO:118; and

(c) the amino acid sequence encoded by the cDNA insert of clone ko258 _—4 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:118. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:118, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:118.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone kv10 _—8 deposited under accession number ATCC 207089;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone kv10 _—8 deposited under accession number ATCC 207089;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ky10 _—8 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ky10 _—8 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:120;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:120;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:119.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739; the nucleotide sequence of the full-length protein coding sequence of clone kv10 _—8 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone kv10_—8 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ky10_—8 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:120.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:119.

(a) a process comprising the steps of:

(aa) SEQ ID NO:119, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:119; and

(ab) the nucleotide sequence of the cDNA insert of clone kv10 _—8 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:119, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:119; and

(bb) the nucleotide sequence of the cDNA insert of clone ky10 _—8 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:119 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:119, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:119. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739.

(a) the amino acid sequence of SEQ ID NO:120;

(b) a fragment of the amino acid sequence of SEQ ID NO:120, the fragment comprising eight contiguous amino acids of SEQ ID NO:120; and

(c) the amino acid sequence encoded by the cDNA insert of clone ky10 _—8 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:120. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:120.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone LL89 _—3 deposited under accession number ATCC 207089;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone LL89 _—3 deposited under accession number ATCC 207089;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone LL89 _—3 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone LL89 _—3 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:122;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:122;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:121.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310; the nucleotide sequence of the full-length protein coding sequence of clone LL89 _—3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone LL89_—3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone LL89_—3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty contiguous amino acids of SEQ ID NO:122, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:122.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:121.

(a) a process comprising the steps of:

(aa) SEQ ID NO:121, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:121; and

(ab) the nucleotide sequence of the cDNA insert of clone LL89 _—3 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:121, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:121; and

(bb) the nucleotide sequence of the cDNA insert of clone LL89 _—3 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:121 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:121, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:121. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310.

(a) the amino acid sequence of SEQ ID NO:122;

(b) a fragment of the amino acid sequence of SEQ ID NO:122, the fragment comprising eight contiguous amino acids of SEQ ID NO:122; and

(c) the amino acid sequence encoded by the cDNA insert of clone LL89 _—3 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:122. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:122, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:122.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288;

clone mc300

_—1 deposited under accession number ATCC 207089;

clone mc300

_—1 deposited under accession number ATCC 207089;

clone mc300

_—1 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone mc300

_—1 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:124;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:124;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:123.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288; the nucleotide sequence of the full-length protein coding sequence of

clone mc300

_—1 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mc300 _—1 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mc300 _—1 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:124.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:123.

(a) a process comprising the steps of:

(aa) SEQ ID NO:123, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:123; and

(ab) the nucleotide sequence of the cDNA insert of

clone mc300

_—1 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:123, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:123; and

(bb) the nucleotide sequence of the cDNA insert of

clone mc300

_—1 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:123 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:123, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:123. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288.

(a) the amino acid sequence of SEQ ID NO:124;

(b) a fragment of the amino acid sequence of SEQ ID NO:124, the fragment comprising eight contiguous amino acids of SEQ ID NO:124; and

(c) the amino acid sequence encoded by the cDNA insert of

clone mc300

_—1 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:124. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:124.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449;

clone ml227

_—1 deposited under accession number ATCC 207089;

clone ml227

_—1 deposited under accession number ATCC 207089;

clone ml227

_—1 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ml227

_—1 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:126;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:126;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:125.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449; the nucleotide sequence of the full-length protein coding sequence of

clone ml227

_—1 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone ml227 _—1 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ml227 _—1 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:126, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 370 to amino acid 379 of SEQ ID NO:126.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:125.

(a) a process comprising the steps of:

(aa) SEQ ID NO:125, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:125; and

(ab) the nucleotide sequence of the cDNA insert of

clone ml227

_—1 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:125, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:125; and

(bb) the nucleotide sequence of the cDNA insert of

clone ml227

_—1 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:125 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:125, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:125. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449.

(a) the amino acid sequence of SEQ ID NO:126;

(b) a fragment of the amino acid sequence of SEQ ID NO:126, the fragment comprising eight contiguous amino acids of SEQ ID NO:126; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ml227

_—1 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:126. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:126, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 370 to amino acid 379 of SEQ ID NO:126.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mm367 _—6 deposited under accession number ATCC 207089;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mm367 _—6 deposited under accession number ATCC 207089;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mm367 _—6 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mm367 _—6 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:128;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:128;

(i) a polynucleotide which is an aelic variant of a polynucleotide of (a)-(f) above;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:127.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980; the nucleotide sequence of the full-length protein coding sequence of clone mm367 _—6 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mm367_—6 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mm367_—6 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 311 to amino acid 320 of SEQ ID NO:128.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:127.

(a) a process comprising the steps of:

(aa) SEQ ID NO:127, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:127; and

(ab) the nucleotide sequence of the cDNA insert of clone mm367 _—6 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:127, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:127; and

(bb) the nucleotide sequence of the cDNA insert of clone mm367 _—6 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:127 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:127, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:127. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980.

(a) the amino acid sequence of SEQ ID NO:128;

(b) a fragment of the amino acid sequence of SEQ ID NO:128, the fragment comprising eight contiguous amino acids of SEQ ID NO:128; and

(c) the amino acid sequence encoded by the cDNA insert of clone mm367 _—6 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:128. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 311 to amino acid 320 of SEQ ID NO:128.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mt124 _—3 deposited under accession number ATCC 207089;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mt124 _—3 deposited under accession number ATCC 207089;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mt124 _—3 deposited under accession number ATCC 207089;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mt124 _—3 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:130;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:130;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:129.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856; the nucleotide sequence of the full-length protein coding sequence of clone mt124 _—3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mt124_—3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mt124_—3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:130.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:129.

(a) a process comprising the steps of:

(aa) SEQ ID NO:129, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:129; and

(ab) the nucleotide sequence of the cDNA insert of clone mt124 _—3 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:129, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:129; and

(bb) the nucleotide sequence of the cDNA insert of clone mt124 _—3 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:129 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:129, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:129. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856.

(a) the amino acid sequence of SEQ ID NO:130;

(b) a fragment of the amino acid sequence of SEQ ID NO:130, the fragment comprising eight contiguous amino acids of SEQ ID NO:130; and

(c) the amino acid sequence encoded by the cDNA insert of clone mt124 _—3 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:130. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:130.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf56 _—3 deposited under accession number ATCC 207089;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf56 _—3 deposited under accession number ATCC 207089;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nf56 _—3 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nf56 _—3 deposited under accession number ATCC 207089;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:132;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:132;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:131.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940; the nucleotide sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940; the nucleotide sequence of the full-length protein coding sequence of clone nf56 _—3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone nf56_—3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nf56_—3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 342 to amino acid 351 of SEQ ID NO:132.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:131.

(a) a process comprising the steps of:

(aa) SEQ ID NO:131, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:131; and

(ab) the nucleotide sequence of the cDNA insert of clone nf56 _—3 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:131, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:131; and

(bb) the nucleotide sequence of the cDNA insert of clone nf56 _—3 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:131 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:131, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:131. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940.

(a) the amino acid sequence of SEQ ID NO:132;

(b) a fragment of the amino acid sequence of SEQ ID NO:132, the fragment comprising eight contiguous amino acids of SEQ ID NO:132; and

(c) the amino acid sequence encoded by the cDNA insert of clone nf56 _—3 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:132. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 342 to amino acid 351 of SEQ ID NO:132.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448;

clone qy442

_—2 deposited under accession number ATCC 207089;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy442 ²deposited under accession number ATCC 207089;

clone qy442

_—2 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone qy442

_—2 deposited under accession number ATCC 207089;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:134;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:134;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:133.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448; the nucleotide sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448; the nucleotide sequence of the full-length protein coding sequence of

clone qy442

_—2 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone qy442 _—2 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy442 _—2 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:134.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:133.

(a) a process comprising the steps of:

(aa) SEQ ID NO:133, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:133; and

(ab) the nucleotide sequence of the cDNA insert of

clone qy442

_—2 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:133, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:133; and

(bb) the nucleotide sequence of the cDNA insert of

clone qy442

_—2 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:133 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:133, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:133. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448.

(a) the amino acid sequence of SEQ ID NO:134;

(b) a fragment of the amino acid sequence of SEQ ID NO:134, the fragment comprising eight contiguous amino acids of SEQ ID NO:134; and

(c) the amino acid sequence encoded by the cDNA insert of

clone qy442

_—2 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:134. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:134.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rj214 _—14 deposited under accession number ATCC 207089;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rj214 _—14 deposited under accession number ATCC 207089;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rj214 _—14 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rj214 _—14 deposited under accession number ATCC 207089;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:136;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:136;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:135.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777; the nucleotide sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777; the nucleotide sequence of the full-length protein coding sequence of clone rj214 _—14 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone rj214_—14 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rj214_—14 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:136, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:136.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:135.

(a) a process comprising the steps of:

(aa) SEQ ID NO:135, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:135; and

(ab) the nucleotide sequence of the cDNA insert of clone rj214 _—14 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:135, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:135; and

(bb) the nucleotide sequence of the cDNA insert of clone rj214 _—14 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:135 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:135, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:135. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777.

(a) the amino acid sequence of SEQ ID NO:136;

(b) a fragment of the amino acid sequence of SEQ ID NO:136, the fragment comprising eight contiguous amino acids of SEQ ID NO:136; and

(c) the amino acid sequence encoded by the cDNA insert of clone rj214 _—14 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:136. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:136, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:136.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of done rk80 _—3 deposited under accession number ATCC 207089;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rk80 _—3 deposited under accession number ATCC 207089;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rk80 _—3 deposited under accession number ATCC 207089;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rk80 _—3 deposited under accession number ATCC 207089;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:138;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:138;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:137.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745; the nucleotide sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745; the nucleotide sequence of the full-length protein coding sequence of clone rk80 _—3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone rk80_—3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rk80_—3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:138, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:138.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:137.

(a) a process comprising the steps of:

(aa) SEQ ID NO:137, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:137; and

(ab) the nucleotide sequence of the cDNA insert of clone rk80 _—3 deposited under accession number ATCC 207089;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:137, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:137; and

(bb) the nucleotide sequence of the cDNA insert of clone rk80 _—3 deposited under accession number ATCC 207089;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:137 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:137, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:137. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745.

(a) the amino acid sequence of SEQ ID NO:138;

(b) a fragment of the amino acid sequence of SEQ ID NO:138, the fragment comprising eight contiguous amino acids of SEQ ID NO:138; and

(c) the amino acid sequence encoded by the cDNA insert of clone rk80 _—3 deposited under accession number ATCC 207089;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:138. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:138, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:138.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:139;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone au36 _—42 deposited under accession number ATCC 207187;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone au36 _—42 deposited under accession number ATCC 207187;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone au36 _—42 deposited under accession number ATCC 207187;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone au36 _—42 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:140;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:140;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:139.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274; the nucleotide sequence of the full-length protein coding sequence of clone au36 _—42 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone au36_—42 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone au36_—42 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:140, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:140.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:139.

(a) a process comprising the steps of:

(aa) SEQ ID NO:139, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:139; and

(ab) the nucleotide sequence of the cDNA insert of done au36 _—42 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:139, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:139; and

(bb) the nucleotide sequence of the cDNA insert of clone au36 _—42 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:139 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:139, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:139. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274.

(a) the amino acid sequence of SEQ ID NO:140;

(b) a fragment of the amino acid sequence of SEQ ID NO:140, the fragment comprising eight contiguous amino acids of SEQ ID NO:140; and

(c) the amino acid sequence encoded by the cDNA insert of clone au36 _—42 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:140. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:140, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:140.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:141;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bo549 _—13 deposited under accession number ATCC 207187;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bo549 _—13 deposited under accession number ATCC 207187;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bo549 _—13 deposited under accession number ATCC 207187;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bo549 _—13 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:142;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:142;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:141.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774; the nucleotide sequence of the full-length protein coding sequence of clone bo549 _—13 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone bo549_—13 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bo549_—13 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:142, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:142.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:141.

(a) a process comprising the steps of:

(aa) SEQ ID NO:141, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:141; and

(ab) the nucleotide sequence of the cDNA insert of clone bo549 _—13 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:141, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:141; and

(bb) the nucleotide sequence of the cDNA insert of clone bo549 _—13 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:141 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:141, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:141. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774.

(a) the amino acid sequence of SEQ ID NO:142;

(b) a fragment of the amino acid sequence of SEQ ID NO:142, the fragment comprising eight contiguous amino acids of SEQ ID NO:142; and

(c) the amino acid sequence encoded by the cDNA insert of clone bo549 _—13 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:142. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:142, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:142.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone da529 _—3 deposited under accession number ATCC 207187;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone da529 _—3 deposited under accession number ATCC 207187;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone da529 _—3 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone da529 _—3 deposited under accession number ATCC 207187;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:144;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:144;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:143.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969; the nucleotide sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969; the nucleotide sequence of the full-length protein coding sequence of clone da529 _—3 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone da529_—3 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone da529_—3 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:144, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:144.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:143.

(a) a process comprising the steps of:

(aa) SEQ ID NO:143, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:143; and

(ab) the nucleotide sequence of the cDNA insert of clone da529 _—3 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:143, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:143; and

(bb) the nucleotide sequence of the cDNA insert of clone da529 _—3 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:143 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:143, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:143. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969.

(a) the amino acid sequence of SEQ ID NO:144;

(b) a fragment of the amino acid sequence of SEQ ID NO:144, the fragment comprising eight contiguous amino acids of SEQ ID NO:144; and

(c) the amino acid sequence encoded by the cDNA insert of clone da529 _—3 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:144. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:144, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:144.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dm365 _—3 deposited under accession number ATCC 207187;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dm365 _—3 deposited under accession number ATCC 207187;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dm365 _—3 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dm365 _—3 deposited under accession number ATCC 207187;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:146;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:146;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:145.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667; the nucleotide sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone dm365 _—3 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone dm365_—3 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dm365_—3 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:146, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:146.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:145.

(a) a process comprising the steps of:

(aa) SEQ ID NO:145, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:145; and

(ab) the nucleotide sequence of the cDNA insert of clone dm365 _—3 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:145, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:145; and

(bb) the nucleotide sequence of the cDNA insert of clone dm365 _—3 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:145 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:145, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:145. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667.

(a) the amino acid sequence of SEQ ID NO:146;

(b) a fragment of the amino acid sequence of SEQ ID NO:146, the fragment comprising eight contiguous amino acids of SEQ ID NO:146; and

(c) the amino acid sequence encoded by the cDNA insert of clone dm365 _—3 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:146. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:146, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:146.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:147;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368;

clone fa171

_—1 deposited under accession number ATCC 207187;

clone fa171

_—1 deposited under accession number ATCC 207187;

clone fa171

_—1 deposited under accession number ATCC 207187;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone fa171

_—1 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:148;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:148;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:147.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368; the nucleotide sequence of the full-length protein coding sequence of

clone fa171

_—1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone fa171 _—1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fa171 _—1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:148, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:148.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:147.

(a) a process comprising the steps of:

(aa) SEQ ID NO:147, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:147; and

(ab) the nucleotide sequence of the cDNA insert of

clone fa171

_—1 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:147, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:147; and

(bb) the nucleotide sequence of the cDNA insert of

clone fa171

_—1 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:147 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:147, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:147. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368.

(a) the amino acid sequence of SEQ ID NO:148;

(b) a fragment of the amino acid sequence of SEQ ID NO:148, the fragment comprising eight contiguous amino acids of SEQ ID NO:148; and

(c) the amino acid sequence encoded by the cDNA insert of

clone fa171

_—1 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:148. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:148, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:148.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407;

clone lp572

_—2 deposited under accession number ATCC 207187;

clone lp572

_—2 deposited under accession number ATCC 207187;

clone lp572

_—2 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone lp572

_—2 deposited under accession number ATCC 207187;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:150;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:150;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:149.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407; the nucleotide sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407; the nucleotide sequence of the full-length protein coding sequence of

clone lp572

_—2 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone lp572 _—2 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lp572 _—2 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:150, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO:150.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:149.

(a) a process comprising the steps of:

(aa) SEQ ID NO:149, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:149; and

(ab) the nucleotide sequence of the cDNA insert of

clone lp572

_—2 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:149, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:149; and

(bb) the nucleotide sequence of the cDNA insert of

clone lp572

_—2 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:149 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:149, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:149. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407.

(a) the amino acid sequence of SEQ ID NO:150;

(b) a fragment of the amino acid sequence of SEQ ID NO:150, the fragment comprising eight contiguous amino acids of SEQ ID NO:150; and

(c) the amino acid sequence encoded by the cDNA insert of

clone lp572

_—2 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:150. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:150 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:150, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO:150.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035;

clone pe246

_—1 deposited under accession number ATCC 207187;

clone pe246

_—1 deposited under accession number ATCC 207187;

clone pe246

_—1 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone pe246

_—1 deposited under accession number ATCC 207187;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:152;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:152;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:151.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035; the nucleotide sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035; the nucleotide sequence of the full-length protein coding sequence of

clone pe246

_—1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone pe246 _—1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pe246 _—1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:152, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:152.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:151.

(a) a process comprising the steps of:

(aa) SEQ ID NO:151, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:151; and

(ab) the nucleotide sequence of the cDNA insert of done pe246 _—1 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:151, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:151; and

(bb) the nucleotide sequence of the cDNA insert of

clone pe246

_—1 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:151 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:151, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:151. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035.

(a) the amino acid sequence of SEQ ID NO:152;

(b) a fragment of the amino acid sequence of SEQ ID NO:152, the fragment comprising eight contiguous amino acids of SEQ ID NO:152; and

(c) the amino acid sequence encoded by the cDNA insert of

clone pe246

_—1 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:152. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:152, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:152.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:153;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qf122 _—3 deposited under accession number ATCC 207187;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qf122 _—3 deposited under accession number ATCC 207187;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qf122 _—3 deposited under accession number ATCC 207187;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qf122 _—3 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:154;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:154;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:153.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281; the nucleotide sequence of the full-length protein coding sequence of clone qf122 _—3 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone qf122_—3 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qf122_—3 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:154, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:154.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:153.

(a) a process comprising the steps of:

(aa) SEQ ID NO:153; and

(ab) the nucleotide sequence of the cDNA insert of clone qf122 _—3 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:153; and

(bb) the nucleotide sequence of the cDNA insert of clone qf122 _—3 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:153 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:153. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281.

(a) the amino acid sequence of SEQ ID NO:154;

(b) a fragment of the amino acid sequence of SEQ ID NO:154, the fragment comprising eight contiguous amino acids of SEQ ID NO:154; and

(c) the amino acid sequence encoded by the cDNA insert of clone qf122 _—3 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:154. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:154, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:154.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742;

clone qv538

_—1 deposited under accession number ATCC 207187;

clone qv538

_—1 deposited under accession number ATCC 207187;

clone qv538

_—1 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone qv538

_—1 deposited under accession number ATCC 207187;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:156;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:156;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:155.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742; the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742; the nucleotide sequence of the full-length protein coding sequence of

clone qv538

_—1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone qv538 _—1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qv538 _—1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:156.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:155.

(a) a process comprising the steps of:

(aa) SEQ ID NO:155, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:155; and

(ab) the nucleotide sequence of the cDNA insert of

clone qv538

_—1 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:155, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:155; and

(bb) the nucleotide sequence of the cDNA insert of

clone qv538

_—1 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:155 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:155, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:155. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742.

(a) the amino acid sequence of SEQ ID NO:156;

(b) a fragment of the amino acid sequence of SEQ ID NO:156, the fragment comprising eight contiguous amino acids of SEQ ID NO:156; and

(c) the amino acid sequence encoded by the cDNA insert of

clone qv538

_—1 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:156. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:156.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:157;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757;

clone ys20

_—1 deposited under accession number ATCC 207187;

clone ys20

_—1 deposited under accession number ATCC 207187;

clone ys20

_—1 deposited under accession number ATCC 207187;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of

clone ys20

_—1 deposited under accession number ATCC 207187;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:158;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:158;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:157.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of done ys20 _—1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone ys20 _—1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ys20 _—1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:158, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:158.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:157.

(a) a process comprising the steps of:

(aa) SEQ ID NO:157, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:157; and

(ab) the nucleotide sequence of the cDNA insert of

clone ys20

_—1 deposited under accession number ATCC 207187;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:157, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:157; and

(bb) the nucleotide sequence of the cDNA insert of

clone ys20

_—1 deposited under accession number ATCC 207187;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:157 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:157, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:157. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757.

(a) the amino acid sequence of SEQ ID NO:158;

(b) a fragment of the amino acid sequence of SEQ ID NO:158, the fragment comprising eight contiguous amino acids of SEQ ID NO:158; and

(c) the amino acid sequence encoded by the cDNA insert of

clone ys20

_—1 deposited under accession number ATCC 207187;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:158. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:158, or a protein comprising a fragment of the amino add sequence of SEQ ID NO:158 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:158.

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone as180 _—1 deposited under accession number ATCC ______;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone as180 _—1 deposited under accession number ATCC ______;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone as180 _—1 deposited under accession number ATCC ______;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone as180 _—1 deposited under accession number ATCC ______;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:160;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:160;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:159.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253; the nucleotide sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253; the nucleotide sequence of the full-length protein coding sequence of done as180 _—1 deposited under accession number ATCC ______; or the nucleotide sequence of a mature protein coding sequence of clone as180_—1 deposited under accession number ATCC ______. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone as180_—1 deposited under accession number ATCC ______. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:160, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising the amino acid sequence from amino acid 366 to amino acid 375 of SEQ ID NO:160.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:159.

(a) a process comprising the steps of:

(aa) SEQ ID NO:159; and

(ab) the nucleotide sequence of the cDNA insert of clone as180 _—1 deposited under accession number ATCC ______;

(iii) isolating the DNA polynucleotides detected with the probe(s); and

(b) a process comprising the steps of:

(ba) SEQ ID NO:159; and

(bb) the nucleotide sequence of the cDNA insert of clone as180 _—1 deposited under accession number ATCC ______;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:159 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253.

(a) the amino acid sequence of SEQ ID NO:160;

(b) a fragment of the amino acid sequence of SEQ ID NO:160, the fragment comprising eight contiguous amino acids of SEQ ID NO:160; and

(c) the amino acid sequence encoded by the cDNA insert of clone as180 _—1 deposited under accession number ATCC ______;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:160. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:160, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising the amino acid sequence from amino acid 366 to amino acid 375 of SEQ ID NO:160.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein. [2865]
FIG. 2 is a schematic representation of the pCMVSport2 vector used for deposit of clone qs14[2866] _—3 disclosed herein.

DETAILED DESCRIPTION

Isolated Proteins and Polynucleotides [2867]
Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing. [2868]
As used herein a “secreted” protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. “Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. “Secreted” proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum. [2869]
Clone “co62[2870] _—12”
A polynucleotide of the present invention has been identified as clone “co62[2871] _—12”. co62_—12 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. co62_—12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “co62_—12 protein”).
The nucleotide sequence of co62[2872] _—12 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the co62_—12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 1 to 11 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino add sequence beginning at amino acid 12. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the co62_—12 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone co62[2873] _—12 should be approximately 2200 bp.
The nucleotide sequence disclosed herein for co62[2874] _—12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. co62_—12 demonstrated at least some similarity with sequences identified as AA019597 (ze60f10.s1 Soares retina N2b4HR Homo sapiens cDNA), AA021678 (mh82c02.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus), AA057573 (zf62d10.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381523 3′ similar to WP T12G3.4 CE06440 STRICTOSIDINE SYNTHASE LIKE, mRNA sequence), AA130982, AA287697 (zs53g02.r1 Soares NbHTGBC Homo sapiens cDNA clone 701234 5′), AI042188 (oy37d10.x1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:1668019 3′ similar to WP:F57C2.5 CE16156, mRNA sequence), R63905 (yi19b03.s1 Homo sapiens cDNA clone 139661 3′), T03538 (IB43 Infant brain, Bento Soares Homo sapiens cDNA clone IB43 3′end), T20257 (Human gene signature HUMGS01405), and T23663 (seq294 Homo sapiens cDNA clone b4HB3MA-Cot109+103-Bio-24 3′). The predicted amino acid sequence disclosed herein for co62_—12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted co62_—12 protein demonstrated at least some similarity to sequences identified as R88502 (Protein sequence for mediating male fertility in plants) and Z83110 (F57C2.5 [Caenorhabditis elegans]). Based upon sequence similarity, co62_—12 proteins and each similar protein or peptide may share at least some activity.
Clone “lo311[2875] _—8”
A polynucleotide of the present invention has been identified as clone “lo311[2876] _—8”. lo311_—8 was isolated from a human adult thyroid cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. lo311_—8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “lo311_—8 protein”).
The nucleotide sequence of lo311[2877] _—8 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the lo311_—8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 17 to 29 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the lo311_—8 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone lo311[2878] _—8 should be approximately 3850 bp.
The nucleotide sequence disclosed herein for lo311[2879] _—8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. lo311_—8 demonstrated at least some similarity with sequences identified as AA046836 (zf14b10.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 376891 5′ similar to WP:ZK686.3 CE00457), AA297716 (EST113273 Infant adrenal gland, subtracted (total cDNA) I Homo sapiens cDNA 5′ end similar to similar to C. elegans hypothetical protein, cosmid ZK686_—3), AF008554 (Rattus norvegicus implantation-associated protein (IAG2) mRNA, partial cds), T68050 (yc39h10.r1 Homo sapiens cDNA clone 83107 5′ similar to SP ZK686.3 CE00457), and U42349 (Human N33 mRNA, complete cds). The predicted amino acid sequence disclosed herein for lo311_—8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted lo311_—8 protein demonstrated at least some similarity to sequences identified as AF008554 (implantation-associated protein [Rattus norvegicus]), R85333 (Human prostate/colon tumour suppressor protein form 1) and U42349 (39 kDa encoded by N33 [Homo sapiens]). Based upon sequence similarity, lo311_—8 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the lo311_—8 protein sequence, centered around amino acids 10, 190, 220, 275, and 310 of SEQ ID NO:4, respectively.
Clone “[2880] ns197 _—1”
A polynucleotide of the present invention has been identified as clone “[2881] ns197 _—1”. ns197 _—1 was isolated from a human adult retina (retinoblastoma WERI-Rb1) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ns197 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ns197 _—1 protein”).
The nucleotide sequence of [2882] ns197 _—1 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ns197 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [2883] clone ns197 _—1 should be approximately 3650 bp.
The nucleotide sequence disclosed herein for [2884] ns197 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ns197 _—1 demonstrated at least some similarity with sequences identified as AA495135 (fa03c11.r1 Zebrafish ICRFzfls Danio rerio cDNA clone 3K8 5′ similar to WP:ZC518.3 CE06603 ALCOHOL DEHYDROGENASE TRANSCRIPTION EFFECTOR LIKE; mRNA sequence). The predicted amino acid sequence disclosed herein for ns197 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ns197_—1 protein demonstrated at least some similarity to the sequence identified as Z68753 (ZC518.3 [Caenorhabditis elegans]). Based upon sequence similarity, ns197 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ns197 _—1 protein sequence centered around amino acid 135 of SEQ ID NO:6. The nucleotide sequence of ns197 _—1 indicates that it may contain one or more repeat sequences, including primate simple repeat GCC, Alu, and other repetitive elements.
Clone “pj1193[2885] _—5”
A polynucleotide of the present invention has been identified as clone “pj193[2886] _—5”. pj193_—5 was isolated from a human fetal carcinoma (NTD2 cells, treated with retinoic acid for 23 days) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pj193_—5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pj193_—5 protein”).
The nucleotide sequence of pj193[2887] _—5 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pj193_—5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 9 to 21 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino add 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pj193_—5 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pj193[2888] _—5 should be approximately 1500 bp.
The nucleotide sequence disclosed herein for pj193[2889] _—5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pj193_—5 demonstrated at least some similarity with sequences identified as AA296889 (EST112653 Cerebellum II Homo sapiens cDNA 5′ end), AA296961 (EST112514 Adrenal gland tumor Homo sapiens cDNA 5′ end), AA661635 (nv02g06.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1219066), and U80744 (Homo sapiens CTG4a mRNA, complete cds). The predicted amino acid sequence disclosed herein for pj193_—5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pj193_—5 protein demonstrated at least some similarity to the sequence identified as U80744 (CTG4a [Homo sapiens]). Based upon sequence similarity, pj193_—5 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of pj193_—5 indicates that it may contain CAG nucleotide repeats; these repeats may create a “hotspot” for certain types of mutations. “Twelve diseases, most with neuropsychiatric features, arise from trinucleotide repeat expansion mutations. Expansion mutations may also cause a number of other disorders, including several additional forms of spinocerebellar ataxia, bipolar affective disorder, schizophrenia, and autism.” (Margolis et al., 1997, Human Genetics 100(1): 114-122, which is incorporated by reference herein.) It is possible that the gene corresponding to pj193_—5 undergoes a similar etiology.
pj193[2890] _—5 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 31 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[2891] pj317 _—2”
A polynucleotide of the present invention has been identified as clone “[2892] pj317 _—2”. pj317 _—2 was isolated from a human fetal carcinoma (NTD2 cells, treated with retinoic acid for 23 days) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pj317 _—2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pj317 _—2 protein”).
The nucleotide sequence of [2893] pj317 _—2 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pj317 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [2894] clone pj317 _—2 should be approximately 2300 bp.
The nucleotide sequence disclosed herein for [2895] pj317 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pj317 _—2 demonstrated at least some similarity with sequences identified as AA305508 (EST176494 Colon carcinoma (Caco-2) cell line II Homo sapiens cDNA 5′ end, mRNA sequence), AA471379 (PMY1151 KG1a Lambda Zap Express cDNA Library Homo sapiens cDNA 5′, mRNA sequence), and AA906311 (ok03f08.s1 Soares NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1506759 3′, mRNA sequence). The predicted amino acid sequence disclosed herein for pj317 _—2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pj317_—2 protein demonstrated at least some similarity to the sequences identified as U37763 (Per9p [Pichia angusta]) and U56965 (Caenorhabditis elegans cosmid C₁₅H9). Per9p is a peroxisomal membrane protein, and the predicted pj317_—2 protein demonstrated at least some similarity to peroxisomal proteins from other species as well. Based upon sequence similarity, pj317 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pj317 _—2 protein sequence centered around amino acid of SEQ ID NO:10. The nucleotide sequence of pj317 _—2 indicates that it may contain a simple AT and MER repeat region.
Clone “[2896] pt332 _—1”
A polynucleotide of the present invention has been identified as clone “[2897] pt332 _—1”. pt332 _—1 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pt332 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pt332 _—1 protein”).
The nucleotide sequence of [2898] pt332 _—1 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pt332 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 287 to 299 of SEQ ID NO:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 300. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pt332 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [2899] clone pt332 _—1 should be approximately 3450 bp.
The nucleotide sequence disclosed herein for [2900] pt332 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pt332_—1 demonstrated at least some similarity with sequences identified as AA167221 (zp13c09.s1 Stratagene fetal retina 937202 Homo sapiens cDNA clone 609328 3′), AA437109 (zv53c07.s1 Soares testis NHT Homo sapiens cDNA clone 757356 3′), H14107 (ym62a06.r1 Homo sapiens cDNA clone 163474 5′), and U41264 (C. elegans cDNA). Based upon sequence similarity, pt332 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pt332 _—1 protein sequence centered around amino acid 270 of SEQ ID NO:12.
pt332[2901] _—1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 100 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “qc297[2902] _—15”
A polynucleotide of the present invention has been identified as clone “qc297[2903] _—15”. qc297_—15 was isolated from a human adult neural (neuroepithelioma HTB-10 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qc297_—15 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qc297_—15 protein”).
The nucleotide sequence of qc297[2904] _—15 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qc297_—15 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qc297[2905] _—15 should be approximately 1400 bp.
The nucleotide sequence disclosed herein for qc297[2906] _—15 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qc297_—15 demonstrated at least some similarity with sequences identified as AA625537 (af72g07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 1047612 5′) and T24537 (EST112 Homo sapiens cDNA clone 4H3). Based upon sequence similarity, qc297_—15 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the qc297_—15 protein sequence, around amino acid 20 of SEQ ID NO:14. The nucleotide/amino acid sequence of qc297_—15 indicates that it may contain an Alu/SVA/MER repeat region.
qc297[2907] _—15 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “qg596[2908] _—12”
A polynucleotide of the present invention has been identified as clone “qg596[2909] _—12”. qg596_—12 was isolated from a human adult neural (neuroepithelioma HTB-10 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qg596_—12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qg596_—12 protein”).
The nucleotide sequence of qg596[2910] _—12 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qg596_—12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qg596[2911] _—12 should be approximately 2750 bp.
The nucleotide sequence disclosed herein for qg596[2912] _—12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qg596_—12 demonstrated at least some similarity with sequences identified as AA332939 (EST37132 Embryo, 8 week I Homo sapiens cDNA 5′ end), AA334678 (EST39190 Embryo, 9 week Homo sapiens cDNA 5′ end), AA362653 (EST72375 Namalwa B cells I Homo sapiens cDNA 5′ end), and AA829841 (od40d01.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1370401 3′ similar to WP:F10G7.1 CE02624). The predicted amino acid sequence disclosed herein for qg596_—12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qg596_—12 protein demonstrated at least some similarity to the sequence identified as U40029 (coded for by C. elegans cDNA yk16b1.3; coded for by C. elegans cDNA yk8g6.5; coded for by C. elegans cDNA yk8g6.3; coded for by C. elegans cDNA yk6d3.5). Based upon sequence similarity, qg596_—12 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the qg596_—12 protein sequence, one centered around amino acid 180 and another around amino acid 660 of SEQ ID NO:16.
qg596[2913] _—12 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 33 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “rb649[2914] _—3”
A polynucleotide of the present invention has been identified as clone “rb649[2915] _—3”. rb649_—3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rb649_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rb649_—3 protein”).
The nucleotide sequence of rb649_as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rb649[2916] _—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 42 to 54 of SEQ ID NO:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rb649_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rb649[2917] _—3 should be approximately 2500 bp.
The nucleotide sequence disclosed herein for rb649[2918] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rb649_—3 demonstrated at least some similarity with sequences identified as AA177001 (nc01h02.s1 NCI_CGAP_Pr1 Homo sapiens cDNA clone IMAGE 182). The predicted amino acid sequence disclosed herein for rb649_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rb649_—3 protein demonstrated at least some similarity to sequences identified as AB002405 (LAK-4p [Homo sapiens]), R89470 (Collagen/TGF-beta-1 fusion protein), and U23516 (Undefined [Caenorhabditis elegans]). Based upon sequence similarity, rb649_—3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight addditional potential transmembrane domains within the rb649_—3 protein sequence, centered around amino acids 140, 240, 280, 325, 370, 425, 475, and 540 of SEQ ID NO:18, respectively. The nucleotide sequence of rb649_—3 indicates that it may contain a simple GGA repeat region.
Clone “ca106[2919] _—19x”
A polynucleotide of the present invention has been identified as clone “ca106[2920] _—19x”. A cDNA clone was first isolated from a mouse embryonic (ES cell embryoid bodies harvested 2-12 days after LIF removed) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate ca106_—19x from a mixture of human fetal brain and human adult brain cDNA libraries.
ca106[2921] _—19x is a full-length human clone, including the entire coding sequence of a secreted protein (also referred to herein as “ca106_—19x protein”).
The nucleotide sequence of ca106[2922] _—19x as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ca106_—19x protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ca106[2923] _—19x should be approximately 4050 bp.
The nucleotide sequence disclosed herein for ca106[2924] _—19x was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ca106_—19x demonstrated at least some similarity with sequences identified as AA886998 (oj30g03.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1499860 3′), F08279 (H. sapiens partial cDNA sequence; clone c-zpe11), F13022 (H. sapiens partial cDNA sequence; clone c-3hf07), H38128 (yp46c12.s1 Homo sapiens cDNA done 190486 3′), T77601 (yc91e07.r1 Homo sapiens cDNA done 23192 5′), U93720 (Homo sapiens TEX28 mRNA, complete cds), W55512 (ma28h03.r1 Life Tech mouse brain Mus musculus cDNA clone 312053 5′), and Z22333 (H.sapiens DNA sequence). The predicted amino acid sequence disclosed herein for ca106_—19x was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ca106_—19x protein demonstrated at least some similarity to sequences identified as U56965 (C₁₅H9.4 gene product [Caenorhabditis elegans]) and U93720 (TEX28 [Homo sapiens]). Based upon sequence similarity, ca106_—19x proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the ca106_—19x protein sequence, centered around amino acids 170, 430, 590, and 625 of SEQ ID NO:20, respectively. The nucleotide sequence of ca106_—19x indicates that it contains at least one repetitive element.
Clone “[2925] ci52 _—2”
A polynucleotide of the present invention has been identified as clone “[2926] ci52 _—2”. A cDNA clone was first isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate ci52 _—2 from a human fetal brain cDNA library. ci52 _—2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ci52 _—2 protein”).
The nucleotide sequence of [2927] ci52 _—2 as presently determined is reported in SEQ ID NO:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ci52 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:22. Amino acids 9 to 21 of SEQ ID NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ci52 _—2 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [2928] clone ci52 _—2 should be approximately 1775 bp.
The nucleotide sequence disclosed herein for [2929] ci52 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ci52 _—2 demonstrated at least some similarity with sequences identified as AA083339 (zn31d10.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 549043 5′), AA514339 (nf56c10.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 923922), AA628942 (af28f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032985 3′, mRNA sequence), M78692 (EST00840 Homo sapiens cDNA clone HHCMC16), N67265 (yz49d04.s1 Homo sapiens cDNA clone 286375 3′), N95514 (yy62d10.r1 Homo sapiens cDNA clone 278131 5′), Q60715 (Human brain Expressed Sequence Tag EST00840; standard; cDNA), and R46588 (yg51a12.s1 Homo sapiens cDNA clone 35984 3′). The predicted amino acid sequence disclosed herein for ci52 _—2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ci52_—2 protein demonstrated at least some similarity to the sequence identified as M68866 (stranded at second [Drosophila melanogaster]). Based upon sequence similarity, ci52 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the ci52 _—2 protein sequence, one around amino acid 146 and another around amino acid 177 of SEQ ID NO:22.
Clone “md124[2930] _—16”
A polynucleotide of the present invention has been identified as clone “md124[2931] _—16”. A cDNA clone was first isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate md124_—16 from a human adult kidney cDNA library. md124_—16 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “md124_—16 protein”).
The nucleotide sequence of md124[2932] _—16 as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the md124_—16 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 152 to 164 of SEQ ID NO:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 165. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the md124_—16 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone md124[2933] _—16 should be approximately 2300 bp.
The nucleotide sequence disclosed herein for md124[2934] _—16 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. md124_—16 demonstrated at least some similarity with sequences identified as AA215643 (zr98d05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone MAGE:683721 3′), AA489121 (aa56b07.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824917 5′), W72865 (zd59e07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344964 3′), and W76100 (zd59e07.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344964 5′). Based upon sequence similarity, md124_—16 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of md124_—16 indicates that it may contain at least one MER repeat sequence.
Clone “pk366[2935] _—7”
A polynucleotide of the present invention has been identified as clone “pk366[2936] _—7”. pk366_—7 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pk366_—7 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pk366_—7 protein”).
The nucleotide sequence of pk366[2937] _—7 as presently determined is reported in SEQ ID NO:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pk366_—7 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:26. Amino acids 361 to 373 of SEQ ID NO:26 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 374. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pk366_—7 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pk366[2938] _—7 should be approximately 3300 bp.
The nucleotide sequence disclosed herein for pk366[2939] _—7 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pk366_—7 demonstrated at least some similarity with sequences identified as AA057428 (zf57c11.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381044 3′), AA457625 (aa89e09.r1 Stratagene fetal retina 937202 Homo sapiens cDNA clone 838504 5′), AA601545 (nn87h11.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone IMAGE:1098213), T19564 (Human gene signature HUMGS00629; standard; cDNA to mRNA), and U94831 (Homo sapiens multispanning membrane protein mRNA, complete cds). The predicted amino acid sequence disdosed herein for pk366_—7 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pk366_—7 protein demonstrated at least some similarity to sequences identified as D87444 (endomembrane protein EMP70 precursor isolog [Arabidopsis thaliana]), U94831 (multispanning membrane protein [Homo sapiens]), and U95973 (endomembrane protein EMP70 precusor isolog [Arabidopsis thaliana]). Based upon sequence similarity, pk366_—7 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts nine additional potential transmembrane domains within the pk366_—7 protein sequence, centered around amino adds 191, 260, 288, 325, 355, 412, 447, 481, and 517 of SEQ ID NO:26, respectively.
Clone “pl741 5”[2940]
A polynucleotide of the present invention has been identified as clone “pl741[2941] _—5”. pl741_—5 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pl741_—5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pl741_—5 protein”).
The nucleotide sequence of pl741[2942] _—5 as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pl741_—5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28. Amino acids 3 to 15 of SEQ ID NO:28 are a predicted leader/signal sequence, with the predicted mature amino add sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pl741_—5 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pl741[2943] _—5 should be approximately 3000 bp.
The nucleotide sequence disclosed herein for pl741[2944] _—5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pl741_—5 demonstrated at least some similarity with sequences identified as AA283176 (zt17a04.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 713358 3′), AA204801 (zq61d12.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 646103 5′), and H59410 (yr19g04.r1 Homo sapiens cDNA clone 205782 5′). The predicted amino acid sequence disclosed herein for pl741_—5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pl741-5 protein demonstrated at least some similarity to sequences identified as U00027 (Cdc23p cell cycle protein [Saccharomyces cerevisiae]) and U58763 (F10C5.1 [Caenorhabditis elegans]). Based upon sequence similarity, pl741-5 proteins and each similar protein or peptide may share at least some activity. Analysis of the amino acid sequence of the predicted pl741-5 protein reveals the presence of four TPR (tetratricopeptide) domains. TPR domains are found in a wide variety of proteins with varying functions and localizations—from the nucleus to the extracellular milieu—and are thought to function as protein-protein interaction domains. The TPR domains are found at amino acid residues 166-194, 328-356, 362-390, and 396-424 of SEQ ID NO:28.
Clone “pp314[2945] _—19”
A polynucleotide of the present invention has been identified as clone “pp314[2946] _—19”. pp314_—19 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pp314_—19 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pp314_—19 protein”).
The nucleotide sequence of pp314[2947] _—19 as presently determined is reported in SEQ ID NO:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pp314_—19 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 147 to 159 of SEQ ID NO:30 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 160; amino acids 238 to 250 of SEQ ID NO:30 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 251. Due to the hydrophobic nature of these possible leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the pp314_—19 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pp314[2948] _—19 should be approximately 2300 bp.
The nucleotide sequence disclosed herein for pp314[2949] _—19 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pp314_—19 demonstrated at least some similarity with sequences identified as AA044042 (zk58g05.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487064 5′, mRNA sequence), AA127902 (zl12d01.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 501697 5′), AA609481 (af14a12.s1 Soares testis NHT Homo sapiens cDNA clone 1031614 3′, mRNA sequence), T26699 (Human gene signature HUMGS08949; standard; cDNA to mRNA), and W93399 (zd95b06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357203 3′). The predicted amino acid sequence disclosed herein for pp314_—19 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pp314_—19 protein demonstrated at least some similarity to sequences identified as AE000857 (chaperonin [Methanobacterium thermoautotrophicum]), AJ006549 (ThsA [Pyrodictium occultum]), and L34691 (thermophilic factor 56 [Sulfolobus shibatae]). Based upon sequence similarity, pp314_—19 proteins and each similar protein or peptide may share at least some activity. Analysis of the amino acid sequence of the predicted pp314_—19 protein revealed the cpn60_TCP1 signature (at amino acids 29-570 of SEQ ID NO:30) which has some ATPase activity and is indicative of chaperonins. A P-loop motif—a common motif in ATP- and GTP-binding proteins—is found around amino acid 200 of SEQ ID NO:30. The presence of the P-loop is interesting when taken in conjunction with the potential ATPase activity associated with the cpn60_TCP1 signature. The TopPredII computer program predicts three additional potential transmembrane domains within the pp314_—19 protein sequence, centered around amino acids 55, 90, and 330 of SEQ ID NO:30, respectively.
pp314[2950] _—19 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 6 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[2951] pv35 _—1”
A polynucleotide of the present invention has been identified as clone “[2952] pv35 _—1”. pv35 _—1 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv35 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pv35 _—1 protein”).
The nucleotide sequence of [2953] pv35 _—1 as presently determined is reported in SEQ ID NO:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv35 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:32.
The EcoRI/NotI restriction fragment obtainable from the deposit containing done pv35[2954] _—1 should be approximately 2300 bp.
The nucleotide sequence disclosed herein for [2955] pv35 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv35 _—1 demonstrated at least some similarity with sequences identified as AA335869 (EST40348 Epididymus Homo sapiens cDNA 5′ end), AA599418 (ag23c03.s1 Jia bone marrow stroma Homo sapiens cDNA clone 1071172 3′), and H03595 (yj42e06.r1 Homo sapiens cDNA clone 151426 5′). The predicted amino acid sequence disclosed herein for pv35 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pv35_—1 protein demonstrated at least some similarity to sequences identified as Z99277 (Y53C12A.3 [Caenorhabditis elegans]). Based upon sequence similarity, pv35 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the pv35 _—1 protein sequence, centered around amino acids 127, 161, 192, and 250 of SEQ ID NO:32, respectively.
Clone “pw337[2956] _—6”
A polynucleotide of the present invention has been identified as clone “pw337[2957] _—6”. pw337_—6 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pw337_—6 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pw337_—6 protein”).
The nucleotide sequence of pw337[2958] _—6 as presently determined is reported in SEQ ID NO:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pw337_—6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:34. Another potential pw337_—6 reading frame and predicted amino acid sequence is encoded by basepairs 648 to 908 of SEQ ID NO:33 and is reported in SEQ ID NO:238. The overlapping reading frames of SEQ ID NO:34 and SEQ ID NO:238 could be joined if a frameshift were introduced into the nucleotide sequence of SEQ ID NO:33 between position 645 and position 736.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pw337[2959] _—6 should be approximately 1000 bp.
The nucleotide sequence disclosed herein for pw337[2960] _—6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pw337_—6 demonstrated at least some similarity with sequences identified as AA682471 (zj18c02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 450626 3′, mRNA sequence), T20708 (Human gene signature HUMGS01925; standard; cDNA to mRNA), W24658 (zb63b05.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 308241 5′), and Z82192 (Homo sapiens DNA sequence from PAC 186O1 on chromosome 22). The predicted amino acid sequence disclosed herein for pw337_—6 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pw337_—6 protein demonstrated at least some similarity to the sequence identified as Z82192 (dJ186O1.1 [Homo sapiens]). Based upon sequence similarity, pw337_—6 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pw337_—6 protein sequence centered around amino acid 75 of SEQ ID NO:34. The nucleotide sequence of pw337_—6 indicates that it may contain one or more repetitive elements.
pw337[2961] _—6 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 22 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[2962] rd610 _—1”
A polynucleotide of the present invention has been identified as clone “[2963] rd610 _—1”. rd610 _—1 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd610 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rd610 _—1 protein”).
The nucleotide sequence of [2964] rd610 _—1 as presently determined is reported in SEQ ID NO:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd610 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:36.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [2965] clone rd610 _—1 should be approximately 1800 bp.
The nucleotide sequence disclosed herein for [2966] rd610 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd610 _—1 demonstrated at least some similarity with sequences identified as AA442056 (zw56f08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 774087 5′), AA992905 (ot92b06.s1 Soares_total_fetus_Nb2HF8_—9w Homo sapiens cDNA clone IMAGE 1624211 3′, mRNA sequence), D31767 (Human mRNA for KIAA0058 gene, complete cds), and T40090 (Human Serrate-1 (HJ1) cDNA; standard; cDNA). Based upon sequence similarity, rd610 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd610 _—1 protein sequence centered around amino acid of SEQ ID NO:36; amino acids 23 to 35 of SEQ ID NO:36 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 36.
rd610[2967] _—1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.
Clone “rd810[2968] _—6”
A polynucleotide of the present invention has been identified as clone “rd810[2969] _—6”. rd810_—6 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd810_—6 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rd810_—6 protein”).
The nucleotide sequence of rd810[2970] _—6 as presently determined is reported in SEQ ID NO:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd810_—6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:38. Amino acids 112 to 124 of SEQ ID NO:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 125. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rd810_—6 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd810[2971] _—6 should be approximately 850 bp.
The nucleotide sequence disclosed herein for rd810[2972] _—6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd810_—6 demonstrated at least some similarity with sequences identified as AA452718 (zx39d04.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 788839 5′, mRNA sequence), AA292888 (zt66c01.r1 Soares testis NHT Homo sapiens cDNA clone 727296 5′), and T23348 (Human gene signature HUMGS05169; standard; cDNA to mRNA). Based upon sequence similarity, rd810_—6 proteins and each similar protein or peptide may share at least some activity.
rd810[2973] _—6 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 23 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[2974] cf85 _—1”
A polynucleotide of the present invention has been identified as clone “[2975] cf85 _—1”. A cDNA clone was first isolated from a human adult placenta library cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate cf85 _—1 from a human adult brain cDNA library. cf85 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “cf85 _—1 protein”).
The nucleotide sequence of [2976] cf85 _—1 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cf85 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [2977] clone cf85 _—1 should be approximately 2000 bp.
The nucleotide sequence disclosed herein for [2978] cf85 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and PASTA search protocols. cf85 _—1 demonstrated at least some similarity with sequences identified as H50932 (yo35f03.r1 Homo sapiens cDNA clone 179933 5′), H51595 (yo35f03.s1 Homo sapiens cDNA clone 179933 3′), and T24664 (Human gene signature HUMGS06728; standard; cDNA to mRNA). Based upon sequence similarity, cf85 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the cf85 _—1 protein sequence, centered around amino acids 150, 195, and 220 of SEQ ID NO:40, respectively. The nucleotide sequence of cf85 _—1 indicates that it may contain an Alu repetitive element.
Clone “dd504[2979] _—18”
A polynucleotide of the present invention has been identified as clone “dd504[2980] _—18”. dd504_—18 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dd504_—18 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “dd504_—18 protein”).
The nucleotide sequence of dd504[2981] _—18 as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dd504_—18 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 134 to 146 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 147. Amino acids 7 to 19 of SEQ ID NO:42 are also a possible leader/signal sequence, with a predicted mature amino acid sequence beginning in that case at amino acid 20. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the dd504_—18 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dd504[2982] _—18 should be approximately 2000 bp.
The nucleotide sequence disclosed herein for dd504[2983] _—18 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dd504_—18 demonstrated at least some similarity with sequences identified as AA393779 (zt77f07.r1 Soares testis NHT Homo sapiens cDNA clone 728389 5′ similar to WP:F41E7.1 CE03301; mRNA sequence), AA429420 (zw51f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773595 5′ similar to WP W02B12.7 CE03767 KINENSIN-LIKE PROTEIN), AC002038 (*** SEQUENCING IN PROGRESS *** Human chromosome 16p12 BAC clone CIT987SK-101B6; HTGS phase 1, 1 unordered pieces; Homo sapiens chromosome 2 clone 101B6 from 2p11, complete sequence), H10672 (yl99g09.r1 Homo sapiens cDNA clone 46448 5′), and R59895 (yh07f12.r1 Homo sapiens cDNA clone 42477 5′). The predicted amino acid sequence disclosed herein for dd504_—18 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dd504_—18 protein demonstrated at least some similarity to sequences identified as AE000854 (Na⁺/H+-exchanging protein Na⁺/H+antiporter [Methanobacterium thermoautotrophicum]) and Z68106 (F41E7.1 [Caenorhabditis elegans]). Based upon sequence similarity, dd504_—18 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight potential transmembrane domains within the dd504_—18 protein sequence, centered around amino acids 20, 48, 118, 144, 191, 220, 268, and 326 of SEQ ID NO:42, respectively.
dd504[2984] _—18 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 36 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “np26[2985] _—3”
A polynucleotide of the present invention has been identified as clone “np26[2986] _—3”. np26_—3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. np26_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “np26_—3 protein”).
The nucleotide sequence of np26[2987] _—3 as presently determined is reported in SEQ ID NO:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the np26_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone np26[2988] _—3 should be approximately 3800 bp.
The nucleotide sequence disclosed herein for np26[2989] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. np26_—3 demonstrated at least some similarity with sequences identified as AA118527 (mo99d08.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone 567855 5′), AA284633 (zt15d04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:713191 3′, mRNA sequence), AA427620 (zw30d02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 770787 3′ similar to contains MER17.b1 MER17 repetitive element; mRNA sequence), and AA496955 (aa42f01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 823609 3′, mRNA sequence). The predicted amino acid sequence disclosed herein for np26_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted np26_—3 protein demonstrated at least some similarity to the sequence identified as M86752 (transformation-sensitive protein [Homo sapiens]). Based upon sequence similarity, np26_—3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the np26_—3 protein sequence centered around amino acid 146 of SEQ ID NO:44.
np26[2990] _—3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 63 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.
Clone “pm412[2991] _—12”
A polynucleotide of the present invention has been identified as clone “pm412[2992] _—12”. pm412_—12 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm412_—12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pm412_—12 protein”).
The nucleotide sequence of pm412[2993] _—12 as presently determined is reported in SEQ ID NO:45, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm412_—12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:46. Amino acids 607 to 619 of SEQ ID NO:46 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 620. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the pm412_—12 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm412[2994] _—12 should be approximately 4000 bp.
The nucleotide sequence disclosed herein for pm412[2995] _—12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm412_—12 demonstrated at least some similarity with sequences identified as AA176820 (zp34a12.s1 Stratagene muscle 937209 Homo sapiens cDNA clone 611326 3′), AA425762 (zw47f10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773227 3′ similar to TR:G285999 G285999 ORF, COMPLETE CDS), AA568580 (nm21a10.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1060794 similar to TR:G642306 G642306 HYPOTHETICAL 153.8 KD PROTEIN), AA610863 (np98h01.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE 1142449 similar to TR G285999 G285999 ORF, COMPLETE CDS), AA769312 (nz39f06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1290179 similar to TR Q15393 Q15393 ORF, COMPLETE CDS; mRNA sequence), D13642 (Human mRNA for KIAA0017 gene, complete cds), and T92977 (ye22e09.r1 Homo sapiens cDNA clone 118504 5′). The predicted amino acid sequence disclosed herein for pm412_—12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pm412_—12 protein demonstrated at least some similarity to sequences identified as AF043699 (ORF; similar to human UV-damaged DNA binding factor [C. elegans]), D13642 (KIAA0017 [Homo sapiens]), R72386 (XAP-1, part of the DNA repair complex), and X54413 (alpha1(IX) collagen precursor [Homo sapiens]). Based upon sequence similarity, pm412_—12 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the pm412_—12 protein sequence, centered around amino acids 277, 415, and 1060 of SEQ ID NO₄₆, respectively.
pm412[2996] _—12 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 119 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “pm421[2997] _—3”
A polynucleotide of the present invention has been identified as done “pm421[2998] _—3”. pm421_—3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm421_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pm421_—3 protein”).
The nucleotide sequence of pm421[2999] _—3 as presently determined is reported in SEQ ID NO:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm421_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Amino acids 10 to 22 of SEQ ID NO:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pm421_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm421[3000] _—3 should be approximately 2800 bp.
The nucleotide sequence disclosed herein for pm421[3001] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm421_—3 demonstrated at least some similarity with sequences identified as AA196485 (zq59a06.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 645874 3′), AA421712 (zu26g11.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 739172 5′, mRNA sequence), AC005026 (Homo sapiens clone GS489L14; HTGS phase 1, 3 unordered pieces), AC005028 (Homo sapiens clone GS539F22; HTGS phase 1, 1 unordered pieces), Q60534 (Human brain Expressed Sequence Tag EST02540; standard; cDNA), and R13985 (yf68h04.r1 Homo sapiens cDNA clone 27722 5′). Based upon sequence similarity, pm421_—3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the pm421_—3 protein sequence centered around amino acid 36 of SEQ ID NO:48.
Clone “[3002] pv6 _—1”
A polynucleotide of the present invention has been identified as clone “[3003] pv6 _—1”. pv6 _—1 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv6 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pv6 _—1 protein”).
The nucleotide sequence of [3004] pv6 _—1 as presently determined is reported in SEQ ID NO:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv6 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:50. Amino acids 39 to 51 of SEQ ID NO:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 52. Amino acids 8 to 20 of SEQ ID NO:50 are also a possible leader/signal sequence, with a predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the pv6 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3005] clone pv6 _—1 should be approximately 1800 bp.
The nucleotide sequence disclosed herein for [3006] pv6 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv6 _—1 demonstrated at least some similarity with sequences identified as B53192 (CIT-HSP-2009D9.TR CIT-HSP Homo sapiens genomic clone 2009D9, genomic survey sequence), R18429 (yg02g05.r1 Homo sapiens cDNA clone 31056 5′), T77089 (yc93b02.r1 Homo sapiens cDNA clone 23653 5′), and X89480 (S.scrofa mRNA for membrane protein). The predicted amino acid sequence disclosed herein for pv6 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pv6_—1 protein demonstrated at least some similarity to the sequence identified as X89480 (transmembrane protein [Sus scrofa]). Based upon sequence similarity, pv6 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pv6 _—1 protein sequence centered around amino acid 21 of SEQ ID NO:50.
Clone “qs14[3007] _—3”
A polynucleotide of the present invention has been identified as clone “qs14[3008] _—3”. A cDNA clone was isolated from a human whole embryo cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate qs14_—3 from a human fetal heart cDNA library. qs14_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qs14_—3 protein”).
The nucleotide sequence of qs14[3009] _—3 as presently determined is reported in SEQ ID NO:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qs14_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:52. Amino acids 15 to 27 of SEQ ID NO:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qs14_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qs14[3010] _—3 should be approximately 5000 bp.
The nucleotide sequence disclosed herein for qs14[3011] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qs14_—3 demonstrated at least some similarity with sequences identified as AA558554 (nl69g02.s1 NCI_CGAP_Pr4.1 Homo sapiens cDNA clone IMAGE 1045970 similar to TR G307329 G307329 PROTOCADHERIN 43), AB002343 (Human mRNA for KIAA0345 gene), and L43592 (Rattus norvegicus protocadherin-3 (pcdh3) mRNA, and translated products). The predicted amino acid sequence disclosed herein for qs14_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASIX search protocol. The predicted qs14_—3 protein demonstrated at least some similarity to sequences identified as AF029343 (protocadherin [Homo sapiens]), AF042192 (protocadherin [Xenopus]), AF052685 (protocadherin 43 [Homo sapiens]), L11373 (protocadherin 43 [Homo sapiens]), R49144 (Product of alternative splicing of human protocadherin-43 mRNA), and Y08715 (protocadherin [Mus musculus]). The cadherins are a family of calcium-binding membrane glycoproteins. Most cadherins are capable of acting as cell adhesion molecules (CAMs). Motif analysis of the predicted qs14_—3 protein also detects the ‘cadherins extracellular repeated domain signature’. Based upon sequence similarity, qs14_—3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the qs14_—3 protein sequence, one centered around amino acid 510 and another around amino acid 721 of SEQ ID NO:52.
qs14[3012] _—3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 132 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “qy338[3013] _—9”
A polynucleotide of the present invention has been identified as clone “qy338[3014] _—9”. qy338_—9 was isolated from a human adult blood (promyelocytic leukemia HL-60) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy338_—9 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qy338_—9 protein”).
The nucleotide sequence of qy338[3015] _—9 as presently determined is reported in SEQ ID NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy338_—9 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 144 to 156 of SEQ ID NO:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 157. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy338_—9 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qy338[3016] _—9 should be approximately 1300 bp.
The nucleotide sequence disclosed herein for qy338[3017] _—9 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy338_—9 demonstrated at least some similarity with sequences identified as AA205412 (zq66a09.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 646552 3′ similar to contains Alu repetitive element; contains element LTR1 repetitive element; mRNA), AA595068 (no40h10.s1 NCI_CGAP_Pr23 Homo sapiens cDNA clone IMAGE 1103203 similar to WP C27F2.4 CE01171 METHYLTRANSFERASE), AJ224442 (Homo sapiens mRNA for putative methyltransferase), and H40834 (yo05g09.r1 Homo sapiens cDNA clone 177088 5′). The predicted amino acid sequence disclosed herein for qy338_—9 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qy338_—9 protein demonstrated at least some similarity to sequences identified as AJ224442 (methyl-transferase [Homo sapiens]), U40419 (similar to S. cerevisiae gene YCR47C, putative 30.7 kd methyltransferase (SP YCT7_YEAST, P25627) [Caenorhabditis elegans]), and Z69240 (putative methyltransferase [S. cerevisiae]). Based upon sequence similarity, qy338_—9 proteins and each similar protein or peptide may share at least some activity.
qy338[3018] _—9 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 34 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3019] rc58 _—1”
A polynucleotide of the present invention has been identified as clone “[3020] rc58 _—1”. rc58 _—1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rc58 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rc58 _—1 protein”).
The nucleotide sequence of [3021] rc58 _—1 as presently determined is reported in SEQ ID NO:55, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rc58 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 2 to 14 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rc58 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3022] clone rc58 _—1 should be approximately 1500 bp.
The nucleotide sequence disclosed herein for [3023] rc58 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rc58 _—1 demonstrated at least some similarity with sequences identified as AA203670 (zx52d04.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 446119 5′ similar to gb X07868_mal PUTATIVE INSULIN-LIKE GROWTH FACTOR II ASSOClATED (HUMAN); mRNA sequence), AA878778 (oe80h01.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1417969 3′, mRNA sequence), and U96448 (Bos taurus cleavage and polyadenylation specificity factor 30 kDa subunit mRNA, complete cds). The predicted amino acid sequence disclosed herein for rc58 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rc58_—1 protein demonstrated at least some similarity to sequences identified as AF033201 (cleavage and polyadenylation specificity factor [Mus musculus]) and U96448 (cleavage and polyadenylation specificity factor 30 kDa subunit [Bos taurus]). Based upon sequence similarity, rc58 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the rc58 _—1 protein sequence centered around amino acid 53 of SEQ ID NO:56.
Clone “rd232[3024] _—5”
A polynucleotide of the present invention has been identified as clone “rd232[3025] _—5”. rd232_—5 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd232_—5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rd232_—5 protein”).
The nucleotide sequence of rd232[3026] _—5 as presently determined is reported in SEQ ID NO:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd232_—5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:58.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd232[3027] _—5 should be approximately 3800 bp.
The nucleotide sequence disclosed herein for rd232[3028] _—5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd232_—5 demonstrated at least some similarity with sequences identified as AA768103 (oc16g01.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1341072), AA831487 (oc61a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1354172 3′, mRNA sequence), and R57296 (F2616 Fetal heart Homo sapiens cDNA clone F2616 5′ end). The predicted amino acid sequence disclosed herein for rd232_—5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rd232_—5 protein demonstrated at least some similarity to the sequence identified as Z79755 (F43G9.2 [Caenorhabditis elegans]). Based upon sequence similarity, rd232_—5 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd232_—5 protein sequence centered around amino acid 225 of SEQ ID NO:58. The nucleotide sequence of rd232_—5 indicates that it may contain a simple AC repeat region.
Clone “ck213[3029] _—12”
A polynucleotide of the present invention has been identified as clone “ck213[3030] _—12”. ck213_—12 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ck213_—12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ck213_—12 protein”).
The nucleotide sequence of ck213[3031] _—12 as presently determined is reported in SEQ ID NO:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ck213_—12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:60.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ck213[3032] _—12 should be approximately 3500 bp.
The nucleotide sequence disclosed herein for ck213[3033] _—12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ck213_—12 demonstrated at least some similarity with sequences identified as AA062731 (zm01h03.s1 Stratagene corneal stroma (#937222) Homo sapiens cDNA clone 512885 3′ similar to TR:G1136390 G1136390 KIAA0164 PROTEIN, mRNA sequence), AA173803 (zp30f05.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 610977 3′, mRNA sequence), D79986 (Human mRNA for KIAA0164 protein gene, complete cds), and R01411 (ye77c11.s1 Homo sapiens cDNA clone 123764 3′). The predicted amino acid sequence disclosed herein for ck213_—12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ck213_—12 protein demonstrated at least some similarity to the sequence identified as D79986 (similar to human DNA-binding protein 5 [Homo sapiens], KIAA0164 protein [Homo sapiens], HUMKIAA04_—1). Based upon sequence similarity, ck213_—12 proteins and each similar protein or peptide may share at least some activity.
Clone “[3034] pg195 _—1”
A polynucleotide of the present invention has been identified as clone “[3035] pg195 _—1”. pg195 _—1 was isolated from a human adult thyroid cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pg195 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pg195 _—1 protein”).
The nucleotide sequence of [3036] pg195 _—1 as presently determined is reported in SEQ ID NO:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pg195 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:62.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3037] clone pg195 _—1 should be approximately 3300 bp.
The nucleotide sequence disclosed herein for [3038] pg195 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pg195 _—1 demonstrated at least some similarity with sequences identified as H72617 (yu02g10.r1 Homo sapiens cDNA clone 232674 5′) and W37280 (zc11a07.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321972 5′, mRNA sequence). The predicted amino acid sequence disclosed herein for pg195 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pg195_—1 protein demonstrated at least some similarity to the sequence identified as AF007270 (contains similarity to myosin heavy chain [Arabidopsis thaliana]). Based upon sequence similarity, pg195 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the pg195 _—1 protein sequence, one centered around amino acid 480 and another around amino acid 520 of SEQ ID NO:62. The nucleotide sequence of pg195 _—1 indicates that it may contain one or more repetitive sequences.
Clone “pw460[3039] _—5”
A polynucleotide of the present invention has been identified as clone “pw460[3040] _—5”. pw460_—5 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pw460_—5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pw460_—5 protein”).
The nucleotide sequence of pw460[3041] _—5 as presently determined is reported in SEQ ID NO:63, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pw460_—5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:64. Amino acids 17 to 29 of SEQ ID NO:64 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pw460_—5 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pw460[3042] _—5 should be approximately 1800 bp.
The nucleotide sequence disclosed herein for pw460[3043] _—5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pw460_—5 demonstrated at least some similarity with sequences identified as AA447258 (zw93e03.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 784540 5′, mRNA sequence), AA617801 (nq04f05.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE 1142913), AC002486 (Human BAC clone RG367O17 from 7p15-p21, complete sequence), AC004837 (human genomic DNA fragments), and H45347 (yo65h03.r1 Homo sapiens cDNA clone 182837 5′). Based upon sequence similarity, pw460_—5 proteins and each similar protein or peptide may share at least some activity.
Clone “[3044] qa136 _—1”
A polynucleotide of the present invention has been identified as clone “[3045] qa136 _—1”. qa136 _—1 was isolated from a human adult cartilage (chondrosarcoma HTB-94 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qa136 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qa136 _—1 protein”).
The nucleotide sequence of [3046] qa136 _—1 as presently determined is reported in SEQ ID NO:65. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qa136 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:66. Amino acids 15 to 27 of SEQ ID NO:66 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qa136 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3047] clone qa136 _—1 should be approximately 1600 bp.
The nucleotide sequence disclosed herein for [3048] qa136 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qa136 _—1 demonstrated at least some similarity with sequences identified as AA758023 (ah67g02.s1 Soares testis NHT Homo sapiens cDNA done 1320722 3′, mRNA sequence), R69911 (yi47c02.r1 Homo sapiens cDNA clone 142370 5′), and T21835 (Human gene signature HUMGS03376; standard; cDNA to mRNA). Based upon sequence similarity, qa136 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the qa136 _—1 protein sequence, centered around amino acids 59, 136, 171, 201, and 268 of SEQ ID NO:66, respectively.
qa136[3049] _—1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3050] qy1261 _—2”
A polynucleotide of the present invention has been identified as clone “[3051] qy1261 _—2”.
qy1261[3052] _—2 was isolated from a human adult blood (promyelocytic Leukemia HL-60) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy1261 _—2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qy1261 _—2 protein”).
The nucleotide sequence of [3053] qy1261 _—2 as presently determined is reported in SEQ ID NO:67, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy1261 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:68. Amino acids 100 to 112 of SEQ ID NO:68 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 113. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy1261 _—2 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3054] clone qy1261 _—2 should be approximately 2500 bp.
The nucleotide sequence disclosed herein for [3055] qy1261 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy1261 _—2 demonstrated at least some similarity with sequences identified as AA076472 (zm91b06.r1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 545267 5′), AA115700 (zl87g10.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 511650 5′, mRNA sequence), and AA190522 (zp85e07.r1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 627012 5′). The predicted amino acid sequence disclosed herein for qy1261 _—2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qy1261_—2 protein demonstrated at least some similarity to the sequence identified as U49082 (transporter protein [Homo sapiens]). Based upon sequence similarity, qy1261 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts ten additional potential transmembrane domains within the qy1261 _—2 protein sequence, centered around amino acids 80, 157, 203, 227, 286, 322, 365, 403, 426, and 462 of SEQ ID NO:68. The nucleotide sequence of qy1261 _—2 indicates that it may contain one or more Alu repeat sequences.
Clone “rd432[3056] _—4”
A polynucleotide of the present invention has been identified as clone “rd432[3057] _—4”. rd432_—4 was isolated from a human kidney (293 embryonal carcinoma cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd432_—4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rd432_—4 protein”).
The nucleotide sequence of rd432[3058] _—4 as presently determined is reported in SEQ ID NO:69, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd432_—4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:70.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd432[3059] _—4 should be approximately 2200 bp.
The nucleotide sequence disclosed herein for rd432[3060] _—4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd432_—4 demonstrated at least some similarity with sequences identified as AA662913 (nu92b03.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1218125, mRNA sequence). Based upon sequence similarity, rd432_—4 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd432_—4 protein sequence, which includes amino acids 102-122 of SEQ ID NO:70. The nucleotide sequence of rd432_—4 indicates that it may contain one or more Alu repetitive elements.
rd432[3061] _—4 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 18 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “rb789[3062] _—14”
A polynucleotide of the present invention has been identified as clone “rb789[3063] _—14”. rb789_—14 was isolated from a human kidney (293 embryonal carcinoma line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rb789_—14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rb789_—14 protein”).
The nucleotide sequence of rb789[3064] _—14 as presently determined is reported in SEQ ID NO:71, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rb789_—14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:72. Amino acids 9 to 21 of SEQ ID NO:72 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rb789_—14 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rb789[3065] _—14 should be approximately 2300 bp.
The nucleotide sequence disclosed herein for rb789[3066] _—14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rb789_—14 demonstrated at least some similarity with sequences identified as AL008582 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 223H9; HTGS phase 1), AL022393 (Homo sapiens DNA sequence from P1 p373c6 on chromosome 6p21.31-21.33. Contains zinc finger proteins, pseudogenes, ESTs and STS), N28823 (yx71f11.r1 Homo sapiens cDNA clone 267213 5′), and Q60944 (Human brain Expressed Sequence Tag EST01025; standard; DNA). Based upon sequence similarity, rb789_—14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the rb789_—14 protein sequence, one centered around amino acid 30 and another around amino acid 75 of SEQ ID NO:72.
Clone “[3067] yd137 _—1”
A polynucleotide of the present invention has been identified as clone “[3068] yd137 _—1”. yd137 _—1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yd137 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “yd137 _—1 protein”).
The nucleotide sequence of [3069] yd137 _—1 as presently determined is reported in SEQ ID NO:73, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yd137 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:74. Amino acids 27 to 39 of SEQ ID NO:74 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 40. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yd137 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3070] clone yd137 _—1 should be approximately 789 bp.
The nucleotide sequence disclosed herein for [3071] yd137 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yd137 _—1 demonstrated at least some similarity with sequences identified as AI015619 (ov29g02.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1638770 3′ similar to WP:C34B2.10 CE16898; mRNA sequence). The predicted amino acid sequence disclosed herein for yd137 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted yd137_—1 protein demonstrated at least some similarity to the sequence identified as AF043693 (Caenorhabditis elegans cosmid C34B2). Based upon sequence similarity, yd137 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the yd137 _—1 protein sequence, one centered around amino acid 30 and another around amino acid 55 of SEQ ID NO:74.
Clone “[3072] yd218 _—1”
A polynucleotide of the present invention has been identified as clone “[3073] yd218 _—1”. yd218 _—1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yd218 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “yd218 _—1 protein”).
The nucleotide sequence of [3074] yd218 _—1 as presently determined is reported in SEQ ID NO:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yd218 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:76. Amino acids 2 to 14 of SEQ ID NO:76 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yd218 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3075] clone yd218 _—1 should be approximately 900 bp.
The nucleotide sequence disclosed herein for [3076] yd218 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yd218 _—1 demonstrated at least some similarity with sequences identified as AA402818 (zu55f06.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 741923 3′, mRNA sequence) and AI150344 (qf35b11.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1751997 3′, mRNA sequence). Based upon sequence similarity, yd218 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the yd218 _—1 protein sequence, one centered around amino acid 66 and another around amino acid 100 of SEQ ID NO:76.
yd218[3077] _—1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 15 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3078] ye11 _—1”
A polynucleotide of the present invention has been identified as clone “[3079] ye11 _—1”. ye11 _—1 was isolated from a humna fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye11 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ye11 _—1 protein”).
The nucleotide sequence of [3080] ye11 _—1 as presently determined is reported in SEQ ID NO:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye11 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:78.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3081] clone ye11 _—1 should be approximately 2700 bp.
The nucleotide sequence disclosed herein for [3082] ye11 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye11 _—1 demonstrated at least some similarity with sequences identified as AC005082 (*** SEQUENCING IN PROGRESS *** Homo sapiens clone RG271G13; HTGS phase 1, 7 unordered pieces). The predicted amino acid sequence disclosed herein for ye11 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ye11_—1 protein demonstrated at least some similarity to sequences identified as AF059569 (actin binding protein MAYVEN [Homo sapiens]) and R94386 (Human neural cell protein marker RR/B). MAYVEN is an actin-binding protein expressed in brain. Hidden markov model analysis reveals the presence of a BTB (BR-c/Ttk) domain in the predicted ye11_—1 protein. BTB domains are characteristic of certain bacterial membrane transport proteins. The MAYVEN protein is thought to contain a similar BTB motif, an indication that ye11 _—1 and MAYVEN may share a similar function. Based upon sequence similarity, ye11 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the ye11 _—1 protein sequence, one centered around amino acid 20 and another around amino acid 480 of SEQ ID NO:78.
ye11[3083] _—1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 57 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3084] ye72 _—1”
A polynucleotide of the present invention has been identified as clone “[3085] ye72 _—1”. ye72 _—1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye72 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ye72 _—1 protein”).
The nucleotide sequence of [3086] ye72 _—1 as presently determined is reported in SEQ ID NO:79, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye72 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:80. Amino acids 24 to 36 of SEQ ID NO:80 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 37. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ye72 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3087] clone ye72 _—1 should be approximately 2261 bp.
The nucleotide sequence disclosed herein for [3088] ye72 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye72 _—1 demonstrated at least some similarity with sequences identified as AA968450 (op49d06.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1580171 3′, mRNA sequence). The predicted amino acid sequence disclosed herein for ye72 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ye72_—1 protein demonstrated at least some similarity to sequences identified as U16258 (I kappa BR [Homo sapiens]) and W15483 (Human P28). Based upon sequence similarity, ye72 _—1 proteins and each similar protein or peptide may share at least some activity. Hidden markov model analysis reveals the presence of three ankyrin repeats in the predicted ye72_—1 protein at amino acids 273 to 306, 307 to 339, and 341 to 373 of SEQ ID NO:80. The ankyrin 33-residue repeating motif, an L-shaped structure with protruding beta-hairpin tips, mediates specific macromolecular interactions with cytoskeletal, membrane, and regulatory proteins. The TopPredII computer program predicts an additional potential transmembrane domain within the ye72 _—1 protein sequence centered around amino acid 140 of SEQ ID NO:80.
Clone “[3089] ye78 _—1”
A polynucleotide of the present invention has been identified as clone “[3090] ye78 _—1”. ye78 _—1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye78 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ye78 _—1 protein”).
The nucleotide sequence of [3091] ye78 _—1 as presently determined is reported in SEQ ID NO:81, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye78 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:82. Amino acids 78 to 90 of SEQ ID NO:82 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 91. Amino acids 42 to 54 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of leader/signal sequences, both of these predicted and possible leader sequences are likely to act as a transmembrane domain should either of them not be separated from the remainder of the ye78 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3092] clone ye78 _—1 should be approximately 2654 bp.
The nucleotide sequence disclosed herein for [3093] ye78 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye78 _—1 demonstrated at least some similarity with sequences identified as AA522797 (ni40c10.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE:979314, mRNA sequence). Based upon sequence similarity, ye78 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the ye78 _—1 protein sequence, centered around amino acids 55, 75, 84, and 480 of SEQ ID NO:12, respectively.
Clone “[3094] ye90 _—1”
A polynucleotide of the present invention has been identified as clone “ye901”. [3095] ye90 _—1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye90 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ye90 _—1 protein”).
The nucleotide sequence of [3096] ye90 _—1 as presently determined is reported in SEQ ID NO:83, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino add sequence of the ye90 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:84. Amino acids 7 to 19 of SEQ ID NO:84 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ye90 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3097] clone ye90 _—1 should be approximately 1505 bp.
The nucleotide sequence disclosed herein for [3098] ye90 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye90 _—1 demonstrated at least some similarity with sequences identified as AI079268 (oz32f06.x1 Soares_total_fetus_Nb2HF8_—9w Homo sapiens cDNA clone IMAGE:1677059 3′, mRNA sequence) and T25543 (Human gene signature HUMGS07715, standard; cDNA to mRNA). Based upon sequence similarity, ye90 _—1 proteins and each similar protein or peptide may share at least some activity. Motifs analysis reveals the presence of a neutral zinc metallopeptidases, zinc-binding region signature beginning around amino acid residue 236 of SEQ ID NO:84; some known secreted proteins have this motif. The TopPredII computer program predicts two additional potential transmembrane domains within the ye90 _—1 protein sequence, one centred around amino acid 195 and another around amino acid 300 of SEQ ID NO:84.
Clone “[3099] yi62 _—1”
A polynucleotide of the present invention has been identified as clone “[3100] yi62 _—1”. yi62 _—1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yi62 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “yi62 _—1 protein”).
The nucleotide sequence of [3101] yi62 _—1 as presently determined is reported in SEQ ID NO:85, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yi62 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:86. Amino acids 2 to 14 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yi62 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3102] clone yi62 _—1 should be approximately 1240 bp.
The nucleotide sequence disclosed herein for [3103] yi62 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yi62 _—1 demonstrated at least some similarity with sequences identified as R57572 (F3589 Fetal heart Homo sapiens cDNA clone F3589 5′ end, mRNA sequence). Based upon sequence similarity, yi62 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the yi62 _—1 protein sequence, centered around amino acids 15, 75, 100, and 125 of SEQ ID NO:86, respectively.
Clone “[3104] yk78 _—1”
A polynucleotide of the present invention has been identified as clone “[3105] yk78 _—1”. yk78 _—1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yk78 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “yk78 _—1 protein”).
The nucleotide sequence of [3106] yk78 _—1 as presently determined is reported in SEQ ID NO:87, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yk78 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:88. Amino acids 57 to 69 of SEQ ID NO:88 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 70. Amino acids 7 to 19 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of leader/signal sequences, both of these predicted and possible leader sequences are likely to act as a transmembrane domain should either of them not be separated from the remainder of the yk78 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3107] clone yk78 _—1 should be approximately 1088 bp.
The nucleotide sequence disclosed herein for [3108] yk78 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yk78 _—1 demonstrated at least some similarity with sequences identified as AC004921 (*** SEQUENCING IN PROGRESS *** Homo sapiens clone DJ0899E09; HTGS phase 1, 11 unordered pieces). Based upon sequence similarity, yk78 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the yk78 _—1 protein sequence, one centered around amino acid 20 and another around amino acids 60 of SEQ ID NO:88.
Clone “[3109] yk251 _—1”
A polynucleotide of the present invention has been identified as clone “[3110] yk251 _—1”. yk251 _—1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yk251 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “yk251 _—1 protein”).
The nucleotide sequence of [3111] yk251 _—1 as presently determined is reported in SEQ ID NO:89, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yk251 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:90. Amino acids 17 to 29 of SEQ ID NO:90 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yk251 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3112] clone yk251 _—1 should be approximately 2558 bp.
The nucleotide sequence disclosed herein for [3113] yk251 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the databases. The TopPredII computer program predicts a potential transmembrane domain within the yk251 _—1 protein sequence centered, around amino acid 20 of SEQ ID NO:90. The nucleotide sequence of yk251 _—1 indicates that it may contain Alu and SVA repetitive elements.
Clone “[3114] yt14 _—1”
A polynucleotide of the present invention has been identified as clone “[3115] yt14 _—1”. yt14 _—1 was isolated from a human adult retina (WERI-Rb1 retinoblastoma line) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yt14 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “yt14 _—1 protein”).
The nucleotide sequence of [3116] yt14 _—1 as presently determined is reported in SEQ ID NO:91, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yt14 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:92. Amino acids 1 to 9 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 10. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yk251 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3117] clone yt14 _—1 should be approximately 2429 bp.
The nucleotide sequence disclosed herein for [3118] yt14 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yt14 _—1 demonstrated at least some similarity with sequences identified as W07167 (za93b12.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 300095 5′, mRNA sequence). The predicted amino acid sequence disclosed herein for yt14 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted yt14_—1 protein demonstrated at least some similarity to the sequence identified as AF002196 (weak similarity to Bacillus and Pseudomonas probable glucarate transporters (GI 709999 and PIR S27616) [Caenorhabditis elegans]). Based upon sequence similarity, yt14 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts six potential transmembrane domains within the yt14 _—1 protein sequence, centered around amino acids 10, 40, 65, 90, 130, and 160 of SEQ ID NO:92, respectively. The nucleotide sequence of yt14 _—1 indicates that it may contain Alu and L1 repetitive elements.
Clone “bf157[3119] _—16”
A polynucleotide of the present invention has been identified as clone “bf157[3120] _—16”. bf157_—16 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bf157_—16 is a full-length done, including the entire coding sequence of a novel protein (also referred to herein as “bf157_—16 protein”).
The nucleotide sequence of bf157[3121] _—16 as presently determined is reported in SEQ ID NO:93, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bf157_—16 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:94.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bf157[3122] _—16 should be approximately 3480 bp.
The nucleotide sequence disclosed herein for bf157[3123] _—16 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bf157_—16 demonstrated at least some similarity with sequences identified as AA186595 (zo71g04.r1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 592374 5′ similar to WP C16A3.3 CE04004 HUMAN ALPHA-FETOPROTEIN ENHANCER-BINDING PROTEIN), AA630405 (ac09b05.s1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 855921 3′ similar to WP C16A3.3 CE04004 HUMAN ALPHA-FETOPROTEIN ENHANCER-BINDING PROTEIN; mRNA sequence), AF075104
([3124] Homo sapiens full length insert cDNA YR39H06), H49655 (yq20h07.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 274428 3′), Z28494 (H. sapiens partial cDNA sequence; clone 22G07; version 1; strand(−), single read), Z56794 (H.sapiens CpG island DNA genomic Mse1 fragment, clone), and Z64553 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 139f5, forward read cpg139f5.ft1a). The predicted amino acid sequence disclosed herein for bf157_—16 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bf157_—16 protein demonstrated at least some similarity to sequences identified as R23962 (AFP-1. DNA encoding protein binding to alpha-fetoprotein gene enhancer-useful for prodn. of biological active protein), and U41534 (similar to yeast hypothetical protein (SP:YB9M YEAST, P38344); similar to human alpha-fetoprotein enhancer-binding protein (PIR:A41948) [Caenorhabditis elegans]). Based upon sequence similarity, bf157_—16 proteins and each similar protein or peptide may share at least some activity. Hidden Markov model and motifs analyses have revealed the presence of the following protein domains in the predicted bf157_—16 protein: four Zinc finger, C₂H2 type, domains at amino acids 4 to 28, 67 to 91, 252 to 275, and 303 to 330 of SEQ ID NO:94; and a D-isomer-specific 2-hydroxyacid dehydrogenases signature at residues 119 to 131 of SEQ ID NO:94. A number of NAD-dependent 2-hydroxyacid dehydrogenases, with at least some specificity for the D-isomer of their substrate, have been shown to be functionally and structurally related. Clone bf157_—16 appears to encode a novel protein which may have NAD-dependent 2-hydroxyacid dehydrogenase activity.
bf157[3125] _—16 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 16 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3126] bk343 _—2”
A polynucleotide of the present invention has been identified as clone “[3127] bk343 _—2”. bk343 _—2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bk343 _—2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “bk343 _—2 protein”).
The nucleotide sequence of [3128] bk343 _—2 as presently determined is reported in SEQ ID NO:95, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bk343 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:96.
Another possible reading frame within the [3129] bk343 _—2 clone extends from nucleotide 45 to nucleotide 188 of SEQ ID NO:95, and encodes the amino acid sequence reported in SEQ ID NO:239. Amino acids 5 to 17 of SEQ ID NO:239 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO:239.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3130] clone bk343 _—2 should be approximately 1600 bp.
The nucleotide sequence disclosed herein for [3131] bk343 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bk343 _—2 demonstrated at least some similarity with sequences identified as AA156969 (zo51d05.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 590409 5′), AA947938 (oe60c08.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1416014 3′, mRNA sequence), N31147 (yx52g05.r1 Homo sapiens cDNA clone 265400 5′), N42759 (yy22a09.r1 Homo sapiens cDNA clone 271960 5′), N47537 (yy90h10.s1 Homo sapiens cDNA clone 280867 3′), R68913 (yi43b04.r1 Homo sapiens cDNA done 141967 5′), T24885 (Human gene signature HUMGS06991; standard; cDNA to mRNA), and T30099 (EST112339 Homo sapiens cDNA 5′ end similar to None). The predicted amino acid sequence disclosed herein for bk343 _—2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bk343_—2 protein demonstrated at least some similarity to sequences identified as Z72508 (F28H7.4 [Caenorhabditis elegans]) and Z78417 (C35C5.3 [Caenorhabditis elegans]). Based upon sequence similarity, bk343 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the bk343 _—2 protein sequence centered around amino acid 36 of SEQ ID NO:96.
Clone “[3132] cd205 _—2”
A polynucleotide of the present invention has been identified as clone “[3133] cd205 _—2”. cd205 _—2 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cd205 _—2 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “cd205 _—2 protein”).
The nucleotide sequence of [3134] cd205 _—2 as presently determined is reported in SEQ ID NO:97, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cd205 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:98. Amino acids 92 to 104 of SEQ ID NO:98 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 105. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the cd205 _—2 protein.
Another possible reading frame within the [3135] cd205 _—2 clone extends from nucleotide 59 to nucleotide 478 of SEQ ID NO:97, and encodes the amino acid sequence reported in SEQ ID NO:240. The open reading frames encoding the amino acid sequences of SEQ ID NO:98 and SEQ ID NO:240 could be joined if one or more frame shifts were made in the nucleotide sequence of SEQ ID NO:97.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3136] clone cd205 _—2 should be approximately 1300 bp.
The nucleotide sequence disclosed herein for [3137] cd205 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cd205 _—2 demonstrated at least some similarity with sequences identified as AA053543 (zl71f10.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 510091 5′ similar to gb:M77830 DESMOPLAKIN I AND II (HUMAN)), AC005332 (Homo sapiens chromosome 17, clone hRPK.147_L_—13, complete sequence), N84944 (j1677F Homo sapiens cDNA clone J1677 5′ similar to CHROMOSOME 4 (CLONE P4-661) STS4-563), N86274 (J7481F Fetal heart, Lambda ZAP Express Homo sapiens cDNA clone J7481 5′ similar to CHROMOSOME 4 (CLONE P4-661) STS4-563), W68823 (zd37f04.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 342847 5′, mRNA sequence), and Z54387 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 10g3, reverse read cpg10g3.rt1a). Based upon sequence similarity, cd205 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the cd205 _—2 protein sequence located around amino acid 105 of SEQ ID NO:98. Clone “cw1292_—8”
A polynucleotide of the present invention has been identified as clone “cw1292[3138] _—8”. cw1292_—8 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cw1292_—8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “cw1292_—8 protein”).
The nucleotide sequence of cw1292[3139] _—8 as presently determined is reported in SEQ ID NO:99, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cw1292_—8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:100. Amino acids 18 to 30 of SEQ ID NO:100 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 31. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the cw1292_—8 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cw1292[3140] _—8 should be approximately 1100 bp.
The nucleotide sequence disclosed herein for cw1292[3141] _—8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cw1292_—8 demonstrated at least some similarity with sequences identified as AA017976 (mh46h10.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus), AA423855 (zv79c04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 759846 3′), AA626784 (ad09f08.s1 Soares NbHFB Homo sapiens cDNA clone 877767 3′, mRNA sequence), H23387 (ym57f05.r1 Homo sapiens cDNA clone 52337 5′), H78534 (yu13d06.r1 Homo sapiens cDNA clone 233675 5′), H79021 (yu13d06.s1 Homo sapiens cDNA clone 233675 3′), R44807 (yg23g06.s1 Homo sapiens cDNA clone 33217 3′), T24772 (Human gene signature HUMGS06848; standard; cDNA to mRNA), T97424 (ye53h08.r1 Homo sapiens cDNA clone 121503 5′), and Z44597 (H. sapiens partial cDNA sequence; clone c-25a05). The predicted amino acid sequence disclosed herein for cw1292_—8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted cw1292_—8 protein demonstrated at least some similarity to the sequence identified as M33521 (HLA-B-associated transcript 3 (BAT3) [Homo]). Based upon sequence similarity, cw1292_—8 proteins and each similar protein or peptide may share at least some activity.
Clone “[3142] cw1475 _—2”
A polynucleotide of the present invention has been identified as clone “[3143] cw1475 _—2”. cw1475 _—2 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cw1475 _—2 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “cw1475 _—2 protein”).
The nucleotide sequence of [3144] cw1475 _—2 as presently determined is reported in SEQ ID NO:101, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cw1475 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:102.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3145] clone cw1475 _—2 should be approximately 2800 bp.
The nucleotide sequence disclosed herein for [3146] cw1475 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cw1475 _—2 demonstrated at least some similarity with sequences identified as AA527429 (ng41a10.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:937338, mRNA sequence), AD000092 (Homo sapiens DNA from chromosome 19p13.²cosmids R31240, R30272 and R28549 containing the EKLF, GCDH, CRTC, and RAD23A genes, genomic sequence), H98508 (yv90f08.r1 Homo sapiens cDNA clone 250023 5′), N25554 (yx76f08.s1 Homo sapiens cDNA clone 267687 3′), N50970 (yy94b06.s1 Homo sapiens cDNA clone 281171 3′), N81188 (yw36g06.r1 Homo sapiens cDNA clone 254362 5′), R32569 (yh54g03.r1 Homo sapiens cDNA clone 133588 5′), R81017 (yi94g02.r1 Homo sapiens cDNA clone 146930 5′ similar to contains Alu repetitive element; contains MER30 repetitive element), T06537 (EST04426 Homo sapiens cDNA clone HFBDU83 similar to EST containing Alu repeat), T31594 (Probe (BLUR11) for Alu repeat sequence), and W30895 (zb78e12.r1 Soares senescent fibroblasts NbHSF Homo). Based upon sequence similarity, cw1475 _—2 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of cw1475 _—2 indicates that it may contain noe or more of the following repetitive elements: Alu, SVA.
Clone “dd428[3147] _—4”
A polynucleotide of the present invention has been identified as clone “dd428[3148] _—4”. dd428_—4 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dd428_—4 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “dd428_—4 protein”).
The nucleotide sequence of dd428[3149] _—4 as presently determined is reported in SEQ ID NO:103, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dd428_—4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:104.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dd428[3150] _—4 should be approximately 1500 bp.
The nucleotide sequence disclosed herein for dd428[3151] _—4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dd428_—4 demonstrated at least some similarity with sequences identified as AC000057 (Human BAC clone RG067M09 from 7q21-7q22; HTGS phase 3, complete sequence), AC005500 (complete sequence), L27428 (Human L1 putative reverse transcriptase gene insertion in hamster, 3′end), T86176 (yd78c11.s1 Homo sapiens cDNA clone 114356 3′ similar to gb L25879 EPOXIDE HYDROLASE (HUMAN); contains L1 repetitive element), X61307 (Staphylococcus aureus spa gene for protein A), and Z69647 (Human DNA sequence from cosmid E118G4, maps to 10cen and 11q13-q14). Based upon sequence similarity, dd428_—4 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dd428_—4 indicates that it may contain L1 repeat sequences.
Clone “dh1073 12”[3152]
A polynucleotide of the present invention has been identified as clone “dh1073[3153] _—12”. dh1073_—12 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dh1073_—12 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “dh1073_—12 protein”).
The nucleotide sequence of dh1073[3154] _—12 as presently determined is reported in SEQ ID NO:105, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dh1073_—12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:106.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dh1073[3155] _—12 should be approximately 2400 bp.
The nucleotide sequence disclosed herein for dh1073[3156] _—12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dh1073_—12 demonstrated at least some similarity with sequences identified as AA257983 (zs35h03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 687221 3′ similar to TR G666014 G666014 SA SA GENE PRODUCT, COMPLETE CDS PRECURSOR; mRNA sequence), AA526325 (ni59g06.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone 981178 similar to contains Alu repetitive element), AF001549 (Human Chromosome 16 BAC done CIT987SK-A-270G1, complete sequence), N57823 (yv59e04.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 247038 3′), and N68408 (za13c05.s1 Homo sapiens cDNA clone 292424 3′). The predicted amino acid sequence disclosed herein for cw1292_—8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dh1073_—12 protein demonstrated at least some similarity to the sequence identified as AC003034 (Gene with similarity to rat kidney-specific (KS) gene [Homo sapiens]). Based upon sequence similarity, dh1073_—12 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dh1073_—12 indicates that it may contain an Alu repetitive element.
Clone “[3157] dw78 _—1”
A polynucleotide of the present invention has been identified as clone “[3158] dw78 _—1”. dw78 _—1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dw78 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “dw78 _—1 protein”).
The nucleotide sequence of [3159] dw78 _—1 as presently determined is reported in SEQ ID NO:107, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dw78 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:108.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3160] clone dw78 _—1 should be approximately 1400 bp.
The nucleotide sequence disclosed herein for [3161] dw78 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dw78 _—1 demonstrated at least some similarity with sequences identified as AA807622 (nv65g11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1234724, mRNA sequence), AF086326 (Homo sapiens full length insert cDNA clone ZD54A02), D37980 (Dictyostelium discoidium DDCOF1 gene for cofilin, complete cds (exon1-2)), H26207 (yl53c04.r1 Homo sapiens cDNA clone 161958 5′), N72717 (za47h03.s1 Homo sapiens cDNA clone 295733 3′ similar to contains Alu repetitive element; contains element L1 repetitive element), T23963 (Human gene signature HUMGS05917; standard; cDNA to mRNA), U14567 (***ALU WARNING Human Alu-J subfamily consensus sequence), U43572 (Human alpha-N-acetylglucosamimidase (NAGLU) gene, complete cds), W42787 (zc25a04.s1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323310 3′), and W73472 (zd54a02.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344426 3′, mRNA sequence). The predicted amino acid sequence disclosed herein for dw78 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dw78_—1 protein demonstrated at least some similarity to the sequence identified as D32202 (alpha 1C adrenergic receptor isoform 2 [Homo sapiens]). Based upon sequence similarity, dw78 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the dw78 _—1 protein sequence, one centered around amino acid 45 and another around amino acid 93 of SEQ ID NO:108. The nucleotide sequence of dw78 _—1 indicates that it may contain an Alu repetitive element.
Clone “fh116[3162] _—11”
A polynucleotide of the present invention has been identified as clone “fh116[3163] _—11”. fh116_—11 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fh116_—11 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “fh116_—11 protein”).
The nucleotide sequence of fh116[3164] _—11 as presently determined is reported in SEQ ID NO:109, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fh116_—11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:110.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fh116[3165] _—11 should be approximately 1200 bp.
The nucleotide sequence disclosed herein for fh116[3166] _—11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fh116_—11 demonstrated at least some similarity with sequences identified as AA054185 (zf51c06.r1 Soares retina N2b4HR Homo sapiens cDNA clone 380458 5′), AA057975 (mj57b02.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 480171 5′ similar to WP:F57A8.2 CE05983), AA128902 (zn90a05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565424 3′), AA426021 (zw49h09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773441 3′), AA505926 (nh98g03.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone 966580), A1079540 (oz04e08.x1 Soares_fetal_liver spleen 1NFLS_Sl Homo sapiens cDNA clone IMAGE:1674374 3′ similar to WP:F57A8.2 CE05983; mRNA sequence), H68794 (yr91h09.s1 Homo sapiens cDNA clone 212705 3′), H86659 (yt02c04.r1 Homo sapiens cDNA clone 223110 5′), T24554 (Human gene signature HUMGS06604; standard; cDNA to mRNA), U96490 (Rattus norvegicus liver mRNA, complete cds), and W00635 (yy71d12.r1 Homo sapiens cDNA clone 278999 5′ similar to contains element PTR5 repetitive element). The predicted amino acid sequence disclosed herein for fh116_—11 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fh116_—11 protein demonstrated at least some similarity to sequences identified as AF004876 (54TMp [Homo sapiens]), U96490 (unknown [Rattus norvegicus]), and Z70781 (F57A8.2 [Caenorhabditis elegans]). Based upon sequence similarity, fh116_—11 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five potential transmembrane domains within the fh116_—11 protein sequence, centered around amino acids 35 to 49, 136, 171, 215, and 270 of SEQ ID NO:110, respectively.
fh116[3167] _—11 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 28 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “f356 14”[3168]
A polynucleotide of the present invention has been identified as clone “fy356[3169] _—14”. fy356_—14 was isolated from a human fetal placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fy356_—14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “fy356_—14 protein”).
The nucleotide sequence of fy356[3170] _—14 as presently determined is reported in SEQ ID NO:111, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fy356_—14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:112. Amino acids 385 to 397 of SEQ ID NO:112 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 398. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the fy356_—14 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fy356[3171] _—14 should be approximately 3700 bp.
The nucleotide sequence disclosed herein for fy356[3172] _—14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fy356_—14 demonstrated at least some similarity with sequences identified as AA017639 (ze38c05.r1 Soares retina N2b4HR Homo sapiens cDNA clone 361256 5′ similar to PIR S55385 S55385 PEA-15 protein—mouse), AA181529 (zp51f07.s1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 612997 3′), AA687129 (nv63d03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1234469), AA811277 (ob68e06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1336546, mRNA sequence), N53623 (yz04e01.r1 Homo sapiens cDNA clone 282072 5′), T25935 (Human gene signature HUMGS08167; standard; cDNA to mRNA), T24538 (Human gene signature HUMGS06585; standard; cDNA to mRNA), and X86809 (H.sapiens mRNA for major astrocytic phosphoprotein PEA-15). The predicted amino acid sequence disclosed herein for fy356_—14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fy356_—14 protein demonstrated at least some similarity to the sequence identified as X86809 (PEA-15 gene product [Homo sapiens]). Based upon sequence similarity, fy356_—14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the fy356_—14 protein sequence, centered around amino acid 398 of SEQ ID NO:112. Clone “iw66 _—1”
A polynucleotide of the present invention has been identified as clone “[3173] iw66 _—1”. iw66 _—1 was isolated from a human adult retina (WERI-Rb1 retinoblastoma line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. iw66 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “iw66 _—1 protein”).
The nucleotide sequence of [3174] iw66 _—1 as presently determined is reported in SEQ ID NO:113, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the iw66 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:114. Amino acids 9 to 21 of SEQ ID NO:114 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the iw66 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3175] clone iw66 _—1 should be approximately 1450 bp.
The nucleotide sequence disclosed herein for [3176] iw66 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. iw66 _—1 demonstrated at least some similarity with sequences identified as AA216917 (mv75h11.r1 Soares mouse 3NME12 5 Mus musculus cDNA clone 660933 5′), AA339406 (EST44484 Fetal brain I Homo sapiens cDNA 5′ end), AI275861 (ql68b12.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:1877471 3′, mRNA sequence), Q61257 (Human brain Expressed Sequence Tag EST01278; standard; DNA), R89651 (ym97c08.r1 Homo sapiens cDNA clone 166862 5′), W53584 (md55f06.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 372323 5′), and Z60886 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 38a8, reverse read cpg38a8.rt1a). The predicted amino acid sequence disclosed herein for iw66 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted iw66_—1 protein demonstrated at least some similarity to sequences identified as AF004874 (latent TGF-beta binding protein-2 [Mus musculus]), L29029 (amino acid feature Rod protein domain, aa 266 468; amino acid feature globular protein domain, aa 32 . . . 265 [Chlamydomonas reinhardtii]), R27150 (PspA fragment), and R79478 (Mouse LTBP-2). Based upon sequence similarity, iw66 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the iw66 _—1 protein sequence, centered around amino acids 45, 74, and 158 of SEQ ID NO:114, 115 respectively. The nucleotide sequence of iw66 _—1 indicates that it may contain one or more of the following repetitive elements: MIR.
Clone “kh13[3177] _—4”
A polynucleotide of the present invention has been identified as clone “kh13[3178] _—4”. kh13_—4 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. kh13_—4 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “kh13_—4 protein”).
The nucleotide sequence of kh13[3179] _—4 as presently determined is reported in SEQ ID NO:115, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the kh13_—4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:116.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone kh13[3180] _—4 should be approximately 950 bp.
The nucleotide sequence disclosed herein for kh13[3181] _—4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. kh13_—4 demonstrated at least some similarity with sequences identified as AA435981 (zu01f08.s1 Soares testis NHT Homo sapiens cDNA clone 730599 3′), AA436078 (zu01f08.r1 Soares testis NHT Homo sapiens cDNA clone 730599 5′), AA778636 (af87c04.s1 Soares testis NHT Homo sapiens cDNA clone 1048998 3′ similar to gb:M94856 PSORIASIS-ASSOCIATED FATTY ACID BINDING PROTEIN HOMOLOG (HUMAN); mRNA sequence), M94856 (Human fatty acid binding protein homologue (PA-FABP) mRNA, complete cds), and Q66842 (Melanogenic inhibitor; standard; DNA). The predicted amino acid sequence disclosed herein for kh13_—4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted kh13_—4 protein demonstrated at least some similarity to sequences identified as M94856 (fatty acid binding protein homologue [Homo sapiens]) and R55866 (Melanogenic inhibitor). Fatty acid binding protein homologue (M94856) is described as “a novel keratinocyte protein (psoriasis-associated fatty add-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins.” Based upon sequence similarity, kh13_—4 proteins and each similar protein or peptide may share at least some activity.
Clone “ko258[3182] _—4”
A polynucleotide of the present invention has been identified as clone “ko258[3183] _—4”. ko258_—4 was isolated from a human adult uterus cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ko258_—4 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “ko258_—4 protein”).
The nucleotide sequence of ko258[3184] _—4 as presently determined is reported in SEQ ID NO:117, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ko258_—4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:118.
The EcoRI/NotI restriction fragment obtainable from the deposit containing done ko258[3185] _—4 should be approximately 2500 bp.
The nucleotide sequence disclosed herein for ko258[3186] _—4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ko258_—4 demonstrated at least some similarity with sequences identified as AC002401 (*** SEQUENCING IN PROGRESS *** Homo sapiens chromosome 17, clone RPC875H18; HTGS phase 1, 4 unordered pieces), AC002401 (Homo sapiens chromosome 17, clone RPC875H18, complete sequence), C15329 (Human fetal brain cDNA 5′-end GEN-133H10, mRNA sequence), AF035306 (Homo sapiens clone 23771 mRNA sequence), and R28382 (IMAGE 3p clone). Based upon sequence similarity, ko258_—4 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ko258_—4 protein sequence, centered around amino acid 28 of SEQ ID NO:118. Clone “ky10_—8”
A polynucleotide of the present invention has been identified as clone “ky10[3187] _—8”. ky10_—8 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ky10_—8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ky10_—8 protein”).
The nucleotide sequence of kv10[3188] _—8 as presently determined is reported in SEQ ID NO:119, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ky10_—8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:120.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ky10[3189] _—8 should be approximately 4300 bp.
The nucleotide sequence disclosed herein for ky10[3190] _—8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ky10_—8 demonstrated at least some similarity with sequences identified as AA418842 (zw01e12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 768046 3′), AC004228 (*** SEQUENCING IN PROGRESS *** Homo sapiens Chromosome 11q12 pac pDJ519o3; HTGS phase 1,18 unordered pieces), AF052108 (Homo sapiens clone 23687 mRNA sequence), R00761 (ye78b11.s1 Homo sapiens cDNA clone 123837 3′), T83434 (yd46b04.r1 Homo sapiens cDNA clone 111247 5′), T84080 (yd46b04.s1 Homo sapiens cDNA clone 111247 3′), and U00594 (Mustela vison unknown mRNA down regulated by TGF-beta, partial sequence). Based upon sequence similarity, kv10_—8 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ky10_—8 protein sequence, centered around amino acids 35 to 45 of SEQ ID NO:120. The nucleotide sequence of ky10_—8 indicates that it may contain one or more of the following repetitive elements: Alu, SVA.
Clone “LL89[3191] _—3”
A polynucleotide of the present invention has been identified as clone “LL89[3192] _—3”. LL89_—3 was isolated from a human adult thyroid cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. LL89_—3 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “LL89_—3 protein”).
The nucleotide sequence of LL89[3193] _—3 as presently determined is reported in SEQ ID NO:121, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the LL89_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:122.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone LL89[3194] _—3 should be approximately 900 bp.
The nucleotide sequence disclosed herein for LL89[3195] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. LL89_—3 demonstrated at least some similarity with sequences identified as AL031010 (Human DNA sequence SEQUENCING IN PROGRESS from clone 422F24, complete sequence), H78002 (yu82h09.r1 Homo sapiens cDNA clone 240353 5′), and W90018 (zh72c08.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 417614 3′). Based upon sequence similarity, LL89_—3 proteins and each similar protein or peptide may share at least some activity.
Clone “[3196] mc300 _—1”
A polynucleotide of the present invention has been identified as clone “[3197] mc300 _—1”. mc300 _—1 was isolated from a human adult thyroid cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. mc300 _—1 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “mc300 _—1 protein”).
The nucleotide sequence of [3198] mc300 _—1 as presently determined is reported in SEQ ID NO:123, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the mc300 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:124.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3199] clone mc300 _—1 should be approximately 2600 bp.
The nucleotide sequence disclosed herein for [3200] mc300 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. mc300 _—1 demonstrated at least some similarity with sequences identified as AA142942 (IMAGE 3p clone), AA315222 (EST187017 Colon carcinoma (HCC) cell line Homo sapiens cDNA 5′ end), AA142942 (zl43c04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 504678 3′), A1246503 (qn64a06.x1 NCI_CGAP_HN4 Homo sapiens cDNA clone IMAGE:1902994 3′, mRNA sequence), D61461 (Human fetal brain cDNA 5′-end GEN-404B08), D79662 (Human aorta cDNA 5′-end GEN-300D05, mRNA sequence), H93575 (yv14h11.s1 Homo sapiens cDNA clone 242757 3′), T25928
(Human gene signature HUMGS08160; standard; cDNA to mRNA), and W93059 (zd93h06.s1 Soares fetal heart NbHH19W [3201] Homo sapiens cDNA clone 357083 3′). Based upon sequence similarity, mc300 _—1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of mc300 _—1 indicates that it may contain one or more Alu repetitive elements.
Clone “[3202] ml227 _—1”
A polynucleotide of the present invention has been identified as clone “[3203] ml227 _—1”. ml227 _—1 was isolated from a human adult brain (caudate nucleus) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ml227 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ml227 _—1 protein”).
The nucleotide sequence of [3204] ml227 _—1 as presently determined is reported in SEQ ID NO:125, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ml227 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:126.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3205] clone ml227 _—1 should be approximately 2700 bp.
The nucleotide sequence disclosed herein for [3206] ml227 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ml227 _—1 demonstrated at least some similarity with sequences identified as AA857826 (oe88e05.s1 NCI_CGAP_Col2 Homo sapiens cDNA clone IMAGE:1418720 3′, mRNA sequence), F18464 (H.sapiens EST sequence (017-T4-16) from skeletal muscle), H30845 (yo78d11.r1 Homo sapiens cDNA clone 184053 5′), T06839 (EST04728 Homo sapiens cDNA clone HFBDZ66), T19759 (Human gene signature HUMGS00834), T26021 (Human gene signature HUMGS08257; standard; cDNA to mRNA), and Z69043 (H.sapiens mRNA translocon-associated protein delta subunit precursor). The predicted amino acid sequence disclosed herein for ml227 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ml227_—1 protein demonstrated at least some similarity to the sequence identified as Z69664 (K04D7.5 [Caenorhabditis elegans]). Based upon sequence similarity, ml27 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts six potential transmembrane domains within the ml227 _—1 protein sequence, centered around amino acids 465, 510, 560, 572, 595, and 615 of SEQ ID NO: 126, respectively.
Clone “mm367[3207] _—6”
A polynucleotide of the present invention has been identified as clone “mm367[3208] _—6”. mm367_—6 was isolated from a human adult retina (WERI-Rb1 retinoblastoma line) cDNA library and was identified as encoding a protein. mm367_—6 is a full-length clone, including the entire coding sequence of a protein (also referred to herein as “mm367_—6 protein”).
The nucleotide sequence of mm367[3209] _—6 as presently determined is reported in SEQ ID NO:127, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the mm367_—6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:128.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone mm367[3210] _—6 should be approximately 2600 bp.
The nucleotide sequence disclosed herein for mm367[3211] _—6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. mm367_—6 demonstrated at least some similarity with sequences identified as AA114127 (zn65f02.r1 Stratagene HeLa cell s3937216 Homo sapiens cDNA clone 563067 5′), AA127284 (zn91c12.r1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565558 5′), AA173842 (zp30d01.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 610945 5′), AF000364 (Homo sapiens heterogeneous nuclear ribonucleoprotein R mRNA, complete CDs), N31934 (yy22d10.s1 Homo sapiens cDNA clone 271987 3′), T24354 (Human gene signature HUMGS06385; standard; cDNA to mRNA), U48271 (Dictyostelium discoideum UbpA deubiquitinase mRNA, complete CDs), W16579 (zb13g11.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 301988 5′), and W72461 (zd67f06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 345731 3′). The predicted amino acid sequence disclosed herein for mm367_—6 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted mm367_—6 protein demonstrated at least some similarity to sequences identified as AF000364 (heterogeneous nuclear ribonucleoprotein R [Homo sapiens]) and W26553 (Human heterogeneous nuclear ribonucleoprotein (hnRNP) A2). Based upon sequence similarity, mm367_—6 proteins and each similar protein or peptide may share at least some activity.
mm367[3212] _—6 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 79 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “mt124[3213] _—3”
A polynucleotide of the present invention has been identified as clone “mt124[3214] _—3”. mt124_—3 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. mt124_—3 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “mt124_—3 protein”).
The nucleotide sequence of mt124[3215] _—3 as presently determined is reported in SEQ ID NO:129, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the mt124_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:130.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone mt124[3216] _—3 should be approximately 1100 bp.
The nucleotide sequence disclosed herein for mt124[3217] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. mt124_—3 demonstrated at least some similarity with sequences identified as AA435386 (ve15h01.r1 Soares mouse NbMH Mus musculus cDNA clone 818257 5′ similar to TR:E198756 E198756 PUTATIVE ORF), A1185116 (qe51g07.x1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE 1742556 3′ similar to TR Q92564 Q92564 MYELOBLAST KIAA0276; mRNA sequence), C03847 (Human Heart cDNA, clone 3NHC2256), N74186 (za76h03.s1 Homo sapiens cDNA clone 298517 3′), T24234 (Human gene signature HUMGS06248; standard; cDNA to mRNA), W87997 (mf65b06.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 419123 5′), and Z86062 (Human DNA sequence from PAC 121G13 on chromosome 6 contains flow sorted chromosome 6 HindIII fragment ESTs, polymorphic CA repeat, CpG island, CpG island genomic fragments). The predicted amino acid sequence disclosed herein for mt124_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted mt124_—3 protein demonstrated at least some similarity to sequences identified as AL024499 (H38K22.2 [Caenorhabditis elegans]) and D87466 (Similar to S.cerevisiae hypothetical protein L3111 (S59316) [Homo sapiens]). Based upon sequence similarity, mt124_—3 proteins and each similar protein or peptide may share at least some activity.
Clone “nf56[3218] _—3”
A polynucleotide of the present invention has been identified as clone “nf56[3219] _—3”. nf56_—3 was isolated from a human adult brain (substantia nigra) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino add sequence of the encoded protein. nf56_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “nf56_—3 protein”).
The nucleotide sequence of nf56[3220] _—3 as presently determined is reported in SEQ ID NO:131, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino add sequence of the nf56_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:132. Amino acids 3 to 15 of SEQ ID NO:132 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the nf56_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone nf56[3221] _—3 should be approximately 5000 bp.
The nucleotide sequence disclosed herein for nf56[3222] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nf56_—3 demonstrated at least some similarity with sequences identified as H08054 (yl86a09.s1 Homo sapiens cDNA clone 44915 3′), Q60495 (Human brain Expressed Sequence Tag EST02500; standard; cDNA), T25509 (Human gene signature HUMGS07678), W34534 (mc58h01.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 352753 5′), and Z64987 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 186b1, reverse read cpg186b1.rt1b). The predicted amino acid sequence disclosed herein for nf56_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted nf56_—3 protein demonstrated at least some similarity to sequences identified as D86983 (similar to D.melanogaster peroxidasin (U11052) [Homo sapiens]), R25079 (Drosophila SLIT protein involved in axon pathway development), and X53959 (slit protein [Drosophila melanogaster]). Based upon sequence similarity, nf56_—3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the nf56_—3 protein sequence, one centered around amino acid 514 and another around amino acid 628 of SEQ ID NO:132.
Clone “[3223] qy442 _—2”
A polynucleotide of the present invention has been identified as clone “[3224] qy442 _—2”. qy442 _—2 was isolated from a human adult blood (promyelocytic leukemia HL-60 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy442 _—2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qy442 _—2 protein”).
The nucleotide sequence of [3225] qy442 _—2 as presently determined is reported in SEQ ID NO:133, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy442 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:134. Amino acids 3 to 15 of SEQ ID NO:134 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy442 _—2 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3226] clone qy442 _—2 should be approximately 1800 bp.
The nucleotide sequence disclosed herein for [3227] qy442 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy442 _—2 demonstrated at least some similarity with sequences identified as AI081522 (on04e12.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1555726 3′ similar to contains Alu repetitive element; mRNA sequence) and AA449854 (zx37a06.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 788626 5′). Based upon sequence similarity, qy442 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the qy442 _—2 protein sequence, centered around amino acid 68 of SEQ ID NO:20. The nucleotide sequence of qy442 _—2 indicates that it may contain one or more Alu repetitive elements.
Clone “rj214[3228] _—14”
A polynucleotide of the present invention has been identified as clone “rj214[3229] _—14”. rj214_—14 was isolated from a human adult neural (neuroepithelioma HTB-10 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rj214_—14 is a full-length done, including the entire coding sequence of a secreted protein (also referred to herein as “rj214_—14 protein”).
The nucleotide sequence of rj214[3230] _—14 as presently determined is reported in SEQ ID NO:135, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rj214_—14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:136. Amino acids 3 to 15 of SEQ ID NO:136 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rj214_—14 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rj214[3231] _—14 should be approximately 900 bp.
The nucleotide sequence disclosed herein for rj214[3232] _—14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rj214_—14 demonstrated at least some similarity with sequences identified as AA167035 (zp05c10.s1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 595506 3′ similar to TR:G563357 G563357 GENES RAS1, RLB1 AND RLC1; mRNA sequence), AA491109 (aa52d09.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 824561 5′ similar to TR G563357 G563357 GENES RAS1, RLB1 AND RLC1), and AI189156 (qd04c02.x1 Soares_placenta_—8 to 9weeks_—2NbHP8 to 9W Homo sapiens cDNA clone IMAGE:1722722 3′ similar to TR:O01437 O01437 SIMILAR TO DROSOPHILA RLC1 GENE PRODUCT; mRNA sequence). The predicted amino acid sequence disclosed herein for rj214_—14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rj214_—14 protein demonstrated at least some similarity to sequences identified as U97016 (similar to drosophila Rlc1 gene product (NID g563361) and S. cerevisiae mitochondrial 60S ribosomal protein L4 (YML4) (NID g459259) [Caenorhabditis elegans]), and X73219 (Rlc1). Drosophila Rlc1 is a basic protein that is bound to the inner face of the cell membrane. Transcription mapping and nucleotide sequence analysis reveal that Rlc1 lies in the same genomic region as Drosophila Ras1 and shows expression patterns that are similar to those of Ras1. It has been demonstrated (Ezer et al., 1994, Dev. Dyn. 201(2): 179-190, which is incorporated by reference herein) that during embryogenesis Ras1 transcripts are restricted mainly to the embryonic central nervous system, suggesting that the Rlc1 gene product also may have a role in these nerve cells. Based upon sequence similarity, rj214_—14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rj214_—14 protein sequence, centered around amino acid 32 of SEQ ID NO:136.
rj214[3233] _—14 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 22 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “rk80[3234] _—3”
A polynucleotide of the present invention has been identified as clone “rk80[3235] _—3”. rk80_—3 was isolated from a human adult tumor (colorectal adenocarcinoma SW480 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rk80_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rk80_—3 protein”).
The nucleotide sequence of rk80[3236] _—3 as presently determined is reported in SEQ ID NO:137, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rk80_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:138. Amino acids 6 to 18 of SEQ ID NO:138 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rk80_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rk80[3237] _—3 should be approximately 1096 bp.
The nucleotide sequence disclosed herein for rk80[3238] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rk80_—3 demonstrated at least some similarity with sequences identified as AA418955 (zw01c10.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 768018 5′, mRNA sequence), AB004061 (domestic pig mRNA for STAT2, complete CDs, a signal transducer and activator of transcription), C06368 (similar to none), and U38443 (Human clone JkA3 mRNA induced upon T-cell activation, 3′ end). The predicted rk80_—3 protein demonstrated at least some similarity to granulocyte-colony stimulating factor (G-CSF) and interleukin-6 (IL-6). Hidden Markov model analysis has revealed the presence of an IL-6/G-CSF/mast cell growth factor (MGF) family signature at amino acids 69 to 181 of SEQ ID NO:138. This family of cytokines are glycoproteins of about 170 to 180 amino acid residues in size that contain four conserved cysteine residues involved in two disulfide bonds. rk80_—3 appears to encode a novel cytokine in the IL-6/G-CSF family. Based upon sequence similarity, rk80_—3 proteins and each similar protein or peptide may share at least some activity.
rk80[3239] _—3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “au36[3240] _—42”
A polynucleotide of the present invention has been identified as clone “au36[3241] _—42”. au36_—42 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. au36_—42 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “au36_—42 protein”).
The nucleotide sequence of au36[3242] _—42 as presently determined is reported in SEQ ID NO:139, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the au36_—42 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:140.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone au36[3243] _—42 should be approximately 1400 bp.
The nucleotide sequence disclosed herein for au36[3244] _—42 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant hits were found in the database. The nucleotide sequence of au36_—42 indicates that it may contain a L1ME repetitive element.
Clone “bo549[3245] _—13”
A polynucleotide of the present invention has been identified as clone “bo549[3246] _—13”. bo549_—13 was isolated from a human adult retina cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bo549_—13 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “bo549_—13 protein”).
The nucleotide sequence of bo549[3247] _—13 as presently determined is reported in SEQ ID NO:141, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bo549_—13 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:142. The region of SEQ ID NO:141 at nucleotides 518 and 519 may represent the border of an alternatively spliced exon.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bo549[3248] _—13 should be approximately 1200 bp.
The nucleotide sequence disclosed herein for bo549[3249] _—13 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bo549_—13 demonstrated at least some similarity with sequences identified as AI261562 (qz30c06.x1 NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE 2028394 3′ similar to TR Q63061 Q63061 HYPOTHETICAL 4.7 KD PROTEIN; mRNA sequence) and J02649 (Rat stomach (H+,K+)-ATPase mRNA, complete cds). The predicted amino acid sequence disclosed herein for bo549_—13 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bo549_—13 protein demonstrated at least some similarity to sequences identified as J02649 (unknown protein [Rattus norvegicus]). Based upon sequence similarity, bo549_—13 proteins and each similar protein or peptide may share at least some activity.
Clone “da529[3250] _—3”
A polynucleotide of the present invention has been identified as clone “da529[3251] _—3”. da529_—3 was isolated from a human fetal placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. da529_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “da529_—3 protein”).
The nucleotide sequence of da529[3252] _—3 as presently determined is reported in SEQ ID NO:143, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the da529_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:144. Amino acids 59 to 71 of SEQ ID NO:144 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 72. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the da529_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone da529[3253] _—3 should be approximately 1150 bp.
The nucleotide sequence disclosed herein for da529[3254] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. da529_—3 demonstrated at least some similarity with sequences identified as AI189911 (qd33e06.x1 Soares_placenta_—8 to 9weeks_—2NbHP8 to 9W Homo sapiens cDNA clone IMAGE 1725538 3′ similar to TR O42204 O42204 PUTATIVE TRANSMEMBRANE PROTEIN E3-16; mRNA sequence), T35254 (EST82005 Homo sapiens cDNA 5′ end similar to None), U76253 (Mus musculus E25B protein mRNA, complete cds), V43619 (Human secreted protein 19 encoding DNA), W28608 (49b1 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA), and W41628 (mc47c10.r1 Soares mouse p3NMF19). The predicted amino acid sequence disclosed herein for da529_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted da529_—3 protein demonstrated at least some similarity to sequences identified as AF03895 (E25 protein [Homo sapiens]) and W63699 (Human secreted protein 19). Based upon sequence similarity, da529_—3 proteins and each similar protein or peptide may share at least some activity.
Clone “dm365[3255] _—3”
A polynucleotide of the present invention has been identified as clone “dm365[3256] _—3”. A cDNA clone was first isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate dm365_—3 from a human fetal brain cDNA library. dm365_—3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “dm365_—3 protein”).
The nucleotide sequence of dm365[3257] _—3 as presently determined is reported in SEQ ID NO:145, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dm365_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:146. Amino acids 1 to 13 of SEQ ID NO:146 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino add 14. Amino acids 40 to 52 of SEQ ID NO:146 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 53. Due to the hydrophobic nature of each of these predicted leader/signal sequences, each predicted leader/signal sequence is likely to act as a transmembrane domain should it not be separated from the remainder of the dm365_—3 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dm365[3258] _—3 should be approximately 1300 bp.
The nucleotide sequence disclosed herein for dm365[3259] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dm365_—3 demonstrated at least some similarity with sequences identified as AC005533 (*** SEQUENCING IN PROGRESS *** Homo sapiens clone DJ0794K21; HTGS phase 1,22 unordered pieces), AI125562 (qd94d09.x1 Soares testis NHT Homo sapiens cDNA clone IMAGE 1737137 3′, mRNA sequence), R02268 (ye85c10.r1 Homo sapiens cDNA clone 124530 5′ similar to contains LTR5 repetitive element), and V90427 (EST clone DM365). Based upon sequence similarity, dm365_—3 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dm365_—3 indicates that it may contain repetitive sequences.
dm365[3260] _—3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 23 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3261] fa171 _—1”
A polynucleotide of the present invention has been identified as clone “[3262] fa171 _—1”. fa171 _—1 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fa171 _—1 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “fa171 _—1 protein”).
The nucleotide sequence of [3263] fa171 _—1 as presently determined is reported in SEQ ID NO:147, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fa171 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:148.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3264] clone fa171 _—1 should be approximately 2500 bp.
The nucleotide sequence disclosed herein for [3265] fa171 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fa171 _—1 demonstrated at least some similarity with sequences identified as AA446057 (zw66d04.r1 Soares testis NHT Homo sapiens cDNA clone 781159 5′, mRNA sequence), AC002099 (*** SEQUENCING IN PROGRESS *** Genomic sequence from Human 9q34; HTGS phase 1, 2 unordered pieces), AC002355 (*** SEQUENCING IN PROGRESS *** Genomic sequence from Human 9q34; HTGS phase 1, 7 unordered pieces), and U10185 (Xenopus laevis XPMC2 protein mRNA, complete cds). The predicted amino acid sequence disclosed herein for fa171 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fa171_—1 protein demonstrated at least some similarity to sequences identified as R67549 (Fruiting body inducing polypeptide) and U10185 (XPMC2 protein [Xenopus laevis]). XPMC2 is a Xenopus cDNA clone that can rescue several different yeast mitotic catastrophe mutants defective in Wee1 kinase function, and is a nuclear protein. Based upon sequence similarity, fa171 _—1 proteins and each similar protein or peptide may share at least some activity.
Clone “[3266] lp572 _—2”
A polynucleotide of the present invention has been identified as clone “[3267] lp572 _—2”. lp572 _—2 was isolated from a human adult blood (peripheral blood mononuclear cells treated with granulocyte-colony stimulating factor in vivo) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. lp572 _—2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “lp572 _—2 protein”).
The nucleotide sequence of [3268] lp572 _—2 as presently determined is reported in SEQ ID NO:149, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the lp572 _—2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:150. Amino acids 79 to 91 of SEQ ID NO:150 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 92. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the lp572 _—2 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3269] clone lp572 _—2 should be approximately 2100 bp.
The nucleotide sequence disclosed herein for [3270] lp572 _—2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. lp572 _—2 demonstrated at least some similarity with sequences identified as AA489012 (aa56a03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 824908 3′), AA533633 (nf73b09.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE 925529, mRNA sequence), AC004686 (Homo sapiens chromosome 17, clone hRPC.1073_F_—15, complete sequence), T18977 (g07030t Testis 1 Homo sapiens cDNA clone g07030 5′ end), T21490 (Human gene signature HUMGS02862), and W73324 (zd01h01.r1 Pancreatic Islet Homo sapiens cDNA clone 339409 5′). The predicted amino acid sequence disclosed herein for lp572 _—2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted lp572_—2 protein demonstrated at least some similarity to sequences identified as AL03262 (predicted using Genefinder [Caenorhabditis elegans]). Based upon sequence similarity, lp572 _—2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the lp572 _—2 protein sequence, centered around amino acids 129, 263, 286, 326, and 378 of SEQ ID NO:150, respectively.
Clone “[3271] pe246 _—1”
A polynucleotide of the present invention has been identified as clone “[3272] pe246 _—1”. pe246 _—1 was isolated from a human adult blood (chronic myelogenous leukemia line K562) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pe246 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pe246 _—1 protein”).
The nucleotide sequence of [3273] pe246 _—1 as presently determined is reported in SEQ ID NO:151, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pe246 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:152. Amino acids 193 to 205 of SEQ ID NO:152 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 206. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pe246 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3274] clone pe246 _—1 should be approximately 1500 bp.
The nucleotide sequence disclosed herein for [3275] pe246 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pe246 _—1 demonstrated at least some similarity with sequences identified as AA234138 (zr51b06.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 666899 5′ similar to SW FCEB_HUMAN Q01362 HIGH AFFINITY IMMUNOGLOBULIN EPSILON RECEPTOR BETA-SUBUNIT), AA418443 (zv92e05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 767264 5′ similar to SW FCEB_RAT P13386 HIGH AFFINITY IMMUNOGLOBULIN EPSILON RECEPTOR BETA-SUBUNIT; mRNA sequence), AC004584 (Homo sapiens chromosome 17, clone hRPC1107_A_—17, complete sequence), M74509 (Human endogenous retrovirus type C oncovirus sequence), and V57903 (Hereditary haemochromatosis subregion from an HH affected individual). The predicted amino acid sequence disclosed herein for pe246 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pe246_—1 protein demonstrated at least some similarity to sequences identified as L35848 (IgE receptor beta subunit [Homo sapiens]), R05026 (Beta subunit of rat high affinity IgE receptor Fc(epsilon)R1), and R42341 (Subunit of the human IgE receptor). The first 359 nucleotides of SEQ ID NO:13 is similar in sequence to that of M74509 (Human endogenous retrovirus type C oncovirus sequence) and also to several genomic sequences as a result. It appears that this region may be retroviral DNA that has been incorporated into the genome. Based upon sequence similarity, pe246 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the pe246 _—1 protein sequence, centered around amino acids 86, 115, and 154 of SEQ ID NO:152, respectively.
Clone “qf122[3276] _—3”
A polynucleotide of the present invention has been identified as clone “qf122[3277] _—3”. qf122_—3 was isolated from a human adult bladder (carcinoma line 5637) cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qf122_—3 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as “qf122_—3 protein”).
The nucleotide sequence of qf122[3278] _—3 as presently determined is reported in SEQ ID NO:153. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qf122_—3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:154.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qf122[3279] _—3 should be approximately 1700 bp.
The nucleotide sequence disclosed herein for qf122[3280] _—3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qf122_—3 demonstrated at least some similarity with sequences identified as AA206909 (zq80d10.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 647923 5′ similar to SW YYAF_BACSU P37518 HYPOTHETICAL 40.1 KD GTP-BINDING PROTEIN IN RPSF-SPO0J INTERGENIC REGION; mRNA sequence), AA237053 (zs01c01.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 683904 5′ similar to SW YBN5_YEAST P38219 HYPOTHETICAL 44.2 KD PROTEIN 1N SCO2-MRF1 INTERGENIC REGION), AA775776 (ad14e03.s1 Soares NbHFB Homo sapiens cDNA clone 878236 3′ sinilar to TR P91917 P91917 W08E3.3; mRNA sequence), AL021878 (Homo sapiens DNA sequence from PAC 257120 on chromosome ²²q13.1-13.2; contains cytochrome P450 pseudogenes CYP2D7P, CYP2D8P, CYP2D6(D), TCF20, NADH ubiquinone oxidoreductase B14 subunit, ESTs, CA repeat, STS, GSS), and N32932 (yy10a02.s1 Homo sapiens cDNA clone 270794 3′ similar to SW:YBN5_YEAST P38219 HYPOTHETICAL 44.2 KD PROTEIN 1N SCO2-MRF1 INTERGENIC REGION). The predicted amino acid sequence disclosed herein for qf122_—3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qf122_—3 protein demonstrated at least some similarity to sequences identified as W48670 (Staphylococcus aureus gbpA protein), Z92773 (W08E3.3 [Caenorhabditis elegans]), and Z92773 (predicted using Genefinder; Similarity to Yeast hypothetical 44.2 KD protein, putative GTP-binding protein (SW P38219); cDNA EST EMBL D64516 comes from this gene). Based upon sequence similarity, qf122_—3 proteins and each similar protein or peptide may share at least some activity. Analysis of protein motifs in SEQ ID NO:154 predicts an ATP/GTP-binding site motif A (P-loop) around amino acid 29 of SEQ ID NO:154.
Clone “[3281] qv538 _—1”
A polynucleotide of the present invention has been identified as clone “[3282] qv538 _—1”. qv538 _—1 was isolated from a human adult testes (embryonal carcinoma NT2D1 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qv538 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qv538 _—1 protein”).
The nucleotide sequence of [3283] qv538 _—1 as presently determined is reported in SEQ ID NO:155, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qv538 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:156. Amino acids 8 to 20 of SEQ ID NO:156 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qv538 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3284] clone qv538 _—1 should be approximately 2600 bp.
The nucleotide sequence disclosed herein for [3285] qv538 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qv538 _—1 demonstrated at least some similarity with sequences identified as W44974 (zc22e11.r1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323084 5′ similar to SW:FKB2_YEAST P32472 FK506-BINDING PROTEIN PRECURSOR; mRNA sequence), and Z62799 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 73c8, reverse read cpg73c8.rt1a). The predicted amino acid sequence disclosed herein for qv538 _—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qv538_—1 protein demonstrated at least some similarity to sequences identified as AF04025 (FK506-binding protein [Mus musculus]) and W88556 (Secreted protein encoded by gene 23 clone HSQEO84). FK506-binding protein (or “FKBP”) is the major high-affinity binding protein, in vertebrates, for the immunosuppressive drug FK506 (used to aid in organ transplantation acceptance among other indications). It exhibits peptidyl-prolyl cis-trans isomerase activity (PPIase or rotamase). PPIase is an enzyme that accelerates protein folding by catalyzing the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Based upon sequence similarity, qv538 _—1 proteins and each similar protein or peptide may share at least some activity. Analysis of protein motifs in SEQ ID NO:156 detects an endoplasmic reticulum targeting sequence around amino acid 208. Hidden Markov Model analysis detects an EF-hand calcium-binding domain at amino acids 183 to 211 of SEQ ID NO:156 (also found by motif analysis) and a FKBP-type peptidyl-prolyl cis-trans isomerase signatures/profile at amino acids 38 to 132 of SEQ ID NO:156. The nucleotide sequence of qv538 _—1 indicates that it may contain an Alu repetitive element.
qv538[3286] _—1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone “[3287] vs20 _—1”
A polynucleotide of the present invention has been identified as clone “[3288] ys ²⁰ _—1”. ys20 _—1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ys20 _—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ys20 _—1 protein”).
The nucleotide sequence of [3289] ys20 _—1 as presently determined is reported in SEQ ID NO:157, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ys20 _—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:158. Amino acids 41 to 53 of SEQ ID NO:158 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 54. Amino acids 121 to 133 of SEQ ID NO:158 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 134. Due to the hydrophobic nature of each of these predicted leader/signal sequences, each predicted leader/signal sequence is likely to act as a transmembrane domain should it not be separated from the remainder of the ys20 _—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing [3290] clone ys20 _—1 should be approximately 2229 bp.
The nucleotide sequence disclosed herein for [3291] ys20 _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ys20 _—1 demonstrated at least some similarity with sequences identified as B76357 (RPCI11-15B19.TV RPCI11 Homo sapiens genomic clone R-15B19, genomic survey sequence). Based upon sequence similarity, ys20 _—1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the ys20 _—1 protein sequence, centered around amino acid 205 of SEQ ID NO:158. The nucleotide sequence of ys20 _—1 indicates that it may contain one or more mammalian transposon-like long terminal repeat elements, such as MCTlb/c.
Clone “as180[3292] _—1”
A polynucleotide of the present invention has been identified as clone “as180[3293] _—1”. as180_—1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. as180_—1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “as180_—1 protein”).
The nucleotide sequence of as180[3294] _—1 as presently determined is reported in SEQ ID NO:159. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the as180_—1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:160. Amino acids 168 to 180 of SEQ ID NO:160 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 181. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the as180_—1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone as180[3295] _—1 should be approximately 3580 bp.
The nucleotide sequence disclosed herein for as180[3296] _—1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. as180_—1 demonstrated at least some similarity with sequences identified as AB018279 (Homo sapiens mRNA for KIAA0736 protein, complete cds), S47919 (p87=transporter-like protein [cattle, mRNA]), V89585 (EST clone CR618), and W28902 (53d11 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA, mRNA sequence). The predicted amino acid sequence disclosed herein for as180_—1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted as180_—1 protein demonstrated at least some similarity to sequences identified as AB018279 (KIAA0736 protein [Homo sapiens]), L05435 (synaptic vesicle protein 2 [Rattus norvegicus]), S47919 (p87 [Bos sp.]), and W64538 (Human liver cell clone HP01293 protein). Synaptic vesicle protein 2 (SV2) is a membrane glycoprotein specifically localized to secretory vesicles in neurons and endocrine cells (Bajjalieh, S. M. et al., 1992, Science August 28; 257(5074):1271-1273, which is incorporated by reference herein). Based upon sequence similarity, as180_—1 proteins and each similar protein or peptide may share at least some activity. Analysis of amino acid motifs detected a sugar-transport protein signature around amino acid 264 of SEQ ID NO: 160, and hidden Markov Model analysis detected a sugar-transporter amino acid profile from amino acid 153 to amino acid 741 of SEQ ID NO:160. The TopPredII computer program predicts twelve potential transmembrane domains within the as 180_—1 protein sequence, centered around amino acids 181, 205, 248, 270, 308, 344, 432, 458, 605, 638, 654, and 710 of SEQ ID NO:160, respectively.
Deposit of Clones [3297]
Clones co62[3298] _—12, lo311_—8, ns197 _—1, pj193_—5, pj317 _—2, pt332 _—1, qc297_—15, qg596_—12, and rb649_—3 were deposited on Jul. 29, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98825, from which each clone comprising a particular polynucleotide is obtainable.
Clones ca106[3299] _—19xx, ci52 _—2, md124_—16, pk366_—7, pl741_—5, pp314_—19, pv35 _—1, pw337_—6, rd6101, and rd810_—6 were deposited on Aug. 11, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98835, from which each clone comprising a particular polynucleotide is obtainable.
Clones cf85[3300] _—1, dd504_—18, np26_—3, pm412_—12, pm421_—3, pv6 _—1, qs14_—3, qy338_—9, rc58 _—1, and rd232_—5 were deposited on Aug. 27, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98850, from which each clone comprising a particular polynucleotide is obtainable.
Clones ck213[3301] _—12, pg195 _—1, pw460_—5, qa136 _—1, qy1261 _—2, and rd432_—4 were deposited on Oct. 8, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98918, from which each clone comprising a particular polynucleotide is obtainable.
Clones rb789[3302] _—14, yd137 _—1, yd218 _—1, ye11 _—1, ye72 _—1, ye78 _—1, ye90 _—1, yi62 _—1, yk78 _—1, yk251 _—1, and yt14 _—1 were deposited on Dec. 15, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207004, from which each clone comprising a particular polynucleotide is obtainable.
Clones bf157[3303] _—16, bk343 _—2, cd205 _—2, cw1292_—8, cw1475 _—2, dd428_—4, dh1073_—12, dw78 _—1, fh116_—11, fy356_—14, and iw66 _—1 were deposited on Feb. 4, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207088, from which each clone comprising a particular polynucleotide is obtainable.
Clones kh13[3304] _—4, ko258_—4, kv108, LL89_—3, mc300 _—1, ml227 _—1, mm367_—6, mt124_—3, nf56_—3, qy442 _—2, rj214 _—1, and rk80_—3 were deposited on Feb. 4, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207089, from which each clone comprising a particular polynucleotide is obtainable.
Clones au36[3305] _—42, bo549_—13, da529_—3, dm365_—3, fa1711, lp572 _—2, pe246 _—1, qf122_—3, qv538 _—1, and ys20 _—1 were deposited on Apr. 2, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207187, from which each clone comprising a particular polynucleotide is obtainable.
Clone as180[3306] _—1 was deposited on Aug. 11, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC ______, from which the as180_—1 clone comprising a particular polynucleotide is obtainable.
All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. §1.808(b), and the term of the deposit will comply with 37 C.F.R. §1.806. [3307]
Each clone has been transfected into separate bacterial cells ([3308] E. coli) in the above composite deposits. Each done can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5′ site, EcoRI; 3′ site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in FIGS. 1A and 1B, respectively, or in the case of clone qs14_—3, in the pCMVSport2 vector (Life Technologies, Inc., Rockville, Md. 20850, U.S.A.) depicted in FIG. 2. The pED6dpc2 vector (“pED6”) was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res. 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al., 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become “flipped” (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5′ site and EcoRI will produce the 3′ site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.
Bacterial cells containing a particular clone can be obtained from the composite deposit as follows: [3309]

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	!Clone? Probe Sequence


	co62_12	SEQ ID NO:161
	lo311_8	SEQ ID NO:162
	ns197_1	SEQ ID NO:163
	pj193_5	SEQ ID NO:164
	pj317_2	SEQ ID NO:165
	pt332_1	SEQ ID NO:166
	qc297_15	SEQ ID NO:167
	qg596_12	SEQ ID NO:168
	rb649_3	SEQ ID NO:169
	ca106_19x	SEQ ID NO:170
	ci52_2	SEQ ID NO:171
	md124_16	SEQ ID NO:172
	pk366_7	SEQ ID NO:173
	pl741_5	SEQ ID NO:174
	pp314_19	SEQ ID NO:175
	pv35_1	SEQ ID NO:176
	pw337_6	SEQ ID NO:177
	rd610_1	SEQ ID NO:178
	rd810_6	SEQ ID NO:179
	cf85_1	SEQ ID NO:180
	dd504_18	SEQ ID NO:181
	np26_3	SEQ ID NO:182
	pm412_12	SEQ ID NO:183
	pm421_3	SEQ ID NO:184
	pv6_1	SEQ ID NO:185
	qs14_3	SEQ ID NO:186
	qy338_9	SEQ ID NO:187
	rc58_1	SEQ ID NO:188
	rd232_5	SEQ ID NO:189
	ck213_12	SEQ ID NO:190
	pg195_1	SEQ ID NO:191
	pw460_5	SEQ ID NO:192
	qa136_1	SEQ ID NO:193
	qy1261_2	SEQ ID NO:194
	rd432_4	SEQ ID NO:195
	rb789_14	SEQ ID NO:196
	yd137_1	SEQ ID NO:197
	ye11_1	SEQ ID NO:198
	ye72_1	SEQ ID NO:199
	ye78_1	SEQ ID NO:200
	ye90_1	SEQ ID NO:201
	yk251_1	SEQ ID NO:202
	yt14_1	SEQ ID NO:203
	bf157_16	SEQ ID NO:204
	bk343_2	SEQ ID NO:205
	cd205_2	SEQ ID NO:206
	cw1292_8	SEQ ID NO:207
	cw1475_2	SEQ ID NO:208
	dd428_4	SEQ ID NO:209
	dh1073_12	SEQ ID NO:210
	dw78_1	SEQ ID NO:211
	fh116_11	SEQ ID NO:212
	fy356_14	SEQ ID NO:213
	iw66_1	SEQ ID NO:214
	kh13_4	SEQ ID NO:215
	ko258_4	SEQ ID NO:216
	kv10_8	SEQ ID NO:217
	LL89_3	SEQ ID NO:218
	mc300_1	SEQ ID NO:219
	ml227_1	SEQ ID NO:220
	mm367_6	SEQ ID NO:221
	mt124_3	SEQ ID NO:222
	nf56_3	SEQ ID NO:223
	qy442_2	SEQ ID NO:224
	rj214_14	SEQ ID NO:225
	rk80_3	SEQ ID NO:226
	au36_42	SEQ ID NO:227
	bo549_13	SEQ ID NO:228
	da529_3	SEQ ID NO:229
	dm365_3	SEQ ID NO:230
	fa171_1	SEQ ID NO:231
	lp572_2	SEQ ID NO:232
	pe246_1	SEQ ID NO:233
	qf122_3	SEQ ID NO:234
	qv538_1	SEQ ID NO:235
	ys20_1	SEQ ID NO:236
	as180_1	SEQ ID NO:237

In the sequences listed above which include an N at [3311] position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramadite) (Glen Research, cat. no. 10-1953)).
The design of the oligonucleotide probe should preferably follow these parameters: [3312]
(a) It should be designed to an area of the sequence which has the fewest ambiguous bases (“N's”), if any; [3313]
(b) It should be designed to have a Tm of approx. 80° C. (assuming 2° for each A or T and 4 degrees for each G or C). [3314]
The oligonucleotide should preferably be labeled with γ-[3315] ³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μg/ml. The culture should preferably be grown to saturation at 37° C., and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37° C. Other known methods of obtaining distinct, well-separated colonies can also be employed. [3316]
Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them. [3317]
The filter is then preferably incubated at 65° C. for 1 hour with gentle agitation in 6×SSC (20×stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 μg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL. The filter is then preferably incubated at 65° C. with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2×SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2×SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1×SSC/0.5% SDS at 65° C. for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed. [3318]
The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing. [3319]
Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through “linker” sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein—IgM fusion would generate a decavalent form of the protein of the invention. [3320]
The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form. [3321]
The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. “Corresponding genes” are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5′ and 3′ untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An “isolated gene” is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated. [3322]
The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes in situ. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the Natlonal Center for Biotechnology Information having the address http://www.ncbi.nlm.nih.gov/UniGene/, in order to identify “UniGene clusters” of overlapping sequences. Many of the “UniGene clusters” so identified will already have been mapped to particular chromosomal sites. [3323]
Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994[3324] , Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1-39; all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA (“RNA intereference” or “RNAi”; Fire et al., 1998, Nature 391 (6669): 806-811; Montgomery et al., 1998, Proc. Natl. Acad. Sci. USA 95 (26): 15502-15507; and Sharp, 1999, Genes Dev. 13 (2): 139-141; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al., 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al., 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al., 1988, Nature 336: 348-352; U.S. Pat. Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmsmbrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s). [3325]
Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins. [3326]
In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., [3327] Methods in Enzymology 266: 460-480; Altschul et al., 1990, Basic local alignment search tool, Journal of Molecular Biology 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, Nature Genetics 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite—BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX—the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (O) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.
Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a “species homologue” is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, [3328] Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus oedipus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canis familiaris, Oryctolagus cuniculus, Bos taurus, Ovis aries, Sus scrofa, and Equus caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuanez, 1988, Ann. Rev. Genet. 22: 323-351; O'Brien et al., 1993, Nature Genetics 3:103-112; Johansson et al., 1995, Genomics 25: 682-690; Lyons et al., 1997, Nature Genetics 15:47-56; O'Brien et al., 1997, Trends in Genetics 13(10): 393-399; Carver and Stubbs, 1997, Genome Research 7:1123-1137; all of which are incorporated by reference herein).
The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species. [3329]
The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein. [3330]

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.



		Hybrid		Wash
Stringency	Polynucleotide	Length	Hybridization Temperature and	Temperature
Condition	Hybrid	(bp)^‡	Buffer^†	and Buffer^†

A	DNA/DNA	≧50	65° C.; 1xSSC -or-	65° C.; 0.3xSSC
			42° C.; 1xSSC, 50% formamide
B	DNA:DNA	<50	T_B*; 1xSSC	T_B*; 1xSSC
C	DNA:RNA	≧50	67° C.; 1xSSC -or-	67° C.; 0.3xSSC
			45° C.; 1xSSC, 50% formamide
D	DNA:RNA	<50	T_D*; 1xSSC	T_D*; 1xSSC
E	RNA:RNA	≧50	70° C.; 1xSSC -or-	70° C.; 0.3xSSC
			50° C.; 1xSSC, 50% formamide
F	RNA:RNA	<50	T_F*; 1xSSC	T_F*; 1xSSC
G	DNA:DNA	≧50	65° C.; 4xSSC -or-	65° C.; 1xSSC
			42° C.; 2xSSC, 50% formamide
H	DNA:DNA	<50	T_H*; 4xSSC	T_H*; 4xSSC
I	DNA:RNA	≧50	67° C.; 4xSSC -or-	67° C.; 1xSSC
			45° C.; 4xSSC, 50% formamide
J	DNA:RNA	<50	T_J*; 4xSSC	T_J*; 4xSSC
K	RNA:RNA	≧50	70° C.; 4xSSC -or-	67° C.; 1xSSC
			50° C.; 4xSSC, 50% formamide
L	RNA:RNA	<50	T_L*; 2xSSC	T_L*; 2xSSC
M	DNA:DNA	≧50	50° C.; 4xSSC -or-	50° C.; 2xSSC
			40° C.; 6xSSC, 50% formamide
N	DNA:DNA	<50	T_N*; 6xSSC	T_N*; 6xSSC
O	DNA:RNA	≧50	55° C.; 4xSSC -or-	55° C.; 2xSSC
			42° C.; 6xSSC, 50% formamide
P	DNA:RNA	<50	T_P*; 6xSSC	T_P*; 6xSSC
Q	RNA:RNA	≧50	60° C.; 4xSSC -or-	60° C.; 2xSSC
			45° C.; 6xSSC, 50% formamide
R	RNA:RNA	<50	T_R*; 4xSSC	T_R*; 4xSSC




# 16.6(log₁₀[Na⁺]) + 0.41(%G + C) − (600/N), where N is the number of bases in the hybrid, and (Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989[3332] , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.
Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. [3333]
The isolated polynucleotide endcoing the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein “operably linked” means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence. [3334]
A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. [3335]
Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include [3336] Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, [3337] Texas Agricultural Experiment Station Bulletin No. 1555 (1987) incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is “transformed.”
The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl(E) or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography. [3338]
Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen Corporation (Carlsbad, Calif.), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope (“Flag”) is commercially available from the Eastman Kodak Company (New Haven, Conn.). [3339]
Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an “isolated protein.”[3340]
The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein. [3341]
The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies. [3342]
The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. [3343]
Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention. [3344]
Uses and Biological Activity [3345]
The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). [3346]
Research uses and Utilities [3347]
The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to “subtract-out” known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a “gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al., 1993[3348] , Cell 75: 791-803 and in Rossi et al., 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.
The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. [3349]
Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products. [3350]
Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987. [3351]
Nutritional uses [3352]
Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured. [3353]
Cytokine and Cell Proliferation/Differentiation Activity [3354]
A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK. [3355]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3356]
Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994. [3357]
Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In [3358] Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ, Schreiber, R. D. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.
Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and [3359] Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6—Nordan, R. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11—Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9—Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K J. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.
Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988. [3360]
Immune Stimulating or Suppressing Activity [3361]
A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer. [3362]
Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention. [3363]
Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent. [3364]
Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens. [3365]
The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA41 g fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease. [3366]
Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856). [3367]
Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically. [3368]
Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo. [3369]
In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo. [3370]
The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (eg., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β[3371] ₂microglobulin protein or an MHC class II a chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
The activity of a protein of the invention may, among other means, be measured by the following methods: [3372]
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994. [3373]
Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In [3374] Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992. [3375]
Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990. [3376]
Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992. [3377]
Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991. [3378]
Hematopoiesis Regulating Activity [3379]
A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy. [3380]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3381]
Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above. [3382]
Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993. [3383]
Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In [3384] Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.
Tissue Growth Activity [3385]
A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers. [3386]
A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery. [3387]
A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes. [3388]
Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art. [3389]
The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention. [3390]
Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like. [3391]
It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity. [3392]
A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage. [3393]
A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above. [3394]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3395]
Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium). [3396]
Assays for wound healing activity include, without limitation, those described in: Winter, [3397] Epidermal Wound Healing. pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).
Activin/Inhibin Activity [3398]
A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs. [3399]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3400]
Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986. [3401]
Chemotactic/Chemokinetic Activity [3402]
A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent. [3403]
A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis. [3404]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3405]
Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994. [3406]
Hemostatic and Thrombolytic Activity [3407]
A protein of the invention may also exhibit hemostatic or thrombolytic activity. [3408]
As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke). [3409]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3410]
Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419,1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglamidins 35:467-474, 1988. [3411]
Receptor/Ligand Activity [3412]
A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions. [3413]
The activity of a protein of the invention may, among other means, be measured by the following methods: [3414]
Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995. [3415]
Anti-Inflammatory Activity [3416]
Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. [3417]
Cadherin/Tumor Invasion Suppressor Activity [3418]
Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities. [3419]
The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins. [3420]
E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression. [3421]
Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize. [3422]
Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody. [3423]
Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and poly-nucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion. [3424]
Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990. [3425]
Tumor Inhibition Activity [3426]
In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth. [3427]
Other Activities [3428]
A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein. [3429]
Administration and Dosing [3430]
A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNP1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent. [3431]
A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form. [3432]
The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention. [3433]
The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. No. 4,235,871; U.S. Pat. No. 4,501,728; U.S. Pat. No. 4,837,028; and U.S. Pat. No. 4,737,323, all of which are incorporated herein by reference. [3434]
As used herein, the term “therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. [3435]
In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors. [3436]
Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred. [3437]
When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention. [3438]
When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. [3439]
The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 ug to about 100 mg (preferably about 0.1 ng to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein of the present invention per kg body weight. [3440]
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention. [3441]
Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term “antibody” includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein. [3442]
Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, Monoclonal antibodies: principles and practice, Academic Press Inc., New York; and Yokoyama, 1992, “Production of Monoclonal Antibodies” in Current Protocols in lnmunology, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, supra; and Andrew et al., 1992, “Fragmentation of Immunoglobulins” in Current Protocols in Immunology, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Pat. Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild et al., 1996[3443] , Nature Biotechnology 14: 845-851; Mendez et al., 1997, Nature Genetics 15: 146-156 (erratum Nature Genetics 16: 410); and U.S. Pat. Nos. 5,877,397 and 5,625,126). Such antibodies maybe obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R. P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J. L. Krstenansky, et al., FEBS Lett. 211 10 (1987).
Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein. [3444]
For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications. [3445]
The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. [3446]
Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix. [3447]
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. [3448]
In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-α and TGF-β), and insulin-like growth factor (IGF). [3449]
The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention. [3450]
The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling. [3451]
Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). [3452]
Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes. [3453]
Patent and literature references cited herein are incorporated by reference as if fully set forth. [3454]
1 240 1 1925 DNA Homo sapiens 1 aggtcgtcac agacgatgat ggccaggccc cggaggctaa ggacggcagc tcctttagcg 60 gcagagtttt ccgagtgacc ttcttgatgc tggctgtttc tctcaccgtt cccctgcttg 120 gagccatgat gctgctggaa tctcctatag atccacagcc tctcagcttc aaagaacccc 180 cgctcttgct tggtgttctg catccaaata cgaagctgcg acaggcagaa aggctgtttg 240 aaaatcaact tgttggaccg gagtccatag cacatattgg ggatgtgatg tttactggga 300 cagcagatgg cccggtcgta aaacttgaaa atggtgaaat agagaccatt gcccggtttg 360 gttcgggccc ttgcaaaacc cgagatgatg agcctgtgtg tgggagaccc ctgggtatcc 420 gtgcagggcc caatgggact ctctttgtgg ccgatgcata caagggacta tttgaagtaa 480 atccctggaa acgtgaagtg aaactgctgc tgtcctccga gacacccatt gaggggaaga 540 acatgtcctt tgtgaatgat cttacagtca ctcaggatgg gaggaagatt tatttcaccg 600 attctagcag caaatggcaa agacgagact acctgcttct ggtgatggag ggcacagatg 660 acgggcgcct gctggagtat gatactgtga ccagggaagt aaaagtttta ttggaccagc 720 tgcggttccc gaatggagtc cagctgtctc ctgcagaaga ctttgtcctg gtggcagaaa 780 caaccatggc caggatacga agctctttag tcaagagacg gtgatgaagt ttgtgccgcg 840 gtacagcctc gtcctagaac tcagcgacag cggtgccttc cggagaagcc tgcatgatcc 900 cgatgggctg gtggccacct acatcaccga ggtgcacgaa cacgatgggc acctgtacct 960 gggctctttc aggtccccct tcctctgcag actcagcctc caggctgttt agccctccca 1020 gatagctgcc cctgccacgc aggccaggag tcttcacact caggcaccag gcctggtcca 1080 ggaggagctg tggacacagt cgtggttcaa gtgtccacat gcacctgtta gtccctgaga 1140 ggtggtggga atggctgctt cattcctcga ggatgcccgg gccccacctg ggcttgtctt 1200 tctgtttaga gggaagtgta acatatctgc catgaggaac ataaattcat gtaaagccat 1260 tttctcttaa acaaaacaaa actttctaag tacaatcatt ctctaggatt tgggaagctc 1320 cttgcacttg gaacagggct caggtgggtg gagcagtaag gcactaccca gagagcttgc 1380 tgctgcggcc ctgtcctgcg gcctcaaagt tcttctttac tatatataac gtgcggtcat 1440 acctttcttc gttgtggtgg ggatggaaga gcagagggag catggcccag gggtgttgag 1500 gccagcggtg agagccgtgt tagccaagac atggaactgt gttctcaagg gttatgtggg 1560 gcgtgggctc tccatagtgt gtatgaaaag cttgttgact ctagcggctc agagaggact 1620 ttgctgggtt tctttctgtg aatatctccg tgctgaccat gctggaattg gatgattctg 1680 caattcggga cctactgcag gggtccgttt agtaacgtct tgtctgtgat ctttgttctt 1740 gacctctaga ccccaagatg tgaacagtgc acgtgttaat gtcatctttg ctcatgtgtt 1800 ataagcccca agttgctgta tattttcaca agtatgtcta cacactggtc atgattttga 1860 taataaataa cgataaatcg acttctgctg attaaccttt aaaaaaaaaa aaaaaaaaaa 1920 aaaaa 1925 2 245 PRT Homo sapiens 2 Met Leu Ala Val Ser Leu Thr Val Pro Leu Leu Gly Ala Met Met Leu 1 5 10 15 Leu Glu Ser Pro Ile Asp Pro Gln Pro Leu Ser Phe Lys Glu Pro Pro 20 25 30 Leu Leu Leu Gly Val Leu His Pro Asn Thr Lys Leu Arg Gln Ala Glu 35 40 45 Arg Leu Phe Glu Asn Gln Leu Val Gly Pro Glu Ser Ile Ala His Ile 50 55 60 Gly Asp Val Met Phe Thr Gly Thr Ala Asp Gly Pro Val Val Lys Leu 65 70 75 80 Glu Asn Gly Glu Ile Glu Thr Ile Ala Arg Phe Gly Ser Gly Pro Cys 85 90 95 Lys Thr Arg Asp Asp Glu Pro Val Cys Gly Arg Pro Leu Gly Ile Arg 100 105 110 Ala Gly Pro Asn Gly Thr Leu Phe Val Ala Asp Ala Tyr Lys Gly Leu 115 120 125 Phe Glu Val Asn Pro Trp Lys Arg Glu Val Lys Leu Leu Leu Ser Ser 130 135 140 Glu Thr Pro Ile Glu Gly Lys Asn Met Ser Phe Val Asn Asp Leu Thr 145 150 155 160 Val Thr Gln Asp Gly Arg Lys Ile Tyr Phe Thr Asp Ser Ser Ser Lys 165 170 175 Trp Gln Arg Arg Asp Tyr Leu Leu Leu Val Met Glu Gly Thr Asp Asp 180 185 190 Gly Arg Leu Leu Glu Tyr Asp Thr Val Thr Arg Glu Val Lys Val Leu 195 200 205 Leu Asp Gln Leu Arg Phe Pro Asn Gly Val Gln Leu Ser Pro Ala Glu 210 215 220 Asp Phe Val Leu Val Ala Glu Thr Thr Met Ala Arg Ile Arg Ser Ser 225 230 235 240 Leu Val Lys Arg Arg 245 3 3508 DNA Homo sapiens 3 gagcgaacat ggcagcgcgt tggcggtttt ggtgtgtctc tgtgaccatg gtggtggcgc 60 tgctcatcgt ttgcgacgtt ccctcagcct ctgcccaaag aaagaaggag atggtgttat 120 ctgaaaaggt tagtcagctg atggaatgga ctaacaaaag acctgtaata agaatgaatg 180 gagacaagtt ccgtcgcctt gtgaaagccc caccgagaaa ttactccgtt atcgtcatgt 240 tcactgctct ccaactgcat agacagtgtg tcgtttgcaa gcaagctgat gaagaattcc 300 agatcctggc aaactcctgg cgatactcca gtgcattcac caacaggata ttttttgcca 360 tggtggattt tgatgaaggc tctgatgtat ttcagatgct aaacatgaat tcagctccaa 420 ctttcatcaa ctttcctgca aaagggaaac ccaaacgggg tgatacatat gagttacagg 480 tgcggggttt ttcagctgag cagattgccc ggtggatcgc cgacagaact gatgtcaata 540 ttagagtgat tagaccccca aattatgctg gtccccttat gttgggattg cttttggctg 600 ttattggtgg acttgtgtat cttcgaagaa gtaatatgga atttctcttt aataaaactg 660 gatgggcttt tgcagctttg tgttttgtgc ttgctatgac atctggtcaa atgtggaacc 720 atataagagg accaccatat gcccataaga atccccacac gggacatgtg aattatatcc 780 atggaagcag tcaagcccag tttgtagctg aaacacacat tgttcttctg tttaatggtg 840 gagttacctt aggaatggtg cttttatgtg aagctgctac ctctgacatg gatattggaa 900 agcgaaagat aatgtgtgtg gctggtattg gacttgttgt attattcttc agttggatgc 960 tctctatttt tagatctaaa tatcatggct acccatacag ctttctgatg agttaaaaag 1020 gtcccagaga tatatagaca ctggagtact ggaaattgaa aaacgaaaat cgtgtgtgtt 1080 tgaaaagaag aatgcaactt gtatattttg tattacctct ttttttttca agtgatttaa 1140 atagttaatc atttaaccaa agaagatgtg tagtgcctta acaagcaatc ctctgtcaaa 1200 atctgaggta tttgaaaata attatcctct taaccttctc ttcccagtga actttatgga 1260 acatttaatt tagtacaatt aagtatatta taaaaattgt aaaactacta ctttgtttta 1320 gttagaacaa agctcaaaac tactttagtt aacttggtca tctgatttta tattgcctta 1380 tccaaagatg gggaaagtaa gtcctgacca ggtgttccca catatgcctg ttacagataa 1440 ctacattagg aattcattct tagcttcttc atctttgtgt ggatgtgtat actttacgca 1500 tctttccttt tgagtagaga aattatgtgt gtcatgtggt cttctgaaaa tggaacacca 1560 ttcttcagag cacacgtcta gccctcagca agacagttgt ttctcctcct ccttgcatat 1620 ttcctactga aatacagtgc tgtctatgat tgtttttgtt ttgttgtttt tttgagacgg 1680 tctcgctgtg tcacacaggc ggagattgca gtgagccgag atcacgctac tgcgctcagc 1740 ctgagtgata gagtgagact ctgtctcaaa aaaaagtatc tctaaataca ggattataat 1800 ttctgcttga gtatggtgtt aactaccttg tatttagaaa gatttcagat tcattccatc 1860 tccttagttt tcttttaagg tgacccatct gtgataaaaa tatagcttag tgctaaaatc 1920 agtgtaactt atacatggcc taaaatgttt ctacaaatta gagtttgtca cttattccat 1980 ttgtacctaa gagaaaaata tgctcagtta gaaaaggact ccctggccag gcgcagtgac 2040 ttacgcctgt tatctcagca ctttgggagg ccaaggcagg cagatcacga ggtcaggagt 2100 tcgagaccat cctggccaac atggtgaaac cccgtctcta ctaaaaatat aaaaattagc 2160 tgggtgtggt ggcaggagcc tgtaatccca gctacacagg aggctgaggc acgagaatca 2220 cttgaactca gggagatgga ggtttcagtg agccaagatc acaccactgc actccagcct 2280 ggcaacagag cgagaattcc atctcaaaaa aaaaaaaaaa agtaagaaaa gaaaaggact 2340 cccttagaat gggaaagaaa aatcataaaa tattgagctg aagcctgtat atagaaatta 2400 agcgtttctc gaaagctgtt ctatgttctg ccgttattta gtctttattc tcttccttga 2460 ggtggagaaa caaagtacca atttgaaggg atttttttta ttttgtcttt tggtttctgt 2520 cagtagaaat aaccatatgt gctaaccaaa tttctgtgaa gaatgttttc atggttatca 2580 ttatatctaa ctataacctc ccccatagtt atgaagagta acctgaaatg ccactattgt 2640 ggaaatagga taattgtaat tgtgaaaaaa taattttaag gaaatcttac aagtattaca 2700 ttaaaaagat actatgactg ccacctgcca tttaccttct aataaccctg ccatgtggtt 2760 tgcagaaaga gatggatata gtagcctcag aagaaatatt ttatgtgggt tttttgtttt 2820 tcgttactag atttcttgga tgaggggtta tggttgacct tttacttttt aatggagcag 2880 ccagtttttg ttaattactc acttgtaaat tgtgagattc tgaattcctt acctgctatt 2940 cttgtacttg tctcaggcca aatctatgct gtggttctta tgagacttgt atgaagatgc 3000 cctgatttgt acagattgac cacgggaata ctactgccat gtaatctgta tagttccaga 3060 taatttgtca tgaacattga cagaatgaca attttttgta tttgcttttt ctccctttaa 3120 gagcacattc ttctgtaagg agaaaggcag cattctggct aaaatgtgta gaaggtaatt 3180 tactacactt ataaaatagt gtgacttttg tgaaaatttt gaattagctt tcatatgaag 3240 tgccttaagt agactcttca tttacttttc tggtaatggt ttaaatatca tttgttatgc 3300 atttttaaga tacagttcag aatgacacat tgtagtggca aagataacca aatgtctggc 3360 tgtttgcttt ttgaccatat caataaactt ttacaatctt aaaaaaaaaa aaaaaaaaaa 3420 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3480 aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3508 4 335 PRT Homo sapiens 4 Met Ala Ala Arg Trp Arg Phe Trp Cys Val Ser Val Thr Met Val Val 1 5 10 15 Ala Leu Leu Ile Val Cys Asp Val Pro Ser Ala Ser Ala Gln Arg Lys 20 25 30 Lys Glu Met Val Leu Ser Glu Lys Val Ser Gln Leu Met Glu Trp Thr 35 40 45 Asn Lys Arg Pro Val Ile Arg Met Asn Gly Asp Lys Phe Arg Arg Leu 50 55 60 Val Lys Ala Pro Pro Arg Asn Tyr Ser Val Ile Val Met Phe Thr Ala 65 70 75 80 Leu Gln Leu His Arg Gln Cys Val Val Cys Lys Gln Ala Asp Glu Glu 85 90 95 Phe Gln Ile Leu Ala Asn Ser Trp Arg Tyr Ser Ser Ala Phe Thr Asn 100 105 110 Arg Ile Phe Phe Ala Met Val Asp Phe Asp Glu Gly Ser Asp Val Phe 115 120 125 Gln Met Leu Asn Met Asn Ser Ala Pro Thr Phe Ile Asn Phe Pro Ala 130 135 140 Lys Gly Lys Pro Lys Arg Gly Asp Thr Tyr Glu Leu Gln Val Arg Gly 145 150 155 160 Phe Ser Ala Glu Gln Ile Ala Arg Trp Ile Ala Asp Arg Thr Asp Val 165 170 175 Asn Ile Arg Val Ile Arg Pro Pro Asn Tyr Ala Gly Pro Leu Met Leu 180 185 190 Gly Leu Leu Leu Ala Val Ile Gly Gly Leu Val Tyr Leu Arg Arg Ser 195 200 205 Asn Met Glu Phe Leu Phe Asn Lys Thr Gly Trp Ala Phe Ala Ala Leu 210 215 220 Cys Phe Val Leu Ala Met Thr Ser Gly Gln Met Trp Asn His Ile Arg 225 230 235 240 Gly Pro Pro Tyr Ala His Lys Asn Pro His Thr Gly His Val Asn Tyr 245 250 255 Ile His Gly Ser Ser Gln Ala Gln Phe Val Ala Glu Thr His Ile Val 260 265 270 Leu Leu Phe Asn Gly Gly Val Thr Leu Gly Met Val Leu Leu Cys Glu 275 280 285 Ala Ala Thr Ser Asp Met Asp Ile Gly Lys Arg Lys Ile Met Cys Val 290 295 300 Ala Gly Ile Gly Leu Val Val Leu Phe Phe Ser Trp Met Leu Ser Ile 305 310 315 320 Phe Arg Ser Lys Tyr His Gly Tyr Pro Tyr Ser Phe Leu Met Ser 325 330 335 5 1697 DNA Homo sapiens 5 ttcaatgaaa acgagggggg cgcggaggag gaggcggcgg cgtcggtggc ggcggcgacg 60 gcggcgcgga ggcgaaggca gcggcgggcg cagcgaggag ggcgaggccg ggggccgaga 120 gggcgggagg gcgtagtggc ggcccgtcgg ggcggctgag gcgggcagcc gaagcagtgg 180 ctctcggagg gggaacaaag agcagcgact aaggcggcag aggagcggcg gcggtggcgg 240 cgctgcagca gcgggcggga ctggtatggt ggttccacag ggcagacccc gctgcactca 300 cagggaggag gaggcggcag cggcggagga aggcggcgca ccccgagagg catgcccaaa 360 gaaaaatacg agccccctga ccctcggagg atgtatacaa ttatgtcttc tgaggaagca 420 gcaaatggaa agaaatccca ctgggcagag cttgaaataa gtggaaaagt aagaagctta 480 agcgcatctt tgtggtcact aactcacctg acagctttgc atttgagtga caattccctg 540 tcccgaattc cttcagacat tgccaagctt cacaatctgg tgtatttgga cctgtcatct 600 aataaaattc gtagcttacc cgcagaactc ggaaacatgg tatcactcag ggagctccat 660 ttaaataaca acctgttacg agttctacct tttgagctgg gaaaactgtt tcagttgcag 720 actttaggcc tgaaaggtat gacttccata tttgtacttc ttatggtttg tgtatatgtc 780 tttgaatcta aggaagccaa gaagctttct gctaggggat tcttttaaag actcattttc 840 ccccagactt catcagtttc ttagctatat cgcaatggtt ttatcttctc tgttcagctg 900 tagactatct actagtcttt gttttctttt tttttgctcc ggacccagcc cttcttttct 960 agcctctgtt ttaatgaacc ctgtgttctg gtgatacatc cctgaggcta tgctttattt 1020 catcatgtta taaacagctg tttttcttag attcaaatct caaaaaacat ggagcctctc 1080 atatagtaca gaaaacagga agtcgaaaat gttgaccatt tgaacctgct gatgatcaag 1140 atttaagcat atttaaaaaa acttgattta tgaggacttg tgattatagg gccataattg 1200 atccagcaag aactattagg aaataaatat tttttaagcc aacaatattg aaagttatat 1260 tttgacagta tgtcaatgcc tataaatttt ttatcatgtt aagcagttct tcaccagcct 1320 tgggtaggtg tgtctagcct actgtacagt tgcttcttca aaaaagtcac tagatgaagt 1380 cgtcaagatt tgcaccctta ggccgggcac agtggctcac acctgtaatc acaaaacttt 1440 gggaggctga ggtgggtgga tatcttgagg ccaagagttc aagaccagca tgagcaacat 1500 ggcaaaaccc aatctctacc aaaaatacaa aagtcagctt ggcatggtgg ttcccacctg 1560 tagtaccacc tacttgggag gctgaggcat gagatttgct tgaacctggg aagcagaggt 1620 tgaagtgagg tgacattgtg gcattgcact ccagcctggg tgacagagcg agactctgtc 1680 ttaaaaaaaa aaaaaaa 1697 6 158 PRT Homo sapiens 6 Met Pro Lys Glu Lys Tyr Glu Pro Pro Asp Pro Arg Arg Met Tyr Thr 1 5 10 15 Ile Met Ser Ser Glu Glu Ala Ala Asn Gly Lys Lys Ser His Trp Ala 20 25 30 Glu Leu Glu Ile Ser Gly Lys Val Arg Ser Leu Ser Ala Ser Leu Trp 35 40 45 Ser Leu Thr His Leu Thr Ala Leu His Leu Ser Asp Asn Ser Leu Ser 50 55 60 Arg Ile Pro Ser Asp Ile Ala Lys Leu His Asn Leu Val Tyr Leu Asp 65 70 75 80 Leu Ser Ser Asn Lys Ile Arg Ser Leu Pro Ala Glu Leu Gly Asn Met 85 90 95 Val Ser Leu Arg Glu Leu His Leu Asn Asn Asn Leu Leu Arg Val Leu 100 105 110 Pro Phe Glu Leu Gly Lys Leu Phe Gln Leu Gln Thr Leu Gly Leu Lys 115 120 125 Gly Met Thr Ser Ile Phe Val Leu Leu Met Val Cys Val Tyr Val Phe 130 135 140 Glu Ser Lys Glu Ala Lys Lys Leu Ser Ala Arg Gly Phe Phe 145 150 155 7 1462 DNA Homo sapiens 7 gctagccgcc tgggaattta agggacccac actaccttcc cgaagttgaa ggcaagcggt 60 gattgtttgt agacggcgct ttgtcatggg acctgtgcgg ttgggaatat tgcttttcct 120 ttttttggcc gtgcacgagg cttgggctgg gatgttgaag gaggaggacg atgacacaga 180 acgcttgccc agcaaatgcg aagtgtgtaa gctgctgagc acagagctac aggcggaact 240 gagtcgcacc ggtcgatctc gagaggtgct ggagctgggg caggtgctgg atacaggcaa 300 gaggaagaga cacgtgcctt acagcgtttc agagacaagg ctggaagagg ccttagagaa 360 tttatgtgag cggatcctgg actatagtgt tcacgctgag cgcaagggct cactgagata 420 tgccaagggt cagagtcaga ccatggcaac actgaaaggc ctagtgcaga agggggtgaa 480 ggtggatctg gggatccctc tggagctttg ggatgagccc agcgtggagg tcacatacct 540 caagaagcag tgtgagacca tgttggagga gtttgaagac attgtgggag actggtactt 600 ccaccatcag gagcagcccc tacaaaattt tctctgtgaa ggtcatgtgc tcccagctgc 660 tgaaactgca tgtctacagg aaacttggac tggaaaggag atcacagatg gggaagagaa 720 aacagaaggg gaggaagagc aggaggagga ggaggaagag gaggaagagg aagggggaga 780 caagatgacc aagacaggaa gccaccccaa acttgaccga gaagatcttt gacccttgcc 840 tttgagcccc caggagggga agggatcatg gagagccctc taaagcctgc actctccctg 900 ctccacagct ttcagggtgt gtttatgagt gactccaccc aagcttgtag ctgttctctc 960 ccatctaacc tcaggcaaga tcctggtgaa acagcatgac atggcttctg gggtggaggg 1020 tgggggtgga ggtcctgctc ctagagatga actctatcca gccccttaat tggcaggtgt 1080 atgtgctgac agtactgaaa gctttcctct ttaactgatc ccacccccac ccaaaagtca 1140 gcagtggcac tggagctgtg ggctttgggg aagtcactta gctccttaag gtctgttttt 1200 agacccttcc aaggaagagg ccagaacgga cattctctgc gatctatata cattgcctgt 1260 atccaggagg ctacacacca gcaaaccgtg aaggagaatg ggacactggg tcatggcctg 1320 gagttgctga taatttaggt gggatagata cttggtctac ttaagctcaa tgtaacccag 1380 agcccaccat atagttttat aggtgctcaa ttttctatat cgctattaaa cttttttctt 1440 tttttctaaa aaaaaaaaaa aa 1462 8 248 PRT Homo sapiens 8 Met Gly Pro Val Arg Leu Gly Ile Leu Leu Phe Leu Phe Leu Ala Val 1 5 10 15 His Glu Ala Trp Ala Gly Met Leu Lys Glu Glu Asp Asp Asp Thr Glu 20 25 30 Arg Leu Pro Ser Lys Cys Glu Val Cys Lys Leu Leu Ser Thr Glu Leu 35 40 45 Gln Ala Glu Leu Ser Arg Thr Gly Arg Ser Arg Glu Val Leu Glu Leu 50 55 60 Gly Gln Val Leu Asp Thr Gly Lys Arg Lys Arg His Val Pro Tyr Ser 65 70 75 80 Val Ser Glu Thr Arg Leu Glu Glu Ala Leu Glu Asn Leu Cys Glu Arg 85 90 95 Ile Leu Asp Tyr Ser Val His Ala Glu Arg Lys Gly Ser Leu Arg Tyr 100 105 110 Ala Lys Gly Gln Ser Gln Thr Met Ala Thr Leu Lys Gly Leu Val Gln 115 120 125 Lys Gly Val Lys Val Asp Leu Gly Ile Pro Leu Glu Leu Trp Asp Glu 130 135 140 Pro Ser Val Glu Val Thr Tyr Leu Lys Lys Gln Cys Glu Thr Met Leu 145 150 155 160 Glu Glu Phe Glu Asp Ile Val Gly Asp Trp Tyr Phe His His Gln Glu 165 170 175 Gln Pro Leu Gln Asn Phe Leu Cys Glu Gly His Val Leu Pro Ala Ala 180 185 190 Glu Thr Ala Cys Leu Gln Glu Thr Trp Thr Gly Lys Glu Ile Thr Asp 195 200 205 Gly Glu Glu Lys Thr Glu Gly Glu Glu Glu Gln Glu Glu Glu Glu Glu 210 215 220 Glu Glu Glu Glu Glu Gly Gly Asp Lys Met Thr Lys Thr Gly Ser His 225 230 235 240 Pro Lys Leu Asp Arg Glu Asp Leu 245 9 2104 DNA Homo sapiens 9 ccccttgccg ctccggtgac agtctctgcg gaaagtcacg tktgtgattt cgggagagca 60 cagaacggga cgacggcgct cttgctgggt catctgggcc aggtgacgaa gaaacagttt 120 cctggtgaag cagtccctca cccctagtca gcccacaccc ctagggccta aagatgctga 180 ggtctgtatg gaattttctg aaacgccaca aaaagaaatg catcttcctg ggcacggtcc 240 ttggaggagt atatattctg gggaaatatg gacagaagaa aatcagagaa atacaggaaa 300 gggaggctgc agaatacatt gcccaagcac gacgacaata tcattttgaa agtaaccaga 360 ggacttgcaa tatgacagtg ctgtccatgc ttccaacact gagagaggcc ttaatgcagc 420 aactgaattc cgagagcctc acagctctgc taaaaaacag gccttcaaac aagctagaaa 480 tatgggagga tctgaagata ataagtttca caagaagtac tgtggctgta tacagtacct 540 gtatgctggt tgttcttttg cgggtccagt taaacataat tggtggatat atttacctgg 600 ataatgcagc agttggcaaa aatggcacta caattcttgc tcccccagat gtccaacagc 660 agtatttatc aagtattcag cacctacttg gagatggcct gacagaattg atcactgtca 720 ttaaacaagc tgtgcagaag gttttaggaa gtgtttctct taaacattct ttgtcccttt 780 tggacttgga gcaaaaacta aaagaaatca gaaatctcgt tgagcagcat aagtcttctt 840 cttggattaa taaagatgga tccaaacctt tattatgcca ttatatgatg ccagatgaag 900 aaactccatt agcagtgcag gcctgtggac tttctcctcg agacattacc actattaaac 960 ttctcaatga aactagagac atgttggaaa gcccagattt tagtacagtt ttgaatacct 1020 gtttaaaccg aggttttagt agacttctag acaatatggc tgagttcttt cgacctactg 1080 aacaggacct gcaacatggt aactctatga atagtctttc cagtgtcagc ctgcctttag 1140 ctaagataat tccaatagta aacggacaga tccattcagt ttgcagtgaa acacctagtc 1200 attttgttca ggatctgttg acaatggagc aagtgaaaga ctttgctgct aatgtgtatg 1260 aagcttttag tacccctcag caactggaga aatgattttt ccttcaagaa aaactacagt 1320 gggattcatt tactttttaa aatacactgg gtaaatcacc tatacttaga gtaacagttt 1380 gttatcaaaa tgcctgataa aatatattct taataaaagt cttcatttca taatgaaatc 1440 aatttatttg gcatcttaat atattttttt agattcatca acagaccagt ttttgtgggc 1500 atatatatat acacgtgcaa atatcagaat tgttaataat ttgttacaca tggacatttg 1560 ttccaaactg actaaaaatc aatatagata ttttatatac atatatatat ataaaaatac 1620 aaaattcagt gtactttacc atattaatac tgaggaaaaa tctgttggag acataggtct 1680 aggatgtgtg aagtttggaa aaatatgcta tttaattata atgttcccta gactgctgta 1740 aacagaagtg aatcagactt ttctccagct acctttcaaa ataataaatt atttgtctca 1800 aatatacctt gatggaggac ttttttattc ttatggaaat agtgaattcc aacaactatg 1860 atgaactatg ttctttgcta tttcttcact atatttttta aggttttatt aaaaagcctt 1920 agaaagttac atattggttt agaggctaaa attgtgttga tgctgtttac tcacctaatt 1980 acatagtttt aatcatttgt acataatttt aaaaacttac tttgtattga ttttgaatac 2040 agtgaaaatc ttattgcaat aaactatttt agtaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100 aaaa 2104 10 373 PRT Homo sapiens 10 Met Leu Arg Ser Val Trp Asn Phe Leu Lys Arg His Lys Lys Lys Cys 1 5 10 15 Ile Phe Leu Gly Thr Val Leu Gly Gly Val Tyr Ile Leu Gly Lys Tyr 20 25 30 Gly Gln Lys Lys Ile Arg Glu Ile Gln Glu Arg Glu Ala Ala Glu Tyr 35 40 45 Ile Ala Gln Ala Arg Arg Gln Tyr His Phe Glu Ser Asn Gln Arg Thr 50 55 60 Cys Asn Met Thr Val Leu Ser Met Leu Pro Thr Leu Arg Glu Ala Leu 65 70 75 80 Met Gln Gln Leu Asn Ser Glu Ser Leu Thr Ala Leu Leu Lys Asn Arg 85 90 95 Pro Ser Asn Lys Leu Glu Ile Trp Glu Asp Leu Lys Ile Ile Ser Phe 100 105 110 Thr Arg Ser Thr Val Ala Val Tyr Ser Thr Cys Met Leu Val Val Leu 115 120 125 Leu Arg Val Gln Leu Asn Ile Ile Gly Gly Tyr Ile Tyr Leu Asp Asn 130 135 140 Ala Ala Val Gly Lys Asn Gly Thr Thr Ile Leu Ala Pro Pro Asp Val 145 150 155 160 Gln Gln Gln Tyr Leu Ser Ser Ile Gln His Leu Leu Gly Asp Gly Leu 165 170 175 Thr Glu Leu Ile Thr Val Ile Lys Gln Ala Val Gln Lys Val Leu Gly 180 185 190 Ser Val Ser Leu Lys His Ser Leu Ser Leu Leu Asp Leu Glu Gln Lys 195 200 205 Leu Lys Glu Ile Arg Asn Leu Val Glu Gln His Lys Ser Ser Ser Trp 210 215 220 Ile Asn Lys Asp Gly Ser Lys Pro Leu Leu Cys His Tyr Met Met Pro 225 230 235 240 Asp Glu Glu Thr Pro Leu Ala Val Gln Ala Cys Gly Leu Ser Pro Arg 245 250 255 Asp Ile Thr Thr Ile Lys Leu Leu Asn Glu Thr Arg Asp Met Leu Glu 260 265 270 Ser Pro Asp Phe Ser Thr Val Leu Asn Thr Cys Leu Asn Arg Gly Phe 275 280 285 Ser Arg Leu Leu Asp Asn Met Ala Glu Phe Phe Arg Pro Thr Glu Gln 290 295 300 Asp Leu Gln His Gly Asn Ser Met Asn Ser Leu Ser Ser Val Ser Leu 305 310 315 320 Pro Leu Ala Lys Ile Ile Pro Ile Val Asn Gly Gln Ile His Ser Val 325 330 335 Cys Ser Glu Thr Pro Ser His Phe Val Gln Asp Leu Leu Thr Met Glu 340 345 350 Gln Val Lys Asp Phe Ala Ala Asn Val Tyr Glu Ala Phe Ser Thr Pro 355 360 365 Gln Gln Leu Glu Lys 370 11 3262 DNA Homo sapiens 11 gccaagatgg agccggcagt cggcggtccg ggcccactga tcgtgaacaa caaacagccc 60 cagcccccgc cacctccgcc gccggcagcc gcacagccac cacccggggc accgcgggcc 120 gccgcgggcc tcctgcctgg gggcaaagcc cgcgagttca accgcaacca gcgcaaagac 180 tcagagggct attcggagtc accagacctg gagtttgagt atgctgacac agacaagtgg 240 gctgcagagc tctcggagct ttacagctac acggaagggc cagaattcct gatgaatcga 300 aaatgctttg aggaggactt ccggatccat gtgacagaca agaagtggac tgagctggat 360 accaaccagc accggaccca tgccatgagg ctcctggatg gcttggaagt cactgccagg 420 gagaagagac tcaaggtggc tcgagcaatt ctctatgttg ctcaaggcac gtttggggag 480 tgcagctcgg aggcagaggt gcagtcctgg atgcgctaca acatctttct cctcctggag 540 gtgggcacgt tcaatgcttt ggtggagctt ctgaacatgg aaatagacaa cagtgccgcc 600 tgcagcagtg ctgtgaggaa gcctgccatc tccctggctg acagcacaga cctcagggtc 660 ctgctcaaca tcatgtacct gatagtggag accgttcatc aggagtgtga gggtgacaag 720 gctgagtgga ggaccatgcg gcagaccttc agagccgagc tgggctcccc gctgtacaac 780 aatgagccat ttgccatcat gctgtttggg atggtgacca aattttgcag tggtcacgcc 840 cctcactttc ccatgaagaa agttctcttg ctgctctgga agacagtatt gtgcacgcta 900 ggcggctttg aggagctgca gagcatgaag gctgagaagc gcagcatcct gggcctcccc 960 ccgcttcctg aggacagcat caaagtgatt cgcaacatga gagcagcctc tccaccagca 1020 tctgcttcag acttgattga gcagcagcag aaacggggcc gccgagagca caaggctctg 1080 ataaagcagg acaacctaga tgccttcaac gagcgggatc cctacaaggc tgatgactct 1140 cgagaagagg aagaggagaa tgatgatgac aacagtctgg agggggagac gtttcccctg 1200 gaacgggatg aagtgatgcc tcccccgcta cagcacccac agactgacag gctgacttgc 1260 cccaaagggc tcccgtgggc tcccaaggtc agagagaaag acattgagat gttccttgag 1320 tccagccgca gcaaatttat aggttacact ctaggcagtg acacgaacac agtggtgggg 1380 ctgcccaggc caatccacga aagcatcaag actctgaaac agcacaagta cacgtcgatt 1440 gcagaggtcc aggcacagat ggaggaggaa tacctccgct cccctctctc agggggagaa 1500 gaagaagttg agcaagtccc tgcagaaacc ctctaccaag gcttgctccc cagcctgcct 1560 cagtatatga ttgccctcct gaagatcctg ttggctgcag cacccacctc aaaagccaaa 1620 acagactcaa tcaacatcct agcggacgtc ttgcctgagg agatgcccac cacagtgttg 1680 cagagcatga agctgggggt ggatgtaaac cgccacaaag aggtcattgt taaggccatt 1740 tctgctgtcc tgctgctgct gctcaagcac tttaagttga accatgtcta ccagtttgaa 1800 tacatggccc agcacctggt gtttgccaac tgcattcctt tgatcctaaa gttcttcaat 1860 caaaacatca tgtcctacat cactgccaag aacagcattt ctgtcctgga ttaccctcac 1920 tgcgtggtgc atgagctgcc agagctgacg gcggagagtt tggaagcagg tgacagtaac 1980 caattttgct ggaggaacct cttttcttgt atcaatctgc ttcggatctt gaacaagctg 2040 acaaagtgga agcattcaag gacaatgatg ctggtggtgt tcaagtcagc ccccatcttg 2100 aagcgggccc taaaggtgaa acaagccatg atgcagctct atgtgctgaa gctgctcaag 2160 gtacagacca aatacttggg gcggcagtgg cgaaagagca acatgaagac catgtctgcc 2220 atctaccaga aggtgcggca tcggctgaac gacgactggg catacggcaa tgatcttgat 2280 gcccggcctt gggacttcca ggcagaggag tgtgcccttc gtgccaacat tgaacgcttc 2340 aacgcccggc gctatgaccg ggcccacagc aaccctgact tcctgccagt ggacaactgc 2400 ctgcagagtg tcctgggcca acgggtggac ctccctgagg actttcagat gaactatgac 2460 ctctggttag aaagggaggt cttctccaag cccatttcct gggaagagct gctgcagtga 2520 ggctgttggt taggggactg aaatggagag aaaagatgat ctgaaggtac ctgtgggact 2580 gtcctagttc attgctgcag tgctcccatc ccccaccagg tggcagcaca gccccactgt 2640 gtcttccgca gtctgtcctg ggcttgggtg agcccagctt gacctcccct tggttcccag 2700 ggtcctgctc cgaagcagtc atctctgcct gagatccatt cttcctttac ttcccccacc 2760 ctcctctctt ggatatggtt ggttttggct catttcacaa tcagcccaag gctgggaaag 2820 ctggaatggg atgggaaccc ctccgccgtg catctgaatt tcaggggtca tgctgatgcc 2880 tctcgagaca tacaaatcct tgctttgtca gcttgcaaag gaggagagtt taggattagg 2940 gccagggcca gaaagtcggt atcttggttg tgctctgggg tgggggtggg gtgtttctga 3000 tgttattcca gcctcctgct acattatatc cagaagtaat tgcggaggct ccttcagctg 3060 cctcagcact ttgattttgg acagggacaa ggtaggaaga gaagcttccc ttaaccagag 3120 gggccatttt tccttttggc tttcgagggc ctgtaaatat ctatatataa ttctgtgtgt 3180 attctgtgtc atgttggggt ttttaatgtg attgtgtatt ctgtttacat taaaaagaag 3240 caaaaataaa aaaaaaaaaa aa 3262 12 837 PRT Homo sapiens 12 Met Glu Pro Ala Val Gly Gly Pro Gly Pro Leu Ile Val Asn Asn Lys 1 5 10 15 Gln Pro Gln Pro Pro Pro Pro Pro Pro Pro Ala Ala Ala Gln Pro Pro 20 25 30 Pro Gly Ala Pro Arg Ala Ala Ala Gly Leu Leu Pro Gly Gly Lys Ala 35 40 45 Arg Glu Phe Asn Arg Asn Gln Arg Lys Asp Ser Glu Gly Tyr Ser Glu 50 55 60 Ser Pro Asp Leu Glu Phe Glu Tyr Ala Asp Thr Asp Lys Trp Ala Ala 65 70 75 80 Glu Leu Ser Glu Leu Tyr Ser Tyr Thr Glu Gly Pro Glu Phe Leu Met 85 90 95 Asn Arg Lys Cys Phe Glu Glu Asp Phe Arg Ile His Val Thr Asp Lys 100 105 110 Lys Trp Thr Glu Leu Asp Thr Asn Gln His Arg Thr His Ala Met Arg 115 120 125 Leu Leu Asp Gly Leu Glu Val Thr Ala Arg Glu Lys Arg Leu Lys Val 130 135 140 Ala Arg Ala Ile Leu Tyr Val Ala Gln Gly Thr Phe Gly Glu Cys Ser 145 150 155 160 Ser Glu Ala Glu Val Gln Ser Trp Met Arg Tyr Asn Ile Phe Leu Leu 165 170 175 Leu Glu Val Gly Thr Phe Asn Ala Leu Val Glu Leu Leu Asn Met Glu 180 185 190 Ile Asp Asn Ser Ala Ala Cys Ser Ser Ala Val Arg Lys Pro Ala Ile 195 200 205 Ser Leu Ala Asp Ser Thr Asp Leu Arg Val Leu Leu Asn Ile Met Tyr 210 215 220 Leu Ile Val Glu Thr Val His Gln Glu Cys Glu Gly Asp Lys Ala Glu 225 230 235 240 Trp Arg Thr Met Arg Gln Thr Phe Arg Ala Glu Leu Gly Ser Pro Leu 245 250 255 Tyr Asn Asn Glu Pro Phe Ala Ile Met Leu Phe Gly Met Val Thr Lys 260 265 270 Phe Cys Ser Gly His Ala Pro His Phe Pro Met Lys Lys Val Leu Leu 275 280 285 Leu Leu Trp Lys Thr Val Leu Cys Thr Leu Gly Gly Phe Glu Glu Leu 290 295 300 Gln Ser Met Lys Ala Glu Lys Arg Ser Ile Leu Gly Leu Pro Pro Leu 305 310 315 320 Pro Glu Asp Ser Ile Lys Val Ile Arg Asn Met Arg Ala Ala Ser Pro 325 330 335 Pro Ala Ser Ala Ser Asp Leu Ile Glu Gln Gln Gln Lys Arg Gly Arg 340 345 350 Arg Glu His Lys Ala Leu Ile Lys Gln Asp Asn Leu Asp Ala Phe Asn 355 360 365 Glu Arg Asp Pro Tyr Lys Ala Asp Asp Ser Arg Glu Glu Glu Glu Glu 370 375 380 Asn Asp Asp Asp Asn Ser Leu Glu Gly Glu Thr Phe Pro Leu Glu Arg 385 390 395 400 Asp Glu Val Met Pro Pro Pro Leu Gln His Pro Gln Thr Asp Arg Leu 405 410 415 Thr Cys Pro Lys Gly Leu Pro Trp Ala Pro Lys Val Arg Glu Lys Asp 420 425 430 Ile Glu Met Phe Leu Glu Ser Ser Arg Ser Lys Phe Ile Gly Tyr Thr 435 440 445 Leu Gly Ser Asp Thr Asn Thr Val Val Gly Leu Pro Arg Pro Ile His 450 455 460 Glu Ser Ile Lys Thr Leu Lys Gln His Lys Tyr Thr Ser Ile Ala Glu 465 470 475 480 Val Gln Ala Gln Met Glu Glu Glu Tyr Leu Arg Ser Pro Leu Ser Gly 485 490 495 Gly Glu Glu Glu Val Glu Gln Val Pro Ala Glu Thr Leu Tyr Gln Gly 500 505 510 Leu Leu Pro Ser Leu Pro Gln Tyr Met Ile Ala Leu Leu Lys Ile Leu 515 520 525 Leu Ala Ala Ala Pro Thr Ser Lys Ala Lys Thr Asp Ser Ile Asn Ile 530 535 540 Leu Ala Asp Val Leu Pro Glu Glu Met Pro Thr Thr Val Leu Gln Ser 545 550 555 560 Met Lys Leu Gly Val Asp Val Asn Arg His Lys Glu Val Ile Val Lys 565 570 575 Ala Ile Ser Ala Val Leu Leu Leu Leu Leu Lys His Phe Lys Leu Asn 580 585 590 His Val Tyr Gln Phe Glu Tyr Met Ala Gln His Leu Val Phe Ala Asn 595 600 605 Cys Ile Pro Leu Ile Leu Lys Phe Phe Asn Gln Asn Ile Met Ser Tyr 610 615 620 Ile Thr Ala Lys Asn Ser Ile Ser Val Leu Asp Tyr Pro His Cys Val 625 630 635 640 Val His Glu Leu Pro Glu Leu Thr Ala Glu Ser Leu Glu Ala Gly Asp 645 650 655 Ser Asn Gln Phe Cys Trp Arg Asn Leu Phe Ser Cys Ile Asn Leu Leu 660 665 670 Arg Ile Leu Asn Lys Leu Thr Lys Trp Lys His Ser Arg Thr Met Met 675 680 685 Leu Val Val Phe Lys Ser Ala Pro Ile Leu Lys Arg Ala Leu Lys Val 690 695 700 Lys Gln Ala Met Met Gln Leu Tyr Val Leu Lys Leu Leu Lys Val Gln 705 710 715 720 Thr Lys Tyr Leu Gly Arg Gln Trp Arg Lys Ser Asn Met Lys Thr Met 725 730 735 Ser Ala Ile Tyr Gln Lys Val Arg His Arg Leu Asn Asp Asp Trp Ala 740 745 750 Tyr Gly Asn Asp Leu Asp Ala Arg Pro Trp Asp Phe Gln Ala Glu Glu 755 760 765 Cys Ala Leu Arg Ala Asn Ile Glu Arg Phe Asn Ala Arg Arg Tyr Asp 770 775 780 Arg Ala His Ser Asn Pro Asp Phe Leu Pro Val Asp Asn Cys Leu Gln 785 790 795 800 Ser Val Leu Gly Gln Arg Val Asp Leu Pro Glu Asp Phe Gln Met Asn 805 810 815 Tyr Asp Leu Trp Leu Glu Arg Glu Val Phe Ser Lys Pro Ile Ser Trp 820 825 830 Glu Glu Leu Leu Gln 835 13 1264 DNA Homo sapiens 13 cttgaacgca cctcaggatg gcccgtactt tggaaccact agcaaagaag atctttaaag 60 gagttttggt agccgaactt gtaggcgttt ttggagcata ttttttgttt agcaagatgc 120 acacaagcca agatttcagg caaacaatga gcaagaaata tcccttcatc ttggaagttt 180 attacaaatc cactgagaag tctggaatgt atggaatcag agagctagat caaaaaacat 240 ggttgaacag caaaaattag atgtaaggaa gatctgcatt caaatgtgag tgggcaccat 300 ccaatctgct ggggccctgg agagaacaaa acaaagaggc aaacatgttg atctgctgtg 360 ctgaggagga aaatggcgga taaggggaca ggactaacgt gcagctccca catggatgga 420 cagaacagcg tgtggcaacg tgtttagtct ccttaaaagg atttcactct gtcacccagg 480 ctggagtgca gtggcgtaat cttggctcac ggcaacctct gactcctgga ttcaggcgat 540 tctcgtgcct ctgcttctcg agtagctggg actacaggtg cgtgccacca tgcccagctc 600 attttttggg gtttttagtg gagacagggt ttcaccgtgt tggccaggct ggtctcgaac 660 tcctgacctc aaacaatctt cctgcctcgg cctgccgagg tgctgggatt acaggtgtga 720 gccacagcgc ctggccccaa atatttctta atcttccact gtgatttgca tgatattctt 780 agctaagtga ttttttaaaa ctaaggccac ttctcccact aatgttccat ggtctattaa 840 cacatagtag tagattattt tacaaagagt caacaaaaca aattaccaat cagctcttca 900 aattcttcat catccacgtc ttctatactt tcttcatctg catcccgttt ttgtttctct 960 ttaacagcaa cttttttata atacctataa tattcatgtt atatatttga caattttatt 1020 aaaggtctaa tcttactata tatcatcaaa gcacctatga ccagtggcaa accacaactg 1080 taaaatctta agtatactca attggaaata aatgactgaa atttgtatct aatatacaaa 1140 aaatagttta actcaataaa aagtagctgg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260 aaaa 1264 14 80 PRT Homo sapiens 14 Met Ala Arg Thr Leu Glu Pro Leu Ala Lys Lys Ile Phe Lys Gly Val 1 5 10 15 Leu Val Ala Glu Leu Val Gly Val Phe Gly Ala Tyr Phe Leu Phe Ser 20 25 30 Lys Met His Thr Ser Gln Asp Phe Arg Gln Thr Met Ser Lys Lys Tyr 35 40 45 Pro Phe Ile Leu Glu Val Tyr Tyr Lys Ser Thr Glu Lys Ser Gly Met 50 55 60 Tyr Gly Ile Arg Glu Leu Asp Gln Lys Thr Trp Leu Asn Ser Lys Asn 65 70 75 80 15 2671 DNA Homo sapiens 15 ccgtacacgc gcgctgcggc atggcggccc accgccccgg cccgctcaag cagcagaata 60 aagctcataa aggcggacgg catcggggtc ggggatctgc acagcgggac ggcaagggcc 120 gtctggcact gaaaacccta agcaagaagg tgagaaaaga actcagcaga gtcgaccaga 180 ggcatcgcgc cagccagctc cgaaagcaga agaaggaggc ggttctggca gagaagagac 240 agctgggtgg caaggatggc cctcctcatc aggtactggt ggtgcccctg cacagcagaa 300 tttccctgcc agaggccatg cagctgcttc aagataggga cactggaaca gtacacttga 360 atgaattggg aaacacccag aactttatgc tgctgtgccc ccgcttgaaa catctgtggt 420 ttttcacctc agcaaggcca ggggatctgc acgttgtgtt agacatggct aaagtagctg 480 ataccatcct gttcctcctt gatccactag aaggctggga cagcacccgt gattactgtc 540 tttcctgcct ctttgctcag ggccttccga cctatacact agctgtccag gggatttctg 600 gcctcccact gaagaaacaa atagatacca ggaagaagct aagtaaagca gtggagaagc 660 gctttccgca tgacaaactc ctcttgttag acactcaaca ggaggcaggg atgctgctta 720 ggcagttggc taaccagaag caacagcatc ttgcttttcg agatcggcgg gcctacctat 780 ttgcccatgc tgttgatttt gttcctagtg aagagaataa cttggtgggc accttgaaaa 840 tttcaggcta tgttcgaggg cagactctga atgtcaatag gttgctgcat atcgttggat 900 atggtgattt gccagatgaa cagatagatg cccccggaga ccctttccct ttaaatccta 960 gaggaattaa accccaaaag gacccagaca tggcaatgga gatttgtgct acggatgctg 1020 tagatgatat ggaagaaggt cttaaagtcc taatgaaggc agaccctggt agacaggaat 1080 ccttgcaagc agaggttatc ccagatccaa tggagggaga gcaaacctgg cccactgagg 1140 aggagctgag cgaggcaaag gatttcttga aggaaagttc taaggtggta aagaaggtcc 1200 ccaaaggaac atccagttac caagctgaat ggattttgga tggtggcagc caaagtggtg 1260 gggaaggaga tgaatatgaa tatgatgata tggaacatga ggattttatg gaggaggaat 1320 ctcaggatga gagtagtgaa gaagaggaag aatatgaaac tatgactatt ggggagtctg 1380 tgcatgatga tctgtatgat aagaaagtag atgaagaagc tgaggcaaaa atgttggaga 1440 aatataaaca agaaagactg gaagagatgt ttccagatga agtggacacg ccccgtgatg 1500 tggctgctcg aattcgattt cagaaataca gaggccttaa gagcttccgg acatctccat 1560 gggatcctaa ggaaaacctt cctcaagatt atgctcgaat atttcagttt cagaacttta 1620 ctaacactag gaaaagcatc tttaaagagg ttgaagaaaa agaggttgaa ggagctgagg 1680 ttggctggta tgtcacactt catgtctctg aagtccccgt ctcagtggtc gagtgcttca 1740 ggcaaggaac acccttgatt gcattttctt tactacctca tgaacagaag atgtcagtat 1800 tgaatatggt ggtgaggcgt gaccctggca acactgaacc tgtgaaagcc aaggaagagc 1860 tcatatttca ctgtggattc aggcgcttcc gagcctcacc tttattctct cagcacactg 1920 cagcggacaa acataaattg cagagattcc tgactgctga catggccctg gtggcgacag 1980 tctatgcgcc aatcactttt cctcctgcat ctgtgctgct tttcaagcaa aaaagcaatg 2040 gaatgcacag cctcattgct acaggccatc ttatgtcagt agatccagac agaatggtca 2100 tcaagagagt tgttctgagt ggtcatcctt tcaaaatttt tactaagatg gcagtagtac 2160 gttacatgtt cttcaacaga gaggatgtgc tgtggtttaa accagtggaa ctgagaacga 2220 agtggggccg gagaggacat atcaaggaac ctttaggtac ccatggccac atgaaatgca 2280 gctttgatgg gaagctaaaa tctcaagaca cagtactgat gaacctgtat aaacgagtct 2340 tccccaaatg gacttatgat ccatatgtac cagaaccagt accctggctg aaaagtgaga 2400 tttcttcaac agtgcctcaa gggggcatgg agtaatggat tcaaagagat tctgtcttac 2460 cggtgccagt cagtactcca gggatgggag gcacaagttg tgattgggca aagtttattt 2520 tctatgtcag cctgtcagtc cactgcccca ttttgcaaga ctttttttta gccttgacaa 2580 aatgtctcag ttaagtataa aagtttttcc actacttagt ccaaaaaaaa ctattaaatc 2640 ttaatgaaat aaaaaaaaaa aaaaaaaaaa a 2671 16 804 PRT Homo sapiens 16 Met Ala Ala His Arg Pro Gly Pro Leu Lys Gln Gln Asn Lys Ala His 1 5 10 15 Lys Gly Gly Arg His Arg Gly Arg Gly Ser Ala Gln Arg Asp Gly Lys 20 25 30 Gly Arg Leu Ala Leu Lys Thr Leu Ser Lys Lys Val Arg Lys Glu Leu 35 40 45 Ser Arg Val Asp Gln Arg His Arg Ala Ser Gln Leu Arg Lys Gln Lys 50 55 60 Lys Glu Ala Val Leu Ala Glu Lys Arg Gln Leu Gly Gly Lys Asp Gly 65 70 75 80 Pro Pro His Gln Val Leu Val Val Pro Leu His Ser Arg Ile Ser Leu 85 90 95 Pro Glu Ala Met Gln Leu Leu Gln Asp Arg Asp Thr Gly Thr Val His 100 105 110 Leu Asn Glu Leu Gly Asn Thr Gln Asn Phe Met Leu Leu Cys Pro Arg 115 120 125 Leu Lys His Leu Trp Phe Phe Thr Ser Ala Arg Pro Gly Asp Leu His 130 135 140 Val Val Leu Asp Met Ala Lys Val Ala Asp Thr Ile Leu Phe Leu Leu 145 150 155 160 Asp Pro Leu Glu Gly Trp Asp Ser Thr Arg Asp Tyr Cys Leu Ser Cys 165 170 175 Leu Phe Ala Gln Gly Leu Pro Thr Tyr Thr Leu Ala Val Gln Gly Ile 180 185 190 Ser Gly Leu Pro Leu Lys Lys Gln Ile Asp Thr Arg Lys Lys Leu Ser 195 200 205 Lys Ala Val Glu Lys Arg Phe Pro His Asp Lys Leu Leu Leu Leu Asp 210 215 220 Thr Gln Gln Glu Ala Gly Met Leu Leu Arg Gln Leu Ala Asn Gln Lys 225 230 235 240 Gln Gln His Leu Ala Phe Arg Asp Arg Arg Ala Tyr Leu Phe Ala His 245 250 255 Ala Val Asp Phe Val Pro Ser Glu Glu Asn Asn Leu Val Gly Thr Leu 260 265 270 Lys Ile Ser Gly Tyr Val Arg Gly Gln Thr Leu Asn Val Asn Arg Leu 275 280 285 Leu His Ile Val Gly Tyr Gly Asp Leu Pro Asp Glu Gln Ile Asp Ala 290 295 300 Pro Gly Asp Pro Phe Pro Leu Asn Pro Arg Gly Ile Lys Pro Gln Lys 305 310 315 320 Asp Pro Asp Met Ala Met Glu Ile Cys Ala Thr Asp Ala Val Asp Asp 325 330 335 Met Glu Glu Gly Leu Lys Val Leu Met Lys Ala Asp Pro Gly Arg Gln 340 345 350 Glu Ser Leu Gln Ala Glu Val Ile Pro Asp Pro Met Glu Gly Glu Gln 355 360 365 Thr Trp Pro Thr Glu Glu Glu Leu Ser Glu Ala Lys Asp Phe Leu Lys 370 375 380 Glu Ser Ser Lys Val Val Lys Lys Val Pro Lys Gly Thr Ser Ser Tyr 385 390 395 400 Gln Ala Glu Trp Ile Leu Asp Gly Gly Ser Gln Ser Gly Gly Glu Gly 405 410 415 Asp Glu Tyr Glu Tyr Asp Asp Met Glu His Glu Asp Phe Met Glu Glu 420 425 430 Glu Ser Gln Asp Glu Ser Ser Glu Glu Glu Glu Glu Tyr Glu Thr Met 435 440 445 Thr Ile Gly Glu Ser Val His Asp Asp Leu Tyr Asp Lys Lys Val Asp 450 455 460 Glu Glu Ala Glu Ala Lys Met Leu Glu Lys Tyr Lys Gln Glu Arg Leu 465 470 475 480 Glu Glu Met Phe Pro Asp Glu Val Asp Thr Pro Arg Asp Val Ala Ala 485 490 495 Arg Ile Arg Phe Gln Lys Tyr Arg Gly Leu Lys Ser Phe Arg Thr Ser 500 505 510 Pro Trp Asp Pro Lys Glu Asn Leu Pro Gln Asp Tyr Ala Arg Ile Phe 515 520 525 Gln Phe Gln Asn Phe Thr Asn Thr Arg Lys Ser Ile Phe Lys Glu Val 530 535 540 Glu Glu Lys Glu Val Glu Gly Ala Glu Val Gly Trp Tyr Val Thr Leu 545 550 555 560 His Val Ser Glu Val Pro Val Ser Val Val Glu Cys Phe Arg Gln Gly 565 570 575 Thr Pro Leu Ile Ala Phe Ser Leu Leu Pro His Glu Gln Lys Met Ser 580 585 590 Val Leu Asn Met Val Val Arg Arg Asp Pro Gly Asn Thr Glu Pro Val 595 600 605 Lys Ala Lys Glu Glu Leu Ile Phe His Cys Gly Phe Arg Arg Phe Arg 610 615 620 Ala Ser Pro Leu Phe Ser Gln His Thr Ala Ala Asp Lys His Lys Leu 625 630 635 640 Gln Arg Phe Leu Thr Ala Asp Met Ala Leu Val Ala Thr Val Tyr Ala 645 650 655 Pro Ile Thr Phe Pro Pro Ala Ser Val Leu Leu Phe Lys Gln Lys Ser 660 665 670 Asn Gly Met His Ser Leu Ile Ala Thr Gly His Leu Met Ser Val Asp 675 680 685 Pro Asp Arg Met Val Ile Lys Arg Val Val Leu Ser Gly His Pro Phe 690 695 700 Lys Ile Phe Thr Lys Met Ala Val Val Arg Tyr Met Phe Phe Asn Arg 705 710 715 720 Glu Asp Val Leu Trp Phe Lys Pro Val Glu Leu Arg Thr Lys Trp Gly 725 730 735 Arg Arg Gly His Ile Lys Glu Pro Leu Gly Thr His Gly His Met Lys 740 745 750 Cys Ser Phe Asp Gly Lys Leu Lys Ser Gln Asp Thr Val Leu Met Asn 755 760 765 Leu Tyr Lys Arg Val Phe Pro Lys Trp Thr Tyr Asp Pro Tyr Val Pro 770 775 780 Glu Pro Val Pro Trp Leu Lys Ser Glu Ile Ser Ser Thr Val Pro Gln 785 790 795 800 Gly Gly Met Glu 17 2321 DNA Homo sapiens 17 ccgaccttgg aatcagaagc ctggggctcc tctagggagt ggctggcccc ccgggaggcc 60 agaggaggcc catcgctgtc ttctgtgctg aacgagctgc ccagtgctgc cacccttcgg 120 taccgagacc ctggggtgct gccttggggg gcgctggagg aggaggagga ggatggagga 180 aggagcagaa aggccttcac agaagtcacc cagacagagc tgcaggaccc tcacccttcc 240 cgggaactgc cctggcccat gcaggccaga cgggcataca ggcaaagaaa tgccagcagg 300 gaccaggtgg tctatggctc tggaactaag acggaccgat gggcgcggct acttcggagg 360 tccaaggaga aaacaaagga aggcttgcga agctgcagcc ctgggcgtgg acactgaaga 420 ggatcggggg ccagtttggc gccggcacgg agtcctactt ctccctgctg cgcttcctgc 480 tccttcttaa cgtgctggcc tctgtgctca tggcctgcat gacgctgctg cccacctggt 540 tgggaggcgc tcccccaggc cctcccggcc ccgacatctc ctcgccctgc ggctcctata 600 acccccactc ccagggcctg gtcacctttg ccacccagct cttcaacttg ctctcgggtg 660 agggttacct ggaatggtcc cctctcttct atggcttcta cacgccccgc ccacgcctgg 720 cggtcaccta cctgtgctgg gcctttgccg ttggcctcat ctgcctcctg ctcatcctgc 780 atcgctcggt gtctgggctg aagcagacac tgctggcgga gtccgaggct ctgaccagct 840 acagccaccg ggtgttctcg gcctgggact tcggtctctg cggggacgtc cacgtgcggc 900 tgcgccagcg catcatcttg tacgaattaa aggtggagct ggaggagaca gtggtgcggc 960 gccaggctgc ggtgcggacg ctgggccagc aagccagggt ttggttggtg cgggtgctgc 1020 tcaacctgct ggtggtcgcg ctcctggggg cagccttcta tggcgtctac tgggctacgg 1080 ggtgcaccgt ggagctgcag gagatgcccc ttgtccagga gttgccactg ctgaagcttg 1140 gggtgaatta ccttccgtcc atcttcatcg ctggggtcaa ttttgtgctg ccgcccgtgt 1200 tcaagctcat tgctccactg gagggctaca ctcggagtcg ccagatcgtt tttatcctgc 1260 tcaggaccgt gtttcttcgc ctcgcctccc tggtggtcct gctcttctct ctctggaatc 1320 agatcacttg tgggggcgac tccgaggctg aggactgcaa aacctgtggc tacaattaca 1380 aacaacttcc gtgctgggag actgtcctgg gccaggaaat gtacaaactt ctgctctttg 1440 atctgctgac tgtcttggca gtcgcgctgc tcatccagtt tcctagaaag ctcctctgtg 1500 gcctctgtcc tggggcgctg ggtcttctgg cggggaccca ggagttccag gtgcccgacg 1560 aggtgctggg gctcatctac gcgcagacgg tggtctgggt ggggagtttt ttctgccctt 1620 tactgcccct gcttaacacg gtcaagttcc tgctgctttt ctacctgaag aagcttaccc 1680 tcttctccac ctgctccccg gctgcccgca ccttccgggc ctccgcggcg aatttctttt 1740 tccccttggt ccttctcctg ggtctggcca tctccagcgt tcccctgctt tacagcatct 1800 tcctgatccc gccttctaag ctgtgtggtc cattccgggg gcagtcgtcc atctgggccc 1860 agatccctga gtctatttcc agcctccctg agaccaccca gaatttcctc ttcttcctgg 1920 ggacccaggc ttttgctgtg ccccttctgc tgatctccag catcctgatg gcgtacactg 1980 tggctctggc taactcctac ggacgcctca tctctgagct caaacgtcag agagagacgg 2040 aggcgcagaa taaagtcttc ctggcacggc gcgctgtggc gctgacctcc accaaaccgg 2100 ctctttgacc cccgcagccc acgtcccgct ttcagacccc aggcccattg taagcctagg 2160 tcacaacatc tgtaaactag gagaactgga gaagactcca cgcccttcca gctttggtat 2220 ctggagattt ccagggcccc tcgccgccac gtccctgact ctcgggtgat cttccttgta 2280 tcaataaata cagccgaggt tgcaaaaaaa aaaaaaaaaa a 2321 18 589 PRT Homo sapiens 18 Met Gly Ala Ala Thr Ser Glu Val Gln Gly Glu Asn Lys Gly Arg Leu 1 5 10 15 Ala Lys Leu Gln Pro Trp Ala Trp Thr Leu Lys Arg Ile Gly Gly Gln 20 25 30 Phe Gly Ala Gly Thr Glu Ser Tyr Phe Ser Leu Leu Arg Phe Leu Leu 35 40 45 Leu Leu Asn Val Leu Ala Ser Val Leu Met Ala Cys Met Thr Leu Leu 50 55 60 Pro Thr Trp Leu Gly Gly Ala Pro Pro Gly Pro Pro Gly Pro Asp Ile 65 70 75 80 Ser Ser Pro Cys Gly Ser Tyr Asn Pro His Ser Gln Gly Leu Val Thr 85 90 95 Phe Ala Thr Gln Leu Phe Asn Leu Leu Ser Gly Glu Gly Tyr Leu Glu 100 105 110 Trp Ser Pro Leu Phe Tyr Gly Phe Tyr Thr Pro Arg Pro Arg Leu Ala 115 120 125 Val Thr Tyr Leu Cys Trp Ala Phe Ala Val Gly Leu Ile Cys Leu Leu 130 135 140 Leu Ile Leu His Arg Ser Val Ser Gly Leu Lys Gln Thr Leu Leu Ala 145 150 155 160 Glu Ser Glu Ala Leu Thr Ser Tyr Ser His Arg Val Phe Ser Ala Trp 165 170 175 Asp Phe Gly Leu Cys Gly Asp Val His Val Arg Leu Arg Gln Arg Ile 180 185 190 Ile Leu Tyr Glu Leu Lys Val Glu Leu Glu Glu Thr Val Val Arg Arg 195 200 205 Gln Ala Ala Val Arg Thr Leu Gly Gln Gln Ala Arg Val Trp Leu Val 210 215 220 Arg Val Leu Leu Asn Leu Leu Val Val Ala Leu Leu Gly Ala Ala Phe 225 230 235 240 Tyr Gly Val Tyr Trp Ala Thr Gly Cys Thr Val Glu Leu Gln Glu Met 245 250 255 Pro Leu Val Gln Glu Leu Pro Leu Leu Lys Leu Gly Val Asn Tyr Leu 260 265 270 Pro Ser Ile Phe Ile Ala Gly Val Asn Phe Val Leu Pro Pro Val Phe 275 280 285 Lys Leu Ile Ala Pro Leu Glu Gly Tyr Thr Arg Ser Arg Gln Ile Val 290 295 300 Phe Ile Leu Leu Arg Thr Val Phe Leu Arg Leu Ala Ser Leu Val Val 305 310 315 320 Leu Leu Phe Ser Leu Trp Asn Gln Ile Thr Cys Gly Gly Asp Ser Glu 325 330 335 Ala Glu Asp Cys Lys Thr Cys Gly Tyr Asn Tyr Lys Gln Leu Pro Cys 340 345 350 Trp Glu Thr Val Leu Gly Gln Glu Met Tyr Lys Leu Leu Leu Phe Asp 355 360 365 Leu Leu Thr Val Leu Ala Val Ala Leu Leu Ile Gln Phe Pro Arg Lys 370 375 380 Leu Leu Cys Gly Leu Cys Pro Gly Ala Leu Gly Leu Leu Ala Gly Thr 385 390 395 400 Gln Glu Phe Gln Val Pro Asp Glu Val Leu Gly Leu Ile Tyr Ala Gln 405 410 415 Thr Val Val Trp Val Gly Ser Phe Phe Cys Pro Leu Leu Pro Leu Leu 420 425 430 Asn Thr Val Lys Phe Leu Leu Leu Phe Tyr Leu Lys Lys Leu Thr Leu 435 440 445 Phe Ser Thr Cys Ser Pro Ala Ala Arg Thr Phe Arg Ala Ser Ala Ala 450 455 460 Asn Phe Phe Phe Pro Leu Val Leu Leu Leu Gly Leu Ala Ile Ser Ser 465 470 475 480 Val Pro Leu Leu Tyr Ser Ile Phe Leu Ile Pro Pro Ser Lys Leu Cys 485 490 495 Gly Pro Phe Arg Gly Gln Ser Ser Ile Trp Ala Gln Ile Pro Glu Ser 500 505 510 Ile Ser Ser Leu Pro Glu Thr Thr Gln Asn Phe Leu Phe Phe Leu Gly 515 520 525 Thr Gln Ala Phe Ala Val Pro Leu Leu Leu Ile Ser Ser Ile Leu Met 530 535 540 Ala Tyr Thr Val Ala Leu Ala Asn Ser Tyr Gly Arg Leu Ile Ser Glu 545 550 555 560 Leu Lys Arg Gln Arg Glu Thr Glu Ala Gln Asn Lys Val Phe Leu Ala 565 570 575 Arg Arg Ala Val Ala Leu Thr Ser Thr Lys Pro Ala Leu 580 585 19 5263 DNA Homo sapiens unsure (848) unsure (1060) unsure (1248) unsure (1377) unsure (2310) unsure (2319) unsure (2839) 19 agtggaagga gcaggcgctt gagctcgagc gacggcgctg gcggagacgc cggctgctcc 60 tcccctcccc gccggtatta atctctggag aagacacatc cacagttagc actttcttca 120 gatgctgacg ctcggtgaac agttgccttt ggtcacaaga tttagaagac acagtgtcca 180 tcctcccaga ttggatctct ttttcatatg gatcttctgt ttctatgtct ttttaaaaaa 240 taactttttg ggaaaccttt tggattacaa ctgttcatcc tcacctatgc aaagaaaggg 300 aagctattgc tgggattttg aggagctttt cctaaaagga ttgtacacct tagaagtgct 360 taaggaagag tgatgaagat aggcatgaag ccttcgtctc acagctgcat gcgtagtcac 420 tgttgaagca aatgcctacc taatttgaca ctcttggtgt gtttaaaaaa tttttttgag 480 tttgcaaata agcatattaa gtctactgat ggagccttcg ggcagtgaac agttatttga 540 ggaccctgat cctggaggca aatcccaaga tgcagaggcc agaaagcaga cagaatcaga 600 acaaaaattg tctaaaatga cccacaatgc tttggagaac attaacgtga ttggccaagg 660 cttgaagcat ctcttccagc accagcgcag gaggtcatca gtgtctccac atgatgtgca 720 gcaaattcag gcagatccag aacctgaaat ggatctggaa agccagaacg catgtgctga 780 gattgatggt gtccccaccc accccacagc tctgaatcgt gtcctgcagc agattcgagt 840 gccacccnag atgaagagag ggacaagctt gcatagtagg cggggcaagc cagaggcccc 900 aaagggaagt ccccaaatca acaggaagtc tggtcaggag atgacagctg ttatgcagtc 960 aggccgaccc atgtcttcat ccacaactga tgcacctacc ggctctgcta tgatggaaat 1020 agcttgtgct gctgctgctg ctgctgctgc atgtctaccn ggagaggagg gaactgcgga 1080 gcggatcgaa cggttggaag taagcagcct tgcccaaaca tccagtgcag tggcctccag 1140 taccgatggc agcatccaca cagactctgt ggatggaaca ccagaccctc agcgcacaaa 1200 ggctgccatt gctcacctgc agcagaagat cctgaagctc acagaacnaa tcaagattgc 1260 acaaacagcc cgggacgaca acgttgctga atacttgaag cttgccaaca gtgcagacaa 1320 acagcaggct gcccgcatca agcaagtctt tgagaagaag aaccagaaat ctgcccnaac 1380 tatcctccag ctgcaaaaga aacttgagca ctaccacagg aagctcagag aggtagagca 1440 gaatgggatc ccccggcagc caaaggatgt cttcagggac atgcaccagg gtctgaagga 1500 tgtaggagca aaggtgactg gcttcagtga aggtgtggtg gatagtgtca aaggtgggtt 1560 ttccagcttc tcccaggcca cccattcagc agcaggcgct gtagtctcaa agcccagaga 1620 gattgcctca ctcattcgga acaaatttgg cagtgcagac aacatcccca acctgaagga 1680 ctctttagag gaagggcaag tggatgatgc ggggaaggct ttgggagtga tttcaaactt 1740 tcagtctagc ccaaaatatg gtagtgaaga agattgttct agtgccactt caggctcagt 1800 gggagccaac agcaccacag ggggcatcgc tgtaggagca tccagctcca aaacaaacac 1860 cctggacatg cagagctcag gatttgatgc actactacat gagatccagg agatccggga 1920 aacccaggcc agactagagg aatcctttga gactctcaag gaacattatc agagggacta 1980 ttccttaata atgcagacct tacaggagga gcgatataga tgtgaacgat tggaagaaca 2040 gctaaatgac ctaacagagc tccaccagaa tgaaatcttg aacttgaagc aggaactggc 2100 aagcatggaa gaaaaaatcg cgtatcagtc ctatgaacgg gcccgggaca tccaggaggc 2160 cctggaggca tgccagacgc gcatctccaa gatggagctg cagcagcagc agcagcaggt 2220 ggtgcagcta gaagggctgg agaatgccac tgcccggaac cttctgggca aactcatcaa 2280 catcctcctg gctgtcatgg cagtcctttn ggtctttgnc tccactgtag ccaactgtgt 2340 ggtccccctc atgaagactc gcaacaggac gttcagcact ttattccttg tggtttttat 2400 tgcctttctc tggaagcact gggacgccct cttcagctat gtggaacggt tcttttcatc 2460 ccctagatga tgctggcaca gaaggcattg ttccctaccc tctggcgagt gcatgcagca 2520 gagagttaga cagcaactta cctactctga agttttctac aacaaaaaaa gagttgagtg 2580 aatctgttta catttagaat aatgtttttt tcttcaagag acgcaattgc aatagtattt 2640 tttagatttt atccaagaag ttttttgggc gaaaatcttg gatcattttt atgtagcatg 2700 attttccttg ggatgcaaat cttaaaacag tcctttaata tgaaccaaca atctggagca 2760 caccgaaggg caatctaaat tgtggcttga aggactgcac taaaacccac taaaaagatg 2820 cgaaaacctg atgagggcna accagttaaa cctaacaccc tgccttgtct gggctcatca 2880 cctctcccta tcccagacta actttactgt gaaatcctac acattccatg tctgaatttt 2940 tggattcggg gtggattttc gttgtccgtg gaagaacaca tggatctctc tggctttctc 3000 acccaagttg gccacttacg ctaatcctgg aagtatgatc acttttgaac ctgcccctta 3060 accttgacga ggatacaaaa gtgaaagcat catcccccaa aggatcactg cacagtccta 3120 ctacagtatt tttaagtagc cctctaaata cttaatttta agcaaaatcc cttggccgca 3180 cttttaaggt ttttttatat gtgtatagtt accaacctaa aaataaaaaa tccgaacagc 3240 atacttgaag aatgtaatac tcaaactctc agtgcttcct tatggtttct aataggattt 3300 tttattattg ttattattat tattgggttt ttttggacag ggttgggagg gtcttttatt 3360 tttcctttga aataaagaag tgatgttttt aaatgaagaa atgtgtggat atttaagtgt 3420 gctgctccct cttgtcttga aacagtttga gtaagaaagt cttgctgtaa atgctgccct 3480 ctgccgcctt tgttttgaga tgcagtttaa actccctctg gctgctgctg ctgctttttg 3540 gtgtcccgac atacctacgc ccccgtttta tgggtttggc ttagttgaag aggaaagggt 3600 tgtgcaagga gagcaggagg ctgtttccaa aaaccagtgt agtaggatag ggattttttt 3660 tttttttttg ccccaagaaa acgttcaccc agtgatcttg ggctggggtt gtctttagga 3720 aaagttgaga ctataagagt cataaataag tccttgtgtt tccttaattt attttgttaa 3780 cacccctaat tacaaccaaa gtgatgatgt ggagtcttct gtcttcattt tggccccagc 3840 attcttaatt tcaaagcttt attctgtctg cctaagagaa tcaaccaaag gtgattctcc 3900 taaagagcag tgaaggaaat gtcaggttag caggacccaa gttttgggtg tgaaatgttg 3960 ccagcttcct ataatgtaaa cggacttgtt aacctaacct aattatgctc agtggacttc 4020 tatagatggt tttgaaaaat gaactgagct gccttcccgc atcgcataac cagttccatc 4080 atcctggtgg aacttgaaca tttagagttt atctagagag cttggttaat ctttccatat 4140 tatttgtagt attggtcaca aatgctgttc cctcttagcc tcattctgtg caaccaagtg 4200 catataagat gccctgaaaa gagtaacaaa gtatgctttg cctgtttcca cttaccagga 4260 aattccttca gaactagatt agcattgccc tgcctgtctg aaaggacagt ttacctaatg 4320 gtgccagcct ccttttgctt tggcaagctg gatttctcag agccagcatg ttgtttccat 4380 aactactttg atattttaac tcaggtactc cagtcttcac cccaacctca gctgattgta 4440 gtacacctgc tagctctgtt gccccctcaa aactgcaccc agagcagggc cacaagggtg 4500 ctttttttct ttaaaaaaaa aaaaattaga accaattcat gttcatgcca aaaacaaatt 4560 gtccccaagc ctatatgtat taaaatgtta actttgccta aaaatattgc agtgactttt 4620 taggcaggag tgccaaagga cactatgaac tttttgaact gacagtttct cctaactttc 4680 tgctttagcg taattgctca gagtagagag cccccacaaa gttatttaaa agatgcccta 4740 gcagcaatcc accagttttt ctaagctaga acctttgagt cccccaaact gcctgaagac 4800 ttaagttttg tgggcactgg aagtcacttt gatagatgga ttgaaactgt tcctatttgc 4860 cctgggacgg tttctatcta tcaaaggaag gttttcacct gtagaaagcc ccctgcctcc 4920 agccaaatag tcccatgctg actttctatc ttcctttctc aaactgtctt aggaaggacc 4980 ttcagtgcag atcaggtgca gtaatggctt tcttgtccct taattattca ccagacccag 5040 aagttgtacg catttaatgc tgtttgtaac catgcatctg ttttcattct ttgctgtacc 5100 ttttgctgcc catcctgtta cttttgagtt tctttcattg tggttgttct tgggttcttt 5160 tgtcttgtca gagctcttct ataacctcgc tctaatggct taacagttgt tctgggtgga 5220 aacgtcccct catttgaatg ctcctctaaa aaaaaaaaaa aaa 5263 20 653 PRT Homo sapiens UNSURE (114) UNSURE (247) UNSURE (290) UNSURE (601) UNSURE (604) 20 Met Glu Pro Ser Gly Ser Glu Gln Leu Phe Glu Asp Pro Asp Pro Gly 1 5 10 15 Gly Lys Ser Gln Asp Ala Glu Ala Arg Lys Gln Thr Glu Ser Glu Gln 20 25 30 Lys Leu Ser Lys Met Thr His Asn Ala Leu Glu Asn Ile Asn Val Ile 35 40 45 Gly Gln Gly Leu Lys His Leu Phe Gln His Gln Arg Arg Arg Ser Ser 50 55 60 Val Ser Pro His Asp Val Gln Gln Ile Gln Ala Asp Pro Glu Pro Glu 65 70 75 80 Met Asp Leu Glu Ser Gln Asn Ala Cys Ala Glu Ile Asp Gly Val Pro 85 90 95 Thr His Pro Thr Ala Leu Asn Arg Val Leu Gln Gln Ile Arg Val Pro 100 105 110 Pro Xaa Met Lys Arg Gly Thr Ser Leu His Ser Arg Arg Gly Lys Pro 115 120 125 Glu Ala Pro Lys Gly Ser Pro Gln Ile Asn Arg Lys Ser Gly Gln Glu 130 135 140 Met Thr Ala Val Met Gln Ser Gly Arg Pro Met Ser Ser Ser Thr Thr 145 150 155 160 Asp Ala Pro Thr Gly Ser Ala Met Met Glu Ile Ala Cys Ala Ala Ala 165 170 175 Ala Ala Ala Ala Ala Cys Leu Pro Gly Glu Glu Gly Thr Ala Glu Arg 180 185 190 Ile Glu Arg Leu Glu Val Ser Ser Leu Ala Gln Thr Ser Ser Ala Val 195 200 205 Ala Ser Ser Thr Asp Gly Ser Ile His Thr Asp Ser Val Asp Gly Thr 210 215 220 Pro Asp Pro Gln Arg Thr Lys Ala Ala Ile Ala His Leu Gln Gln Lys 225 230 235 240 Ile Leu Lys Leu Thr Glu Xaa Ile Lys Ile Ala Gln Thr Ala Arg Asp 245 250 255 Asp Asn Val Ala Glu Tyr Leu Lys Leu Ala Asn Ser Ala Asp Lys Gln 260 265 270 Gln Ala Ala Arg Ile Lys Gln Val Phe Glu Lys Lys Asn Gln Lys Ser 275 280 285 Ala Xaa Thr Ile Leu Gln Leu Gln Lys Lys Leu Glu His Tyr His Arg 290 295 300 Lys Leu Arg Glu Val Glu Gln Asn Gly Ile Pro Arg Gln Pro Lys Asp 305 310 315 320 Val Phe Arg Asp Met His Gln Gly Leu Lys Asp Val Gly Ala Lys Val 325 330 335 Thr Gly Phe Ser Glu Gly Val Val Asp Ser Val Lys Gly Gly Phe Ser 340 345 350 Ser Phe Ser Gln Ala Thr His Ser Ala Ala Gly Ala Val Val Ser Lys 355 360 365 Pro Arg Glu Ile Ala Ser Leu Ile Arg Asn Lys Phe Gly Ser Ala Asp 370 375 380 Asn Ile Pro Asn Leu Lys Asp Ser Leu Glu Glu Gly Gln Val Asp Asp 385 390 395 400 Ala Gly Lys Ala Leu Gly Val Ile Ser Asn Phe Gln Ser Ser Pro Lys 405 410 415 Tyr Gly Ser Glu Glu Asp Cys Ser Ser Ala Thr Ser Gly Ser Val Gly 420 425 430 Ala Asn Ser Thr Thr Gly Gly Ile Ala Val Gly Ala Ser Ser Ser Lys 435 440 445 Thr Asn Thr Leu Asp Met Gln Ser Ser Gly Phe Asp Ala Leu Leu His 450 455 460 Glu Ile Gln Glu Ile Arg Glu Thr Gln Ala Arg Leu Glu Glu Ser Phe 465 470 475 480 Glu Thr Leu Lys Glu His Tyr Gln Arg Asp Tyr Ser Leu Ile Met Gln 485 490 495 Thr Leu Gln Glu Glu Arg Tyr Arg Cys Glu Arg Leu Glu Glu Gln Leu 500 505 510 Asn Asp Leu Thr Glu Leu His Gln Asn Glu Ile Leu Asn Leu Lys Gln 515 520 525 Glu Leu Ala Ser Met Glu Glu Lys Ile Ala Tyr Gln Ser Tyr Glu Arg 530 535 540 Ala Arg Asp Ile Gln Glu Ala Leu Glu Ala Cys Gln Thr Arg Ile Ser 545 550 555 560 Lys Met Glu Leu Gln Gln Gln Gln Gln Gln Val Val Gln Leu Glu Gly 565 570 575 Leu Glu Asn Ala Thr Ala Arg Asn Leu Leu Gly Lys Leu Ile Asn Ile 580 585 590 Leu Leu Ala Val Met Ala Val Leu Xaa Val Phe Xaa Ser Thr Val Ala 595 600 605 Asn Cys Val Val Pro Leu Met Lys Thr Arg Asn Arg Thr Phe Ser Thr 610 615 620 Leu Phe Leu Val Val Phe Ile Ala Phe Leu Trp Lys His Trp Asp Ala 625 630 635 640 Leu Phe Ser Tyr Val Glu Arg Phe Phe Ser Ser Pro Arg 645 650 21 3349 DNA Homo sapiens 21 ccccctccag gccccgctcc tgcgccctat ttggtcattc ggggggcaag cggcgggagg 60 ggaaacgtgc gcggccgaag gggaagcgga gccggcgccg gctgcgcaga ggagccgctc 120 tcgccgccgc cacctcggct gggagcccac gaggctgccg catcctgccc tcggaacaat 180 gggactcggc gcgcgaggtg cttgggccgc gctgctcctg gggacgctgc aggtgctagc 240 gctgctgggg gccgcccatg aaagcgcagc catggcggca tctgcaaaca tagagaattc 300 tgggcttcca cacaactcca gtgctaactc aacagagact ctccaacatg tgccttctga 360 ccatacaaat gaaacttcca acagtactgt gaaaccacca acttcagttg cctcagactc 420 cagtaataca acggtcacca ccatgaaacc tacagcggca tctaatacaa caacaccagg 480 gatggtctca acaaatatga cttctaccac cttaaagtct acacccaaaa caacaagtgt 540 ttcacagaac acatctcaga tatcaacatc cacaatgacc gtaacccaca atagttcagt 600 gacatctgct gcttcatcag taacaatcac aacaactatg cattctgaag caaagaaagg 660 atcaaaattt gatactggga gctttgttgg tggtattgta ttaacgctgg gagttttatc 720 tattctttac attggatgca aaatgtatta ctcaagaaga ggcattcggt atcgaaccat 780 agatgaacat gatgccatca tttaaggaaa tccatggacc aaggatggaa tacagattga 840 tgctgcccta tcaattaatt ttggtttatt aatagtttaa aacaatattc tctttttgaa 900 aatagtataa acaggccatg catataatgt acagtgtatt agtaaatatg taaagattct 960 tcaaggtaac aagggtttgg gttttgaaat aaacatctgg atcttataga ccgttcatac 1020 aatggtttta gcaagttcat agtaagacaa acaagtccta tctttttttt tttggctggg 1080 gtgggggcat tggtcacata tgaccagtaa ttgaaagacg tcatcactga aagacagaat 1140 gccatctggg catacaaata agaagtttgt cacagcactc aggattttgg gtatcttttg 1200 tagctcacat aaagaacttc agtgcttttc agagctggat atatcttaat tactaatgcc 1260 acacagaaat tatacaatca aactagatct gaagcataat ttaagaaaaa catcaacatt 1320 ttttgtgctt taaactgtag tagttggtct agaaacaaaa tactccaaga aaaagaaaat 1380 tttcaaataa aacccaaaat aatagctttg cttagccctg ttagggatcc attggagcat 1440 taaggagcac atatttttat taacttcttt tgagctttca atgttgatgt aatttttgtt 1500 ctctgtgtaa tttaggtaaa ctgcagtgtt taacataata atgttttaaa gacttagttg 1560 tcagtattaa ataatcctgg cattataggg aaaaaacctc ctagaagtta gattatttgc 1620 tactgtgaga atattgtcac cactggaagt tactttagtt catttaattt taattttata 1680 ttttgtgaat attttaagaa ctgtagagct gctttcaata tctagaaatt tttaattgag 1740 tgtaaacaca cctaacttta agaaaaagaa ccccttgtat gattttcaaa agaacattta 1800 gaattctata gagtcaaaac tatagcgtaa tgctgtgttt attaagccag ggattgtggg 1860 acttccccca ggctactaaa cctgcaggat gaaaatgcta tattttcttt catgcactgt 1920 cgatattact cagatttggg gaaatgacat ttttatacta aaacaaacac caaaatattt 1980 tagaataaat tcttagaaag ttttgagagg aatttttaga gaggacattt cctccttcct 2040 gatttggata ttccctcaaa tccctcctct tactccatgc tgaaggagaa gtactctcag 2100 atgcattatg ttaatggaga gaaaaagcac agtattgtag agacaccaat attagctaat 2160 gtattttgga gtgttttcca ttttacagtt tatattccag cactcaaaac tcagggtcaa 2220 gttttaacaa aagaggtatg tagtcacagt aaatactaag atggcatttc tatctcagag 2280 ggccaaagtg aatcacacca gtttctgaag gtcctaaaaa tagctcagat gtcctaatga 2340 acatgcacct acatttaata ggagtacaat aaaactgttg tcagcttttg ttttacagag 2400 aacgctagat attaagaatt ttgaaatgga tcatttctac ttgctgtgca ttttaaccaa 2460 taatctgatg aatatagaaa aaaatgatcc aaaatatgga tatgattgga tgtatgtaac 2520 acatacatgg agtatggagg aaattttctg aaaaatacat ttagattagt ttagtttgaa 2580 ggagaggtgg gctgatggct gagttgtatg ttactaactt ggccctgact ggttgtgcaa 2640 ccattgcttc atttctttgc aaaatgtagt taagatatac tttattctaa tgaaggcctt 2700 ttaaatttgt ccactgcatt cttggtattt cactacttca agtcagtcag aacttcgtag 2760 accgacctga agtttctttt tgaatacttg tttctttagc actttgaaga tagaaaaacc 2820 actttttaag tactaagtca tcatttgcct tgaaagtttc ctctgcattg ggtttgaagt 2880 agtttagtta tgtctttttc tctgtatgta agtagtataa tttgttactt tcaaataccc 2940 gtactttgaa tgtaggtttt tttgttgttg ttatctataa aaattgaggg aaatggttat 3000 gcaaaaaaat attttgcttt ggaccatatt tcttaagcat aaaaaaaatg ctcagttttg 3060 cttgcattcc ttgagaatgt atttatctga agatcaaaac aaacaatcca gatgtataag 3120 tactaggcag aagccaattt taaaatttcc ttgaataatc catgaaagga ataattcaaa 3180 tacagataaa cagagttggc agtatattat agtgataatt ttgtattttc acaaaaaaaa 3240 agttaaactc ttcttttctt tttattataa tgaccagctt ttggtatttc attgttacca 3300 agttctattt ttagaataaa attgttctcc ttctaaaaaa aaaaaaaaa 3349 22 208 PRT Homo sapiens 22 Met Gly Leu Gly Ala Arg Gly Ala Trp Ala Ala Leu Leu Leu Gly Thr 1 5 10 15 Leu Gln Val Leu Ala Leu Leu Gly Ala Ala His Glu Ser Ala Ala Met 20 25 30 Ala Ala Ser Ala Asn Ile Glu Asn Ser Gly Leu Pro His Asn Ser Ser 35 40 45 Ala Asn Ser Thr Glu Thr Leu Gln His Val Pro Ser Asp His Thr Asn 50 55 60 Glu Thr Ser Asn Ser Thr Val Lys Pro Pro Thr Ser Val Ala Ser Asp 65 70 75 80 Ser Ser Asn Thr Thr Val Thr Thr Met Lys Pro Thr Ala Ala Ser Asn 85 90 95 Thr Thr Thr Pro Gly Met Val Ser Thr Asn Met Thr Ser Thr Thr Leu 100 105 110 Lys Ser Thr Pro Lys Thr Thr Ser Val Ser Gln Asn Thr Ser Gln Ile 115 120 125 Ser Thr Ser Thr Met Thr Val Thr His Asn Ser Ser Val Thr Ser Ala 130 135 140 Ala Ser Ser Val Thr Ile Thr Thr Thr Met His Ser Glu Ala Lys Lys 145 150 155 160 Gly Ser Lys Phe Asp Thr Gly Ser Phe Val Gly Gly Ile Val Leu Thr 165 170 175 Leu Gly Val Leu Ser Ile Leu Tyr Ile Gly Cys Lys Met Tyr Tyr Ser 180 185 190 Arg Arg Gly Ile Arg Tyr Arg Thr Ile Asp Glu His Asp Ala Ile Ile 195 200 205 23 2361 DNA Homo sapiens 23 aagaggccta gacttaagaa gcttctgaaa gaccatgcct catccatgcc taacgcagag 60 tcctggcctg tcgtaggtca gttttcaagc gttggctcct tgggagccga tgaatcaaag 120 tggttatgtt ctgagtttaa agagagcatg ctgacactgg ggaaggaaag caagactcca 180 ggaaaaagct ctgttcctct ttacttgatc tatccttctg tggaaaatgt gcggaccagt 240 ttagaaggat atcctgctgg gggctctctt ccctatagca tccagacagc tgaaaaacag 300 aattggctgc attcctattt tcacaaatgg tcagctgaga cttctggccg cagcaatgcc 360 atgccacata ttaagacata tatgaggcct tctccagact tcagtaaaat tgcttggttc 420 cttgtcacaa gcgcaaatct gtccaaggct gcctggggag cattggagaa gaatggcacc 480 cagctgatga tccgctccta cgagctcggg gtccttttcc tcccttcagc atttggtcta 540 gacagtttca aagtgaaaca gaagttcttc gctggcagcc aggagccaat ggccaccttt 600 cctgtgccat atgatttgcc tccagaactg tatggaagta aagatcggcc atggatatgg 660 aacattcctt atgtcaaagc accggatacg catgggaaca tgtgggtgcc ctcctgagaa 720 tcttgaggca ctgtgaaatt taagtgtaag acattgagcc acaaacatgg aatctcttct 780 ttgtactgga tgtccacttc ccttaaagtc ttatttgcac ccttacaaaa tctttccaaa 840 ggtcactctt atgaatggat gttggttata cttttaatgg acattaacat tcctaataaa 900 gtattagttt cttaattcac ttttatatgt tttggaaaga aaattagtga acttctctat 960 gttaaaaata cgtactgctt gagtatcccc tgtctgaaat gcttgggacc agaagtgttt 1020 cagcttttgg atttttttga attttggaat atttgcatag cataatgaga tatcttggga 1080 atgggaccca aatctaaaca caaaattcat ttatgtttca tatacacctt atatacaata 1140 acctaaaggt gattttatat gatattttga gtaattttat gcatgaaaca aagttttgac 1200 aggcttttga ccgtgattca tcacatgagt tcaggcatgg aaattttcat ttggagcatc 1260 atgtcagcac tcaaaaagtt ctggatcttg gagcagttca gattttcaga ttagggatgc 1320 tcaaatctat atagatataa aattatcctc acagtaacat agaatctctt ggtgctgtca 1380 gctgttggga attgaagatt gactttgtgc ttccaccctc catccagaaa ggcacccttc 1440 attccaccag aattttaccc aggaagaaca cgatcatttc ctttttcacc gatgccctct 1500 ctcagctttc tgagtacgtc tcttggggtc gctggaggtg atcctaggat ctgtctctga 1560 gaccaatgtg ctgtttcagc cccctgcagc taagaattgt attgactgtc ctcacagcgg 1620 cttttcatag ctttcagctt cagctttacg aggcttctcc tctctccctg gcacctgctg 1680 gctgcctcac tgcttacaga caggtcccac caaacccaaa cacctgccta gggtaaatgg 1740 gtctctcttc tatccccaga aactttcaga ggaagcagct catagaaaca tacaaaagca 1800 cacaagtatt ttgggaaaaa atcctaaaag gtgacttaat ttgatgcctt aaattcacaa 1860 gtgaggaagc taaggcctag aaggttaagg atgtccccag ggtcacacag tgagcggggc 1920 tcagagcttg agtgtctttg tgctttgtgt acattgtgtt ctccctaggg tgctttagac 1980 cctgtttgtt ttcttctgca tgaggctgat ttccagtttg tcatcaacct ctttatctta 2040 taatttagga tagagttgaa cgttagtctt gaaagatttt ctaaagtagt ctttcaaact 2100 gttcctcaga ggcctaggat tttccaaaag taccttagga accttgtagg ctgcagtggg 2160 ggtgtggcga tagagcagga ggcagggaga cagggctgca gggcctccca ccttccaaca 2220 gacaggctct gctgtatctg ttgtacatac tgggattctg taaaggacat tatctggggt 2280 gtcgtaggta tttttgtgtg ttctgctttt tttaaataaa cttgaaaagc tactgaacta 2340 aaaaaaaaaa aaaaaaaaaa a 2361 24 223 PRT Homo sapiens 24 Met Pro Asn Ala Glu Ser Trp Pro Val Val Gly Gln Phe Ser Ser Val 1 5 10 15 Gly Ser Leu Gly Ala Asp Glu Ser Lys Trp Leu Cys Ser Glu Phe Lys 20 25 30 Glu Ser Met Leu Thr Leu Gly Lys Glu Ser Lys Thr Pro Gly Lys Ser 35 40 45 Ser Val Pro Leu Tyr Leu Ile Tyr Pro Ser Val Glu Asn Val Arg Thr 50 55 60 Ser Leu Glu Gly Tyr Pro Ala Gly Gly Ser Leu Pro Tyr Ser Ile Gln 65 70 75 80 Thr Ala Glu Lys Gln Asn Trp Leu His Ser Tyr Phe His Lys Trp Ser 85 90 95 Ala Glu Thr Ser Gly Arg Ser Asn Ala Met Pro His Ile Lys Thr Tyr 100 105 110 Met Arg Pro Ser Pro Asp Phe Ser Lys Ile Ala Trp Phe Leu Val Thr 115 120 125 Ser Ala Asn Leu Ser Lys Ala Ala Trp Gly Ala Leu Glu Lys Asn Gly 130 135 140 Thr Gln Leu Met Ile Arg Ser Tyr Glu Leu Gly Val Leu Phe Leu Pro 145 150 155 160 Ser Ala Phe Gly Leu Asp Ser Phe Lys Val Lys Gln Lys Phe Phe Ala 165 170 175 Gly Ser Gln Glu Pro Met Ala Thr Phe Pro Val Pro Tyr Asp Leu Pro 180 185 190 Pro Glu Leu Tyr Gly Ser Lys Asp Arg Pro Trp Ile Trp Asn Ile Pro 195 200 205 Tyr Val Lys Ala Pro Asp Thr His Gly Asn Met Trp Val Pro Ser 210 215 220 25 3370 DNA Homo sapiens 25 cgcgctgtgg ctgctgctgc tgctgctgcc ccggacccgg gcggacgagc acgaacacac 60 gtatcaagat aaagaggaag ttgtcttatg gatgaatact gttgggccct accataatcg 120 tcaagaaaca tataagtact tttcacttcc attctgtgtg gggtcaaaaa aaagtatcag 180 tcattaccat gaaactctgg gagaagcact tcaaggggtt gaattggaat ttagtggtct 240 ggatattaaa tttaaagatg atgtgatgcc agccacttac tgtgaaattg atttagataa 300 agaaaagaga gatgcatttg tatatgccat aaaaaatcat tactggtacc agatgtacat 360 agatgattta ccaatatggg gtattgttgg tgaggctgat gaaaatggag aagattacta 420 tctttggacc tataaaaaac ttgaaatagg ttttaatgga aatcgaattg ttgatgttaa 480 tctaactagt gaaggaaagg tgaaactggt tccaaatact aaaatccaga tgtcatattc 540 agtaaaatgg aaaaagtcag atgtgaaatt tgaagatcga tttgacaaat atcttgatcc 600 gtcctttttt caacatcgga ttcattggtt ttcaattttc aactccttca tgatggtgat 660 cttcttggtg ggcttagttt caatgatttt aatgagaaca ttaagaaaag attatgctcg 720 gtacagtaaa gaggaagaaa tggatgatat ggatagagac ctaggagatg aatatggatg 780 gaaacaggtg catggagatg tatttagacc atcaagtcac ccactgatat tttcctctct 840 gattggttct ggatgtcaga tatttgctgt gtctctcatc gttattattg ttgcaatgat 900 agaagattta tatactgaga ggggatcaat gctcagtaca gccatatttg tctatgctgc 960 tacgtctcca gtgaatggtt attttggagg aagtctgtat gctagacaag gaggaaggag 1020 atggataaag cagatgttta ttggggcatt ccttatccca gctatggtgt gtggcactgc 1080 cttcttcatc aatttcatag ccatttatta ccatgcttca agagccattc cttttggaac 1140 aatggtggcc gtttgttgca tctgtttttt tgttattctt cctctaaatc ttgttggtac 1200 aatacttggc cgaaatctgt caggtcagcc caactttcct tgtcgtgtca atgctgtgcc 1260 tcgtcctata ccggagaaaa aatggttcat ggagcctgcg gttattgttt gcctgggtgg 1320 aattttacct tttggttcaa tctttattga aatgtatttc atcttcacgt ctttctgggc 1380 atataagatc tattatgtct atggcttcat gatgctggtg ctggttatcc tgtgcattgt 1440 gactgtctgt gtgactattg tgtgcacata ttttctacta aatgcagaag attacccgtg 1500 gcaatggaca agttttctct ctgctgcatc aactgcaatc tatgtttaca tgtattcctt 1560 ttactactat tttttcaaaa caaagatgta tggcttattt caaacatcat tttactttgg 1620 atatatggcg gtatttagca cagccttggg gataatgtgt ggagcgattg gttacatggg 1680 aacaagtgcc tttgtccgaa aaatctatac taatgtgaaa attgactaga gacccaagaa 1740 aacctggaac tttggatcaa tttctttttc ataggggtgg aacttgcaca gcaaaaacaa 1800 acaaacgcaa gaagagattt gggctttaac acactgggta ctttgtgggt ctgtctttcg 1860 tcggtggctt aaagtaacat ctatttccat tgatcctagg ttcttcctga ctgctttctc 1920 caactgttca cagcaaatgc ttggatttta tgcagtaggc attactacag tacatggcta 1980 atcttcccaa aaactagctc attaaagatg aaatagacca gctctcttca gtgaagagga 2040 caaatagttt atttaaagca tttgttccaa taaaataaat agagggaaac ttggatgcta 2100 aaattacatg aataggaatc ttcctggcac ttagtgtttc tatgttattg aaaaatgatg 2160 ttccagaaag attacttttt tcctcttatt tttactgcca ttgtcgacct attgtgggac 2220 atttttatat attgaatctg ggttcttttt tgactttttt ttttcccaat ccaacagcat 2280 cctttttttt aaaagagaga attagaaaat attaaatcct gcatgtaata tatctgctgt 2340 catcttagtt ggaccaactt cccatttatt tatcttaaaa ctatacagtt acatcttaat 2400 tccatccaaa gaagatacag tttgaagaca gaagtgtact ctctacaatg caatttactg 2460 tacagttaga aagcaaagtg ttaaatggag aagatacttg tttttattaa acattttgag 2520 atttagataa actacatttt aactgaatgt ctaaagtgat tatctttttt ccccccaagt 2580 tagtcttaaa tcttttgggt ttgaatgaag gttttacata agaaattatt aaaaacaagg 2640 ggggtgggta ataaatgtat ataacattaa ataatgtaac gtaggtgtag attcccaaat 2700 gcatttggat gtacagatcg actacagagt acttttttct tatgatgatt ggtgtagaaa 2760 tgtgtgattt gggtgggctt ttacatcttg cctaccattg catgaaacat tggggtttct 2820 tcaaaatgtg tgtgtcatac ttcttttggg aggggggttg ttttcttctg tttattttct 2880 gagactccta caggacccaa atttgtaatt tagagacact taattttgtt aatcctgcct 2940 gggacactta agtaacatct aaagcattat tgctttagaa tgttcaaata aaatttcctg 3000 accaaattgt tttgtggaaa tagatgtgtt tgcaatttga agatatcttt ctgtccagaa 3060 ggcaaaatta ccgaatgcca tttttaaaag tatgctataa actatgctac tctcatacag 3120 gggacccgta ttttaaaatc tccagacttg cttacatcta gattatccag cacaatcata 3180 aagtgaatga caaacccttt gaatgaaatt gtggcacaaa atctgttcag gttggtgtac 3240 cgtgtaaagt ggggatgggg taaaagtggt taacgtactg ttggatcaac aaataaaggt 3300 tacagttttg tttgagaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3360 aaaaaaaaaa 3370 26 545 PRT Homo sapiens 26 Met Asn Thr Val Gly Pro Tyr His Asn Arg Gln Glu Thr Tyr Lys Tyr 1 5 10 15 Phe Ser Leu Pro Phe Cys Val Gly Ser Lys Lys Ser Ile Ser His Tyr 20 25 30 His Glu Thr Leu Gly Glu Ala Leu Gln Gly Val Glu Leu Glu Phe Ser 35 40 45 Gly Leu Asp Ile Lys Phe Lys Asp Asp Val Met Pro Ala Thr Tyr Cys 50 55 60 Glu Ile Asp Leu Asp Lys Glu Lys Arg Asp Ala Phe Val Tyr Ala Ile 65 70 75 80 Lys Asn His Tyr Trp Tyr Gln Met Tyr Ile Asp Asp Leu Pro Ile Trp 85 90 95 Gly Ile Val Gly Glu Ala Asp Glu Asn Gly Glu Asp Tyr Tyr Leu Trp 100 105 110 Thr Tyr Lys Lys Leu Glu Ile Gly Phe Asn Gly Asn Arg Ile Val Asp 115 120 125 Val Asn Leu Thr Ser Glu Gly Lys Val Lys Leu Val Pro Asn Thr Lys 130 135 140 Ile Gln Met Ser Tyr Ser Val Lys Trp Lys Lys Ser Asp Val Lys Phe 145 150 155 160 Glu Asp Arg Phe Asp Lys Tyr Leu Asp Pro Ser Phe Phe Gln His Arg 165 170 175 Ile His Trp Phe Ser Ile Phe Asn Ser Phe Met Met Val Ile Phe Leu 180 185 190 Val Gly Leu Val Ser Met Ile Leu Met Arg Thr Leu Arg Lys Asp Tyr 195 200 205 Ala Arg Tyr Ser Lys Glu Glu Glu Met Asp Asp Met Asp Arg Asp Leu 210 215 220 Gly Asp Glu Tyr Gly Trp Lys Gln Val His Gly Asp Val Phe Arg Pro 225 230 235 240 Ser Ser His Pro Leu Ile Phe Ser Ser Leu Ile Gly Ser Gly Cys Gln 245 250 255 Ile Phe Ala Val Ser Leu Ile Val Ile Ile Val Ala Met Ile Glu Asp 260 265 270 Leu Tyr Thr Glu Arg Gly Ser Met Leu Ser Thr Ala Ile Phe Val Tyr 275 280 285 Ala Ala Thr Ser Pro Val Asn Gly Tyr Phe Gly Gly Ser Leu Tyr Ala 290 295 300 Arg Gln Gly Gly Arg Arg Trp Ile Lys Gln Met Phe Ile Gly Ala Phe 305 310 315 320 Leu Ile Pro Ala Met Val Cys Gly Thr Ala Phe Phe Ile Asn Phe Ile 325 330 335 Ala Ile Tyr Tyr His Ala Ser Arg Ala Ile Pro Phe Gly Thr Met Val 340 345 350 Ala Val Cys Cys Ile Cys Phe Phe Val Ile Leu Pro Leu Asn Leu Val 355 360 365 Gly Thr Ile Leu Gly Arg Asn Leu Ser Gly Gln Pro Asn Phe Pro Cys 370 375 380 Arg Val Asn Ala Val Pro Arg Pro Ile Pro Glu Lys Lys Trp Phe Met 385 390 395 400 Glu Pro Ala Val Ile Val Cys Leu Gly Gly Ile Leu Pro Phe Gly Ser 405 410 415 Ile Phe Ile Glu Met Tyr Phe Ile Phe Thr Ser Phe Trp Ala Tyr Lys 420 425 430 Ile Tyr Tyr Val Tyr Gly Phe Met Met Leu Val Leu Val Ile Leu Cys 435 440 445 Ile Val Thr Val Cys Val Thr Ile Val Cys Thr Tyr Phe Leu Leu Asn 450 455 460 Ala Glu Asp Tyr Pro Trp Gln Trp Thr Ser Phe Leu Ser Ala Ala Ser 465 470 475 480 Thr Ala Ile Tyr Val Tyr Met Tyr Ser Phe Tyr Tyr Tyr Phe Phe Lys 485 490 495 Thr Lys Met Tyr Gly Leu Phe Gln Thr Ser Phe Tyr Phe Gly Tyr Met 500 505 510 Ala Val Phe Ser Thr Ala Leu Gly Ile Met Cys Gly Ala Ile Gly Tyr 515 520 525 Met Gly Thr Ser Ala Phe Val Arg Lys Ile Tyr Thr Asn Val Lys Ile 530 535 540 Asp 545 27 3136 DNA Homo sapiens 27 gctgcgagta cctccatggt cccggtggct gtgacggcgg cagtggcgcc tgtcctgtcc 60 ataaacagcg atttctcaga tttgcgggaa attaaaaagc aactgctgct tattgcgggc 120 cttacccggg agcggggcct actacacagt agcaaatggt cggcggagtt ggctttctct 180 ctccctgcat tgcctctggc cgagctgcaa ccgcctccgc ctattacaga ggaagatgcc 240 caggatatgg atgcctatac cctggccaag gcctactttg acgttaaaga gtatgatcgg 300 gcagcacatt tcctgcatgg ctgcaatagc aagaaagcct attttctgta tatgtattcc 360 agatatctgt ctggagaaaa aaagaaggac gatgaaacag ttgatagctt aggccccctg 420 gaaaaaggac aagtgaaaaa tgaggcgctt agagaattga gagtggagct cagcaaaaaa 480 caccaagctc gagaacttga tggatttgga ctttatctgt atggtgtggt gcttcgaaaa 540 ctggacttgg ttaaagaggc cattgatgtg tttgtggaag ctactcatgt tttgcccttg 600 cattggggag cctggttaga actctgtaac ctgatcacag acaaagagat gctgaagttc 660 ctgtctttgc cagacacctg gatgaaagag ttttttctgg ctcatatata cacagagttg 720 cagttgatag aggaggccct gcaaaagtat cagaatctca ttgatgtggg cttctctaag 780 agctcgtata ttgtttccca aattgcagtt gcctatcaca atatcagaga tattgacaaa 840 gccctctcca tttttaatga gctaaggaaa caagaccctt acaggattga aaatatggac 900 acattctcca accttcttta tgtcaggagc atgaaatcgg agttgagtta tctggctcat 960 aacctctgtg agattgataa atatcgtgta gaaacgtgct gtgtaattgg caattattac 1020 agtttacgtt ctcagcatga gaaagcagcc ttatatttcc agagagccct gaaattaaat 1080 cctcggtatc ttggtgcctg gacactaatg ggacatgagt acatggagat gaagaacacg 1140 tctgctgcta tccaggctta tagacatgcc attgaggtca acaaacggga ctacagagct 1200 tggtatggcc tcgggcagac ctatgaaatc cttaagatgc cattttactg cctttattat 1260 tatagacggg cccaccagct tcgacccaat gattctcgca tgctggttgc tttaggagaa 1320 tgttacgaga aactcaatca actagtggaa gccaaaaagt gtttttggat agcttacgcc 1380 gtgggagatg tggagaaaat ggctctggtg aaactggcaa agcttcatga acagttgact 1440 gagtcagaac aggctgccca gtgttacatc aaatatatcc aagatatcta tacctgtggg 1500 gaaatagtag aacacttgga ggaaagcact gcctttcgct atctggccca gtactatttt 1560 aagtgcaaac tgtgggatga agcttcaact tgtgcacaaa agtgttgtgc atttaatgat 1620 acccgggaag aaggtaaggc cttactccgg caaatcctac agcttcggaa ccaaggcgag 1680 actcctacca ccgaggtgcc tgctcccttt ttcctacctg cttcactctc tgctaacaat 1740 acccccacac gcagagtttc tccactcaac ttgtcttctg tcacgccata gttggctact 1800 ctcaagccag cacattgtta gacccatctt aattaagcct tacctccatg taaagaacag 1860 cacgtctgtt ccaaggacct cagctcttct tgtgtctaca gatggcaaca gctccatagg 1920 ggacagcttg tataattacc ttcagaggcc aactgacaga atcctggcag gaacagacat 1980 tatcttgcca gttagaagta cttctgtctc acttatgtcc aaagagtggc tatagatctt 2040 ggccttcttc cctgaatgct tttttttttt tggcccccaa gaaagtccct tttatagcac 2100 tttagcacag gcaatgctac aggaacaaag tttcaatgct gctgagagtg aaagaaagga 2160 ggaaagtctg ccactctacc ctgagctggc agtagggcac tgagtaccct aggaagaagt 2220 cagagcaatg gatacaaatg accttgctct tggatttgct gagcatgatc cctattctga 2280 tgtcagagat taggtttaaa tggaatagag ctatccattt gttcttactc tctagggaga 2340 caatcttcca aaacagtttt gggggggtct tctaaagctt tcaaattgga agtaacttta 2400 ttcaactaga gttgaataaa agaagggcaa aaataatctc acagagcttg gaactgctga 2460 tagcccttac tgagggcaaa agatggctat attgttagct atactcctac caaagcaagc 2520 aaggagatag gattatagat aatttcacgg acatttggaa ataacattgg tgattataca 2580 gacaagaata aactcacttc aagctggtct gttttaataa attttcaacg taattgtcta 2640 tttttttccc tcccatctgc aacagaatac atttttttca gcctttatct agatgaggta 2700 aagggaatca ttcttatggt gctcttggag agtttcaggc ctgtgcatgt gtgtacagca 2760 ggaggtaata tgctataatg tctgctgtaa tatatttgca cagtagatgc tatggatcat 2820 tctgagctca gggtccagac tttattctta ttcccagaat tttgtgttac gtttttacct 2880 cctaacatat gacacttcat cttatattaa ggaaggttta gaatatctaa tacgacttga 2940 attcatttgt tactaagcct tctcaggcaa gctgtatact agttactggt ctccactgcc 3000 atgccttttc aaggttccca tggtccagaa tgatgtttga ttcttaattt ttctgtccct 3060 tttataattt gttttaatga ttttgctaca tttggaattc aataaaaaat gtgaacaata 3120 aaaaaaaaaa aaaaaa 3136 28 591 PRT Homo sapiens 28 Met Val Pro Val Ala Val Thr Ala Ala Val Ala Pro Val Leu Ser Ile 1 5 10 15 Asn Ser Asp Phe Ser Asp Leu Arg Glu Ile Lys Lys Gln Leu Leu Leu 20 25 30 Ile Ala Gly Leu Thr Arg Glu Arg Gly Leu Leu His Ser Ser Lys Trp 35 40 45 Ser Ala Glu Leu Ala Phe Ser Leu Pro Ala Leu Pro Leu Ala Glu Leu 50 55 60 Gln Pro Pro Pro Pro Ile Thr Glu Glu Asp Ala Gln Asp Met Asp Ala 65 70 75 80 Tyr Thr Leu Ala Lys Ala Tyr Phe Asp Val Lys Glu Tyr Asp Arg Ala 85 90 95 Ala His Phe Leu His Gly Cys Asn Ser Lys Lys Ala Tyr Phe Leu Tyr 100 105 110 Met Tyr Ser Arg Tyr Leu Ser Gly Glu Lys Lys Lys Asp Asp Glu Thr 115 120 125 Val Asp Ser Leu Gly Pro Leu Glu Lys Gly Gln Val Lys Asn Glu Ala 130 135 140 Leu Arg Glu Leu Arg Val Glu Leu Ser Lys Lys His Gln Ala Arg Glu 145 150 155 160 Leu Asp Gly Phe Gly Leu Tyr Leu Tyr Gly Val Val Leu Arg Lys Leu 165 170 175 Asp Leu Val Lys Glu Ala Ile Asp Val Phe Val Glu Ala Thr His Val 180 185 190 Leu Pro Leu His Trp Gly Ala Trp Leu Glu Leu Cys Asn Leu Ile Thr 195 200 205 Asp Lys Glu Met Leu Lys Phe Leu Ser Leu Pro Asp Thr Trp Met Lys 210 215 220 Glu Phe Phe Leu Ala His Ile Tyr Thr Glu Leu Gln Leu Ile Glu Glu 225 230 235 240 Ala Leu Gln Lys Tyr Gln Asn Leu Ile Asp Val Gly Phe Ser Lys Ser 245 250 255 Ser Tyr Ile Val Ser Gln Ile Ala Val Ala Tyr His Asn Ile Arg Asp 260 265 270 Ile Asp Lys Ala Leu Ser Ile Phe Asn Glu Leu Arg Lys Gln Asp Pro 275 280 285 Tyr Arg Ile Glu Asn Met Asp Thr Phe Ser Asn Leu Leu Tyr Val Arg 290 295 300 Ser Met Lys Ser Glu Leu Ser Tyr Leu Ala His Asn Leu Cys Glu Ile 305 310 315 320 Asp Lys Tyr Arg Val Glu Thr Cys Cys Val Ile Gly Asn Tyr Tyr Ser 325 330 335 Leu Arg Ser Gln His Glu Lys Ala Ala Leu Tyr Phe Gln Arg Ala Leu 340 345 350 Lys Leu Asn Pro Arg Tyr Leu Gly Ala Trp Thr Leu Met Gly His Glu 355 360 365 Tyr Met Glu Met Lys Asn Thr Ser Ala Ala Ile Gln Ala Tyr Arg His 370 375 380 Ala Ile Glu Val Asn Lys Arg Asp Tyr Arg Ala Trp Tyr Gly Leu Gly 385 390 395 400 Gln Thr Tyr Glu Ile Leu Lys Met Pro Phe Tyr Cys Leu Tyr Tyr Tyr 405 410 415 Arg Arg Ala His Gln Leu Arg Pro Asn Asp Ser Arg Met Leu Val Ala 420 425 430 Leu Gly Glu Cys Tyr Glu Lys Leu Asn Gln Leu Val Glu Ala Lys Lys 435 440 445 Cys Phe Trp Ile Ala Tyr Ala Val Gly Asp Val Glu Lys Met Ala Leu 450 455 460 Val Lys Leu Ala Lys Leu His Glu Gln Leu Thr Glu Ser Glu Gln Ala 465 470 475 480 Ala Gln Cys Tyr Ile Lys Tyr Ile Gln Asp Ile Tyr Thr Cys Gly Glu 485 490 495 Ile Val Glu His Leu Glu Glu Ser Thr Ala Phe Arg Tyr Leu Ala Gln 500 505 510 Tyr Tyr Phe Lys Cys Lys Leu Trp Asp Glu Ala Ser Thr Cys Ala Gln 515 520 525 Lys Cys Cys Ala Phe Asn Asp Thr Arg Glu Glu Gly Lys Ala Leu Leu 530 535 540 Arg Gln Ile Leu Gln Leu Arg Asn Gln Gly Glu Thr Pro Thr Thr Glu 545 550 555 560 Val Pro Ala Pro Phe Phe Leu Pro Ala Ser Leu Ser Ala Asn Asn Thr 565 570 575 Pro Thr Arg Arg Val Ser Pro Leu Asn Leu Ser Ser Val Thr Pro 580 585 590 29 2472 DNA Homo sapiens 29 tatgagcctt cggaacttgt ggagagacta caaagttttg gttgttatgg tccctttagt 60 tgggctcata catttggggt ggtacagaat caaaagcagc cctgttttcc aaatacctaa 120 aaacgacgac attcctgagc aagatagtct gggactttca aatcttcaga agagccaaat 180 ccaggggaag tagcaggctt gcaatcttca ggtaaagaag cagctttgaa tctgagcttc 240 atatcgaaag aagagatgaa aaataccagt tggattagaa agaactggct tcttgtagct 300 gggatatctt tcataggtgt ccatcttgga acatactttt tgcagaggtc tgcaaagcag 360 tctgtaaaat ttcagtctca aagcaaacaa aagagtattg aagagtgaag taaaataaat 420 atttggaatt actaatttgt cattaaatca ttctatgctg attagcttca taaacattga 480 actttttgat tttatagcca caatgctgca tattcatact ttaattccta aagaataatt 540 tttaatgtta aaacgtgata atgcaataaa tagaaaaatg tggtttacaa aataaaaacg 600 gtcttcacta gttaccacct gaagtaagat gtctcgtttg gaagctaaga agccatcatt 660 gtgtaagagt gaaccactga caactgagag agtcaggacc acactttctg tcttgaaaag 720 aattgtaaca tcatgctatg gcccctcagg taggctgaag cagctgcaca atggctttgg 780 aggttacgtg tgtacaacct cacagtcctc agctctgctc agtcaccttt tggtcacaca 840 tcccatttta aagatcctga cagcctccat acagaatcat gtgtcaagct tcagtgattg 900 tggcttattc acagctattc tttgctgcaa cctgattgaa aatgttcaga gattaggctt 960 gacacccacc actgtcatta gattaaataa acatcttttg agtctttgca tcagttatct 1020 caagtctgat acctgtggtt gtcgaatccc agtggacttt agtagtactc agatcctcct 1080 ttgtttggtg cgtagtatat taacaagtaa acctgcctgt atgctcacca gaaaggaaac 1140 agagcatgtc agtgctttga tcctgagagc ctttttgctt acaattccag aaaatgctga 1200 aggccacatc attttaggaa agagtttaat tgtaccttta aaaggtcaaa gagttataga 1260 ttccactgta ttacctggga tactcattga aatgtcagaa gttcaattaa tgaggctatt 1320 acctatcaaa aaatcaactg ccctcaaggt ggcactcttt tgtacaactt tatccggaga 1380 cacttctgac actggagaag gaactgtggt ggtcagttat ggggtttctc ttgaaaatgc 1440 agtcttggac cagctgctta acctaggaag gcagctaatc agtgaccacg tagatcttgt 1500 cctgtgccaa aaagttatac atccatcttt gaagcagttt ctcaatatgc atcgtattat 1560 tgccatagac agaattggag tgactctgat ggaacccctg actaaaatga caggaacaca 1620 gcctattgga tccctaggct caatatgtcc taatagttat ggaagtgtga aagatgtgtg 1680 cactgcaaaa tttggctccc aacatttttt tcatcttatt cctaatgaag caacaatctg 1740 cagcttgctt ctctgcaaca gaaatgacac tgcctgggat gagctgaagc tcacgtgtca 1800 gacggcactg catgtcctgc agttaacact caaggaacca tgggctttgt tgggaggtgg 1860 ctgtactgaa actcatttgg ctgcatatat cagacacaag actcacaacg acccagaaag 1920 cattctcaaa gatgatgaat gtactcaaac agaacttcaa ttaattgctg aagcattttg 1980 cagtgcccta gaatctgttg ttggctcttt agaacatgat ggaggtgaaa ttctcactga 2040 catgaagtat ggacaccttt ggtcagttca ggcagattct ccctgtgttg ctaactggcc 2100 agatttgctt tcacagtgtg gctgtggatt atacaatagc caggaagaac tcaactggtc 2160 tttcttaaga agcacacgtc gtccatttgt gccacaaagc tgccttccac atgaagctgt 2220 gggctcagcc agcaacctga ccttggactg tttgactgca aagcttagtg gcctacaggt 2280 ggctgtagag acagccaatt tgatttggga tctttcatat gttattgaag ataaaaacta 2340 agagaatagc atgttcgtat tacaagagaa acaaataaac tagtctgttg gcaattgaga 2400 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2460 aaaaaaaaaa aa 2472 30 570 PRT Homo sapiens 30 Met Ser Arg Leu Glu Ala Lys Lys Pro Ser Leu Cys Lys Ser Glu Pro 1 5 10 15 Leu Thr Thr Glu Arg Val Arg Thr Thr Leu Ser Val Leu Lys Arg Ile 20 25 30 Val Thr Ser Cys Tyr Gly Pro Ser Gly Arg Leu Lys Gln Leu His Asn 35 40 45 Gly Phe Gly Gly Tyr Val Cys Thr Thr Ser Gln Ser Ser Ala Leu Leu 50 55 60 Ser His Leu Leu Val Thr His Pro Ile Leu Lys Ile Leu Thr Ala Ser 65 70 75 80 Ile Gln Asn His Val Ser Ser Phe Ser Asp Cys Gly Leu Phe Thr Ala 85 90 95 Ile Leu Cys Cys Asn Leu Ile Glu Asn Val Gln Arg Leu Gly Leu Thr 100 105 110 Pro Thr Thr Val Ile Arg Leu Asn Lys His Leu Leu Ser Leu Cys Ile 115 120 125 Ser Tyr Leu Lys Ser Asp Thr Cys Gly Cys Arg Ile Pro Val Asp Phe 130 135 140 Ser Ser Thr Gln Ile Leu Leu Cys Leu Val Arg Ser Ile Leu Thr Ser 145 150 155 160 Lys Pro Ala Cys Met Leu Thr Arg Lys Glu Thr Glu His Val Ser Ala 165 170 175 Leu Ile Leu Arg Ala Phe Leu Leu Thr Ile Pro Glu Asn Ala Glu Gly 180 185 190 His Ile Ile Leu Gly Lys Ser Leu Ile Val Pro Leu Lys Gly Gln Arg 195 200 205 Val Ile Asp Ser Thr Val Leu Pro Gly Ile Leu Ile Glu Met Ser Glu 210 215 220 Val Gln Leu Met Arg Leu Leu Pro Ile Lys Lys Ser Thr Ala Leu Lys 225 230 235 240 Val Ala Leu Phe Cys Thr Thr Leu Ser Gly Asp Thr Ser Asp Thr Gly 245 250 255 Glu Gly Thr Val Val Val Ser Tyr Gly Val Ser Leu Glu Asn Ala Val 260 265 270 Leu Asp Gln Leu Leu Asn Leu Gly Arg Gln Leu Ile Ser Asp His Val 275 280 285 Asp Leu Val Leu Cys Gln Lys Val Ile His Pro Ser Leu Lys Gln Phe 290 295 300 Leu Asn Met His Arg Ile Ile Ala Ile Asp Arg Ile Gly Val Thr Leu 305 310 315 320 Met Glu Pro Leu Thr Lys Met Thr Gly Thr Gln Pro Ile Gly Ser Leu 325 330 335 Gly Ser Ile Cys Pro Asn Ser Tyr Gly Ser Val Lys Asp Val Cys Thr 340 345 350 Ala Lys Phe Gly Ser Gln His Phe Phe His Leu Ile Pro Asn Glu Ala 355 360 365 Thr Ile Cys Ser Leu Leu Leu Cys Asn Arg Asn Asp Thr Ala Trp Asp 370 375 380 Glu Leu Lys Leu Thr Cys Gln Thr Ala Leu His Val Leu Gln Leu Thr 385 390 395 400 Leu Lys Glu Pro Trp Ala Leu Leu Gly Gly Gly Cys Thr Glu Thr His 405 410 415 Leu Ala Ala Tyr Ile Arg His Lys Thr His Asn Asp Pro Glu Ser Ile 420 425 430 Leu Lys Asp Asp Glu Cys Thr Gln Thr Glu Leu Gln Leu Ile Ala Glu 435 440 445 Ala Phe Cys Ser Ala Leu Glu Ser Val Val Gly Ser Leu Glu His Asp 450 455 460 Gly Gly Glu Ile Leu Thr Asp Met Lys Tyr Gly His Leu Trp Ser Val 465 470 475 480 Gln Ala Asp Ser Pro Cys Val Ala Asn Trp Pro Asp Leu Leu Ser Gln 485 490 495 Cys Gly Cys Gly Leu Tyr Asn Ser Gln Glu Glu Leu Asn Trp Ser Phe 500 505 510 Leu Arg Ser Thr Arg Arg Pro Phe Val Pro Gln Ser Cys Leu Pro His 515 520 525 Glu Ala Val Gly Ser Ala Ser Asn Leu Thr Leu Asp Cys Leu Thr Ala 530 535 540 Lys Leu Ser Gly Leu Gln Val Ala Val Glu Thr Ala Asn Leu Ile Trp 545 550 555 560 Asp Leu Ser Tyr Val Ile Glu Asp Lys Asn 565 570 31 1527 DNA Homo sapiens 31 cactccgcgc gcggggctag cgcgggtttc agcgacggga gccctcaagg gacatggcaa 60 ctacagcggc gccggcgggc ggcgccgaaa tggagctggc ccggaatggg gagggttcga 120 agaaaacatc cagggcggag gctcagctgt gattgacatg gagaacatgg atgatacctc 180 aggctctagc ttcgaggata tgggtgagct gcatcagcgc ctgcgcgagg aagaagtaga 240 cgctgatgca gctgatgcag ctgctgctga agaggaggat ggagagttcc tgggcatgaa 300 gggctttaag ggacagctga gccggcaggt ggcagatcag atgtggcagg ctgggaaaag 360 acaagcctcc agggccttca gcttgtacgc caacatcgac atcctcagac cctactttga 420 tgtggagcct gctcaggtgc gaagcaggct cctggagtcc atgatcccta tcaagatggt 480 caacttcccc cagaaaattg caggtgaact ctatggacct ctcatgctgg tcttcactct 540 ggttgctatc ctactccatg ggatgaagac gtctgacact attatccggg agggcaccct 600 gatgggcaca gccattggca cctgcttcgg ctactggctg ggagtctcat ccttcattta 660 cttccttgcc tacctgtgca acgcccagat caccatgctg cagatgttgg cactgctggg 720 ctatggcctc tttgggcatt gcattgtcct gttcatcacc tataatatcc acctccacgc 780 cctcttctac ctcttctggc ggttggtggg tggactgtcc acactgcgca tggtagcagt 840 gttggtgtct cggaccgtgg gccccacaca gcggctgctc ctctgtggca ccctggctgc 900 cctacacatg ctcttcctgc tctatctgca ttttgcctac cacaaagtgg tagaggggat 960 cctggacaca ctggagggcc ccaacatccc gcccatccag agggtcccca gagacatccc 1020 tgccatgctc cctgctgctc ggcttcccac caccgtcctc aacgccacag ccaaagctgt 1080 tgcggtgacc ctgcagtcac actgacccca cctgaaattc ttggccagtc ctctttcccg 1140 cagctgcaga gaggaggaag actattaaag gacagtcctg atgacatgtt tcgtagatgg 1200 ggtttgcagc tgccactgag ctgtagctgc gtaagtacct ccttgatgcc tgtcggcact 1260 tctgaaaggc acaaggccaa gaactcctgg ccaggactgc aaggctctgc agccaatgca 1320 gaaaatgggt cagctccttt gagaacccct ccccacctac cccttccttc ctctttatct 1380 ctcccacatt gtcttgctta aatatagaac ttggtcttaa aaaaaaaaaa aaaaaaaaaa 1440 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500 aaaaaaaaaa aaaaaaaaaa aaaaaaa 1527 32 315 PRT Homo sapiens 32 Met Glu Asn Met Asp Asp Thr Ser Gly Ser Ser Phe Glu Asp Met Gly 1 5 10 15 Glu Leu His Gln Arg Leu Arg Glu Glu Glu Val Asp Ala Asp Ala Ala 20 25 30 Asp Ala Ala Ala Ala Glu Glu Glu Asp Gly Glu Phe Leu Gly Met Lys 35 40 45 Gly Phe Lys Gly Gln Leu Ser Arg Gln Val Ala Asp Gln Met Trp Gln 50 55 60 Ala Gly Lys Arg Gln Ala Ser Arg Ala Phe Ser Leu Tyr Ala Asn Ile 65 70 75 80 Asp Ile Leu Arg Pro Tyr Phe Asp Val Glu Pro Ala Gln Val Arg Ser 85 90 95 Arg Leu Leu Glu Ser Met Ile Pro Ile Lys Met Val Asn Phe Pro Gln 100 105 110 Lys Ile Ala Gly Glu Leu Tyr Gly Pro Leu Met Leu Val Phe Thr Leu 115 120 125 Val Ala Ile Leu Leu His Gly Met Lys Thr Ser Asp Thr Ile Ile Arg 130 135 140 Glu Gly Thr Leu Met Gly Thr Ala Ile Gly Thr Cys Phe Gly Tyr Trp 145 150 155 160 Leu Gly Val Ser Ser Phe Ile Tyr Phe Leu Ala Tyr Leu Cys Asn Ala 165 170 175 Gln Ile Thr Met Leu Gln Met Leu Ala Leu Leu Gly Tyr Gly Leu Phe 180 185 190 Gly His Cys Ile Val Leu Phe Ile Thr Tyr Asn Ile His Leu His Ala 195 200 205 Leu Phe Tyr Leu Phe Trp Arg Leu Val Gly Gly Leu Ser Thr Leu Arg 210 215 220 Met Val Ala Val Leu Val Ser Arg Thr Val Gly Pro Thr Gln Arg Leu 225 230 235 240 Leu Leu Cys Gly Thr Leu Ala Ala Leu His Met Leu Phe Leu Leu Tyr 245 250 255 Leu His Phe Ala Tyr His Lys Val Val Glu Gly Ile Leu Asp Thr Leu 260 265 270 Glu Gly Pro Asn Ile Pro Pro Ile Gln Arg Val Pro Arg Asp Ile Pro 275 280 285 Ala Met Leu Pro Ala Ala Arg Leu Pro Thr Thr Val Leu Asn Ala Thr 290 295 300 Ala Lys Ala Val Ala Val Thr Leu Gln Ser His 305 310 315 33 988 DNA Homo sapiens 33 caaggctata gtaactaaaa gagaatagta ctggtacaaa aataggatca gatcaatgta 60 acagagtaga gaacccagca ataaagccat gtgcctgcaa ccaactgatc tttgataaag 120 ttgagaaaaa taaacaatga agaaaagaca ctgtattcaa taaatgttgc taggaaaatt 180 ggctagccat atacagaaaa atgaaactga acccgtatct ctcactttat acaaaaatta 240 agttggatta aagacttaaa tgtaaaacct gatactataa aaattataga agaaaaccca 300 ggaaaagctc ttctggacac tggcctaggc aaagaattta tgactaagtc atcaaaagca 360 tatgtaacaa aaaaaaaaaa aaagcgcccg ggtgaggggc ggagctgggg gcatggcgtc 420 cggagcggct cgctggctag tattggcacc cgtcaggtcc ggggctctcc ggagcgggcc 480 tagcttgagg aaagatggcg atgtctccgc cgcatggagc ggctcaggcc ggagcctggt 540 accgtcgagg tcagtcatcg ttacccgcag cggcgccatt ttgcccaaac cggtgaaaat 600 gtccttcggc cttctccgtg tgttctccat tgtgatcccc tttctctatg tcgggacact 660 cattagcaag aactttgctg ctctacttga ggaacatgac atttttgttc cagaggatga 720 tgatgatgat gactaacagg aattacagaa aggagaaagc actaactgaa gaaatggtga 780 tgctctcagt ttctctgcct tccctatcag cagaaaggct cggggaaggc cctcagcctc 840 ccagtctggt gaagcttcct gtatggtcca tgaccgtatt ccaccccagg ctctgggagg 900 ctccctgaga tgtgctgtcc actaagcact gcacaaacaa gcaatcaaat tatgaataaa 960 cataataaat atcaaaaaaa aaaaaaaa 988 34 107 PRT Homo sapiens 34 Met Ala Ser Gly Ala Ala Arg Trp Leu Val Leu Ala Pro Val Arg Ser 1 5 10 15 Gly Ala Leu Arg Ser Gly Pro Ser Leu Arg Lys Asp Gly Asp Val Ser 20 25 30 Ala Ala Trp Ser Gly Ser Gly Arg Ser Leu Val Pro Ser Arg Ser Val 35 40 45 Ile Val Thr Arg Ser Gly Ala Ile Leu Pro Lys Pro Val Lys Met Ser 50 55 60 Phe Gly Leu Leu Arg Val Phe Ser Ile Val Ile Pro Phe Leu Tyr Val 65 70 75 80 Gly Thr Leu Ile Ser Lys Asn Phe Ala Ala Leu Leu Glu Glu His Asp 85 90 95 Ile Phe Val Pro Glu Asp Asp Asp Asp Asp Asp 100 105 35 1759 DNA Homo sapiens 35 tttttttttt tgaggtgtaa tgcaacttca tcactttatt caaatcttca aaatagtctt 60 tattctacat ttttagtata aaaattccac aagttaagtg caccacagtg tagagagaga 120 catacaacgc tgaacttcca taacagtcaa tggtacagtc aaacatcaca tgtacagaac 180 acacaattta gatgaactga aattataaga taaaataaaa taaaatccaa tttcagaaaa 240 caaaaatcaa aacattaagg atccctgaaa tattcttaaa ccctaatgag atttcactgg 300 actcaagtca ttttgtagtg agacattcac aatatgaccc tatcaaccca gtctaggaat 360 tctggggagc cgaatgagtg gccgcatcag acactctgac aaaaaatggt aaccaatttt 420 tgatctgaaa actcctctta atttagctct gaacacagag atttatccaa gtgccagatt 480 actcagtgct ataattttct tttagttaaa caaagggggt cagacagaca ttgcatcatc 540 cagacatgcc ttgttggaca tgtagaatcc gatggagcac tgcacaccag aatgattggc 600 caatgagcag cttctctccc tgaaacaata actgcccatt tggcaaaggg aaagatgaca 660 ataatcagaa gaagaaaatg aatgggatgc ataccataga cgaacgaggc ggagactatt 720 gcgggaatct tactgttcag gagctgttcc tagaactaac tcccttactg tcattgatgt 780 gcattccact ctgtgctttt ctgtacaacc attcaagttt taatttccca ggtgaaccat 840 ctttatctgc cattaccaca agctttcaag tttccagtta ttttcatcat cataaccagt 900 acggtgctat tatttaccta tgtacgtgta gttatgtata attttgtaat tagttacaat 960 ggtaaaaaaa atcgaaatat ataaaaagtg atttgtacag aactttattt tagctctttt 1020 ttaaaaatga tttgcatggt tagaaaacgg cgaggacagc caggggaggg aagggcctct 1080 agggaacttt gcactttcta taacctttgt acttatgcca ctgccctatt tgattctaca 1140 cccaataatg attattactt gaaacccatc tgtaagaaac tgcttcggaa attcatttgt 1200 gtgtatgtaa ataacacaac atagaaacag gaagggaaaa aaagtctgca gtaatgcacg 1260 tatttttttc tttcctgttt attttcggtt ttgctttaag tccttttatt tttaattccc 1320 tttttgtttt tctttttggg ttttggttcc ttttgggttt atgggtgccc tgatactcca 1380 gcagagatca gaaggctaca gatccattct atccatccgt tatgtggctt tgccatccca 1440 gcttggagtg tctttacaaa gataataaca gttgtgttct ttgctctcgt tttggatgca 1500 tagactgaaa aattaaaaca aataacttgt aaaatggctt gttaaaaaat acaattacct 1560 ctaattagta gtacgcgtaa atgttttaca gaatgaaagg cgtgcttttt attttcttac 1620 ttcgttacat tggtggcgaa agaagtctgt atgaaaatca gttctttgct gacacaagtt 1680 ccatttgtta caaatgaatt ctaataaaaa tgtcagtgtt aaaaaaaaaa aaaaaaaaaa 1740 aaaaaaaaaa aaaaaaaaa 1759 36 87 PRT Homo sapiens 36 Met Asn Gly Met His Thr Ile Asp Glu Arg Gly Gly Asp Tyr Cys Gly 1 5 10 15 Asn Leu Thr Val Gln Glu Leu Phe Leu Glu Leu Thr Pro Leu Leu Ser 20 25 30 Leu Met Cys Ile Pro Leu Cys Ala Phe Leu Tyr Asn His Ser Ser Phe 35 40 45 Asn Phe Pro Gly Glu Pro Ser Leu Ser Ala Ile Thr Thr Ser Phe Gln 50 55 60 Val Ser Ser Tyr Phe His His His Asn Gln Tyr Gly Ala Ile Ile Tyr 65 70 75 80 Leu Cys Thr Cys Ser Tyr Val 85 37 643 DNA Homo sapiens 37 tcagcctccg cctccgagcc tcagttgtct tctctgtgag gtgggaatgc cggtgaatcc 60 tgccgctggc gtggatgaga agtgaatgcg tgctcggagc tgcgagtgac agcgggcagg 120 aggcgcccag ggacacttgg tttctccagg gctggaaggc ttctagaagg ttcctcatca 180 agggaagtgt ggctgggggc gccgtctacc tggtgtacga ccaggagctg ctggggccca 240 gcgacaagag ccaggcagcc ctacagaagg ctggggaggt ggtccccccc gccatgtacc 300 agttcagcca gtacgtgtgt cagcagacag gcctgcagat accccagctc ccagcccctc 360 caaagattta ctttcccatc cgtgactcct ggaatgcagg catcatgacg gtgatgtcag 420 ctctgtcggt ggccccctcc aaggcccgcg agtactccaa ggagggctgg gagtatgtga 480 aggcgcgcac caagtagcga gtcagcaggg gccgcctgcc ccggccagaa cgggcagggc 540 tgccactgac ctgaagactc cggactggga ccccactccg agggcagctc ccggccttgc 600 cggcccaata aaggacttca gaagtgaaaa aaaaaaaaaa aaa 643 38 140 PRT Homo sapiens 38 Met Arg Ser Glu Cys Val Leu Gly Ala Ala Ser Asp Ser Gly Gln Glu 1 5 10 15 Ala Pro Arg Asp Thr Trp Phe Leu Gln Gly Trp Lys Ala Ser Arg Arg 20 25 30 Phe Leu Ile Lys Gly Ser Val Ala Gly Gly Ala Val Tyr Leu Val Tyr 35 40 45 Asp Gln Glu Leu Leu Gly Pro Ser Asp Lys Ser Gln Ala Ala Leu Gln 50 55 60 Lys Ala Gly Glu Val Val Pro Pro Ala Met Tyr Gln Phe Ser Gln Tyr 65 70 75 80 Val Cys Gln Gln Thr Gly Leu Gln Ile Pro Gln Leu Pro Ala Pro Pro 85 90 95 Lys Ile Tyr Phe Pro Ile Arg Asp Ser Trp Asn Ala Gly Ile Met Thr 100 105 110 Val Met Ser Ala Leu Ser Val Ala Pro Ser Lys Ala Arg Glu Tyr Ser 115 120 125 Lys Glu Gly Trp Glu Tyr Val Lys Ala Arg Thr Lys 130 135 140 39 2015 DNA Homo sapiens 39 aggctgtctg ctagtcagaa ttgcctcaaa aagagtctag aagatgttgt cattgacatc 60 cagtcatctc tttctaaggg aatcagaggc aatgagcccg tatatacttc aactcaagaa 120 gactgcatta attcttgctg ttcaacaaaa aacatatcag gggacaaagc atgtaacttg 180 atgatcttcg acactcgaaa aacagctaga caacccaact gctacctatt tttctgtccc 240 aacgaggaag cctgtccatt gaaaccagca aaaggactta tgagttacag gataattaca 300 gattttccat ctttgaccag aaatttgcca agccaagagt taccccagga agattctctc 360 ttacatggcc aattttcaca agcagtcact cccctagccc atcatcacac agattattca 420 aagcccaccg atatctcatg gagagacaca ctttctcaga agtttggatc ctcagatcac 480 ctggagaaac tatttaagat ggatgaagca agtgcccagc tccttgctta taaggaaaaa 540 ggccattctc agagttcaca attttcctct gatcaagaaa tagctcatct gctgcctgaa 600 aatgtgagtg cgctcccagc tacggtggca gttgcttctc cacataccac ctcggctact 660 ccaaagcccg ccacccttct acccaccaat gcttcagtga caccttctgg gacttcccag 720 ccacagctgg ccaccacagc tccacctgta accactgtca cttctcagcc tcccacgacc 780 ctcatttcta cagtttttac acgggctgcg gctacactcc aagcaatggc tacaacagca 840 gttctgacta ccacctttca ggcacctacg gactcgaaag gcagcttaga aaccataccg 900 tttacagaaa tctccaactt aactttgaac acagggaatg tgtataaccc tactgcactt 960 tctatgtcaa atgtggagtc ttccactatg aataaaactg cttcctggga aggtagggag 1020 gccagtccag gcagttcctc cccagggcag tgttccagaa aatcagtacg gccttccatt 1080 tgaaaaatgg cttcttatcg ggtccctgct ctttggtgtc ctgttcctgg tgataggcct 1140 cgtcctcctg ggtagatcct ctcggaatca ctccgcagga aacgttactc aagactggat 1200 tatttgatca atgggatcta tgtggacatc taaggatgga actcggtgtc tcttaattca 1260 tttagtaacc agaagcccaa atgcaatgag tttctgctga cttgctagtc ttagcaggag 1320 gttgtatttt gaagacagga aaatgccccc ttctgctttc cttttttttt ttggagacag 1380 agtcttgctc tgttgcccag gctggagtgc agtagcacga tctcggctct caccgcaacc 1440 tccgtctcct gggttcaagc gattctcctg cctcagcctc ctagtatctg ggattacagg 1500 catgtgccac cacacctggg tgatttttgt atttttagta gagacgggtt tcaccatgtt 1560 ggtcaggctg gtctcaaact cctgacctag tgatccaccc tcctcggcct cccaaagtgc 1620 tgggataaca ggcatgagcc accacagctg gcccccttct gttttatgtt tggtttttga 1680 gaaggaatga agtgggaacc aaattaggta attttgggta atctgtctct aaaatattag 1740 ctgaaaacaa agctgtatgt aaagtaataa ggtataattg ccatataaat ttcaaaattc 1800 aactggcttt tatgcaaaga aacaggttag gacatctagg ttccaattca ttcacattct 1860 tggttccaga taaaatcaac tgtttatatc aatttctaat ggatttgcct ttctttttat 1920 atggattcct ttaaaactta ttccagatgt agttccttcc aattaaatat ttgaataaat 1980 cttttgttac tcaaaaaaaa aaaaaaaaaa aaaaa 2015 40 300 PRT Homo sapiens 40 Met Ile Phe Asp Thr Arg Lys Thr Ala Arg Gln Pro Asn Cys Tyr Leu 1 5 10 15 Phe Phe Cys Pro Asn Glu Glu Ala Cys Pro Leu Lys Pro Ala Lys Gly 20 25 30 Leu Met Ser Tyr Arg Ile Ile Thr Asp Phe Pro Ser Leu Thr Arg Asn 35 40 45 Leu Pro Ser Gln Glu Leu Pro Gln Glu Asp Ser Leu Leu His Gly Gln 50 55 60 Phe Ser Gln Ala Val Thr Pro Leu Ala His His His Thr Asp Tyr Ser 65 70 75 80 Lys Pro Thr Asp Ile Ser Trp Arg Asp Thr Leu Ser Gln Lys Phe Gly 85 90 95 Ser Ser Asp His Leu Glu Lys Leu Phe Lys Met Asp Glu Ala Ser Ala 100 105 110 Gln Leu Leu Ala Tyr Lys Glu Lys Gly His Ser Gln Ser Ser Gln Phe 115 120 125 Ser Ser Asp Gln Glu Ile Ala His Leu Leu Pro Glu Asn Val Ser Ala 130 135 140 Leu Pro Ala Thr Val Ala Val Ala Ser Pro His Thr Thr Ser Ala Thr 145 150 155 160 Pro Lys Pro Ala Thr Leu Leu Pro Thr Asn Ala Ser Val Thr Pro Ser 165 170 175 Gly Thr Ser Gln Pro Gln Leu Ala Thr Thr Ala Pro Pro Val Thr Thr 180 185 190 Val Thr Ser Gln Pro Pro Thr Thr Leu Ile Ser Thr Val Phe Thr Arg 195 200 205 Ala Ala Ala Thr Leu Gln Ala Met Ala Thr Thr Ala Val Leu Thr Thr 210 215 220 Thr Phe Gln Ala Pro Thr Asp Ser Lys Gly Ser Leu Glu Thr Ile Pro 225 230 235 240 Phe Thr Glu Ile Ser Asn Leu Thr Leu Asn Thr Gly Asn Val Tyr Asn 245 250 255 Pro Thr Ala Leu Ser Met Ser Asn Val Glu Ser Ser Thr Met Asn Lys 260 265 270 Thr Ala Ser Trp Glu Gly Arg Glu Ala Ser Pro Gly Ser Ser Ser Pro 275 280 285 Gly Gln Cys Ser Arg Lys Ser Val Arg Pro Ser Ile 290 295 300 41 1549 DNA Homo sapiens 41 tgatcctaat aatactgcac atgaagaaac taaaactgtc ttatcagata cagaagaaat 60 aaaaccacag acaaaaaagg agacatacat ttcttgtcct ctaagaggag tattgaatgt 120 aattattaca aatggagtta tactgtttgt gatatggtgt atgacctggt caatcttagg 180 ctctgaagct ctccctggtg gaaatttatt tgggttgttc attatttttt atagtgccat 240 tattggggga aaaattttac aactcattag aataccttta gtgcctccac ttccacctct 300 tcttgggatg ttactggctg gttttacgat taggaatgtt ccattcatca atgaacatgt 360 ccatgttcct aacacatggt cttcaatttt aagaagcatt gcccttacca ttattctaat 420 aagagctggg cttggactcg atccacaggc tttgaggcat ttgaaggtcg tttgtttcag 480 attggctgta ggtccatgcc ttatggaggc aagtgcagct gctgtttttt cacacttcat 540 tatgaaattt ccctggcaat gggcatttct attaggtttt gttctaggtg ctgtctctcc 600 tgctgttgtt gtcccttaca tgatggtgct gcaagaaaat ggatatggtg ttgaggaagg 660 cattccaacc ttattaatgg ctgctagcag tatggatgac attctggcta tcactggatt 720 caatacatgc ttgagcatag tcttttcctc aggtggtata cttaataacg ccatagcctc 780 tataaggaac gtatgtatta gtctgctggc aggaattgtt ttgggatttt ttgttcgata 840 ttttccaagt gaagaccaga aaaaacttac attgaagaga ggattccttg ttttgactat 900 gtgtgtttct gccgtcttag gcagccaacg tattggttta catggatctg gaggattatg 960 cacactagtg ttgagtttca ttgcagggac aaaatggtcc caagaaaaga tgaaagtcca 1020 aaagattatt acgactgtat gggatatttt tcaaccactt ctttttggtt tagttggagc 1080 agaagtatct gtttcatcgc ttgaatcaaa tattgttggc atatctgttg ccactctaag 1140 tttggcatta tgtgttcgaa ttttaaccac atatctattg atgtgctttg ctggttttag 1200 ttttaaggag aaaatattta ttgctttagc atggatgccc aaagctacag tacagattaa 1260 tcaagctatc cttctgttgt ttcttcttcg ggaggaatgg acgaactgca aggtagccaa 1320 gaagtgcgag tacaccaagg aaaggcaata accgaagcca ttctgaaact aaacatgtag 1380 atgtgtcaga atctgcagtg ctcttggaaa agaattcaaa atagcatgtc gtttcatcct 1440 tgagcttatt ctttgttact ttttacatta attccttttt aatggatcca taaaactgtg 1500 aataaataac acaataaagc cagctctacc aaaaaaaaaa aaaaaaaaa 1549 42 396 PRT Homo sapiens 42 Met Thr Trp Ser Ile Leu Gly Ser Glu Ala Leu Pro Gly Gly Asn Leu 1 5 10 15 Phe Gly Leu Phe Ile Ile Phe Tyr Ser Ala Ile Ile Gly Gly Lys Ile 20 25 30 Leu Gln Leu Ile Arg Ile Pro Leu Val Pro Pro Leu Pro Pro Leu Leu 35 40 45 Gly Met Leu Leu Ala Gly Phe Thr Ile Arg Asn Val Pro Phe Ile Asn 50 55 60 Glu His Val His Val Pro Asn Thr Trp Ser Ser Ile Leu Arg Ser Ile 65 70 75 80 Ala Leu Thr Ile Ile Leu Ile Arg Ala Gly Leu Gly Leu Asp Pro Gln 85 90 95 Ala Leu Arg His Leu Lys Val Val Cys Phe Arg Leu Ala Val Gly Pro 100 105 110 Cys Leu Met Glu Ala Ser Ala Ala Ala Val Phe Ser His Phe Ile Met 115 120 125 Lys Phe Pro Trp Gln Trp Ala Phe Leu Leu Gly Phe Val Leu Gly Ala 130 135 140 Val Ser Pro Ala Val Val Val Pro Tyr Met Met Val Leu Gln Glu Asn 145 150 155 160 Gly Tyr Gly Val Glu Glu Gly Ile Pro Thr Leu Leu Met Ala Ala Ser 165 170 175 Ser Met Asp Asp Ile Leu Ala Ile Thr Gly Phe Asn Thr Cys Leu Ser 180 185 190 Ile Val Phe Ser Ser Gly Gly Ile Leu Asn Asn Ala Ile Ala Ser Ile 195 200 205 Arg Asn Val Cys Ile Ser Leu Leu Ala Gly Ile Val Leu Gly Phe Phe 210 215 220 Val Arg Tyr Phe Pro Ser Glu Asp Gln Lys Lys Leu Thr Leu Lys Arg 225 230 235 240 Gly Phe Leu Val Leu Thr Met Cys Val Ser Ala Val Leu Gly Ser Gln 245 250 255 Arg Ile Gly Leu His Gly Ser Gly Gly Leu Cys Thr Leu Val Leu Ser 260 265 270 Phe Ile Ala Gly Thr Lys Trp Ser Gln Glu Lys Met Lys Val Gln Lys 275 280 285 Ile Ile Thr Thr Val Trp Asp Ile Phe Gln Pro Leu Leu Phe Gly Leu 290 295 300 Val Gly Ala Glu Val Ser Val Ser Ser Leu Glu Ser Asn Ile Val Gly 305 310 315 320 Ile Ser Val Ala Thr Leu Ser Leu Ala Leu Cys Val Arg Ile Leu Thr 325 330 335 Thr Tyr Leu Leu Met Cys Phe Ala Gly Phe Ser Phe Lys Glu Lys Ile 340 345 350 Phe Ile Ala Leu Ala Trp Met Pro Lys Ala Thr Val Gln Ile Asn Gln 355 360 365 Ala Ile Leu Leu Leu Phe Leu Leu Arg Glu Glu Trp Thr Asn Cys Lys 370 375 380 Val Ala Lys Lys Cys Glu Tyr Thr Lys Glu Arg Gln 385 390 395 43 4433 DNA Homo sapiens 43 ggctcaagta gcggacacgg aacagggaac tatcagcccg tcggcctccg ggccctgcat 60 tctctagcca tggaccggga ccttttgcgg cagtcgctaa attgccacgg gtcgtctttg 120 ctctctctac ttcggagcga acagcaggac aatccacact tccgtagcct cctggggtcg 180 gccgccgagc cagcccgggg cccgccgccc cagcacccgt tgcagggcag aaaagagaag 240 agagttgaca acatcgagat acagaaattc atctccaaaa aagcggatct gctttttgca 300 ctttcctgga aatcagatgc acctgcaact tctgaaatta atgaagacag tgaagatcat 360 tatgcaatca tgccaccttt agagcaattc atggagatac ctagtatgga tcggagagag 420 ctgtttttcc gagatattga gcgtggtgat atagtgattg gaagaattag ttctattcgg 480 gaattcggtt ttttcatggt gttgatctgt ttaggaagtg gtatcatgag agatatagcc 540 cacttagaaa tcacagctct ttgtccctta agagatgtgc cttctcacag taaccatggg 600 gatcctttat catattacca aactggtgac atcattcgag ctggaatcaa ggatattgac 660 agataccatg aaaagctagc agtatctctg tatagctctt ctcttccacc acacctatct 720 ggtattaaat taggtgtaat tagctctgaa gagcttcctt tatactacag gagaagtgtt 780 gagctaaata gcaattcttt ggagtcctat gaaaatgtca tgcagagttc cttgggattt 840 gttaatccag gagtagttga attccttcta gaaaaactag gaatagatga atctaatcca 900 ccatctttaa tgagaggcct acaaagcaaa aatttctctg aagatgattt tgcttctgca 960 ttgagaaaaa aacaatccgc atcttgggct ttaaaatgtg tgaagatcgg agttgactat 1020 tttaaagttg gacgccatgt ggatgctatg aatgaataca ataaagcttt ggaaatagac 1080 aaacaaaacg tggaagcttt ggtagctcgt ggagcattat atgcgacaaa aggaagtttg 1140 aacaaagcaa tagaagattt tgagcttgca ttagaaaact gtccaactca cagaaatgca 1200 agaaaatacc tctgccagac acttgtagag agaggaggac agttagaaga agaagaaaag 1260 tttttaaatg ctgaaagtta ctataagaaa gccttggctt tggatgagac ttttaaagat 1320 gcagaggatg ctttgcagaa acttcataaa tatatgcagg tgattcctta tttcctctta 1380 gaaatttagt gatatttgaa ataatgccca aacttaattt tctcctgagg aaaaactatt 1440 ctacattact taagtaaggc attatgaaaa gtttcttttt aggtatagtt tttcctaatt 1500 gggtttgaca ttgcttcata gtgcctctgt ttttgtccat aatcgaaagt aaagatagct 1560 gtgagaaaac tattacctaa atttggtatg ttgttttgag aaatgtcctt atagggagct 1620 cacctggtgg tttttaaatt attgttgcta ctataattga gctaattata aaaacctttt 1680 tgagacatat tttaaattgt cttttcctgt aatactgatg atgatgtttt ctcatgcatt 1740 ttcttctgaa ttggaccatt gctgctgtgt ctgtgacatc tggtgctgct catccccatc 1800 cacaaactgg aaaatgattt cctatgtaat catgcattca actgggctgt gctatttttt 1860 taaatggttt gtatttgaac atggtgattc ctccttcact tcaccttaac ggaatgtctt 1920 tatttgaatt ttatttgtaa aatgtgtcct gtttaaattt ttcaatcttt aaaaataatt 1980 tttatgtact tttttttttt tttaaccttt cttgcactct gggtcatggg taccactgca 2040 atggcttccc ctttttttat gggataccaa ctgcaatatg gtcctcaatg ctgttctggc 2100 catttcaatg actaatgcca aacatctgta tgactaattt ttttatgtta aaaaaatact 2160 gtttaatgct ggctctatgg tgatttggtt ttactaaatt gggtttctcg ttgggggtgg 2220 tcttttgaat actgggtttt atatattctg ctatttttaa cgtgtggttt ttttcgatat 2280 ctgggttcta aaagaaatct ttggaattaa gagaaaaaca agctgaaaag gaagaaaagc 2340 agaaaacaaa gaaaatagaa acaagtgcag aaaagttgcg taagctctta aaagaagaga 2400 agaggtaaac tataatattc agtattttta aacttaaggc actactgaat tgaacccaaa 2460 gtgccatact ggaagtaaag taaataaaaa tatgaaagta tttcaagtgc caatcagtga 2520 ctgttaagaa tctttagcaa atatgtgttc catgtatttc ctattaaaga gatgaagtgg 2580 aatttaaggc tgaattctac aaaaaagagt acttagaaat taaaatatag aaaaagttac 2640 ttcaattatg ttttaggaag aaatattttt aaaactagag cagtggtctc actaggaggt 2700 gagttcatca gaccggaccc ttgacagatt atttggctga aaataccaat aatcaggtga 2760 agaaaccatg aactagaggt agccaaataa aaaagttgag ttctccttta tgtgttcagt 2820 agtcttaagt ttttaaggta gtgttgaaaa aagtctgtct ttcagagatg atggatttgc 2880 ttacaatgat acctgtctgc aagcattttt tcccccaaaa gtgcttaata gtaaaattag 2940 atcttgtagt agccgagatt attgtatcat ttatctgaac cacagctttt ataaaatctt 3000 taaaggaaac aaatagggcc cacatcttta tgaataattt agaaacattt ttgtatatat 3060 atgacaaatg aactgttttt tttaggctaa agaagaaaag aagaaaatca acttcttctt 3120 caagtgtttc ttctgctgat gaatcagtgt cttcatcatc atcctcttcc tcttctggtc 3180 acaaaaggca taagaaacat aagaggaacc gttcagagtc ttctcgcagt tccagaaggc 3240 attcatctag ggcatcctca aatcagatag atcagaatag gaaagatgag tgctacccag 3300 ttccagctaa tacttcagca tcttttctta accataaaca agaagtggag aaactactgg 3360 ggaagcagga taggttacag tatgaaaaga cacagataaa agagaaagat agacgccctc 3420 tctcttcatc ttcacttgaa ataccggatg attttggagt gtactcctat ttatttaaaa 3480 agttaactat aaaacagcct caggcaggtc cttcaggaga tattccagaa gagggcattg 3540 ttatcataga tgacagctcc attcatgtta ctgaccctga agaccttcaa gtgggacaag 3600 atatggaggt ggaagacagt ggtattgatg atcctgacca cgggtaggct taggtttatg 3660 tgtgtgtatg tgtcttagtt tttaacaaaa aaattaaaaa gtaaaaaaac taaaaataga 3720 aaaatgctta gagaataagg atataaagaa tatttttgtg cagttgaaca atgagtgctt 3780 aagctaaatg tcatcacaaa agagtaaaaa aattttacaa aattaaaaat gtttaaagtt 3840 aaaaagctct aggaagctaa ggtcaattta ttattggaga aataaaatta tttttatgaa 3900 tttactgtag cctaggtgta cattatttat catgtctaca gtagtgttca gcaattaggc 3960 cttcacattc tctcaccact cactcactca gtcactcacc cagagcagct tccagtcccg 4020 caagctccat ttatggtaag tgccctgtac aggtgtacca tttttttaat ccattatacc 4080 atatttttat tgtacctttt ctatgtttag atttgtttag atacacaagt accactgtgt 4140 tacagttgcc tatagtactc agtacagtaa cacactttac aagcttatag cctaggaaca 4200 ataggctata ccatctaggt ttgtgtaagt acactcttat gatgttcaca cagtgacaaa 4260 atcgcccaag gatgcattca tcagaacaca ttcccattgt tatccaatgc atgactgtat 4320 aatggtttta tggattaaat tttttatgta attcaactgg aaagtatttt tatgttattt 4380 tggaaaaaat aaaacaatga caattggaaa aaaaaaaaaa aaaaaaaaaa aaa 4433 44 439 PRT Homo sapiens 44 Met Asp Arg Asp Leu Leu Arg Gln Ser Leu Asn Cys His Gly Ser Ser 1 5 10 15 Leu Leu Ser Leu Leu Arg Ser Glu Gln Gln Asp Asn Pro His Phe Arg 20 25 30 Ser Leu Leu Gly Ser Ala Ala Glu Pro Ala Arg Gly Pro Pro Pro Gln 35 40 45 His Pro Leu Gln Gly Arg Lys Glu Lys Arg Val Asp Asn Ile Glu Ile 50 55 60 Gln Lys Phe Ile Ser Lys Lys Ala Asp Leu Leu Phe Ala Leu Ser Trp 65 70 75 80 Lys Ser Asp Ala Pro Ala Thr Ser Glu Ile Asn Glu Asp Ser Glu Asp 85 90 95 His Tyr Ala Ile Met Pro Pro Leu Glu Gln Phe Met Glu Ile Pro Ser 100 105 110 Met Asp Arg Arg Glu Leu Phe Phe Arg Asp Ile Glu Arg Gly Asp Ile 115 120 125 Val Ile Gly Arg Ile Ser Ser Ile Arg Glu Phe Gly Phe Phe Met Val 130 135 140 Leu Ile Cys Leu Gly Ser Gly Ile Met Arg Asp Ile Ala His Leu Glu 145 150 155 160 Ile Thr Ala Leu Cys Pro Leu Arg Asp Val Pro Ser His Ser Asn His 165 170 175 Gly Asp Pro Leu Ser Tyr Tyr Gln Thr Gly Asp Ile Ile Arg Ala Gly 180 185 190 Ile Lys Asp Ile Asp Arg Tyr His Glu Lys Leu Ala Val Ser Leu Tyr 195 200 205 Ser Ser Ser Leu Pro Pro His Leu Ser Gly Ile Lys Leu Gly Val Ile 210 215 220 Ser Ser Glu Glu Leu Pro Leu Tyr Tyr Arg Arg Ser Val Glu Leu Asn 225 230 235 240 Ser Asn Ser Leu Glu Ser Tyr Glu Asn Val Met Gln Ser Ser Leu Gly 245 250 255 Phe Val Asn Pro Gly Val Val Glu Phe Leu Leu Glu Lys Leu Gly Ile 260 265 270 Asp Glu Ser Asn Pro Pro Ser Leu Met Arg Gly Leu Gln Ser Lys Asn 275 280 285 Phe Ser Glu Asp Asp Phe Ala Ser Ala Leu Arg Lys Lys Gln Ser Ala 290 295 300 Ser Trp Ala Leu Lys Cys Val Lys Ile Gly Val Asp Tyr Phe Lys Val 305 310 315 320 Gly Arg His Val Asp Ala Met Asn Glu Tyr Asn Lys Ala Leu Glu Ile 325 330 335 Asp Lys Gln Asn Val Glu Ala Leu Val Ala Arg Gly Ala Leu Tyr Ala 340 345 350 Thr Lys Gly Ser Leu Asn Lys Ala Ile Glu Asp Phe Glu Leu Ala Leu 355 360 365 Glu Asn Cys Pro Thr His Arg Asn Ala Arg Lys Tyr Leu Cys Gln Thr 370 375 380 Leu Val Glu Arg Gly Gly Gln Leu Glu Glu Glu Glu Lys Phe Leu Asn 385 390 395 400 Ala Glu Ser Tyr Tyr Lys Lys Ala Leu Ala Leu Asp Glu Thr Phe Lys 405 410 415 Asp Ala Glu Asp Ala Leu Gln Lys Leu His Lys Tyr Met Gln Val Ile 420 425 430 Pro Tyr Phe Leu Leu Glu Ile 435 45 4017 DNA Homo sapiens 45 acactggcaa agtacatacc ctactcactg tggaagtatt cggtgttatc cggtcactca 60 tggcctttag gctgacaggt ggcaccaaag actacattgt agttggcagt gactctggtc 120 gaattgttat tttggaatac cagccatcta agaatatgtt tgagaagatt caccaagaaa 180 cctttggcaa gagtggatgc agtcgcatcg ttcctggcca gttcttagct gtggatccca 240 aagggcgagc cgttatgatt agtgccattg agaaacagaa attggtgtat attttgaaca 300 gagatgctgc agcccgactt accatttcat ctcccctgga agcccacaaa gcaaacactt 360 tagtgtatca tgtagttgga gtagatgtcg gatttgaaaa tccaatgttt gcttgtctgg 420 aaatggatta tgaggaagca gacaatgatc caacagggga agcagcagct aatacccagc 480 agacacttac tttctatgag ctagaccttg gtttaaatca tgtggtccga aaatacagtg 540 aacctttgga ggaacacggc aacttcctta ttacagttcc aggagggtca gatggtccaa 600 gtggagtact gatctgctct gaaaactata ttacttacaa gaactttggt gaccagccag 660 atatccgctg tccaattccc aggaggcgga atgacctgga tgaccctgaa agaggaatga 720 tttttgtctg ctctgcaacc cataaaacca aatcgatgtt cttctttttg gctcaaactg 780 agcagggaga tatctttaag atcactttgg agacagatga agatatggtt actgagatcc 840 ggctcaaata ttttgatact gtacccgttg ctgctgccat gtgtgtgctt aaaacagggt 900 tcctttttgt agcatcagaa tttggaaacc attacttata tcaaattgca catcttggag 960 atgatgatga agaacctgag ttttcatcag ccatgcctct ggaagaagga gacacattct 1020 tttttcagcc aagaccactt aaaaaccttg tgctggttga tgagttggac agcctctctc 1080 ccattctgtt ttgccagata gctgatctgg ccaatgaaga tactccacag ttgtatgtgg 1140 cctgtggtag gggaccccga tcatctctga gagtcctaag acatggactt gaggtgtcag 1200 aaatggctgt ttctgagcta cctggtaacc ccaacgctgt ctggacagtg cgtcgacaca 1260 ttgaagatga gtttgatgcc tacatcattg tgtctttcgt gaatgccacc ctagtgttgt 1320 ccattggaga aactgtagaa gaagtgactg actctgggtt cctggggacc accccgacct 1380 tgtcctgctc cttattagga gatgatgcct tggtgcaggt ctatccagat ggcattcggc 1440 acatacgagc agacaagaga gtcaatgagt ggaagacccc tggaaagaaa acaattgtga 1500 agtgtgcagt gaaccagcga caagtggtga ttgccctgac aggaggagag ctggtctatt 1560 tcgagatgga tccttcagga cagctgaatg agtacacaga acggaaggag atgtcagcag 1620 atgtggtgtg catgagtctg gccaatgtac cccctggaga gcagcggtct cgcttcctgg 1680 ctgtggggct tgtggacaac actgtcagaa tcatctccct ggatccctca gactgtttgc 1740 aacctctaag catgcaggct ctcccagccc agcctgagtc cttgtgtatc gtggaaatgg 1800 gtgggactga gaagcaggat gagctgggtg agaggggctc gattggcttc ctatacctga 1860 atattgggct acagaacggt gtgctgctga ggactgtctt ggaccctgtc actggggatt 1920 tgtctgatac tcgcactcgg tacctggggt cccgtcctgt gaagctcttc cgagtccgaa 1980 tgcaaggcca ggaggcagta ttggccatgt caagccgctc atggttgagc tattcttacc 2040 aatctcgctt ccatctcacc ccactgtctt acgagacact ggaatttgca tcgggttttg 2100 cctcggaaca gtgtcccgag ggcattgtgg ccatctccac caacacccta cggattttgg 2160 cattagagaa gctcggtgct gtcttcaatc aagtagcctt cccactgcag tacacaccca 2220 ggaaatttgt catccaccct gagagtaaca accttattat cattgaaacg gaccacaatg 2280 cctacactga ggccacgaaa gctcagagaa agcagcagat ggcagaggaa atggtggaag 2340 cagcagggga ggatgagcgg gagctggccg cagagatggc agcagcattc ctcaatgaaa 2400 acctccctga atccatcttt ggagctccca aggctggcaa tgggcagtgg gcctctgtga 2460 tccgagtgat gaatcccatt caagggaaca cactggacct tgtccagctg gaacagaatg 2520 aggcagcttt tagtgtggct gtgtgcaggt tttccaacac tggtgaagac tggtatgtgc 2580 tggtgggtgt ggccaaggac ctgatactaa acccccgatc tgtggcaggg ggcttcgtct 2640 atacttacaa gcttgtgaac aatggggaaa aactggagtt tttgcacaag actcctgtgg 2700 aagaggtccc tgctgctatt gccccattcc aggggagggt gttgattggt gtggggaagc 2760 tgttgcgtgt ctatgacctg ggaaagaaga agttactccg aaaatgtgag aataagcata 2820 ttgccaatta tatctctggg atccagacta tcggacatag ggtaattgta tctgatgtcc 2880 aagaaagttt catctgggtt cgctacaagc gtaatgaaaa ccagcttatc atctttgctg 2940 atgataccta cccccgatgg gtcactacag ccagcctcct ggactatgac actgtggctg 3000 gggcagacaa gtttggcaac atatgtgtgg tgaggctccc acctaacacc aatgatgaag 3060 tagatgagga tcctacagga aacaaagccc tgtgggaccg tggcttgctc aatggggcct 3120 cccagaaggc agaggtgatc atgaactacc atgtcgggga gacggtgctg tccttgcaga 3180 agaccacgct gatccctgga ggctcagaat cacttgtcta taccaccttg tctggaggaa 3240 ttggcatcct tgtgccattc acgtcccatg aggaccatga cttcttccag catgtggaaa 3300 tgcacctgcg gtctgaacat ccccctctct gtgggcggga ccacctcagc tttcgctcct 3360 actacttccc tgtgaagaat gtgattgatg gagacctctg tgagcagttc aattccatgg 3420 aacccaacaa acaaaagaac gtctctgaag aactggaccg aaccccaccc gaagtgtcca 3480 agaaactcga ggatatccgg acccgctacg ccttctgagc cctcctttcc cggtggggct 3540 tgccagagac tgtgtgtttt gtttccccca ccaccatcac tgccacctgg cttctgccat 3600 gtggcaggag ggtgactgga taattaagac tgcattatga aagtcaacag ctctttcccc 3660 tcagctcttc tcctggaatg actggcttcc cctcaaattg gcactgagat ttgctacact 3720 tctccccacc tggtacatga tacatgaccc caggttccag tgtagaacct gagtccccca 3780 ttccccaaag ccatccctgc attgatatgt cttgactctc ctgtctactt ttgcacacac 3840 ccttaatttt taattggttt tcttgtaaat acagttttgt acaatgttat ctctgtggga 3900 ggaaggaggc aggctgtggt gggactgggt agggtatagt atcactcctg agttccactg 3960 ctctagaatc taaccagaaa tagaaaccta gtttttaagg tgaaaaaaaa aaaaaaa 4017 46 1152 PRT Homo sapiens 46 Met Ala Phe Arg Leu Thr Gly Gly Thr Lys Asp Tyr Ile Val Val Gly 1 5 10 15 Ser Asp Ser Gly Arg Ile Val Ile Leu Glu Tyr Gln Pro Ser Lys Asn 20 25 30 Met Phe Glu Lys Ile His Gln Glu Thr Phe Gly Lys Ser Gly Cys Ser 35 40 45 Arg Ile Val Pro Gly Gln Phe Leu Ala Val Asp Pro Lys Gly Arg Ala 50 55 60 Val Met Ile Ser Ala Ile Glu Lys Gln Lys Leu Val Tyr Ile Leu Asn 65 70 75 80 Arg Asp Ala Ala Ala Arg Leu Thr Ile Ser Ser Pro Leu Glu Ala His 85 90 95 Lys Ala Asn Thr Leu Val Tyr His Val Val Gly Val Asp Val Gly Phe 100 105 110 Glu Asn Pro Met Phe Ala Cys Leu Glu Met Asp Tyr Glu Glu Ala Asp 115 120 125 Asn Asp Pro Thr Gly Glu Ala Ala Ala Asn Thr Gln Gln Thr Leu Thr 130 135 140 Phe Tyr Glu Leu Asp Leu Gly Leu Asn His Val Val Arg Lys Tyr Ser 145 150 155 160 Glu Pro Leu Glu Glu His Gly Asn Phe Leu Ile Thr Val Pro Gly Gly 165 170 175 Ser Asp Gly Pro Ser Gly Val Leu Ile Cys Ser Glu Asn Tyr Ile Thr 180 185 190 Tyr Lys Asn Phe Gly Asp Gln Pro Asp Ile Arg Cys Pro Ile Pro Arg 195 200 205 Arg Arg Asn Asp Leu Asp Asp Pro Glu Arg Gly Met Ile Phe Val Cys 210 215 220 Ser Ala Thr His Lys Thr Lys Ser Met Phe Phe Phe Leu Ala Gln Thr 225 230 235 240 Glu Gln Gly Asp Ile Phe Lys Ile Thr Leu Glu Thr Asp Glu Asp Met 245 250 255 Val Thr Glu Ile Arg Leu Lys Tyr Phe Asp Thr Val Pro Val Ala Ala 260 265 270 Ala Met Cys Val Leu Lys Thr Gly Phe Leu Phe Val Ala Ser Glu Phe 275 280 285 Gly Asn His Tyr Leu Tyr Gln Ile Ala His Leu Gly Asp Asp Asp Glu 290 295 300 Glu Pro Glu Phe Ser Ser Ala Met Pro Leu Glu Glu Gly Asp Thr Phe 305 310 315 320 Phe Phe Gln Pro Arg Pro Leu Lys Asn Leu Val Leu Val Asp Glu Leu 325 330 335 Asp Ser Leu Ser Pro Ile Leu Phe Cys Gln Ile Ala Asp Leu Ala Asn 340 345 350 Glu Asp Thr Pro Gln Leu Tyr Val Ala Cys Gly Arg Gly Pro Arg Ser 355 360 365 Ser Leu Arg Val Leu Arg His Gly Leu Glu Val Ser Glu Met Ala Val 370 375 380 Ser Glu Leu Pro Gly Asn Pro Asn Ala Val Trp Thr Val Arg Arg His 385 390 395 400 Ile Glu Asp Glu Phe Asp Ala Tyr Ile Ile Val Ser Phe Val Asn Ala 405 410 415 Thr Leu Val Leu Ser Ile Gly Glu Thr Val Glu Glu Val Thr Asp Ser 420 425 430 Gly Phe Leu Gly Thr Thr Pro Thr Leu Ser Cys Ser Leu Leu Gly Asp 435 440 445 Asp Ala Leu Val Gln Val Tyr Pro Asp Gly Ile Arg His Ile Arg Ala 450 455 460 Asp Lys Arg Val Asn Glu Trp Lys Thr Pro Gly Lys Lys Thr Ile Val 465 470 475 480 Lys Cys Ala Val Asn Gln Arg Gln Val Val Ile Ala Leu Thr Gly Gly 485 490 495 Glu Leu Val Tyr Phe Glu Met Asp Pro Ser Gly Gln Leu Asn Glu Tyr 500 505 510 Thr Glu Arg Lys Glu Met Ser Ala Asp Val Val Cys Met Ser Leu Ala 515 520 525 Asn Val Pro Pro Gly Glu Gln Arg Ser Arg Phe Leu Ala Val Gly Leu 530 535 540 Val Asp Asn Thr Val Arg Ile Ile Ser Leu Asp Pro Ser Asp Cys Leu 545 550 555 560 Gln Pro Leu Ser Met Gln Ala Leu Pro Ala Gln Pro Glu Ser Leu Cys 565 570 575 Ile Val Glu Met Gly Gly Thr Glu Lys Gln Asp Glu Leu Gly Glu Arg 580 585 590 Gly Ser Ile Gly Phe Leu Tyr Leu Asn Ile Gly Leu Gln Asn Gly Val 595 600 605 Leu Leu Arg Thr Val Leu Asp Pro Val Thr Gly Asp Leu Ser Asp Thr 610 615 620 Arg Thr Arg Tyr Leu Gly Ser Arg Pro Val Lys Leu Phe Arg Val Arg 625 630 635 640 Met Gln Gly Gln Glu Ala Val Leu Ala Met Ser Ser Arg Ser Trp Leu 645 650 655 Ser Tyr Ser Tyr Gln Ser Arg Phe His Leu Thr Pro Leu Ser Tyr Glu 660 665 670 Thr Leu Glu Phe Ala Ser Gly Phe Ala Ser Glu Gln Cys Pro Glu Gly 675 680 685 Ile Val Ala Ile Ser Thr Asn Thr Leu Arg Ile Leu Ala Leu Glu Lys 690 695 700 Leu Gly Ala Val Phe Asn Gln Val Ala Phe Pro Leu Gln Tyr Thr Pro 705 710 715 720 Arg Lys Phe Val Ile His Pro Glu Ser Asn Asn Leu Ile Ile Ile Glu 725 730 735 Thr Asp His Asn Ala Tyr Thr Glu Ala Thr Lys Ala Gln Arg Lys Gln 740 745 750 Gln Met Ala Glu Glu Met Val Glu Ala Ala Gly Glu Asp Glu Arg Glu 755 760 765 Leu Ala Ala Glu Met Ala Ala Ala Phe Leu Asn Glu Asn Leu Pro Glu 770 775 780 Ser Ile Phe Gly Ala Pro Lys Ala Gly Asn Gly Gln Trp Ala Ser Val 785 790 795 800 Ile Arg Val Met Asn Pro Ile Gln Gly Asn Thr Leu Asp Leu Val Gln 805 810 815 Leu Glu Gln Asn Glu Ala Ala Phe Ser Val Ala Val Cys Arg Phe Ser 820 825 830 Asn Thr Gly Glu Asp Trp Tyr Val Leu Val Gly Val Ala Lys Asp Leu 835 840 845 Ile Leu Asn Pro Arg Ser Val Ala Gly Gly Phe Val Tyr Thr Tyr Lys 850 855 860 Leu Val Asn Asn Gly Glu Lys Leu Glu Phe Leu His Lys Thr Pro Val 865 870 875 880 Glu Glu Val Pro Ala Ala Ile Ala Pro Phe Gln Gly Arg Val Leu Ile 885 890 895 Gly Val Gly Lys Leu Leu Arg Val Tyr Asp Leu Gly Lys Lys Lys Leu 900 905 910 Leu Arg Lys Cys Glu Asn Lys His Ile Ala Asn Tyr Ile Ser Gly Ile 915 920 925 Gln Thr Ile Gly His Arg Val Ile Val Ser Asp Val Gln Glu Ser Phe 930 935 940 Ile Trp Val Arg Tyr Lys Arg Asn Glu Asn Gln Leu Ile Ile Phe Ala 945 950 955 960 Asp Asp Thr Tyr Pro Arg Trp Val Thr Thr Ala Ser Leu Leu Asp Tyr 965 970 975 Asp Thr Val Ala Gly Ala Asp Lys Phe Gly Asn Ile Cys Val Val Arg 980 985 990 Leu Pro Pro Asn Thr Asn Asp Glu Val Asp Glu Asp Pro Thr Gly Asn 995 1000 1005 Lys Ala Leu Trp Asp Arg Gly Leu Leu Asn Gly Ala Ser Gln Lys Ala 1010 1015 1020 Glu Val Ile Met Asn Tyr His Val Gly Glu Thr Val Leu Ser Leu Gln 1025 1030 1035 1040 Lys Thr Thr Leu Ile Pro Gly Gly Ser Glu Ser Leu Val Tyr Thr Thr 1045 1050 1055 Leu Ser Gly Gly Ile Gly Ile Leu Val Pro Phe Thr Ser His Glu Asp 1060 1065 1070 His Asp Phe Phe Gln His Val Glu Met His Leu Arg Ser Glu His Pro 1075 1080 1085 Pro Leu Cys Gly Arg Asp His Leu Ser Phe Arg Ser Tyr Tyr Phe Pro 1090 1095 1100 Val Lys Asn Val Ile Asp Gly Asp Leu Cys Glu Gln Phe Asn Ser Met 1105 1110 1115 1120 Glu Pro Asn Lys Gln Lys Asn Val Ser Glu Glu Leu Asp Arg Thr Pro 1125 1130 1135 Pro Glu Val Ser Lys Lys Leu Glu Asp Ile Arg Thr Arg Tyr Ala Phe 1140 1145 1150 47 2635 DNA Homo sapiens 47 aaggggttac acttccagct tttaaaattc tcctttacat gtgctcagtg ttttgttttg 60 tgttttggtt tctgtttttt attttaattc ccacattggg cacaagaatc agaatatgga 120 tagctagttt aagaaacttt tgtgggtgca ctgtagcata gatgacagaa tatttatgag 180 ttgctgtgtt tgttgattag ttccatctct ttcccatttt aactgagaat tgattatata 240 tagctctaag tatataggta tttaaacaac cccacaagcg gctgtatcag taacatttat 300 taattccact atagtgaggg aggatttcca ttctaaatac cttattttga gggatttata 360 aaacttagtt gtaaaagaga aagcccacat agtgggaata aattgcttca gccattttta 420 gtatttgaga gcactaggga agatgtttag tagctgtgtg gatgcctttt ttcacaccct 480 gtctattgaa tgctgcatcc attcacgaag ttaaatgtta catgcagtta gtccttaatg 540 tggactggat ctgtactttt gttttggatt aaaacattta aagatttttg aagtgcagct 600 actccccacg tgcatttgat acacataaaa gtcatactgt gtgtgcacaa agagtacatg 660 gattttccag catattgctt taaaaaatta tataaactgt taaaatatta acacctcagg 720 ctacctgctg tattctgtcc cattgacccc tggaattgga tttactgcaa gtgattgata 780 attcaattat gtggcttttc ccctttaatc ttgccattta aattacagta gaaagacaaa 840 atcaagtaaa ataaagtgtt agataataga aagagtgtta agaccagccc acttttctca 900 tgtttatgtt ctttcatttg gaccaagaat ctccgcatgg aggttgattt gccactgggg 960 actttggcta agactattag gtttgctttc aactagatgt tcctgagaca agcagaggga 1020 cactgcaatt ccccttccat gcctgctgtt ctcccccatg taagtcttct ttgaaattaa 1080 cggatgtgtc tcctttggaa cagccccata acaaaagaga actactgatc tgagcatagg 1140 aaagtagagg ctctaccact tttcagttga aaaagcaaga ctttctctgt gtttctgaaa 1200 caaggcataa tgttgtcaca gaatcagaga tccagtctca cttttccaca aatctccaaa 1260 tctccagtct tatcttgtgt gctctaatgg tttggttcaa tccctttcca actcttgttt 1320 tcaaagcatg gggcctgagt gttctccact cctcctaaga aaggagcttg ggtggaaggg 1380 accatgctga cctcctccat cagagggctc ttccagtagt attctcggat gcaacctcca 1440 tttctcagtt accattattt cctgtatcag ctttgtcctt cctggaggga tgcacagtga 1500 tccggcccac cactgttgtt gtcttgtgct tctgctcttt cctatggttt caggttattt 1560 tctgggtttc ccctattctt cttttatttc tttttttttt atatttgctt tcctttctac 1620 tgcttttaga tttgcaggag atgcaagttt cagctcaatg tttggcttct ctcaatatgg 1680 aaatttcaga aggacagagg agaggaggga ggaagaagaa agtatactcc tccagaattt 1740 cagtgatctg ttgtggcagt ccagtggaag gaaggtcttt tgaggtcact tagaagcatc 1800 tttttgggac atccttttgg gatctctgta ggctaggcat ctcatatctt gagactcacc 1860 cccagcctcc aagcctctct ccatttctct aacctatgca ttttagagcg agaggaccgc 1920 ctcactagtg tcaccatcct gccttttcta aaacatgcag gctcacacat tctactcctg 1980 cttaatgtct gtgttaaatg ttttctaacc atttttgttt tatttttctg aaaaagttaa 2040 cccctcccaa ctcctcacac attggctctt cctcttgagc cacaaagttt tgattcttgc 2100 gatgtatgtg ccttatttta tgttaatctt gtcaatgaga gggaccagtt ggtgttgccc 2160 aatcagcact ccaaggctgt gtgtgcacca gccagagagc gcacggtggt agcagagtcg 2220 aggctgtctt gtatcctggt atcatatgtt gttttgaact gataggagga tgttctcttc 2280 tgacaagtta cccttgtgta tcctgcagac atgtaaaata aaatacaagt tcattttttt 2340 cacctttttt agattttttt aaaaaataaa atgtgtaatc ctttttttaa aagaaacaca 2400 tgtaaataca tttaagtatt gtaggcatag cgttcagatg tgactggccc aggcgttcct 2460 cggacaagcc tgcattcccc gtgatcacgc ccacctcaag cccaggggct gcagcccagc 2520 cacagatgaa ctctaccttt gctttcagaa ccacttagtc cttttgtaac aaagaaaaaa 2580 aaatgtttct tacaatgtca ataaaaaatt ctttgtatgg aaaaaaaaaa aaaaa 2635 48 97 PRT Homo sapiens 48 Met His Ser Asp Pro Ala His His Cys Cys Cys Leu Val Leu Leu Leu 1 5 10 15 Phe Pro Met Val Ser Gly Tyr Phe Leu Gly Phe Pro Tyr Ser Ser Phe 20 25 30 Ile Ser Phe Phe Phe Ile Phe Ala Phe Leu Ser Thr Ala Phe Arg Phe 35 40 45 Ala Gly Asp Ala Ser Phe Ser Ser Met Phe Gly Phe Ser Gln Tyr Gly 50 55 60 Asn Phe Arg Arg Thr Glu Glu Arg Arg Glu Glu Glu Glu Ser Ile Leu 65 70 75 80 Leu Gln Asn Phe Ser Asp Leu Leu Trp Gln Ser Ser Gly Arg Lys Val 85 90 95 Phe 49 1594 DNA Homo sapiens 49 gccagtgaga aaggagctta ccaaaggcag tgtacgaaga aggttcctgg gagactgtca 60 gaaatgagtt tttcactgaa cttcaccctg ccggcgaaca caacgtcctc tcctgtcaca 120 ggtgggaaag aaacggactg tgggccctct cttggattag cggcgggcat accattgctg 180 gtggccacag ccctgctggt ggctttacta tttactttga ttcacccaag aagaagcagc 240 attgaggcca tggaggaaag tgacagacca tgtgaaattt cagaaattga tgacaatccc 300 aagatatctg agaatcctag gagatcaccc acacatgaga agaatacgat gggagcacaa 360 gaggcccaca tatatgtgaa gactgtagca ggaagcgagg aacctgtgca tgaccgttac 420 cgtcctacta tagaaatgga aagaaggagg ggattgtggt ggcttgtgcc cagactgagc 480 ctggaatgat gcagctcagt caaggagcag cagacctggc ctggaacagg ttgaaaaccc 540 agggttttgt acttggagag gaaagatgcc aagctgcttc ttaatcaatc caaatttcat 600 ttacagctct ggaacacttt ggggctgatt tgtctcttta ggggacatcc ccaacatggt 660 taattccaac tctcagatct tgtgctttag ttagtacatg tgactcacca gatggggtcc 720 ttagatccta ttcctgctcc cagtgggaat ttgcttttct ttgtcatttt gggaaagggg 780 cttggtttct gagtgtcttg ccttctcatc tttttttttc atatcctttt tctcaaaaaa 840 gccatcagat ctgactttca tggaagtgtt gctgaggtca gcctggtgca agttgggata 900 caaatgaaac ttatgcagga tgtgtgagag gaagcagtta attgtttctg aatatctcag 960 ggtaggaacc atgtggagcc acacattccc tgaccacagg gaagcacctg gctcaatcat 1020 gtcacacagc agtggaaaga atacggactc ttaagtcaca cctaccactg agcagctgta 1080 cgactttgga gaagttgttt aacattttca agcctcagtt tttgcttttt taaaggaggg 1140 gaaatatttg cctcatgtca taattgaaaa gattaaataa gaaataaagg gaagtgtctg 1200 ctacttagtt gccagtcaaa atgttagttc tctctctcta ccaccttctt cctacctctt 1260 cccatattgc ttgcctgata aaacagctaa tcaccagcat ttgttcccca tagtcacagg 1320 gccacacaag ggaacattta ggacaaactt tctccatggc ctatgatcca aattgttatc 1380 taaagatgat tctaggtgtt gctggtagta tgtgaatctt ccaatctagg tgtgatcgtg 1440 tcctcatatg aatcaggaaa aggcagtttc ttacaagttc cgaattccaa atacagagac 1500 tggtggtgtt acatttaacc ttaaagatgt taatgttgat ggaaattcat gtttcatatt 1560 aaaacaacac tttgtcttta aaaaaaaaaa aaaa 1594 50 141 PRT Homo sapiens 50 Met Ser Phe Ser Leu Asn Phe Thr Leu Pro Ala Asn Thr Thr Ser Ser 1 5 10 15 Pro Val Thr Gly Gly Lys Glu Thr Asp Cys Gly Pro Ser Leu Gly Leu 20 25 30 Ala Ala Gly Ile Pro Leu Leu Val Ala Thr Ala Leu Leu Val Ala Leu 35 40 45 Leu Phe Thr Leu Ile His Pro Arg Arg Ser Ser Ile Glu Ala Met Glu 50 55 60 Glu Ser Asp Arg Pro Cys Glu Ile Ser Glu Ile Asp Asp Asn Pro Lys 65 70 75 80 Ile Ser Glu Asn Pro Arg Arg Ser Pro Thr His Glu Lys Asn Thr Met 85 90 95 Gly Ala Gln Glu Ala His Ile Tyr Val Lys Thr Val Ala Gly Ser Glu 100 105 110 Glu Pro Val His Asp Arg Tyr Arg Pro Thr Ile Glu Met Glu Arg Arg 115 120 125 Arg Gly Leu Trp Trp Leu Val Pro Arg Leu Ser Leu Glu 130 135 140 51 5160 DNA Homo sapiens 51 gatatcttaa gcccgggtac gtcgacccac gcgtccggaa tcgctcagga aagacacact 60 gcagactcca ccggcaccct gcaatagatg gattccgact acacaaggga gaaaacgcgg 120 aggtgacact ctcctgcctg gaaagaggac gaacgaccaa acaaacgcaa ggactggact 180 ccatgccgaa ggtatctgga agtcgtgaca cggtgtgtat aaaacaaaag tttgcgagct 240 gttaattgct gtgctgtgtt attaagagac gctttcaagt ttcaagtacc aaatgtagct 300 ttacgttgcc aaaggaagtt gaggcaattg ctttgctgtt ttaacttgct ctgtgaggga 360 aatctcataa actgaccaat gcaccaaatg aatgctaaaa tgcactttag gtttgttttt 420 gcacttctga tagtatcttt caaccacgat gtactgggca agaatttgaa atacaggatt 480 tatgaggaac agagggttgg atcagtaatt gcaagactat cagaggatgt ggctgatgtt 540 ttattgaagc ttcctaatcc ttctactgtt cgatttcgag ccatgcagag gggaaattct 600 cctctacttg tagtaaacga ggataatggg gaaatcagca taggggctac aattgaccgt 660 gaacaactgt gccagaaaaa cttgaactgt tccatagagt ttgatgtgat cactctaccc 720 acagagcatc tgcagctttt ccatattgaa gttgaagtgc tggatattaa tgacaattct 780 ccccagtttt caagatctct catacctatt gagatatctg agagtgcagc agttgggact 840 cgcattcccc tggacagtgc atttgatcca gatgttgggg aaaattccct ccacacatac 900 tcgctctctg ccaatgattt ttttaatatc gaggttcgga ccaggactga tggagccaag 960 tatgcagaac tcatagtggt cagagagtta gatcgggagc tgaagtcaag ctacgagctt 1020 cagctcactg cctcagacat gggagtacct cagaggtctg gctcatccat actaaaaata 1080 agcatttcag actccaatga caacagccct gcttttgagc agcaatctta tataatacaa 1140 ctcttagaaa actccccggt tggcactttg ctcttagatc tgaatgccac ggatccagat 1200 gagggcgcta atgggaaaat tgtatattcc ttcagcagtc atgtgtctcc caaaattatg 1260 gagactttta aaattgattc tgaaagagga catttgactc ttttcaagca agtggattat 1320 gaaatcacca aatcctatga gattgatgtt caggctcaag atttgggtcc aaattcaatc 1380 ccagcccatt gcaaaattat aattaaggtt gtggatgtta atgacaataa acctgaaatt 1440 aacatcaacc tcatgtcccc tggaaaagaa gaaatatctt atatttttga aggggatcct 1500 attgatacat ttgttgcttt ggtcagagtt caggacaagg attctgggct gaatggagaa 1560 atagtttgta agcttcatgg acatggtcac tttaaacttc agaagacata tgaaaacaat 1620 tatttaatct taactaatgc cacactggat agagaaaaga gatctgagta tagtttgact 1680 gtaatcgctg aggacagggg gacacccagt ctctctacag tgaaacattt tacagttcaa 1740 atcaatgata tcaatgacaa tccaccccac ttccagagaa gccgatatga atttgtaatt 1800 tcagaaaata actcaccagg ggcatatatc accactgtta cagccacaga tcctgatctt 1860 ggagaaaatg ggcaagtgac atacaccatc ttggagagtt ttattctagg aagttccata 1920 actacatatg taaccattga cccatctaat ggagccatct atgccctcag aatctttgat 1980 catgaagaag tgagtcagat cacttttgtg gtagaagcaa gagatggagg aagcccgaag 2040 caactggtaa gcaataccac agttgtgctc accatcattg acgaaaatga caacgttcct 2100 gtggttatag ggcctgcatt gcgtaataat acggcagaaa tcaccattcc caaaggggct 2160 gaaagtggct ttcatgtcac aagaataagg gcaattgaca gagactctgg tgtgaatgct 2220 gaactcagct gcgccatagt agcaggtaat gaggagaata tcttcataat tgatccacga 2280 tcatgtgaca tccataccaa cgttagcatg gattctgttc cctacacaga atgggagctg 2340 tcagttatca ttcaggacaa aggcaatcct cagctacata ccaaagtcct tctgaagtgc 2400 atgatctttg aatatgcaga gtcggtgaca agtacagcaa tgacttcagt aagccaggca 2460 tccttggatg tctccatgat aataattatt tccttaggag caatttgtgc agtgttgctg 2520 gttattatgg tgctatttgc aactaggtgt aaccgcgaga agaaagacac tagatcctat 2580 aactgcaggg tggccgaatc aacttaccag caccacccaa aaaggccatc ccggcagatt 2640 cacaaagggg acatcacatt ggtgcctacc ataaatggca ctctgcccat cagatctcat 2700 cacagatcgt ctccatcttc atctcctacc ttagaaagag ggcagatggg cagccggcag 2760 agtcacaaca gtcaccagtc actcaacagt ttggtgacaa tctcatcaaa ccacgtgcca 2820 gagaatttct cattagaact cacccacgcc actcctgctg ttgagcaggt ctctcagctt 2880 ctttcaatgc ttcaccaggg gcaatatcag ccaagaccaa gttttcgagg aaacaaatat 2940 tccaggagct acagatatgc ccttcaagac atggacaaat ttagcttgaa agacagtggc 3000 cgtggtgaca gtgaggcagg agacagtgat tatgatttgg ggcgagattc tccaatagat 3060 aggctgttgg gtgaaggatt cagcgacctg tttctcacag atggaagaat tccagcagct 3120 atgagactct gcacggagga gtgcagggtc ctgggacact ctgaccagtg ctggatgcca 3180 ccactgccct caccgtcttc tgattatagg agtaacatgt tcattccagg ggaagaattc 3240 ccaacgcaac cccagcagca gcatccacat cagagtcttg aggatgacgc tcagcctgca 3300 gattccggtg aaaagaagaa gagtttttcc acctttggaa aggactcccc aaacgatgag 3360 gacactgggg ataccagcac atcatctctg ctctcggaaa tgagcagtgt gttccagcgt 3420 ctcttaccgc cttccctgga cacctattct gaatgcagtg aggtggatcg gtccaactcc 3480 ctggagcgca ggaagggacc cttgccagcc aaaactgtgg gttacccaca gggggtagcg 3540 gcatgggcag ccagtacgca ttttcaaaat cccaccacca actgtgggcc gccacttgga 3600 actcactcca gtgtgcagcc ttcttcaaaa tggctgccag ccatggagga gatccctgaa 3660 aattatgagg aagatgattt tgacaatgtg ctcaaccacc tcaatgatgg gaaacacgaa 3720 ctcatggatg ccagtgaact ggtggcagag attaacaaac tgcttcaaga tgtccgccag 3780 agctaggaga ttttagcgaa gcatttttgt ttccatgtat atggaaatag ggaacaacaa 3840 caacaacaaa aaaccctgaa agaactggca ttgccaaata gttgcattta tcataaatgt 3900 gtctgtgtat attgaatatt aaatactgta ttttcgtatg tacacaatgc aagtgtgatt 3960 attttaatct gtattttaaa aatacatttg taccttatat ttatgtgtaa tttaacaaac 4020 aaattttatt tttttactcc catgacagac atgtttttcc tagtcgtgta gaaactagcc 4080 actgttcaaa tctgatacac tattcaacca caaagtgtaa aggcactgct tagattagtt 4140 ttgttgggga agaattatta tgttgtatga acaaccccac tgaagcatta tacaattctt 4200 aattccatta agtgatccca ctttttttca ataacttttt agaaattaag aatcattaaa 4260 attgttaagc tattttattg ttattttctc tactttctac tagccccaat agttgaactc 4320 ttataggaaa atcgaaagat aaagtgaaag tttatttcag gactgagaaa tatcttgaag 4380 gttatttatt agatgactat ctcaaatgaa ctttttatag acaatgatga aaacagaatt 4440 aaagtcaatg tttcctgact cccaggcccc tactattcca ggccatcaca ctggcctgtt 4500 ccggagaata tttctctcac aatattatta tctacttata attatggtaa acaataaatt 4560 ttattccatc cttgtagtat gaaacatgct ccaaggaaat ggaatctgtc ctttaaatgg 4620 ataacagtat gtgttctaat ggcataaaat attactggat aaaaacagtt gtgtcagtgt 4680 ctctcctaag gtagtaaata taattgactt attctgaacc cattctattt tgaatctccc 4740 ctttcctctc acaatacttg aacattttaa tcttttggaa tattgtcttt ctttgttata 4800 actattcatt tttagctttt gtctccagtg catgatctca tatttttgct tttattttta 4860 gtataagaac atttataaaa tcatattttt gttactgcaa ttgttttatt tgttgtgtgg 4920 caaatgagaa atcctttatt tattgtgctg tgatctctct gtgtggaatg ccttggtgag 4980 agagatgctt attatgacta ttatcatttc tgaccaagct tctattaatg ttatttctaa 5040 taatacacta tcttgattgt actctccaga aaatttttct gtcagtgaaa ataaaagaaa 5100 aattaaagta aagctaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 5160 52 1135 PRT Homo sapiens 52 Met His Gln Met Asn Ala Lys Met His Phe Arg Phe Val Phe Ala Leu 1 5 10 15 Leu Ile Val Ser Phe Asn His Asp Val Leu Gly Lys Asn Leu Lys Tyr 20 25 30 Arg Ile Tyr Glu Glu Gln Arg Val Gly Ser Val Ile Ala Arg Leu Ser 35 40 45 Glu Asp Val Ala Asp Val Leu Leu Lys Leu Pro Asn Pro Ser Thr Val 50 55 60 Arg Phe Arg Ala Met Gln Arg Gly Asn Ser Pro Leu Leu Val Val Asn 65 70 75 80 Glu Asp Asn Gly Glu Ile Ser Ile Gly Ala Thr Ile Asp Arg Glu Gln 85 90 95 Leu Cys Gln Lys Asn Leu Asn Cys Ser Ile Glu Phe Asp Val Ile Thr 100 105 110 Leu Pro Thr Glu His Leu Gln Leu Phe His Ile Glu Val Glu Val Leu 115 120 125 Asp Ile Asn Asp Asn Ser Pro Gln Phe Ser Arg Ser Leu Ile Pro Ile 130 135 140 Glu Ile Ser Glu Ser Ala Ala Val Gly Thr Arg Ile Pro Leu Asp Ser 145 150 155 160 Ala Phe Asp Pro Asp Val Gly Glu Asn Ser Leu His Thr Tyr Ser Leu 165 170 175 Ser Ala Asn Asp Phe Phe Asn Ile Glu Val Arg Thr Arg Thr Asp Gly 180 185 190 Ala Lys Tyr Ala Glu Leu Ile Val Val Arg Glu Leu Asp Arg Glu Leu 195 200 205 Lys Ser Ser Tyr Glu Leu Gln Leu Thr Ala Ser Asp Met Gly Val Pro 210 215 220 Gln Arg Ser Gly Ser Ser Ile Leu Lys Ile Ser Ile Ser Asp Ser Asn 225 230 235 240 Asp Asn Ser Pro Ala Phe Glu Gln Gln Ser Tyr Ile Ile Gln Leu Leu 245 250 255 Glu Asn Ser Pro Val Gly Thr Leu Leu Leu Asp Leu Asn Ala Thr Asp 260 265 270 Pro Asp Glu Gly Ala Asn Gly Lys Ile Val Tyr Ser Phe Ser Ser His 275 280 285 Val Ser Pro Lys Ile Met Glu Thr Phe Lys Ile Asp Ser Glu Arg Gly 290 295 300 His Leu Thr Leu Phe Lys Gln Val Asp Tyr Glu Ile Thr Lys Ser Tyr 305 310 315 320 Glu Ile Asp Val Gln Ala Gln Asp Leu Gly Pro Asn Ser Ile Pro Ala 325 330 335 His Cys Lys Ile Ile Ile Lys Val Val Asp Val Asn Asp Asn Lys Pro 340 345 350 Glu Ile Asn Ile Asn Leu Met Ser Pro Gly Lys Glu Glu Ile Ser Tyr 355 360 365 Ile Phe Glu Gly Asp Pro Ile Asp Thr Phe Val Ala Leu Val Arg Val 370 375 380 Gln Asp Lys Asp Ser Gly Leu Asn Gly Glu Ile Val Cys Lys Leu His 385 390 395 400 Gly His Gly His Phe Lys Leu Gln Lys Thr Tyr Glu Asn Asn Tyr Leu 405 410 415 Ile Leu Thr Asn Ala Thr Leu Asp Arg Glu Lys Arg Ser Glu Tyr Ser 420 425 430 Leu Thr Val Ile Ala Glu Asp Arg Gly Thr Pro Ser Leu Ser Thr Val 435 440 445 Lys His Phe Thr Val Gln Ile Asn Asp Ile Asn Asp Asn Pro Pro His 450 455 460 Phe Gln Arg Ser Arg Tyr Glu Phe Val Ile Ser Glu Asn Asn Ser Pro 465 470 475 480 Gly Ala Tyr Ile Thr Thr Val Thr Ala Thr Asp Pro Asp Leu Gly Glu 485 490 495 Asn Gly Gln Val Thr Tyr Thr Ile Leu Glu Ser Phe Ile Leu Gly Ser 500 505 510 Ser Ile Thr Thr Tyr Val Thr Ile Asp Pro Ser Asn Gly Ala Ile Tyr 515 520 525 Ala Leu Arg Ile Phe Asp His Glu Glu Val Ser Gln Ile Thr Phe Val 530 535 540 Val Glu Ala Arg Asp Gly Gly Ser Pro Lys Gln Leu Val Ser Asn Thr 545 550 555 560 Thr Val Val Leu Thr Ile Ile Asp Glu Asn Asp Asn Val Pro Val Val 565 570 575 Ile Gly Pro Ala Leu Arg Asn Asn Thr Ala Glu Ile Thr Ile Pro Lys 580 585 590 Gly Ala Glu Ser Gly Phe His Val Thr Arg Ile Arg Ala Ile Asp Arg 595 600 605 Asp Ser Gly Val Asn Ala Glu Leu Ser Cys Ala Ile Val Ala Gly Asn 610 615 620 Glu Glu Asn Ile Phe Ile Ile Asp Pro Arg Ser Cys Asp Ile His Thr 625 630 635 640 Asn Val Ser Met Asp Ser Val Pro Tyr Thr Glu Trp Glu Leu Ser Val 645 650 655 Ile Ile Gln Asp Lys Gly Asn Pro Gln Leu His Thr Lys Val Leu Leu 660 665 670 Lys Cys Met Ile Phe Glu Tyr Ala Glu Ser Val Thr Ser Thr Ala Met 675 680 685 Thr Ser Val Ser Gln Ala Ser Leu Asp Val Ser Met Ile Ile Ile Ile 690 695 700 Ser Leu Gly Ala Ile Cys Ala Val Leu Leu Val Ile Met Val Leu Phe 705 710 715 720 Ala Thr Arg Cys Asn Arg Glu Lys Lys Asp Thr Arg Ser Tyr Asn Cys 725 730 735 Arg Val Ala Glu Ser Thr Tyr Gln His His Pro Lys Arg Pro Ser Arg 740 745 750 Gln Ile His Lys Gly Asp Ile Thr Leu Val Pro Thr Ile Asn Gly Thr 755 760 765 Leu Pro Ile Arg Ser His His Arg Ser Ser Pro Ser Ser Ser Pro Thr 770 775 780 Leu Glu Arg Gly Gln Met Gly Ser Arg Gln Ser His Asn Ser His Gln 785 790 795 800 Ser Leu Asn Ser Leu Val Thr Ile Ser Ser Asn His Val Pro Glu Asn 805 810 815 Phe Ser Leu Glu Leu Thr His Ala Thr Pro Ala Val Glu Gln Val Ser 820 825 830 Gln Leu Leu Ser Met Leu His Gln Gly Gln Tyr Gln Pro Arg Pro Ser 835 840 845 Phe Arg Gly Asn Lys Tyr Ser Arg Ser Tyr Arg Tyr Ala Leu Gln Asp 850 855 860 Met Asp Lys Phe Ser Leu Lys Asp Ser Gly Arg Gly Asp Ser Glu Ala 865 870 875 880 Gly Asp Ser Asp Tyr Asp Leu Gly Arg Asp Ser Pro Ile Asp Arg Leu 885 890 895 Leu Gly Glu Gly Phe Ser Asp Leu Phe Leu Thr Asp Gly Arg Ile Pro 900 905 910 Ala Ala Met Arg Leu Cys Thr Glu Glu Cys Arg Val Leu Gly His Ser 915 920 925 Asp Gln Cys Trp Met Pro Pro Leu Pro Ser Pro Ser Ser Asp Tyr Arg 930 935 940 Ser Asn Met Phe Ile Pro Gly Glu Glu Phe Pro Thr Gln Pro Gln Gln 945 950 955 960 Gln His Pro His Gln Ser Leu Glu Asp Asp Ala Gln Pro Ala Asp Ser 965 970 975 Gly Glu Lys Lys Lys Ser Phe Ser Thr Phe Gly Lys Asp Ser Pro Asn 980 985 990 Asp Glu Asp Thr Gly Asp Thr Ser Thr Ser Ser Leu Leu Ser Glu Met 995 1000 1005 Ser Ser Val Phe Gln Arg Leu Leu Pro Pro Ser Leu Asp Thr Tyr Ser 1010 1015 1020 Glu Cys Ser Glu Val Asp Arg Ser Asn Ser Leu Glu Arg Arg Lys Gly 1025 1030 1035 1040 Pro Leu Pro Ala Lys Thr Val Gly Tyr Pro Gln Gly Val Ala Ala Trp 1045 1050 1055 Ala Ala Ser Thr His Phe Gln Asn Pro Thr Thr Asn Cys Gly Pro Pro 1060 1065 1070 Leu Gly Thr His Ser Ser Val Gln Pro Ser Ser Lys Trp Leu Pro Ala 1075 1080 1085 Met Glu Glu Ile Pro Glu Asn Tyr Glu Glu Asp Asp Phe Asp Asn Val 1090 1095 1100 Leu Asn His Leu Asn Asp Gly Lys His Glu Leu Met Asp Ala Ser Glu 1105 1110 1115 1120 Leu Val Ala Glu Ile Asn Lys Leu Leu Gln Asp Val Arg Gln Ser 1125 1130 1135 53 1207 DNA Homo sapiens 53 atggcgtccc gcggccggcg tccggagcat ggcggacccc cagagctgtt ttatgacgag 60 acagaagccc ggaaatacgt tcgcaactca cggatgattg atatccagac caggatggct 120 gggcgagcat tggagcttct ttatctgcca gagaataagc cctgttacct gctggatatt 180 ggctgtggca ctgggctgag tggaagttat ctgtcagatg aagggcacta ttgggtgggc 240 ctggatatca gccctgccat gctggatgag gctgtggacc gagagataga gggagacctg 300 ctgctggggg atatgggcca gggcatccca ttcaagccag gcacatttga tggttgcatc 360 agcatttctg ctgtgcattg gctctgtaat gctaacaaga agtctgaaaa ccctgccaag 420 cgcctgtact gcttttttgc ttctcttttt tctgttctcg tccggggatc ccgagctgtc 480 ctgcagctgt accctgagaa ctcagagcag ttggagctga tcacaaccca ggccacaaag 540 gcaggcttct ccggtggcat ggtggtagac taccctaaca gtgccaaagc aaagaaattc 600 tacctctgct tgttttctgg gccttcgacc tttataccag aggggctgag tgaaaatcag 660 gatgaagttg aacccaggga gtctgtgttc accaatgaga ggttcccatt aaggatgtcg 720 aggcggggaa tggtgaggaa gagtcgggca tgggtgctgg agaagaagga gcggcacagg 780 cgccagggca gggaagtcag acctgacacc cagtacaccg gccgcaagcg caagccccgc 840 ttctaagtca ccacgcggtt ctggaaaggc acttgcctct gcacttttct atattgttca 900 gctgacaaag tagtatttta gaaaagttct aaagttataa aaatgttttc tgcagtaaaa 960 aaaaagttct ctgggccggg cgtggtggct cacacctgta atcccagcac cttgggaggc 1020 tgaggtggga ggatcatttg aggccaggag tttgagacct gcctgggcaa cataatgaaa 1080 cttcctttcc agggagaaaa aaaaaaaaaa aaaaaaaagc tctgagagca tcttattttg 1140 tttaaaggca agaaataaaa tttccttttg tggaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200 aaaaaaa 1207 54 281 PRT Homo sapiens 54 Met Ala Ser Arg Gly Arg Arg Pro Glu His Gly Gly Pro Pro Glu Leu 1 5 10 15 Phe Tyr Asp Glu Thr Glu Ala Arg Lys Tyr Val Arg Asn Ser Arg Met 20 25 30 Ile Asp Ile Gln Thr Arg Met Ala Gly Arg Ala Leu Glu Leu Leu Tyr 35 40 45 Leu Pro Glu Asn Lys Pro Cys Tyr Leu Leu Asp Ile Gly Cys Gly Thr 50 55 60 Gly Leu Ser Gly Ser Tyr Leu Ser Asp Glu Gly His Tyr Trp Val Gly 65 70 75 80 Leu Asp Ile Ser Pro Ala Met Leu Asp Glu Ala Val Asp Arg Glu Ile 85 90 95 Glu Gly Asp Leu Leu Leu Gly Asp Met Gly Gln Gly Ile Pro Phe Lys 100 105 110 Pro Gly Thr Phe Asp Gly Cys Ile Ser Ile Ser Ala Val His Trp Leu 115 120 125 Cys Asn Ala Asn Lys Lys Ser Glu Asn Pro Ala Lys Arg Leu Tyr Cys 130 135 140 Phe Phe Ala Ser Leu Phe Ser Val Leu Val Arg Gly Ser Arg Ala Val 145 150 155 160 Leu Gln Leu Tyr Pro Glu Asn Ser Glu Gln Leu Glu Leu Ile Thr Thr 165 170 175 Gln Ala Thr Lys Ala Gly Phe Ser Gly Gly Met Val Val Asp Tyr Pro 180 185 190 Asn Ser Ala Lys Ala Lys Lys Phe Tyr Leu Cys Leu Phe Ser Gly Pro 195 200 205 Ser Thr Phe Ile Pro Glu Gly Leu Ser Glu Asn Gln Asp Glu Val Glu 210 215 220 Pro Arg Glu Ser Val Phe Thr Asn Glu Arg Phe Pro Leu Arg Met Ser 225 230 235 240 Arg Arg Gly Met Val Arg Lys Ser Arg Ala Trp Val Leu Glu Lys Lys 245 250 255 Glu Arg His Arg Arg Gln Gly Arg Glu Val Arg Pro Asp Thr Gln Tyr 260 265 270 Thr Gly Arg Lys Arg Lys Pro Arg Phe 275 280 55 1490 DNA Homo sapiens 55 agcccacctg gtggggagga ggccctgctg tggaatccct accccaggag ccctggccct 60 cctcctggtg gggctcccta gaggagggtc ctctcagccc gagaacgcag ctcagtgtgt 120 caggctccaa ctgtttttct gtgacttgct cgccgtgtag gctgctaaac atctggctga 180 accaagcgtt catcctgacc tgaagccaga acctcagaaa ccaaagtaag gcctgatcat 240 gccctcgccc cactgcccca gagacctcct cttgtctctt tgatgttttg ttttctattt 300 tatttttcgt ttttgtgtgt ctgcatggtg tttttcgggc agtggcttct gccatcatca 360 ccacatgttt ctctgctgcc cactgtcctg aggtgggccg tcgtggaagc cctgcttcct 420 gccgtttgcg ggacgagtcc cgccctcttt tttcctgtcc ccatcggtag tctgcgtgca 480 cgtgttttcc acagtaaaac cgtgttgtgt aactctttcc agcaaagtaa caatccgcca 540 ttacaaaggt cgtcctcctt gatccagtta acgagtcaga actcttctcc caatcagcag 600 agaaccccgc aggtcatcgg ggtcatgcag agtcaaaaca gcagcggggg caaccgggga 660 cccggccact ggagcaggtc acctgttaca agtgtggcga gaaaggacac tacgccaaca 720 gatgcaccaa agggcacttg gcctttctca gtggacagtg acagcagctg gagccagctc 780 cgagcagccc gggggccccg ctgttgggag tgtgcattta actgtttcat gcgcttgttg 840 gcgcgactgt ggctcgagct ggcccgcaga cacgtgggtt tcatcactct gaggggccac 900 gtctgttagt ttcctatcat tttgccttag tattttttga aaaaggacat gtgtcctgtg 960 ggtccctgca gtcgacatca tgtttggctg ggcatcgatg cctcctttct gggactcccg 1020 gcacaactcc ctgccctgct gaatcctaaa gctgtgccta tatctgtgat ttgaatgagg 1080 gagccctttg gggcaaattc aggtgccccc attgcctcag gctggccctg gtcccaggtg 1140 gcagcggttg aggaggggta cagggctctc aagcctgagg ttttcttctc tgggcttaat 1200 tttctcttgg ggtacgtgcc tgacagtgtt taaggtgtcc gttgaactgg agttgcagac 1260 ttttaaatag atgacccctt cagatcatct gtgcctacct cctgcccatc aggcgtctac 1320 actgtcactc agacacctgt ggcatgtgga ggagactgcc ctgtcctgag cctggaaaat 1380 gtgaaactgt ctcctgcaac ctgctgggca tgtgggcctg gctgtgttca attgcaagaa 1440 caatttttat gaaatggatt aaagcttgtt ttttaaaaaa aaaaaaaaaa 1490 56 208 PRT Homo sapiens 56 Met Phe Cys Phe Leu Phe Tyr Phe Ser Phe Leu Cys Val Cys Met Val 1 5 10 15 Phe Phe Gly Gln Trp Leu Leu Pro Ser Ser Pro His Val Ser Leu Leu 20 25 30 Pro Thr Val Leu Arg Trp Ala Val Val Glu Ala Leu Leu Pro Ala Val 35 40 45 Cys Gly Thr Ser Pro Ala Leu Phe Phe Pro Val Pro Ile Gly Ser Leu 50 55 60 Arg Ala Arg Val Phe His Ser Lys Thr Val Leu Cys Asn Ser Phe Gln 65 70 75 80 Gln Ser Asn Asn Pro Pro Leu Gln Arg Ser Ser Ser Leu Ile Gln Leu 85 90 95 Thr Ser Gln Asn Ser Ser Pro Asn Gln Gln Arg Thr Pro Gln Val Ile 100 105 110 Gly Val Met Gln Ser Gln Asn Ser Ser Gly Gly Asn Arg Gly Pro Gly 115 120 125 His Trp Ser Arg Ser Pro Val Thr Ser Val Ala Arg Lys Asp Thr Thr 130 135 140 Pro Thr Asp Ala Pro Lys Gly Thr Trp Pro Phe Ser Val Asp Ser Asp 145 150 155 160 Ser Ser Trp Ser Gln Leu Arg Ala Ala Arg Gly Pro Arg Cys Trp Glu 165 170 175 Cys Ala Phe Asn Cys Phe Met Arg Leu Leu Ala Arg Leu Trp Leu Glu 180 185 190 Leu Ala Arg Arg His Val Gly Phe Ile Thr Leu Arg Gly His Val Cys 195 200 205 57 4184 DNA Homo sapiens 57 agcagggaaa gaaaaacttg acgtgtggaa tacagaggga ggagatttta acattatggc 60 agggaggcat cagaatcgta gttttcctct tccaggagtt cagtcaagtg gtcaagtaca 120 tgcatttgga aattgttcag acagtgatat tttggaggag gatgctgaag tgtatgagct 180 tcgatccaga ggaaaagaga aagtccgaag aagtacatca agagatagac ttgacgacat 240 tatagtatta acaaaagata tacaagaagg agatacatta aatgcaatag cccttcagta 300 ctgttgtacg gtagcagata tcaagagagt taacaatctc atcagtgatc aagacttttt 360 tgcccttagg tctatcaaaa ttccagtaaa aaagttcagt tccttgaccg aaacactttg 420 tcctccaaaa ggaagacaga cttcacgtca ttcatctgtt caatactctt ccgaacaaca 480 ggaaattttg ccagctaatg attctcttgc ttacagtgac tcagctggta gctttttaaa 540 agaagtagac cgagacatag aacaaatagt aaagtgtaca gacaataaga gagagaacct 600 ccatgaggta gtatcggcct tcacagcaca acaaatgcgt tttgaacctg ataacaaaaa 660 cactcaacgt aaagacccct attatggagc agactgggga atagggtggt ggacagctgt 720 agtgataatg ttgatagtag gtataataac accagtgttt tatttgttgt attatgaaat 780 tttagctaag gtggatgtta gtcatcattc aacagtggac tcttcacatt tacattcaaa 840 aatcacaccc ccatcacagc agagagaaat ggaaaatgga attgtgccaa ctaaaggaat 900 acatttcagc caacaagatg atcataaact gtatagtcaa gattctcagt cacctgctgc 960 tcaacaggaa acatagcaat tagctcataa tcaaatgtta gtggtcaggt cacatgtgca 1020 tctggaatgt ggtgaatcag ttatatccaa taatagcttc aaaggcagaa tttagagaga 1080 ttgaggatgc ttttgttttt aacaaaaggg tttcacactt tgaaaatttt ttgagcaact 1140 agttgttgat gttgagagca gttgatccat aaatctggtg tgtgaatgtt tcaagcagaa 1200 attaatttaa atgtgtgttt aggaagtact taacttggaa gatgtatcat ttttcttaaa 1260 atgcatgttt aaattttatt tttttaagta atttttaaaa agtttattaa tgttaaattt 1320 atgatgcaga atgatagcat cagatgtctg cagctgaaaa aaatttacta ctatgaaccc 1380 ccaaaatatt cagttgcaag aaaatttgat tctaaaatta ttcatggtag gatacgtaac 1440 acaccccttc caaactttta aaaaatacat ttagcacatg tgctatgaaa gcatacgtac 1500 aaagagaaag gggaaagtga tttataattc ctacaacaga ggccaagaaa tagattaaaa 1560 tattttcaag accccaaaat aatgtattat ggttgggaag tcagtagaac actggaatag 1620 gtgaagacct gacagtaatt tttgtcttaa gaatgctttc tttaggacag accctttaac 1680 ctcacctctg tgcatctgtt tttaaaatga ttatatttgc ctctgatatt tgaaagcact 1740 tttgtagttt tgatgatgaa aaatatatta aacgtgcata ttaccattat ttaggaaata 1800 attccttata tactgtgata aatcattgct gttacataca gtaacatgcc ttaattacat 1860 ttaatgcctt actgctttat gtaagtaaat ccaagtttca gaattaaaaa taagcattat 1920 ttcatatggt ccaatcagat tcgttacata ggctatataa atttgtctcc attttcacca 1980 tcaagcacaa ataattgggt caaaactgcc tttgaggtct gttgaagaaa atggttcatt 2040 aagcaaaaaa agagtagagg tattttatat tagcagtaac agacaaatta tttagtaatc 2100 ccttaacctc tgtttttcaa agagaaaata tccaatttag acttttttcc tgatctctat 2160 atatagcatc aaattgggaa acaaaggcca aaggtgtata gattgcttga aagggggtgg 2220 taggcctctt tttaagatct gtgagtcggc tacagtctgg ctaagtaaga agcatttgca 2280 tactgattcc atcatttaat ctttaaaagt atgtgtttta aaaatgtaac cagaatgatt 2340 cttcaataga aatgagattt ggtggagtct ggattgcctg ttttgtatat aatatatact 2400 taagatatat aataccacct cattttctgg gcattatttc ctaattgttg atgtttcagg 2460 cttttgataa gtcattttat atatttcaaa tttaactcag aataagtaaa tatttatggc 2520 aaatgcagtt ttatgtactt tcaggagaag accatcagga aaagacagga caaagaagtc 2580 aaacattaaa gcccttgcaa atattagagg accttagaca attaccaaaa agtgtttaat 2640 agggaagttg caaatgattc tcttagtaaa ttaaacattt aaaaagtagt tttaatgtgc 2700 cttgggcatc ttgaaaagaa gagtgtgata taatttatgc ttagtgttaa ctggtcattt 2760 tacattgtat ttattaagtc tgctgaaaaa tgaggtttta aggaagaaaa tgcagattat 2820 tttagggtaa acaggccagg tgtcctttga agaactttgt ttacatcaaa ttgatgaaat 2880 tacagtcagt gattccttac tttttttgct agttgtactt tgaaattgtt atgggttcgt 2940 tttccaaaat atgtaactta ttttttaaag gaataaggtg tgctgtgtat ttgttgatta 3000 aaaatcattt gtcttgcaga gtatcctttt ttgaaggaaa tatacatcct tataacacat 3060 caggtagttt tcttttttct gtatttaaat tatatatttg aattaattga atataatttg 3120 agttacatat aattctatat aaaggttaca tattgaatta tggttctaat ctgtttagga 3180 aagaaatgaa ttttctaagc atttaataca tttggaataa ttttagtttc taaaaagtac 3240 taatgtaagt taagtttata tcaaatgcaa attaccttgt ataactaaca agcacagtta 3300 ttgtttaaca ttatggattt taattgtgtt gacacccttc tttgaatttg ttgctttaca 3360 tgtgtgtctg tgtgtgtgtc tgcatgtgtg cacgcatgta cttgtatgca atgtaaaagt 3420 aacagcagaa tcattgcatt tggtttactt aaaattttgg agttagcaag taaacaaaaa 3480 gctgatagtt ttatgaagtc tcggttaaaa taaaatttct ttgctatctc actcctagga 3540 agttatggag ttcatatttt caaaagatat gttaaaaatg gttacacact ctgctggcca 3600 cattaaaaat tagaagactc atgttaaatt atctcctcca aaggactttt tatttacagc 3660 ttttcttttc ctggactcta cctgcttggt tcagtgtcct gaagagttat ttaaatgaac 3720 cactacttag taattagttc ttttttaaag tatctacttc taaaattacc tagttgaaaa 3780 tatgaaggat atgcttagtt ttagaaatat catgaagcaa ggatctagtc agtgttacag 3840 ggtaaaggtg gagtttttta aagtctgtat ttaaatggtg cactgatgga ttcattttta 3900 atttgcatta caaaaatgtt gctcaggtaa tcagtatttt cttccacgta tgtgcatatt 3960 gcactgttag atcatagaaa tatctgaatg ctttaatttt tatgtatgca aaatctataa 4020 atcttttgta taatgtattt tatacaaatg taactgtaga acattgttag catgtgtatc 4080 tgtaaaacca gtttttaaaa ttttttgccc cttatttttc atattttgaa agatctccaa 4140 catgtaataa agtttctctt attcaatcta aaaaaaaaaa aaaa 4184 58 306 PRT Homo sapiens 58 Met Ala Gly Arg His Gln Asn Arg Ser Phe Pro Leu Pro Gly Val Gln 1 5 10 15 Ser Ser Gly Gln Val His Ala Phe Gly Asn Cys Ser Asp Ser Asp Ile 20 25 30 Leu Glu Glu Asp Ala Glu Val Tyr Glu Leu Arg Ser Arg Gly Lys Glu 35 40 45 Lys Val Arg Arg Ser Thr Ser Arg Asp Arg Leu Asp Asp Ile Ile Val 50 55 60 Leu Thr Lys Asp Ile Gln Glu Gly Asp Thr Leu Asn Ala Ile Ala Leu 65 70 75 80 Gln Tyr Cys Cys Thr Val Ala Asp Ile Lys Arg Val Asn Asn Leu Ile 85 90 95 Ser Asp Gln Asp Phe Phe Ala Leu Arg Ser Ile Lys Ile Pro Val Lys 100 105 110 Lys Phe Ser Ser Leu Thr Glu Thr Leu Cys Pro Pro Lys Gly Arg Gln 115 120 125 Thr Ser Arg His Ser Ser Val Gln Tyr Ser Ser Glu Gln Gln Glu Ile 130 135 140 Leu Pro Ala Asn Asp Ser Leu Ala Tyr Ser Asp Ser Ala Gly Ser Phe 145 150 155 160 Leu Lys Glu Val Asp Arg Asp Ile Glu Gln Ile Val Lys Cys Thr Asp 165 170 175 Asn Lys Arg Glu Asn Leu His Glu Val Val Ser Ala Phe Thr Ala Gln 180 185 190 Gln Met Arg Phe Glu Pro Asp Asn Lys Asn Thr Gln Arg Lys Asp Pro 195 200 205 Tyr Tyr Gly Ala Asp Trp Gly Ile Gly Trp Trp Thr Ala Val Val Ile 210 215 220 Met Leu Ile Val Gly Ile Ile Thr Pro Val Phe Tyr Leu Leu Tyr Tyr 225 230 235 240 Glu Ile Leu Ala Lys Val Asp Val Ser His His Ser Thr Val Asp Ser 245 250 255 Ser His Leu His Ser Lys Ile Thr Pro Pro Ser Gln Gln Arg Glu Met 260 265 270 Glu Asn Gly Ile Val Pro Thr Lys Gly Ile His Phe Ser Gln Gln Asp 275 280 285 Asp His Lys Leu Tyr Ser Gln Asp Ser Gln Ser Pro Ala Ala Gln Gln 290 295 300 Glu Thr 305 59 3191 DNA Homo sapiens 59 cagaggcttt tatccatggg gccaatataa ccgaggaggc tatggaaact atcgctcaaa 60 ttggcagaat taccggcaag catacagtcc tcgtcgaggc cgttcaagat cccggtcccc 120 aaagagaagg tccccttcac caaggtccag gagccattct agaaactctg ataagtcgtc 180 ttctgaccgg tcaaggcgct cctcatcctc ccgttcttcc tccaaccata gccgagttga 240 atcttctaag cgcaagtctg caaaggagaa aaagtcctct tctaaggata gccggccatc 300 tcaggctgcc ggggataacc agggagatga ggtcaaggag cagacattct ctggaggcac 360 ctctcaagat acaaaagcat ctgagagctc gaagccatgg ccagatgcca cctacggcac 420 tggttctgca tcacgggcct cagcagtttc tgagctgagt cctcgggagc gaagcccagc 480 tctcaaaagc cccctccagt ctgtggtggt gaggcggcgg tcaccccgtc ctagcccgtg 540 ccaaaaacct agtcctccac tttccagcac atcccagatg ggctcaactc tgccgagtgg 600 tgccgggtat cagtctggga cacaccaagg tcagttcgac catggttctg ggtccctgag 660 tccatccaaa aagagccctg tgggtaagag tccaccatcc actggctcca catatggctc 720 atctcagaag gaggagagtg ctgcttcagg aggagcagcc tatacaaaga ggtttctaga 780 agagcagaag acagagaatg gaaaagataa ggaacagaaa caaacaaata ccgattaaga 840 aaaaataaaa gagaaaggga gcttctctga cacaggcttg ggtgatggaa aaatgaaatc 900 tgattctttt gctcccaaaa ctgattctga gaagcctttt cggggcagtc agtctcccaa 960 aaggtataag ctccgagatg actttgagaa gaagatggct gacttccaca aggaggagat 1020 ggatgatcaa gataaggaca aagctaaggg aagaaaggaa tctgagtttg atgatgaacc 1080 caaatttatg tctaaagtca taggtgcaaa caaaaaccag gaggaggaga agtcaggcaa 1140 atgggagggc ctggtatatg cacctccagg gaaggaaaag cagagaaaaa cagaggagct 1200 ggaggaggag tctttcccag agagatccaa aaaggaagat cggggcaaga gaagcgaagg 1260 tgggcacagg ggctttgtgc ctgagaagaa tttccgagtg actgcttata aagcagtcca 1320 ggagaaaagc tcatcacctc ccccaagaaa gacctctgag agccgagaca agctgggagc 1380 gaaaggagat tttcccacag gaaagtcttc cttttccatt actcgagagg cacaggtcaa 1440 tgtccggatg gactcttttg atgaggacct cgcacgaccc agtggcttat tggctcagga 1500 acgcaagctt tgccgagatc tagtccatag caacaaaaag gaacaggagt ttcgttccat 1560 tttccagcac atacaatcag ctcagtctca gcgtagcccc tcagaactgt ttgcccaaca 1620 tatagtgacc attgttcacc atgttaaaga gcatcacttt gggtcctcag gaatgacatt 1680 acatgaacgc tttactaaat acctaaagag aggaactgag caggaggcag ccaaaaacaa 1740 gaaaagccca gagatacaca ggagaataga catttccccc agtacattca gaaaacatgg 1800 tttggctcat gatgaaatga aaagtccccg ggaacctggc tacaaggctg agggaaaata 1860 caaagatgat cctgttgatc tccgccttga tattgaacgt cgtaaaaaac ataaggagag 1920 agatcttaaa cgaggtaaat cgagagaatc agtggattcc cgagactcca gtcactcaag 1980 ggaaaggtca gctgaaaaaa cagagaaaac tcataaagga tcaaagaaac agaagaagca 2040 tccgagagca agagacaggt ccagatcctc ctcctcttcc tcccagtcat ctcactccta 2100 caaagcagaa gagtacactg aagagacaga ggaaagagag gagagcacca cgggctttga 2160 caaatcaaga ctggggacca aagactttgt gggtccaagt gaaagaggag gtggcagagc 2220 tcgaggaacc tttcagtttc gagccagagg aagaggctgg ggcagaggca actactctgg 2280 gaacaataac aacaacagca acaacgattt tcaaaaaaga aaccgggaag aggagtggga 2340 cccagagtac acacccaaaa gcaagaagta taacttgcat gatgaccgtg aaggcgaagg 2400 cagtgacaag tgggtgagcc ggggccgggg ccgaggagcc tttcctcggg gtcggggccg 2460 gttcatgttc cggaaatcaa gtaccagccc caagtgggcc catgacaagt tcagtgggga 2520 ggaaggggag attgaagacg acgagagtgg gacagagaac cgagaagaga aggacaatat 2580 acagcccaca accgagtagg ggccaccctt gacgggattc ctgcccaggg gagagaggcg 2640 ctgggaagat ggctggtgag gagcttaaca gaggaacctc aagaagattc tgaaaatcct 2700 acccccaccc cccaccagcc gcacagattg tactaccgcg agaggcatcc ctggcgctgt 2760 ctcccactgg acagaggagg ctggccatgg ggcccagggg tcaggcccag cttttgagca 2820 gaatacaacg cattgggctt tagctgtttt tctcatttgt tggtgtgtgg ggtgggggca 2880 ggggtagggc gggagagcga tgcttggatt tttgtttcct attagaaacc aacagttttg 2940 ttctaatttc atttcattgg gagctaagat gactaattgg atgattttcg atctcttttc 3000 ccctgtcctg attttaaaag ccccctcctt tttttttttt tttttctttt tttaggcata 3060 tgtagtaata ttagaaacat ttaatttggg aaactttgat tcttgaaaga gaaaacaaaa 3120 gcatgtgaat aaactttgaa gtgttcacct caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3180 aaaaaaaaaa a 3191 60 568 PRT Homo sapiens 60 Met Lys Ser Asp Ser Phe Ala Pro Lys Thr Asp Ser Glu Lys Pro Phe 1 5 10 15 Arg Gly Ser Gln Ser Pro Lys Arg Tyr Lys Leu Arg Asp Asp Phe Glu 20 25 30 Lys Lys Met Ala Asp Phe His Lys Glu Glu Met Asp Asp Gln Asp Lys 35 40 45 Asp Lys Ala Lys Gly Arg Lys Glu Ser Glu Phe Asp Asp Glu Pro Lys 50 55 60 Phe Met Ser Lys Val Ile Gly Ala Asn Lys Asn Gln Glu Glu Glu Lys 65 70 75 80 Ser Gly Lys Trp Glu Gly Leu Val Tyr Ala Pro Pro Gly Lys Glu Lys 85 90 95 Gln Arg Lys Thr Glu Glu Leu Glu Glu Glu Ser Phe Pro Glu Arg Ser 100 105 110 Lys Lys Glu Asp Arg Gly Lys Arg Ser Glu Gly Gly His Arg Gly Phe 115 120 125 Val Pro Glu Lys Asn Phe Arg Val Thr Ala Tyr Lys Ala Val Gln Glu 130 135 140 Lys Ser Ser Ser Pro Pro Pro Arg Lys Thr Ser Glu Ser Arg Asp Lys 145 150 155 160 Leu Gly Ala Lys Gly Asp Phe Pro Thr Gly Lys Ser Ser Phe Ser Ile 165 170 175 Thr Arg Glu Ala Gln Val Asn Val Arg Met Asp Ser Phe Asp Glu Asp 180 185 190 Leu Ala Arg Pro Ser Gly Leu Leu Ala Gln Glu Arg Lys Leu Cys Arg 195 200 205 Asp Leu Val His Ser Asn Lys Lys Glu Gln Glu Phe Arg Ser Ile Phe 210 215 220 Gln His Ile Gln Ser Ala Gln Ser Gln Arg Ser Pro Ser Glu Leu Phe 225 230 235 240 Ala Gln His Ile Val Thr Ile Val His His Val Lys Glu His His Phe 245 250 255 Gly Ser Ser Gly Met Thr Leu His Glu Arg Phe Thr Lys Tyr Leu Lys 260 265 270 Arg Gly Thr Glu Gln Glu Ala Ala Lys Asn Lys Lys Ser Pro Glu Ile 275 280 285 His Arg Arg Ile Asp Ile Ser Pro Ser Thr Phe Arg Lys His Gly Leu 290 295 300 Ala His Asp Glu Met Lys Ser Pro Arg Glu Pro Gly Tyr Lys Ala Glu 305 310 315 320 Gly Lys Tyr Lys Asp Asp Pro Val Asp Leu Arg Leu Asp Ile Glu Arg 325 330 335 Arg Lys Lys His Lys Glu Arg Asp Leu Lys Arg Gly Lys Ser Arg Glu 340 345 350 Ser Val Asp Ser Arg Asp Ser Ser His Ser Arg Glu Arg Ser Ala Glu 355 360 365 Lys Thr Glu Lys Thr His Lys Gly Ser Lys Lys Gln Lys Lys His Pro 370 375 380 Arg Ala Arg Asp Arg Ser Arg Ser Ser Ser Ser Ser Ser Gln Ser Ser 385 390 395 400 His Ser Tyr Lys Ala Glu Glu Tyr Thr Glu Glu Thr Glu Glu Arg Glu 405 410 415 Glu Ser Thr Thr Gly Phe Asp Lys Ser Arg Leu Gly Thr Lys Asp Phe 420 425 430 Val Gly Pro Ser Glu Arg Gly Gly Gly Arg Ala Arg Gly Thr Phe Gln 435 440 445 Phe Arg Ala Arg Gly Arg Gly Trp Gly Arg Gly Asn Tyr Ser Gly Asn 450 455 460 Asn Asn Asn Asn Ser Asn Asn Asp Phe Gln Lys Arg Asn Arg Glu Glu 465 470 475 480 Glu Trp Asp Pro Glu Tyr Thr Pro Lys Ser Lys Lys Tyr Asn Leu His 485 490 495 Asp Asp Arg Glu Gly Glu Gly Ser Asp Lys Trp Val Ser Arg Gly Arg 500 505 510 Gly Arg Gly Ala Phe Pro Arg Gly Arg Gly Arg Phe Met Phe Arg Lys 515 520 525 Ser Ser Thr Ser Pro Lys Trp Ala His Asp Lys Phe Ser Gly Glu Glu 530 535 540 Gly Glu Ile Glu Asp Asp Glu Ser Gly Thr Glu Asn Arg Glu Glu Lys 545 550 555 560 Asp Asn Ile Gln Pro Thr Thr Glu 565 61 3145 DNA Homo sapiens 61 gtccccgtcc ggcagactac tctcccccat ggcggacttc gctgggccgt cttctgccgg 60 ccgcaaggcc ggggctcccc gctgctctcg aaaagccgca ggtactaaac agacgagtac 120 tttgaaacaa gaagatgctt ctaaaagggg aggttcatta cgacctgctc actacagtga 180 tgtcgtggat gaacgttcta ttgtcaaact ctgtggttat cctttatgtc agaagaagct 240 gggaattgta ccaaaacaga aatataaaat ttctaccaaa accaataaag tctatgatat 300 tactgaaaga aagtcttttt gcagcaattt ttgttatcaa gcatctaagt tttttgaagc 360 acaaattccc aaaactccag tatgggttcg agaagaagag aggcatcctg attttcaact 420 gctaaaggaa gaacaaagtg gccattctgg agaagaagta cagttatgca gtaaagccat 480 taaaacatca gatatcgaca atcctagcca ctttgaaaag caatatgaat ctagttcttc 540 tagcactcac agtgatagta gcagtgacaa tgagcaagac tttgtttcct ccattctacc 600 aggaaacaga ccaaattcaa caaatattag accacagctg caccaaaaaa gcataatgaa 660 aaagaaagct ggtcacaaag ctaactccaa acacaagcac aaagaacaga cagtagtaga 720 tgtcactgag cagttaggcg attgcaaatt agatagtcag gagaaagatg ctacatgtga 780 acttccttta cagaaagtaa atactcagag ttcttcaaat agcactttgc ctgaaagatt 840 aaaagcgtca gaaaattctg aaagtgaata cagtaggtca gaaataactc tggtaggcat 900 aagtaagaaa agtgcagagc attttaagag aaaatttgcc aaatcaaacc aagtgtctag 960 gtcagtgtct aattcagtgc aggtgtgtcc tgaagttgga aagagaaact tacttaaagt 1020 tttgaaggag actttgattg agtggaagac agaagaaaca ttgaggtttt tgtatggcca 1080 gaattatgct tctgtgtgtc tgaaacccga agcctctctg gttaaagaag aacttgatga 1140 agatgacata atctcagatc cagatagtcc tttccctgcc tggagggaat ctcagaacag 1200 cttggatgag tctttacctt ttaggggctc aggtacagcc attaaaccac tgccaagtta 1260 cgagaatttg aaaaaagaaa ctgaaaagtt aaatctgagg atcagggagt tttacagagg 1320 acggtatgtt ttgggtgaag aaaccaccaa atcacaagac tcagaagagc atgattccac 1380 ctttccactg atagactcaa gttcccagaa ccagattaga aaacgcatcg tacttgaaaa 1440 gttgagtaaa gtgttgcctg ggcttctggt tcctcttcag attacattgg gagatattta 1500 cacacaactt aaaaatcttg ttcgaacttt caggttaaca aatagaaata ttatacacaa 1560 acctgcggaa tggactttaa ttgctatggt gttgctgtca ttactgaccc caattcttgg 1620 cattcagaaa cattctcagg aaggtatggt gtttacacgg tttctagaca ccctccttga 1680 agaattacat ctaaaaaatg aagaccttga aagtctaacc atcatattta gaaccagctg 1740 tttaccagag tgatatattc catgaagaca aaatagaaga tgaacttcta ttcaccgttt 1800 ctggaattct agccgccatg atggtctggt ggtgactgat aactagtttt attccaagac 1860 atacctttac ctctttaagt ttcaatctcc catctcccag tccttcagtc cccaactgca 1920 gaggatgacc tccccagata gaggagaatc attactccaa caagaataac caagtctttg 1980 tatccctagt acaagacata gtatttttat tcgaaaatga atgtttaagt attaaattga 2040 aacttgaatg aatattcaag aaaatataat gatctctact ttttctggat gatttccagc 2100 catcatatca gtttgccaaa aaaattgaga aagttatgat tttgacctcc caacctaaac 2160 tctaaattct aaagatcagt aaacaattag gtcaataaat acatacaatt taagatgaag 2220 ccctttggaa gtctagtcca aaacaggaaa atctcagaac tttctggact caaggaaatg 2280 ctttaaatgg aatctgtagt ttgtttgcag gagagacaat ttctagaatt tagattgctt 2340 ttcaaaatgt ttatcaggta ggcaagttag cagttgaggc ggaacacaga caacttgggg 2400 agctttactg gaaggccaag aaaatactct tggacactgg aggaaatgac agctactaaa 2460 gcccaatcat ggaaaaggac cagaaagcag cccactggaa tggggagctt agtgggcaag 2520 gaggtaggga tataatttct cttcttggct ccaccagtaa ttagctctgt ggcccagtca 2580 cctaaacttt ctggacttca gttcaggttg tatggcagta ggccatagaa ttggctactg 2640 ccatacaatc tctatgggaa aggactgcaa aaactaaatt ttatctctgt atgggcaaag 2700 gctactgtca tcctgttgtt ggtctggggc cactctgaca atttttttta acctcatttg 2760 attgtgtaag ggtctaacca caacaaaaaa tcatagtgta atagaattaa tcaagttcag 2820 caaggtcaca ggctagatca atatacagaa aatcaattgt atttttctgt tcagaaaact 2880 ccaaaaatga aataaagaaa attgtgttca caatatcacc aaagagatta aatacttagg 2940 aataaattta acaaaataag tgtaagactt gtataacgaa aactataaaa cattcaagag 3000 ggctgggcat ggtggctcat gcctttagtt ctagcgcttt ggaggcagag gcaggaggac 3060 tgcttgagcc caggagttca agaccagcct gggcaacaaa gtgagaccct gtctccacaa 3120 aaaaaaaaaa aaaaaaaaaa aaaaa 3145 62 574 PRT Homo sapiens 62 Met Ala Asp Phe Ala Gly Pro Ser Ser Ala Gly Arg Lys Ala Gly Ala 1 5 10 15 Pro Arg Cys Ser Arg Lys Ala Ala Gly Thr Lys Gln Thr Ser Thr Leu 20 25 30 Lys Gln Glu Asp Ala Ser Lys Arg Gly Gly Ser Leu Arg Pro Ala His 35 40 45 Tyr Ser Asp Val Val Asp Glu Arg Ser Ile Val Lys Leu Cys Gly Tyr 50 55 60 Pro Leu Cys Gln Lys Lys Leu Gly Ile Val Pro Lys Gln Lys Tyr Lys 65 70 75 80 Ile Ser Thr Lys Thr Asn Lys Val Tyr Asp Ile Thr Glu Arg Lys Ser 85 90 95 Phe Cys Ser Asn Phe Cys Tyr Gln Ala Ser Lys Phe Phe Glu Ala Gln 100 105 110 Ile Pro Lys Thr Pro Val Trp Val Arg Glu Glu Glu Arg His Pro Asp 115 120 125 Phe Gln Leu Leu Lys Glu Glu Gln Ser Gly His Ser Gly Glu Glu Val 130 135 140 Gln Leu Cys Ser Lys Ala Ile Lys Thr Ser Asp Ile Asp Asn Pro Ser 145 150 155 160 His Phe Glu Lys Gln Tyr Glu Ser Ser Ser Ser Ser Thr His Ser Asp 165 170 175 Ser Ser Ser Asp Asn Glu Gln Asp Phe Val Ser Ser Ile Leu Pro Gly 180 185 190 Asn Arg Pro Asn Ser Thr Asn Ile Arg Pro Gln Leu His Gln Lys Ser 195 200 205 Ile Met Lys Lys Lys Ala Gly His Lys Ala Asn Ser Lys His Lys His 210 215 220 Lys Glu Gln Thr Val Val Asp Val Thr Glu Gln Leu Gly Asp Cys Lys 225 230 235 240 Leu Asp Ser Gln Glu Lys Asp Ala Thr Cys Glu Leu Pro Leu Gln Lys 245 250 255 Val Asn Thr Gln Ser Ser Ser Asn Ser Thr Leu Pro Glu Arg Leu Lys 260 265 270 Ala Ser Glu Asn Ser Glu Ser Glu Tyr Ser Arg Ser Glu Ile Thr Leu 275 280 285 Val Gly Ile Ser Lys Lys Ser Ala Glu His Phe Lys Arg Lys Phe Ala 290 295 300 Lys Ser Asn Gln Val Ser Arg Ser Val Ser Asn Ser Val Gln Val Cys 305 310 315 320 Pro Glu Val Gly Lys Arg Asn Leu Leu Lys Val Leu Lys Glu Thr Leu 325 330 335 Ile Glu Trp Lys Thr Glu Glu Thr Leu Arg Phe Leu Tyr Gly Gln Asn 340 345 350 Tyr Ala Ser Val Cys Leu Lys Pro Glu Ala Ser Leu Val Lys Glu Glu 355 360 365 Leu Asp Glu Asp Asp Ile Ile Ser Asp Pro Asp Ser Pro Phe Pro Ala 370 375 380 Trp Arg Glu Ser Gln Asn Ser Leu Asp Glu Ser Leu Pro Phe Arg Gly 385 390 395 400 Ser Gly Thr Ala Ile Lys Pro Leu Pro Ser Tyr Glu Asn Leu Lys Lys 405 410 415 Glu Thr Glu Lys Leu Asn Leu Arg Ile Arg Glu Phe Tyr Arg Gly Arg 420 425 430 Tyr Val Leu Gly Glu Glu Thr Thr Lys Ser Gln Asp Ser Glu Glu His 435 440 445 Asp Ser Thr Phe Pro Leu Ile Asp Ser Ser Ser Gln Asn Gln Ile Arg 450 455 460 Lys Arg Ile Val Leu Glu Lys Leu Ser Lys Val Leu Pro Gly Leu Leu 465 470 475 480 Val Pro Leu Gln Ile Thr Leu Gly Asp Ile Tyr Thr Gln Leu Lys Asn 485 490 495 Leu Val Arg Thr Phe Arg Leu Thr Asn Arg Asn Ile Ile His Lys Pro 500 505 510 Ala Glu Trp Thr Leu Ile Ala Met Val Leu Leu Ser Leu Leu Thr Pro 515 520 525 Ile Leu Gly Ile Gln Lys His Ser Gln Glu Gly Met Val Phe Thr Arg 530 535 540 Phe Leu Asp Thr Leu Leu Glu Glu Leu His Leu Lys Asn Glu Asp Leu 545 550 555 560 Glu Ser Leu Thr Ile Ile Phe Arg Thr Ser Cys Leu Pro Glu 565 570 63 1812 DNA Homo sapiens 63 atttacttta aaaagaaatt aatatggctt caccaagaag caaagttcaa cttatttcat 60 aattgcctac atttatcatg gtcctgaatg tagcgtgtaa gcttgtgttt cttgggcagt 120 ctttcttgaa attgaagagg tgaaatgggg gtggggagtg ggaggaaagg tgacttcctc 180 tggtgtttat tataaagctt aaattttata tcattttaaa atgtcttggt cttctactgc 240 cttgaaaaat gacaattgtg aacatgatag ttaaactacc acttttttta accattatta 300 tgcaaaattt agaagaaaag ttattggcat ggttgttgca tatagttaaa ctgagagtaa 360 ttcatctgtg aatctgcttt aattacctgg tgagtaactt agaaaagtgg tgtaaacttg 420 tacatggaat tttttgaata tgccttaatt tagaaactga aaaatatctg gttatatcat 480 tctgggtgtg ttcttactga caccaggggt ccgctgcccc atgtgtcctg gtgagaaata 540 tatgcctggc acagcttttg tatagaaaat tcttgagaag taactgtccg ctagaagtct 600 gtccaaattt aaaatgtgtg ccatattctg gttcttgaaa ataagattcc agagctcttt 660 gatcgctttt ataactgcag ttcattttaa tgaagggcca gcatatatac ttgcaagata 720 attttcagct gcaaggattc agcaccagtt atgtttgaat gaacctcttt tctctgagat 780 tctggtcctg gaaatccctt ctgctagtgg tgagcatgta agtgtaagtt ttaatctggg 840 agcagggcat aggaagaaaa tgtcagtagt gctaatgcat tttgcactag aacgcttcgg 900 gaaaatattc atgcttgcca tctgttcatt tctaaattta tattcataaa gttacagttt 960 gatacaggaa ttattaggag taattctttt cttgtttctg tttataatga agaacactgt 1020 agctacattt tcagaagtta acatcaagcc atcaaacctg ggtatagtgc agaaaacgtg 1080 gcacacactg accacacatt aggctgtgtc accattgtgt ggtgtacctg ctggaagaat 1140 tctagcatgc tacttgggga cataatttca gtgggaaata tgccactgac cgattttttt 1200 tttttcctct ttgcagtggg gctaggacag ttgattcaac aaagtatttt tttctttttt 1260 ctcagtccta atttgaacag gtcaaagatg tgttcaggca ttccaggtaa caggtgtgta 1320 tgtaaagtta aaaataggct ttttaggaac tcactcttta gatatttaca tccagcttct 1380 catgttaaat atttgtcctt aaagggtttg agatgtacat ctttcatttc gtatttctca 1440 taggctatgc catgtgcgga attcaagtta ccaatgtaac actggccagc gggcccagca 1500 atctccatgt gtacttatta cagtcttatt taaccagggg tcctaaccac taacattgtg 1560 actttgcttt gagacctttc ctctcctggg tactgaggtg ctatgaagcc aactgacaaa 1620 gatgcatcac gtgtcttagg ctgatgccac tacccgattt gtttatttgc aatttgagcc 1680 atttaaagac caataaactt ccttttttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1800 aaaaaaaaaa aa 1812 64 98 PRT Homo sapiens 64 Met Leu Leu Gly Asp Ile Ile Ser Val Gly Asn Met Pro Leu Thr Asp 1 5 10 15 Phe Phe Phe Phe Leu Phe Ala Val Gly Leu Gly Gln Leu Ile Gln Gln 20 25 30 Ser Ile Phe Phe Phe Phe Leu Ser Pro Asn Leu Asn Arg Ser Lys Met 35 40 45 Cys Ser Gly Ile Pro Gly Asn Arg Cys Val Cys Lys Val Lys Asn Arg 50 55 60 Leu Phe Arg Asn Ser Leu Phe Arg Tyr Leu His Pro Ala Ser His Val 65 70 75 80 Lys Tyr Leu Ser Leu Lys Gly Leu Arg Cys Thr Ser Phe Ile Ser Tyr 85 90 95 Phe Ser 65 1558 DNA Homo sapiens 65 gtcgacaggg ccgcagctag agtcggcgcc accagggggc cgagcatggt gcggcggcgg 60 cggggcgctc cggggaggcc aggacagctg atggttgtgg cagaaacatc tcaaggtagc 120 tggtccgccc cccacttccc catctacctc ttgtcctccc ccccaacacc accaccaccc 180 tggctcccct ccctcatgac cgcctggatc ctcctgcctg tcagcctgtc agcgttctcc 240 atcactggca tatggactgt gtatgccatg gctgtgatga accaccatgt atgccctgtg 300 gagaactggt cctacaacga gtcctgccct cctgaccctg ctgagcaagg gggtcccaag 360 acctgctgca ccctggacga tgtccccctc atcagcaagt gtggctccta tcccccagaa 420 agctgcctct tcagcctcat tggcaacatg ggtgctttca tggtggccct gatctgcctc 480 ctgcgctacg ggcagctcct ggagcagagt cggcactctt gggttaacac cacggcactc 540 atcacaggct gcaccaacgc tgcgggcctc ttggtggttg gcaactttca ggtggatcat 600 gccaggtctc tgcactacgt tggagctggc gtggccttcc ctgcggggct gctctttgtt 660 tgcctgcact gtctctctcc taccaagggg ccaccgcccc gctggacctg gctgtggcct 720 atctgcgaag tgtgctggct gtcatcgcct ttatcaccct ggtcctcagt ggagtcttct 780 ttgtccatga gagttctcag ctgcaacatg gggcagccct gtgtgagtgg gtgtgtgtca 840 tccatatcgt cattttctat ggcaccttca gctacgagtt tggggcagtc tcctcagaca 900 cactggtggc tgcactgcag cctacccctg gccgggcctg caagtcctcc gggagcagca 960 gcactccacc cacctcaact gtgcccccga gagcatcgct atgatctaag gtctggggag 1020 ggtggctggc ccggctccac agcaccccac cccatatctt ctttccattt atttcgtacc 1080 aaaaacaatt ttgagaaagt attctgttgg gatctgggct tcctcacttc tggagaagtg 1140 gccatcccat gcccacctgt gccatggagg agtgggccct gccagctgcc acagctgcat 1200 gacctgcttc ccaccccacg gtgtcgtttt gtttttaaag gtcacctgtc ctcactcacc 1260 cagccagccc ttcaggtgcc ttctactccc agtgccaaag ccagaccact ggggtttcct 1320 gctgcaggaa ttgggggctg ggaacagcag aggggataga agtctggtgg aggtggagtg 1380 ggcacgcctt agcctacgga aaggcccatt tctgggccca ctgagctgca ctgggattct 1440 tcagtctgcc cctcacttcc tttagggcaa ataacacagc agaaccacgt gggtatttta 1500 gtactttttt ttatattaaa agaattctaa tttgaaatcc cgattgaatt ctagacct 1558 66 437 PRT Homo sapiens 66 Met Val Arg Arg Arg Arg Gly Ala Pro Gly Arg Pro Gly Gln Leu Met 1 5 10 15 Val Val Ala Glu Thr Ser Gln Gly Ser Trp Ser Ala Pro His Phe Pro 20 25 30 Ile Tyr Leu Leu Ser Ser Pro Pro Thr Pro Pro Pro Pro Trp Leu Pro 35 40 45 Ser Leu Met Thr Ala Trp Ile Leu Leu Pro Val Ser Leu Ser Ala Phe 50 55 60 Ser Ile Thr Gly Ile Trp Thr Val Tyr Ala Met Ala Val Met Asn His 65 70 75 80 His Val Cys Pro Val Glu Asn Trp Ser Tyr Asn Glu Ser Cys Pro Pro 85 90 95 Asp Pro Ala Glu Gln Gly Gly Pro Lys Thr Cys Cys Thr Leu Asp Asp 100 105 110 Val Pro Leu Ile Ser Lys Cys Gly Ser Tyr Pro Pro Glu Ser Cys Leu 115 120 125 Phe Ser Leu Ile Gly Asn Met Gly Ala Phe Met Val Ala Leu Ile Cys 130 135 140 Leu Leu Arg Tyr Gly Gln Leu Leu Glu Gln Ser Arg His Ser Trp Val 145 150 155 160 Asn Thr Thr Ala Leu Ile Thr Gly Cys Thr Asn Ala Ala Gly Leu Leu 165 170 175 Val Val Gly Asn Phe Gln Val Asp His Ala Arg Ser Leu His Tyr Val 180 185 190 Gly Ala Gly Val Ala Phe Pro Ala Gly Leu Leu Phe Val Cys Leu His 195 200 205 Cys Leu Ser Pro Thr Lys Gly Pro Pro Pro Arg Trp Thr Trp Leu Trp 210 215 220 Pro Ile Cys Glu Val Cys Trp Leu Ser Ser Pro Leu Ser Pro Trp Ser 225 230 235 240 Ser Val Glu Ser Ser Leu Ser Met Arg Val Leu Ser Cys Asn Met Gly 245 250 255 Gln Pro Cys Val Ser Gly Cys Val Ser Ser Ile Ser Ser Phe Ser Met 260 265 270 Ala Pro Ser Ala Thr Ser Leu Gly Gln Ser Pro Gln Thr His Trp Trp 275 280 285 Leu His Cys Ser Leu Pro Leu Ala Gly Pro Ala Ser Pro Pro Gly Ala 290 295 300 Ala Ala Leu His Pro Pro Gln Leu Cys Pro Arg Glu His Arg Tyr Asp 305 310 315 320 Leu Arg Ser Gly Glu Gly Gly Trp Pro Gly Ser Thr Ala Pro His Pro 325 330 335 Ile Ser Ser Phe His Leu Phe Arg Thr Lys Asn Asn Phe Glu Lys Val 340 345 350 Phe Cys Trp Asp Leu Gly Phe Leu Thr Ser Gly Glu Val Ala Ile Pro 355 360 365 Cys Pro Pro Val Pro Trp Arg Ser Gly Pro Cys Gln Leu Pro Gln Leu 370 375 380 His Asp Leu Leu Pro Thr Pro Arg Cys Arg Phe Val Phe Lys Gly His 385 390 395 400 Leu Ser Ser Leu Thr Gln Pro Ala Leu Gln Val Pro Ser Thr Pro Ser 405 410 415 Ala Lys Ala Arg Pro Leu Gly Phe Pro Ala Ala Gly Ile Gly Gly Trp 420 425 430 Glu Gln Gln Arg Gly 435 67 2336 DNA Homo sapiens unsure (418) 67 atttattgag tgtctactgt gtgccaggca ctatatctat gtgcatagaa aaacctggaa 60 gggcctacca caatacatat agagtgatcg tctctgcttg ctgagctaac aggggtgtca 120 agcttccatt ttggtatcta cttctaaata cactcagaac aggagaaatt tggactaatt 180 ttcaaactac agacactttc taatcatgat gcatttcaaa agtggactcg aattaactga 240 gttgcaaaac atgacagtgc ccgaggatga taacatcagc aatgactcca atgatttcac 300 cgaagtagaa aatggtcaga taaatagcaa gtttatttct gatcgtgaaa gtagaagaag 360 tctcacaaac agccatttgg aaaaaaagaa gtgtgatgag tatattccag gtacaacntc 420 cttaggcatg tttgttttta acctaagcaa ctccatgatg ggcagtggga tttgggactc 480 gctttgccct ggcaacactg gaatcctact ttttctggta cttttgactt cagtgacatt 540 gctgtctata tattcaataa acctcctatt gatctgttca aaagaaacag gctgcatggt 600 gtatgaaaag ctgggggaac aagtctttgg caccacaggg aagttcgtaa tctttggagc 660 cacctctcta cagaacactg gagcaatgct gagctacctc ttcatcgtaa aaaatgaact 720 accctctgcc ataaagtttc taatgggaaa ggaagagaca ttttcagcct ggtacgtgga 780 tggccgcgtt ctggtggtga tagttacctt tggcataatt ctccctctgt gtctcttgaa 840 gaacttaggg tatcttggct atactagtgg attttccttg agctgtatgg tttttttcct 900 aattgtggtt atttacaaga aatttcaaat tccctgcatt gttccagagc taaattcaac 960 aataagtgct aattcaacaa atgctgacac gtgtacgcca aaatatgtta ccttcaattc 1020 aaagaccgtg tatgctttac ccaccattgc atgtgcattt gtttgccacc cgtcagtcct 1080 gccaatttac agtgagctta aagaccgatc acagaaaaaa atgcagatgg tttcaaacat 1140 ctcctttttc gccatgtttg ttatgtactt cttgactgcc atttttggct acttgacatt 1200 ctatgacaac gtgcagtccg acctccttca caaatatcag agtaaagatg acattctcat 1260 cctgacagtg cggctggctg tcattgttgc tgtgatcctc acagtgccgg tgttattttt 1320 cacggttcgt tcatctttat ttgaactggc taagaaaaca aagtttaatt tatgtcgtca 1380 taccgtggtt acctgcatac tcttggttgt tatcaacttg ttggtgatct tcataccctc 1440 catgaaggat atttttggag tcgtaggagt tacatctgct aacatgctta ttttcattct 1500 tccttcatct ctttatttaa aaatcacaga ccaggatgga gataaaggaa ctcaaagaat 1560 ttgggtatgt ctcttgccag ccactctaac ttttctgatt agttttccat ttaaatttac 1620 aaaataaata gtccacctct ctatcaagac tactttcagt tgccttgaaa ggaggcagaa 1680 gccctgtagc tttgctactt gggagatatt taaaatatca tatcagaatc ttctcccatc 1740 cctccaaata tcttttctgg ttttactctt tttttttgag atggagtctc actctgtcgc 1800 ccaggctgga gtgcagtggc cagatctcag ctcactgtaa gctccacctc ccgggttcat 1860 gccattcttc tgcctcagag agtagctggg actacaggcg cccgccacca tgcctggcta 1920 attttttttc ttttttcttt tttctttttt gtatttttag tagagacggg gtttcaccat 1980 gttagccagg atggtctgta tctcctgacc tcatgatccg tctgcctcgg cctcccacag 2040 tgctgggatt acaggcatga gccatcgcgc ccggccctct ggttttactg ttattgtgcc 2100 tcagcttttg ttctgatcca gggcatggcc agtcagaaga atggacattc atcctcctgt 2160 gtctgtatag gacagtgtct agtcttcagc aagagaggaa gtgacgaggg actcacagat 2220 gttatgcagt ccactgtttc catatgattt ctagtcatgt aactcctccc tacagcccag 2280 ggaacatgca atgccttaat taaaatgtct gagttagctt aaaaaaaaaa aaaaaa 2336 68 473 PRT Homo sapiens 68 Met Met His Phe Lys Ser Gly Leu Glu Leu Thr Glu Leu Gln Asn Met 1 5 10 15 Thr Val Pro Glu Asp Asp Asn Ile Ser Asn Asp Ser Asn Asp Phe Thr 20 25 30 Glu Val Glu Asn Gly Gln Ile Asn Ser Lys Phe Ile Ser Asp Arg Glu 35 40 45 Ser Arg Arg Ser Leu Thr Asn Ser His Leu Glu Lys Lys Lys Cys Asp 50 55 60 Glu Tyr Ile Pro Gly Thr Thr Ser Leu Gly Met Phe Val Phe Asn Leu 65 70 75 80 Ser Asn Ser Met Met Gly Ser Gly Ile Trp Asp Ser Leu Cys Pro Gly 85 90 95 Asn Thr Gly Ile Leu Leu Phe Leu Val Leu Leu Thr Ser Val Thr Leu 100 105 110 Leu Ser Ile Tyr Ser Ile Asn Leu Leu Leu Ile Cys Ser Lys Glu Thr 115 120 125 Gly Cys Met Val Tyr Glu Lys Leu Gly Glu Gln Val Phe Gly Thr Thr 130 135 140 Gly Lys Phe Val Ile Phe Gly Ala Thr Ser Leu Gln Asn Thr Gly Ala 145 150 155 160 Met Leu Ser Tyr Leu Phe Ile Val Lys Asn Glu Leu Pro Ser Ala Ile 165 170 175 Lys Phe Leu Met Gly Lys Glu Glu Thr Phe Ser Ala Trp Tyr Val Asp 180 185 190 Gly Arg Val Leu Val Val Ile Val Thr Phe Gly Ile Ile Leu Pro Leu 195 200 205 Cys Leu Leu Lys Asn Leu Gly Tyr Leu Gly Tyr Thr Ser Gly Phe Ser 210 215 220 Leu Ser Cys Met Val Phe Phe Leu Ile Val Val Ile Tyr Lys Lys Phe 225 230 235 240 Gln Ile Pro Cys Ile Val Pro Glu Leu Asn Ser Thr Ile Ser Ala Asn 245 250 255 Ser Thr Asn Ala Asp Thr Cys Thr Pro Lys Tyr Val Thr Phe Asn Ser 260 265 270 Lys Thr Val Tyr Ala Leu Pro Thr Ile Ala Cys Ala Phe Val Cys His 275 280 285 Pro Ser Val Leu Pro Ile Tyr Ser Glu Leu Lys Asp Arg Ser Gln Lys 290 295 300 Lys Met Gln Met Val Ser Asn Ile Ser Phe Phe Ala Met Phe Val Met 305 310 315 320 Tyr Phe Leu Thr Ala Ile Phe Gly Tyr Leu Thr Phe Tyr Asp Asn Val 325 330 335 Gln Ser Asp Leu Leu His Lys Tyr Gln Ser Lys Asp Asp Ile Leu Ile 340 345 350 Leu Thr Val Arg Leu Ala Val Ile Val Ala Val Ile Leu Thr Val Pro 355 360 365 Val Leu Phe Phe Thr Val Arg Ser Ser Leu Phe Glu Leu Ala Lys Lys 370 375 380 Thr Lys Phe Asn Leu Cys Arg His Thr Val Val Thr Cys Ile Leu Leu 385 390 395 400 Val Val Ile Asn Leu Leu Val Ile Phe Ile Pro Ser Met Lys Asp Ile 405 410 415 Phe Gly Val Val Gly Val Thr Ser Ala Asn Met Leu Ile Phe Ile Leu 420 425 430 Pro Ser Ser Leu Tyr Leu Lys Ile Thr Asp Gln Asp Gly Asp Lys Gly 435 440 445 Thr Gln Arg Ile Trp Val Cys Leu Leu Pro Ala Thr Leu Thr Phe Leu 450 455 460 Ile Ser Phe Pro Phe Lys Phe Thr Lys 465 470 69 1999 DNA Homo sapiens 69 tttttttttt tttttttttt ttttttaaag acagggtctc actctgtcac tcaggctgga 60 atgtagtggc atgattatgg ctcactgcag cctctacttc ctgggcccag gcaatcctct 120 cacctcagct cctgagtagc tgggactaca ggcgcacacc acctcacttg gctaattaaa 180 aaaaattttt ttttgtagaa atgggggtct tccaatgttg cccatgctgg tcttgaactc 240 ctggcctcaa gtgatcctcc caccttggcc tcctaaattg ctgagattac agatgtgagc 300 caccacgccc aacctaactt caagaactct tgaccatctc tgtttctttc ctgattttag 360 gcccacaatg ttcactgtct tagttttagg atgagactct aaatcttttt ttttttgaga 420 tggagtctcg ctctgttgcc caggctggag tgcagtggca cgatctcggc tcaccacaac 480 ctctgcctcc aggattcaag cgattgtcct gcctcagcta ctcctcggga ggctgaggca 540 ggagaatggc gtgaactccg gaggtggagc ctgtagtgag ccgagatggc accactgcgc 600 tccagcctgg gcgacagagc aagactccat atcaaaaaaa aaaaaaaaaa aaaagataat 660 ccaaagaatt taaattgtaa tcatgtttca tgtatttgtt ttattactta cttttatagc 720 acttagtccc agtggtatta gactgctatt tggtttcata caaaaaggat taaatttaaa 780 ttcattcatg tttagacttg agttattaca tttttaaaac tatcatcttg cctttaatgt 840 ttgtggtcct acacaaacta ttagtacatt tcagtatcct cttacccctt tgtttttaag 900 tttttgattg ctaaagcaag acttttttct tctagaattt aagtcaacca agtgttatct 960 atgttgtaaa aatggataat agtagatttt aggtgataaa acaacttgtt agtaagacat 1020 ttcctagctt aaaaaaaaaa atcaaaaatt ccatgataga aatgcagacc tgtgagggaa 1080 actcctgaaa agcataagaa gcatcccaga gagccatggg ttttctagac cagagaattt 1140 agagggagat tgtggaactg aggcttaggt ggtcagatcg tttcccttat cactgtaata 1200 tttctggggg aaaaatgctt tctgagttgt ttaaacaagc atccttacat tttttttttt 1260 aattaaacag cctgtctagg cttgggattc cctaatacta cagtagcagt atatgaatat 1320 gattttgtga ttgtgttttt taaaagataa gtaatttgat gaactgttct tttgcagtca 1380 gaaaaacact cacaaaaaga caaaaaaagt tccacagtat tatatttcat gtcagttcag 1440 gcctaaaatc ctttgcaaat aagatgttta taggctggtc acaattaaca atgtattatt 1500 ggcagcactt cttggatgga taccttttgg gacctttcat tagaaagagg gaaagaatgg 1560 ggtggttttg tatgggctcc tgtttggggg taaaaatagc agagtcagtt gctgaggaca 1620 atgaccttcc ttataacatt agtttcatac ccatattagg tcttgtcttg aggacccttt 1680 atatgtgctt gtttactagt ggccttccag ccatagcatt cttacctttt tttcctattc 1740 taagaattaa aaaaaaaaat tatagagcca gcaagggagg aggcaggaaa cagaaatcga 1800 atttcatcat tccagtatag ttgtcccttt ttttgtattt ctgacttggt tttataatta 1860 tatttactta ctaattattg ttttttaaca ttctttattg tggcttactc ttcatactta 1920 gaattgaaat tgttggacat cacatgtata ttcacattat aaatacatca ttcttccact 1980 gttaaaaaaa aaaaaaaaa 1999 70 153 PRT Homo sapiens 70 Met Asn Cys Ser Phe Ala Val Arg Lys Thr Leu Thr Lys Arg Gln Lys 1 5 10 15 Lys Phe His Ser Ile Ile Phe His Val Ser Ser Gly Leu Lys Ser Phe 20 25 30 Ala Asn Lys Met Phe Ile Gly Trp Ser Gln Leu Thr Met Tyr Tyr Trp 35 40 45 Gln His Phe Leu Asp Gly Tyr Leu Leu Gly Pro Phe Ile Arg Lys Arg 50 55 60 Glu Arg Met Gly Trp Phe Cys Met Gly Ser Cys Leu Gly Val Lys Ile 65 70 75 80 Ala Glu Ser Val Ala Glu Asp Asn Asp Leu Pro Tyr Asn Ile Ser Phe 85 90 95 Ile Pro Ile Leu Gly Leu Val Leu Arg Thr Leu Tyr Met Cys Leu Phe 100 105 110 Thr Ser Gly Leu Pro Ala Ile Ala Phe Leu Pro Phe Phe Pro Ile Leu 115 120 125 Arg Ile Lys Lys Lys Asn Tyr Arg Ala Ser Lys Gly Gly Gly Arg Lys 130 135 140 Gln Lys Ser Asn Phe Ile Ile Pro Val 145 150 71 2020 DNA Homo sapiens 71 ggaggggtgt gtgtgtgtgt atttggtttg ctgtcctttt ttaaaggatt ccaagccatg 60 tgaaacttcc cttctggatg tgattctggg tcgcaagtcc ttatttatat gtgaggctgg 120 ggaatgggct gggggtattg gcagtccttt tgcagggcag tgtgtgtggt ggggtgacac 180 cgctgtggct tagcccaaga cactcccaga ggaaaacact gcagaaggaa ctggtttgca 240 gactgtggaa ggatctgcag ttttgttttt gaccaaaaaa ataataataa gttagctctg 300 aagggcagag ggaataccca agcccctgat gcctatgaga agtccctgga cttcaaccct 360 cctgttgttt ggccttagcc cagagggagc tgctcacctg agcacccttg ggggtgggca 420 gagaggcagg gtgggatttt agagttagtg tctgtgcggg ggcagccctg agcctggagt 480 tgagactttg gggtctctta gtttggaggt gttgagtgca tttgtgcccc tgcctggttg 540 agagcttctt ggtacctctt gccacccctt ctcactgccc tgacccaacc ccactggacc 600 ttgatgctgc gaggagtggt gtcctgacgg actcagcact cccgcctgat gtattggatc 660 ataggagagc acttgctctc ctgcctctgc caggagaggg cttgttcctc caactctagg 720 aggccaggca agcatggaca ggagccaagg gagcagggtc attaactttt tcttctttgc 780 aaagtgggca cttggcatca gggtcccaat caccagaaag caccaaagcc cctggcaccc 840 cacccactcc atcctaccca gggaccccaa gtaggcaact gttatggcag tgggtccagc 900 ccaggccagc actggcagcc tcctctccct gcagtatgca ccagctctac ctcccccggc 960 aggcaatgtc ctggcttctc agcccagcac catctgttcc cctatacttc tcaggggcca 1020 gcccagtctg ggccaccctt tgtttccctc atcctcggct cccacacagg tgacagaccc 1080 agcagatagc ttctctctgg gaaaggttgg atgctgcctt acatcccctt ctagccctcc 1140 tcccatccac acacacaggc acccacccac accaggtcgg cttgtttctc acatgtaggg 1200 agagagggga gaccaacccc tttgtgtctt ttgaaatacg aagaaaaatg tgtgttcagg 1260 agcatgactc cagtgctgcg ctcttgggcc cagttcagtc tgtcttgtct caaatctagg 1320 catttttgct tcaattttat tttttttaag aatacaaaaa cagaaatctg cactaattta 1380 cctggtttcg taggaaaact tttttttatt ttttacattt tttggtgtcc gtttgtattg 1440 aataatttgc tacatttgta aaatgtaaga ggtatataat atatgtatat ttctaacgta 1500 aaaaacataa tttttttctt ttcaagattt ttttcttaaa aagatgagag aaacatattt 1560 tttcaggaaa aacaaacttt aaaaaaaaaa gaggagaaat aaaacctttt ctcccctttc 1620 cccatcctct atctatccct ctttcccagg aacaaatcaa aaggtggatt atcttctgaa 1680 gaatggaaac tgttagtcca gaatgatgtg tttttctcaa tgcagtgagt gatagattct 1740 ctagttttct ccctagggat gggaaggggg cattgaggca agcctggaga ggagcctggg 1800 gagcagggtc atgaactttt ttctttagtg aaggaggaat acaatcaagg gttttgtatt 1860 cagaatgttg tgcaatattt tggaatggga cattggtgtg tttagagatt ttagtttaaa 1920 aacaaaacaa aaagattgat caaatctgta cagtttctat tgttccagat ttttttaagt 1980 ttgtattaaa agcacgatac ataataaaaa aaaaaaaaaa 2020 72 104 PRT Homo sapiens 72 Met Ala Val Gly Pro Ala Gln Ala Ser Thr Gly Ser Leu Leu Ser Leu 1 5 10 15 Gln Tyr Ala Pro Ala Leu Pro Pro Pro Ala Gly Asn Val Leu Ala Ser 20 25 30 Gln Pro Ser Thr Ile Cys Ser Pro Ile Leu Leu Arg Gly Gln Pro Ser 35 40 45 Leu Gly His Pro Leu Phe Pro Ser Ser Ser Ala Pro Thr Gln Val Thr 50 55 60 Asp Pro Ala Asp Ser Phe Ser Leu Gly Lys Val Gly Cys Cys Leu Thr 65 70 75 80 Ser Pro Ser Ser Pro Pro Pro Ile His Thr His Arg His Pro Pro Thr 85 90 95 Pro Gly Arg Leu Val Ser His Met 100 73 760 DNA Homo sapiens 73 cttaagtctt ggcgcgctcg cctcgcagcc tgcaacccgc gctcagctgc ccgcctcctc 60 agccagccat gctggagcat ctgagctcgc tgcccacgca gatggattac aagggccaga 120 agctagctga acagatgttt cagggaatta ttcttttttc tgcaatagtt ggatttatct 180 acgggtacgt ggctgaacag ttcgggtgga ctgtctatat agttatggcc ggatttgctt 240 tttcatgttt gctgacactt cctccatggc ccatctatcg ccggcatcct ctcaagtggt 300 tacctgttca agaatcaagc acagacgaca agaaaccagg ggaaagaaaa attaagaggc 360 atgctaaaaa taattgaggt tttcatgatt cagcacctgc ttttgtttct gtgagatgag 420 ctaaattgct ttcatacccc agataagagc taaaaccacc taatgctctt atggcacagc 480 tgtgtataga tttagttctc tttatacttc atttctagcc cagttgggtt ttgatttata 540 taagtagttt agaccttctc ttcataatct tgctctgaga tggggaacag aacacacaag 600 tatgaagttt ctttcaggtg taaataatga aaaataaatg cctcataaat gatagtacaa 660 tgtaactatc aaagttttat aattcattat gagttaacca ttttaatgtt tccaattaac 720 cctcatagtg caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 760 74 102 PRT Homo sapiens 74 Met Leu Glu His Leu Ser Ser Leu Pro Thr Gln Met Asp Tyr Lys Gly 1 5 10 15 Gln Lys Leu Ala Glu Gln Met Phe Gln Gly Ile Ile Leu Phe Ser Ala 20 25 30 Ile Val Gly Phe Ile Tyr Gly Tyr Val Ala Glu Gln Phe Gly Trp Thr 35 40 45 Val Tyr Ile Val Met Ala Gly Phe Ala Phe Ser Cys Leu Leu Thr Leu 50 55 60 Pro Pro Trp Pro Ile Tyr Arg Arg His Pro Leu Lys Trp Leu Pro Val 65 70 75 80 Gln Glu Ser Ser Thr Asp Asp Lys Lys Pro Gly Glu Arg Lys Ile Lys 85 90 95 Arg His Ala Lys Asn Asn 100 75 875 DNA Homo sapiens 75 ctagctcatg ctgctcttgt cagcctctgg ttctcctcga gtccttgggg acgtggcaga 60 tgccagcgac catcagacaa cgtggaggcc ctcatgggca atggctgagg gggccgggct 120 gaggctgtgc acatgcagtc tgcacgccac tcttgggctc tgctggcgga gatccccttc 180 cttctgggtg cagactgcac ctccggatgc agttttgatg tccatcttcc aggagagaga 240 cggtctcggg tccagggagt ggagggggct gcccctgccg tgcaggtcct ggccgatggc 300 gccttaccct gctgccctgg gcttttggcc tgaagcaaat tcctgagtgg ggggtactgg 360 ggcctgccgc atcctgtcct gtccactgcc cacccccgtg tgctggctcc ctcacttctg 420 gctgcagtgg gagccgccag tctgaccctt gtcaccgcac gctctgcccc caccccgttg 480 caagaggtca caccatgtca gcagccttgc actgaccgca gccggccccc aggcctcaga 540 gttctggatg cttccgtgcg gctccaacag gcatcgtctt cccttccgca ggtggagggg 600 ccgcttcccg caggcatctg agctctgtgc cggggccgtg gccatgggaa gatgttccac 660 gctgcctcct cctcgagttt tcctcggaaa cactcttgaa tgtctgagtg agggtcctgc 720 ttagctcttt ggcctgtgag atgctttgaa aatttttatt tttttaagat gaagcaagat 780 gtctgtagcg gtaattgcct cacattaaac tgtcgccgac tgcaggcgca gtgactgctg 840 aatgtaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 875 76 112 PRT Homo sapiens 76 Met Leu Leu Leu Ser Ala Ser Gly Ser Pro Arg Val Leu Gly Asp Val 1 5 10 15 Ala Asp Ala Ser Asp His Gln Thr Thr Trp Arg Pro Ser Trp Ala Met 20 25 30 Ala Glu Gly Ala Gly Leu Arg Leu Cys Thr Cys Ser Leu His Ala Thr 35 40 45 Leu Gly Leu Cys Trp Arg Arg Ser Pro Ser Phe Trp Val Gln Thr Ala 50 55 60 Pro Pro Asp Ala Val Leu Met Ser Ile Phe Gln Glu Arg Asp Gly Leu 65 70 75 80 Gly Ser Arg Glu Trp Arg Gly Leu Pro Leu Pro Cys Arg Ser Trp Pro 85 90 95 Met Ala Pro Tyr Pro Ala Ala Leu Gly Phe Trp Pro Glu Ala Asn Ser 100 105 110 77 2848 DNA Homo sapiens unsure (2526) 77 ctttgttctg tccttggtgt gtggtgcatt cgtgaaattc tgcagcacat cggcgaaaga 60 aaacgttgtg tgacgtgatc ctcatggtcc aggaaagaaa gatacctgct catcgtgttg 120 ttcttgctgc agccagtcat ttttttaact taatgttcac aactaacatg cttgaatcaa 180 agtcctttga agtagaactc aaagatgctg aacctgatat tattgaacaa ctggtggaat 240 ttgcttatac tgctagaatt tccgtgaata gcaacaatgt tcagtctttg ctggatgcag 300 caaaccaata tcagattgaa cctgtgaaga aaatgtgtgt tgattttttg aaagaacaag 360 ttgatgcttc aaattgtctt ggtataagtg tgctagcgga gtgtctagat tgtcctgaat 420 tgaaagcaac tgcagatgac tttattcatc agcactttac tgaagtttac aaaactgatg 480 aatttcttca acttgatgtc aagcgagtaa cacatcttct caaccaggac actctgactg 540 tgagagcaga ggatcaggtt tatgatgctg cagtcaggtg gttgaaatac gatgaaccta 600 atcgccagcc atttatggtt gatatccttg ctaaagtcag gtttcctctt atatcaaaga 660 atttcttaag taaaacggta caagctgaac cacttattca agacaatcct gaatgcctta 720 agatggtgat aagtggaatg aggtaccatc tactgtctcc agaggaccga gaagaacttg 780 tagatggccc aagacctaga agaaagaaac atgactaccg catagcccta tttggaggct 840 ctcaaccaca gtcttgtaga tattttaacc ccaaggatta tagctggaca gacatccgct 900 gcccctttga aaaaccaaga gatgcagcat gcgtgttttg ggacaatgta gtatacattt 960 tgggaggctc tcagcttttc ccaataaagc gaatggactg ctataatgta gtgaaggata 1020 gctggtattc gaaactgggt cctccgacac ctcgagacag ccttgctgca tgtgctgcag 1080 aaggcaaaat ttatacatct ggaggttcag aagtaggaaa ctcagctctg tatttatttg 1140 agtgctatga tacgagaact gaaagctggc acacaaagcc cagcatgctg acccagcgct 1200 gcagccatgg gatggtggaa gccaatggcc taatctatgt ttgtggtgga agtttaggaa 1260 acaatgtttc tgggagagtg cttaattcct gtgaagttta tgatcctgcc acagaaacat 1320 ggactgagct gtgtccaatg attgaagcca ggaagaatca tgggctggta tttgtaaaag 1380 acaagatatt tgctgtgggt ggtcagaatg gtttaggtgg tctggacaat gtggaatatt 1440 acgatattaa gttgaacgaa tggaagatgg tctcaccaat gccatggaag ggtgtaacag 1500 tgaaatgtgc agcagttggc tctatagttt atgtcttggc tggttttcaa ggtgttggtc 1560 gattaggaca cattctccaa tataataccg aaacagacaa atgggttgcc aactcccaag 1620 ttcgtgcttt tccagtcaca aagttgttta atttgtgttg tcgatacttg tggagcaaat 1680 gaagagaccc ttgaaacatg aaaaatgagt ggacttcaga ctcatcagag actctaaaat 1740 atagccacca gtgctttgtt ccaggagttt ggtgacaaag ttttggtttg gtgttttggt 1800 aaagaaagtt tcaagtgaaa tgaggttcct ataaaataga tgtttctttt atatggattt 1860 ccttaattca aagatcatat tttagctggc cacaaaacca agaacatatc tagcaagaaa 1920 acttgaaaaa gtataagcat ttgttaaaaa tgtgaatttc ttgaatgaat ttcacatttg 1980 taactatgat tttggcagaa tagaagattg gctcatcagt gaagcgcagt atcttagctc 2040 tagattctat tttcatgcat cacagaagtg ctatacggtt aggtctgttt gtgctcagtc 2100 aagaactaag aaatagtatg aattgtaagt caagatgggc aactcagatg gagcagctta 2160 gtctcacagt ttgcttgtct atttatttta tttagtgcca aatgtattcc attttaaaag 2220 taagccagag tgagtcaagg catatacaca ctttctcaca aaacttccta aacagatttg 2280 ggggtttaat atgtccaact cctcatgaaa tatattcaat ccacttaaat atattccatc 2340 tttttaacat aaaatgtaaa gcttagcacc catcattaat ttatgtctct gttttatcca 2400 gtggttaaaa aaggattctg cctctttagt cctccctgtt aaataaaacc caatcatagt 2460 aggtgattac ctagcaaaaa gtaaagctat ttatagcaaa tttttagatc attagaaaag 2520 cggggnggtt gaacaataac agtgttgact ttgaacttct ttaacgagat catgaattct 2580 tttcccttag ccaaaacatg aaatatttaa cctagttgtc tctaaaagtt ttgtaatcat 2640 gagttagata tatgtcatct cctattcatt gcttttatgt gatcaataaa tcttttacaa 2700 acccaactac tcatttcctt cctagtaata ctttgccttt ttcactgtgt atggaatgaa 2760 acatgtaaag ctgtcacaat caatgttttt atctgataat attaaatatt ttttaacttc 2820 aaaaaaaaaa aaaaaaaaaa aaaaaaaa 2848 78 532 PRT Homo sapiens 78 Met Val Gln Glu Arg Lys Ile Pro Ala His Arg Val Val Leu Ala Ala 1 5 10 15 Ala Ser His Phe Phe Asn Leu Met Phe Thr Thr Asn Met Leu Glu Ser 20 25 30 Lys Ser Phe Glu Val Glu Leu Lys Asp Ala Glu Pro Asp Ile Ile Glu 35 40 45 Gln Leu Val Glu Phe Ala Tyr Thr Ala Arg Ile Ser Val Asn Ser Asn 50 55 60 Asn Val Gln Ser Leu Leu Asp Ala Ala Asn Gln Tyr Gln Ile Glu Pro 65 70 75 80 Val Lys Lys Met Cys Val Asp Phe Leu Lys Glu Gln Val Asp Ala Ser 85 90 95 Asn Cys Leu Gly Ile Ser Val Leu Ala Glu Cys Leu Asp Cys Pro Glu 100 105 110 Leu Lys Ala Thr Ala Asp Asp Phe Ile His Gln His Phe Thr Glu Val 115 120 125 Tyr Lys Thr Asp Glu Phe Leu Gln Leu Asp Val Lys Arg Val Thr His 130 135 140 Leu Leu Asn Gln Asp Thr Leu Thr Val Arg Ala Glu Asp Gln Val Tyr 145 150 155 160 Asp Ala Ala Val Arg Trp Leu Lys Tyr Asp Glu Pro Asn Arg Gln Pro 165 170 175 Phe Met Val Asp Ile Leu Ala Lys Val Arg Phe Pro Leu Ile Ser Lys 180 185 190 Asn Phe Leu Ser Lys Thr Val Gln Ala Glu Pro Leu Ile Gln Asp Asn 195 200 205 Pro Glu Cys Leu Lys Met Val Ile Ser Gly Met Arg Tyr His Leu Leu 210 215 220 Ser Pro Glu Asp Arg Glu Glu Leu Val Asp Gly Pro Arg Pro Arg Arg 225 230 235 240 Lys Lys His Asp Tyr Arg Ile Ala Leu Phe Gly Gly Ser Gln Pro Gln 245 250 255 Ser Cys Arg Tyr Phe Asn Pro Lys Asp Tyr Ser Trp Thr Asp Ile Arg 260 265 270 Cys Pro Phe Glu Lys Pro Arg Asp Ala Ala Cys Val Phe Trp Asp Asn 275 280 285 Val Val Tyr Ile Leu Gly Gly Ser Gln Leu Phe Pro Ile Lys Arg Met 290 295 300 Asp Cys Tyr Asn Val Val Lys Asp Ser Trp Tyr Ser Lys Leu Gly Pro 305 310 315 320 Pro Thr Pro Arg Asp Ser Leu Ala Ala Cys Ala Ala Glu Gly Lys Ile 325 330 335 Tyr Thr Ser Gly Gly Ser Glu Val Gly Asn Ser Ala Leu Tyr Leu Phe 340 345 350 Glu Cys Tyr Asp Thr Arg Thr Glu Ser Trp His Thr Lys Pro Ser Met 355 360 365 Leu Thr Gln Arg Cys Ser His Gly Met Val Glu Ala Asn Gly Leu Ile 370 375 380 Tyr Val Cys Gly Gly Ser Leu Gly Asn Asn Val Ser Gly Arg Val Leu 385 390 395 400 Asn Ser Cys Glu Val Tyr Asp Pro Ala Thr Glu Thr Trp Thr Glu Leu 405 410 415 Cys Pro Met Ile Glu Ala Arg Lys Asn His Gly Leu Val Phe Val Lys 420 425 430 Asp Lys Ile Phe Ala Val Gly Gly Gln Asn Gly Leu Gly Gly Leu Asp 435 440 445 Asn Val Glu Tyr Tyr Asp Ile Lys Leu Asn Glu Trp Lys Met Val Ser 450 455 460 Pro Met Pro Trp Lys Gly Val Thr Val Lys Cys Ala Ala Val Gly Ser 465 470 475 480 Ile Val Tyr Val Leu Ala Gly Phe Gln Gly Val Gly Arg Leu Gly His 485 490 495 Ile Leu Gln Tyr Asn Thr Glu Thr Asp Lys Trp Val Ala Asn Ser Gln 500 505 510 Val Arg Ala Phe Pro Val Thr Lys Leu Phe Asn Leu Cys Cys Arg Tyr 515 520 525 Leu Trp Ser Lys 530 79 2232 DNA Homo sapiens unsure (2168) 79 gttcttcatg cccttctaga gaacgttcta cagctcttct tcacctgcat cctccttgga 60 agtctccagc catgtcgaga tattatttag agttgtttca gtgtccaact tgtatgaaag 120 gagcatggtc tttagtagaa gtccttatca ggtcttgcct tttcaatgaa agcttttgtc 180 atcaaatttc agaaaatatt ggctccaagg tgctccacct gacgctactc aaatttttct 240 ttaatttaat tgaaagtgaa gtacaacatc tgagtcaaaa gttgtatgac tggtcagatt 300 ctcagaatct gaaaataaca ggaaaggcaa tgcttcttga aattttttgg tcaggaagtg 360 aaacctctgg gcttttgacc aaaccagtaa atatgctttt ggaatggact atatattctc 420 acaaggaaaa attcaagtct aatgatactt ttcttccaca ggaattagag attttcattt 480 gctccttttc ctcctcctgg cttcaaatgt ttgttgcaga ggcagtcttt aaaaagttgt 540 gtctacagag ctctggcagt gtttcttctg agccactctc tcttcagaaa atggtatatt 600 cctatttacc agccttgggg aaaactggtg tgcttgggtc tggaaagatt caggtgtcaa 660 agaaaatagg acagcggcct tgttttgact ctcagagaac cttactaatg ctgaatggta 720 ctaaacaaaa acaagtcgaa gggctgccag agttactaga cctgaacctt gctaaatgtt 780 cctcatcatt aaaaaaattg aaaaagaagt cagaaggaga attgtcatgt tccaaggaga 840 attgcccctc tgtagttaaa aagatgaatt ttcacaagac taatctaaaa ggagaaacag 900 ccctgcatag agcttgcata aataaccaag tggagaaatt gattcttctt ctctctttgc 960 caggaataga catcaatgtt aaagacaatg ctggctggac gcctttgcat gaagcctgta 1020 actatggcaa cacagtgggt gtccaggaaa ttttgcaacg ttgtccagag gtagatctgc 1080 tcactcaagt ggacggggtg actcctttgc atgatgcact gtcaaacgga catgtagaaa 1140 ttggcaagct gctactacag catgggggcc cagtgctttt acaacagagg aatgctaagg 1200 gagaattgcc cttggattat gtggtttcac ctcaaatcaa agaagaactg tttgctatta 1260 caaaaataga agatacagtg gagaactttc atgcacaagc agagaaacat tttcattacc 1320 agcaacttga atttggctcc tttttactta gtaggatgtt gctaaatttt tgttcaattt 1380 ttgatttatc ttcagagttc attttagctt ccaaagggtt aactcatcta aatgaactgc 1440 ttatggcttg taaaagtcat aaagaaacca ccagtgttca tactgactgg ttactggatc 1500 tttatgctgg aaatataaag acattgcaga aactcccaca cattcttaag gaactgcctg 1560 agaatttgaa agtgtgtcct ggggtacaca ctgaggcctt gatgataaca ttggaaatga 1620 tgtgtcggtc agtcatggag ttttcatgat gatgctagaa agtatggatt gactttctaa 1680 atctgttcag tttgcattgg tacttactgt ggacttcata gcttactgac agatagtaat 1740 ttgatttatt tattgacaga ctttgcagcc ttgctaaatt ttaaaagcat ttttaaaaaa 1800 acttctacaa aactctagta tgggcttctg actttttcca gggtgtagaa tttgactcaa 1860 aagtaaaaat aattttgttt tagtatattc tactttcatt aatgtttttt tgttctgaaa 1920 gtgatattat attgtacatg taaaattaat ttaaatattt tttcaaataa aaatgtaatg 1980 tcctgtattc tagatgttct aggtcttaga atcatggcaa gcatattcat acaaatgcgt 2040 acctataaac ttgtagctcc tgactcttag ggatggattt tgaggaaaaa acaagactaa 2100 acaaaaacat gtagctccct atttcttctc tctaggttgt tggactgaaa tatgcatttt 2160 agctttgntg tttctaaaat aaacatttct aaaatttaca ggaaaaaaaa aaaaaaaaaa 2220 aaaaaaaaaa aa 2232 80 525 PRT Homo sapiens 80 Met Ser Arg Tyr Tyr Leu Glu Leu Phe Gln Cys Pro Thr Cys Met Lys 1 5 10 15 Gly Ala Trp Ser Leu Val Glu Val Leu Ile Arg Ser Cys Leu Phe Asn 20 25 30 Glu Ser Phe Cys His Gln Ile Ser Glu Asn Ile Gly Ser Lys Val Leu 35 40 45 His Leu Thr Leu Leu Lys Phe Phe Phe Asn Leu Ile Glu Ser Glu Val 50 55 60 Gln His Leu Ser Gln Lys Leu Tyr Asp Trp Ser Asp Ser Gln Asn Leu 65 70 75 80 Lys Ile Thr Gly Lys Ala Met Leu Leu Glu Ile Phe Trp Ser Gly Ser 85 90 95 Glu Thr Ser Gly Leu Leu Thr Lys Pro Val Asn Met Leu Leu Glu Trp 100 105 110 Thr Ile Tyr Ser His Lys Glu Lys Phe Lys Ser Asn Asp Thr Phe Leu 115 120 125 Pro Gln Glu Leu Glu Ile Phe Ile Cys Ser Phe Ser Ser Ser Trp Leu 130 135 140 Gln Met Phe Val Ala Glu Ala Val Phe Lys Lys Leu Cys Leu Gln Ser 145 150 155 160 Ser Gly Ser Val Ser Ser Glu Pro Leu Ser Leu Gln Lys Met Val Tyr 165 170 175 Ser Tyr Leu Pro Ala Leu Gly Lys Thr Gly Val Leu Gly Ser Gly Lys 180 185 190 Ile Gln Val Ser Lys Lys Ile Gly Gln Arg Pro Cys Phe Asp Ser Gln 195 200 205 Arg Thr Leu Leu Met Leu Asn Gly Thr Lys Gln Lys Gln Val Glu Gly 210 215 220 Leu Pro Glu Leu Leu Asp Leu Asn Leu Ala Lys Cys Ser Ser Ser Leu 225 230 235 240 Lys Lys Leu Lys Lys Lys Ser Glu Gly Glu Leu Ser Cys Ser Lys Glu 245 250 255 Asn Cys Pro Ser Val Val Lys Lys Met Asn Phe His Lys Thr Asn Leu 260 265 270 Lys Gly Glu Thr Ala Leu His Arg Ala Cys Ile Asn Asn Gln Val Glu 275 280 285 Lys Leu Ile Leu Leu Leu Ser Leu Pro Gly Ile Asp Ile Asn Val Lys 290 295 300 Asp Asn Ala Gly Trp Thr Pro Leu His Glu Ala Cys Asn Tyr Gly Asn 305 310 315 320 Thr Val Gly Val Gln Glu Ile Leu Gln Arg Cys Pro Glu Val Asp Leu 325 330 335 Leu Thr Gln Val Asp Gly Val Thr Pro Leu His Asp Ala Leu Ser Asn 340 345 350 Gly His Val Glu Ile Gly Lys Leu Leu Leu Gln His Gly Gly Pro Val 355 360 365 Leu Leu Gln Gln Arg Asn Ala Lys Gly Glu Leu Pro Leu Asp Tyr Val 370 375 380 Val Ser Pro Gln Ile Lys Glu Glu Leu Phe Ala Ile Thr Lys Ile Glu 385 390 395 400 Asp Thr Val Glu Asn Phe His Ala Gln Ala Glu Lys His Phe His Tyr 405 410 415 Gln Gln Leu Glu Phe Gly Ser Phe Leu Leu Ser Arg Met Leu Leu Asn 420 425 430 Phe Cys Ser Ile Phe Asp Leu Ser Ser Glu Phe Ile Leu Ala Ser Lys 435 440 445 Gly Leu Thr His Leu Asn Glu Leu Leu Met Ala Cys Lys Ser His Lys 450 455 460 Glu Thr Thr Ser Val His Thr Asp Trp Leu Leu Asp Leu Tyr Ala Gly 465 470 475 480 Asn Ile Lys Thr Leu Gln Lys Leu Pro His Ile Leu Lys Glu Leu Pro 485 490 495 Glu Asn Leu Lys Val Cys Pro Gly Val His Thr Glu Ala Leu Met Ile 500 505 510 Thr Leu Glu Met Met Cys Arg Ser Val Met Glu Phe Ser 515 520 525 81 2625 DNA Homo sapiens unsure (2559) unsure (2561) 81 gtctcctagc accgcatctg tccaggaagc cactgcctgc ttgttgctca tctgtagttt 60 gcaggtgggg gttgcttttc ctttgttctg ccaggcggct tcagggctcc ctgtctgtag 120 gtcagtatat ttcaccagtt ctgaaaaccc caacctactc cttgacagcc attgtttcct 180 ctgcctctgg gacatccatc aaatgtacgt tagccctcat tccatcttcc gcgtccctta 240 ttctgtcctc tgccttccca cgttattctc tgtaataatt tatctgaaat ttttttatct 300 tcctattcac tgggtaagtt cttaatcttc ctatttactg tttctctctt ctactgtatc 360 tagactggca ccaaatatgt ccactgagta cattagtgtt tcatttctaa aagagctgtt 420 tggttttctt tcaaatttgc tgtatctgtt tttagaattt tcagttcccg tcatattcag 480 agtttgttgt tcatttctgc aaacgctgag cgtagctgcc tcacggtgcg tctgcggtgc 540 catctgagtg ttcttggcag cactgccagg tctccctggg agctgcgctc tttgaccctg 600 tgacgtcctg aggcctgggc cagatgctgc ttcctccagg gaagatttgt tctccctccc 660 agtagctccc cagggacctc ccacaccact gccctgggcc ctgtgtgtat aggcccagat 720 ttttctctgt gtcctttatt accagctctg tttacagatc cctggagtca ggggaagggg 780 tgagctcaga tctgaggcca agaggccatt tcccagctgg ctgcagctga gcctggtggc 840 tgtgtctgag cgtcgtggag ccagggtcca cggcacccag gtggcggggg gcaggcgccc 900 tgaccagcca cggcctcaaa gtgactctcc tgctctgctc cagccacacc tgcatgctgt 960 ggcgggcgct ggcggtggag cctcgcctag ctgcccaggt cctggggctg ctgctggaga 1020 agatgagtag ggacgtccct ttcaaggaga gccgggcctt cctgctgggc cgcaccccag 1080 accgcgtggc cacgctgctg cctctctcgg ctacctgtgc actgtttgag gtcatgtcca 1140 cgcctgcagc ggggcccgcg gtgctcgagc tctaccccca gctgtttgtg gtgcttctgc 1200 tgcgcgtcag ctgcaccgtg ggtgtccagc tgccccggaa cctgcaggcc caggaaagga 1260 ggggtgccag tccagcccta gccaccagga acctggaacc ctgcagctct gcagtggaca 1320 ccctgcggtc catgctactc cgcagcggca gcgaggatgt ggtacagcgc atggacctgg 1380 agggaggctg ggaactgctc aggacctcgg cggggcatga ggagggggcc accaggttgg 1440 ccagggccat ggctgagcac gcagggcccc gactccccct ggtgctgaag acgctggcat 1500 gcacacacag cagtgcgtat gagaaccaga gggtgaccac caccgccttc ctggccgagc 1560 tgctgaacag caacgtggcc aacgacctca tgctcttgga ctcgctgctg gagagcctgg 1620 cggctcgcca gaaggacaca tgcgccagcg tgcggaggct ggtgctccgc ggcctggcca 1680 acctggcctc cggctgccct gacaaggtgc gaacccacgg cccccagctc ctcacagcca 1740 tgattggcgg gctggacgac ggggacaacc ctcacagccc agtggccctg gaggccatgc 1800 tgggccttgc gaggctggtg cacctggtgg agtcctggga cctgcgctca gggctgctgc 1860 acgtggccat ccgcatccgg cctttcttcg acagtgagaa gatggagttc cggacggcat 1920 ctatccgcct ctttgggcac cttaacaagg tctgccacgg agactgtgag gacgtcttcc 1980 tggaccaggt ggtgggcggg ctggcgcccc tgctgctgca cctgcaggac cctcaggcca 2040 ccgtggccag cgcctgcagg tttgccctgc gcatgtgtgg ccccaatctg gcatgtgagg 2100 agctctcagc tgctttccag aaacacctgc aggagggccg agccctgcac ttcggggagt 2160 tcctcaacac cacctgcaag cacctgatgc accatttccc agacctgctg ggccgtctcc 2220 tgaccacctg cctgttctac ttcaagagca gctgggagaa cgtccgagct gctgcacccc 2280 tgttcaccgg taagcaccac cccctgcccc acccccacgc cgcccggcag ccccgcctga 2340 tgcccccact tcacagggtt cctggtgctg cactcggagc ccaggcagca gccgcaggtg 2400 gacctggacc agctcattgc gggtgagcac ccctccacgg ggcccctccg ctgggccctg 2460 ctgaccctgt aggcacccgc agggactaag tgattttcct ggatttcagg actttttccc 2520 tgtcactggt gacctcatcg tctctagtaa ttcacggana nttcttaact gttccaaaag 2580 agcttaaaaa acaccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 2625 82 490 PRT Homo sapiens 82 Met Leu Trp Arg Ala Leu Ala Val Glu Pro Arg Leu Ala Ala Gln Val 1 5 10 15 Leu Gly Leu Leu Leu Glu Lys Met Ser Arg Asp Val Pro Phe Lys Glu 20 25 30 Ser Arg Ala Phe Leu Leu Gly Arg Thr Pro Asp Arg Val Ala Thr Leu 35 40 45 Leu Pro Leu Ser Ala Thr Cys Ala Leu Phe Glu Val Met Ser Thr Pro 50 55 60 Ala Ala Gly Pro Ala Val Leu Glu Leu Tyr Pro Gln Leu Phe Val Val 65 70 75 80 Leu Leu Leu Arg Val Ser Cys Thr Val Gly Val Gln Leu Pro Arg Asn 85 90 95 Leu Gln Ala Gln Glu Arg Arg Gly Ala Ser Pro Ala Leu Ala Thr Arg 100 105 110 Asn Leu Glu Pro Cys Ser Ser Ala Val Asp Thr Leu Arg Ser Met Leu 115 120 125 Leu Arg Ser Gly Ser Glu Asp Val Val Gln Arg Met Asp Leu Glu Gly 130 135 140 Gly Trp Glu Leu Leu Arg Thr Ser Ala Gly His Glu Glu Gly Ala Thr 145 150 155 160 Arg Leu Ala Arg Ala Met Ala Glu His Ala Gly Pro Arg Leu Pro Leu 165 170 175 Val Leu Lys Thr Leu Ala Cys Thr His Ser Ser Ala Tyr Glu Asn Gln 180 185 190 Arg Val Thr Thr Thr Ala Phe Leu Ala Glu Leu Leu Asn Ser Asn Val 195 200 205 Ala Asn Asp Leu Met Leu Leu Asp Ser Leu Leu Glu Ser Leu Ala Ala 210 215 220 Arg Gln Lys Asp Thr Cys Ala Ser Val Arg Arg Leu Val Leu Arg Gly 225 230 235 240 Leu Ala Asn Leu Ala Ser Gly Cys Pro Asp Lys Val Arg Thr His Gly 245 250 255 Pro Gln Leu Leu Thr Ala Met Ile Gly Gly Leu Asp Asp Gly Asp Asn 260 265 270 Pro His Ser Pro Val Ala Leu Glu Ala Met Leu Gly Leu Ala Arg Leu 275 280 285 Val His Leu Val Glu Ser Trp Asp Leu Arg Ser Gly Leu Leu His Val 290 295 300 Ala Ile Arg Ile Arg Pro Phe Phe Asp Ser Glu Lys Met Glu Phe Arg 305 310 315 320 Thr Ala Ser Ile Arg Leu Phe Gly His Leu Asn Lys Val Cys His Gly 325 330 335 Asp Cys Glu Asp Val Phe Leu Asp Gln Val Val Gly Gly Leu Ala Pro 340 345 350 Leu Leu Leu His Leu Gln Asp Pro Gln Ala Thr Val Ala Ser Ala Cys 355 360 365 Arg Phe Ala Leu Arg Met Cys Gly Pro Asn Leu Ala Cys Glu Glu Leu 370 375 380 Ser Ala Ala Phe Gln Lys His Leu Gln Glu Gly Arg Ala Leu His Phe 385 390 395 400 Gly Glu Phe Leu Asn Thr Thr Cys Lys His Leu Met His His Phe Pro 405 410 415 Asp Leu Leu Gly Arg Leu Leu Thr Thr Cys Leu Phe Tyr Phe Lys Ser 420 425 430 Ser Trp Glu Asn Val Arg Ala Ala Ala Pro Leu Phe Thr Gly Lys His 435 440 445 His Pro Leu Pro His Pro His Ala Ala Arg Gln Pro Arg Leu Met Pro 450 455 460 Pro Leu His Arg Val Pro Gly Ala Ala Leu Gly Ala Gln Ala Ala Ala 465 470 475 480 Ala Gly Gly Pro Gly Pro Ala His Cys Gly 485 490 83 1476 DNA Homo sapiens 83 cctctctcca aattggcctc tcaactcaca ggaagacaca gctgcccaga gcagcccagg 60 ccgtggtgag gaggcggagg catcggcggc ggaggctcag ggtggggagc aggcctacct 120 ggcaggcctg gcagggcagt accacttgga gcggtacccg gacagttacg agtccatgtc 180 cgagccgccc attgctcatc ttttgcgccc cgtgcttccc cgggccttcg ccttccccgt 240 ggacccccag gtccagtctg ccgctgatga gactgctgtg cagctgagcg agttgctgac 300 gctgcccgtg ctcatgaagc gctccatcac ggcaccgctg gccgcccaca tctccttggt 360 gaacaaggcc gctgtcgact acttcttcgt ggagctgcac ctggaggcgc actatgaggc 420 actgcggcac ttcctgctga tggaggacgg cgagttcgcc cagtccctca gcgacctgct 480 ctttgagaag cttggagctg ggcaaacgcc ccggagagct gctcaacccg ctggtgctga 540 actctgtgct gacaaggccc tgcagtgcag cctgcatggg gacaccccgc acgcctccaa 600 cctctccctc gctctcaagt acctgcccga ggtgtttgcc cccaacgccc cggatgtgct 660 gagctgcctg gagctcaggt acaaggtgga ctggcctctc aacattgtca tcaccgaggg 720 ctgcctgagc aagtacagcg gcgtcttctc cttcctgctg cagctgaagc tcatgatgtg 780 ggcgctcaag gacgtctgct tccacctcaa gcgcacagcc ctgctgagcc acatggccgg 840 ctctgtgcag ttccgtcagc tgcagctgtt caagcacgag atgcagcatt tcgtgaaggt 900 catccagggc tacatcgcca accagatcct gcacgtcacc tggtgcgagt tcagggccag 960 gttggccacc gtgggcgacc tggaggagat ccagcgtgcg cacgcagagt acctgcacaa 1020 ggccgtcttc aggggcctgc tcacggagaa ggcggcgccc gtcatgaacg tcatccacag 1080 catcttcagc ctcgtgctca agttccgcag ccagctcatc tcccaggcct gggggccccc 1140 tgggggcccg cggggtgcag agcaccccaa ctttgcactc atgcagcagt cctacaacac 1200 cttcaagtac tactcccact ttctcttcaa agtggtgacc aagctggtga accgcggcta 1260 ccagccccac ctggaggact ttctgctgcg catcaacttc aacaactact accaggacgc 1320 ctgaggctgc tctgcggggg acgtgcacaa taaaggtgtt ctcgggaaaa aaaaaaaaaa 1380 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1440 aaaaataaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1476 84 382 PRT Homo sapiens 84 Met Ser Glu Pro Pro Ile Ala His Leu Leu Arg Pro Val Leu Pro Arg 1 5 10 15 Ala Phe Ala Phe Pro Val Asp Pro Gln Val Gln Ser Ala Ala Asp Glu 20 25 30 Thr Ala Val Gln Leu Ser Glu Leu Leu Thr Leu Pro Val Leu Met Lys 35 40 45 Arg Ser Ile Thr Ala Pro Leu Ala Ala His Ile Ser Leu Val Asn Lys 50 55 60 Ala Ala Val Asp Tyr Phe Phe Val Glu Leu His Leu Glu Ala His Tyr 65 70 75 80 Glu Ala Leu Arg His Phe Leu Leu Met Glu Asp Gly Glu Phe Ala Gln 85 90 95 Ser Leu Ser Asp Leu Leu Phe Glu Lys Leu Gly Ala Gly Gln Thr Pro 100 105 110 Arg Arg Ala Ala Gln Pro Ala Gly Ala Glu Leu Cys Ala Asp Lys Ala 115 120 125 Leu Gln Cys Ser Leu His Gly Asp Thr Pro His Ala Ser Asn Leu Ser 130 135 140 Leu Ala Leu Lys Tyr Leu Pro Glu Val Phe Ala Pro Asn Ala Pro Asp 145 150 155 160 Val Leu Ser Cys Leu Glu Leu Arg Tyr Lys Val Asp Trp Pro Leu Asn 165 170 175 Ile Val Ile Thr Glu Gly Cys Leu Ser Lys Tyr Ser Gly Val Phe Ser 180 185 190 Phe Leu Leu Gln Leu Lys Leu Met Met Trp Ala Leu Lys Asp Val Cys 195 200 205 Phe His Leu Lys Arg Thr Ala Leu Leu Ser His Met Ala Gly Ser Val 210 215 220 Gln Phe Arg Gln Leu Gln Leu Phe Lys His Glu Met Gln His Phe Val 225 230 235 240 Lys Val Ile Gln Gly Tyr Ile Ala Asn Gln Ile Leu His Val Thr Trp 245 250 255 Cys Glu Phe Arg Ala Arg Leu Ala Thr Val Gly Asp Leu Glu Glu Ile 260 265 270 Gln Arg Ala His Ala Glu Tyr Leu His Lys Ala Val Phe Arg Gly Leu 275 280 285 Leu Thr Glu Lys Ala Ala Pro Val Met Asn Val Ile His Ser Ile Phe 290 295 300 Ser Leu Val Leu Lys Phe Arg Ser Gln Leu Ile Ser Gln Ala Trp Gly 305 310 315 320 Pro Pro Gly Gly Pro Arg Gly Ala Glu His Pro Asn Phe Ala Leu Met 325 330 335 Gln Gln Ser Tyr Asn Thr Phe Lys Tyr Tyr Ser His Phe Leu Phe Lys 340 345 350 Val Val Thr Lys Leu Val Asn Arg Gly Tyr Gln Pro His Leu Glu Asp 355 360 365 Phe Leu Leu Arg Ile Asn Phe Asn Asn Tyr Tyr Gln Asp Ala 370 375 380 85 1212 DNA Homo sapiens unsure (1146)..(1147) 85 taggctcttt ggccgcccag ctctccctgt gctaactgcc tgcaccttgg acagagcggg 60 tgcgcaaatc agaaggatta gttgggacct gccttggcga ccccatggca tcccccagaa 120 ccgtaactat tgtggccctc tcagtggccc tgggactctt ctttgttttc atggggacta 180 tcaagctgac ccccaggctc agcaaggatg cctacagtga gatgaaacgt gcttacaaga 240 gctatgttcg agccctccct ctgctgaaga aaatggggat caattccatt ctcctccgaa 300 aaagcattgg tgcccttgaa gtggcctgtg gcatcgtcat gacccttgtg cctgggcgtc 360 ccaaagatgt ggccaacttc ttcctactgt tgctggtgtt ggctgtgctc ttcttccacc 420 agctggtcgg tgatcctctc aaacgctacg cccatgctct ggtgtttgga atcctgctca 480 cttgccgcct gctgattgct cgcaagcccg aagaccggtc ttctgagaag aagcctttgc 540 cagggaatgc tgaggagcaa ccctccttat atgagaaggc ccctcagggc aaagtgaagg 600 tgtcatagaa aagtggaagt gcaaagagtg gaccttccag gcagttgcgt ccatgacacc 660 aggaagatgt cagtgtgtgt ttttcatttg atttatttat cttggggaaa gtgaaaaatg 720 taatctgcaa gttaatgatc tattggcttg tgtacatcta tatgctaaaa tgacttcccc 780 acattgacat ttgtgcgcca cctttaatca ctctggggca actctcacat cttgctgcat 840 gtacatgtat acggctacta ttgaagtgta attgtgagat ggactccaac aagcatgtga 900 ctgtgagatt gtgtgtggga aaatgtattt aactactctg tgtgtgtgtg tgtgtgtgtg 960 tgcgcgcgcg cgcacgcgca cacactcacg cacacacaag cagagaaggc gctgatcttg 1020 aactaatcct gcacaggcat ccttcccttt atagattgat tccagcaaag gcggaataaa 1080 acaaatttcc tatgaagaga atcctgatat gaaacaagtc atgtagtctc atggccggga 1140 atctcnncac agatactaac aacttaaact tactacttta ggaaaaaaaa aaaaaaaaaa 1200 aaaaaaaaaa aa 1212 86 167 PRT Homo sapiens 86 Met Ala Ser Pro Arg Thr Val Thr Ile Val Ala Leu Ser Val Ala Leu 1 5 10 15 Gly Leu Phe Phe Val Phe Met Gly Thr Ile Lys Leu Thr Pro Arg Leu 20 25 30 Ser Lys Asp Ala Tyr Ser Glu Met Lys Arg Ala Tyr Lys Ser Tyr Val 35 40 45 Arg Ala Leu Pro Leu Leu Lys Lys Met Gly Ile Asn Ser Ile Leu Leu 50 55 60 Arg Lys Ser Ile Gly Ala Leu Glu Val Ala Cys Gly Ile Val Met Thr 65 70 75 80 Leu Val Pro Gly Arg Pro Lys Asp Val Ala Asn Phe Phe Leu Leu Leu 85 90 95 Leu Val Leu Ala Val Leu Phe Phe His Gln Leu Val Gly Asp Pro Leu 100 105 110 Lys Arg Tyr Ala His Ala Leu Val Phe Gly Ile Leu Leu Thr Cys Arg 115 120 125 Leu Leu Ile Ala Arg Lys Pro Glu Asp Arg Ser Ser Glu Lys Lys Pro 130 135 140 Leu Pro Gly Asn Ala Glu Glu Gln Pro Ser Leu Tyr Glu Lys Ala Pro 145 150 155 160 Gln Gly Lys Val Lys Val Ser 165 87 1059 DNA Homo sapiens 87 tcaggattta aacttgtcaa ctttggatgt gattatcatc aataccgaga taaattttcc 60 aaacacctga ctctgtgtgt ttttaccaac catacaggaa gtttgtgtgt atgttacagc 120 ccgaagtgtg cctcttggga acaaatcaca tattcagtgt tttacattca taaaggacac 180 agcaagacct tcaccacttc tcttgagaat gttggctcac acatgacaaa gggcattact 240 tttctcaacc ttgactatta tgtggctgtt tacttacctg gtcatttctt ccacctactt 300 aatgttcaac atccagacct gatctgccac aatctctttc tgacaggaaa taatgaaatg 360 attgatatgc tacctcattg ccctttacag tcattgtcag ggtccctggt attggattgt 420 tgttctggaa agctctatag agcactgctc agccagtcgt ctttattaca gcttctgcag 480 aacacttgct tagactgtga gaagatggct gcgttgcact gtgcgctcta ctgcggtcaa 540 ggtgcgcagt tcctggaagc ccagattatt cagtggattt ctgagaatgt ctctgcctgc 600 cattcatttg acctcattca ggaatttata attgcttctt catactggag tgtatattca 660 gagacaagta acatggacaa actattgcca cattcctcag tgctcacttg gaatacagaa 720 attcctggaa taactcttgt gacagaagac attgcattgc ctcttatgaa ggttttgaaa 780 aatgtcctgg gcagtaaata aatttagcag gaaagtacgc ctactccatt tatccaaatg 840 ttaatgaact ttctcttagt gaacatggca ctgttgacac cacctaagtc ataaaaacgg 900 gtctcaaggg aggaaatgac tcagtgtgtt taatacaggt ttccctgcta agcctcaatc 960 tggggaagtc ctgttggttt tgggaagtga gcagcagttc tctatgtggt ttaaaaaaac 1020 aacgacaaca aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1059 88 192 PRT Homo sapiens 88 Met Thr Lys Gly Ile Thr Phe Leu Asn Leu Asp Tyr Tyr Val Ala Val 1 5 10 15 Tyr Leu Pro Gly His Phe Phe His Leu Leu Asn Val Gln His Pro Asp 20 25 30 Leu Ile Cys His Asn Leu Phe Leu Thr Gly Asn Asn Glu Met Ile Asp 35 40 45 Met Leu Pro His Cys Pro Leu Gln Ser Leu Ser Gly Ser Leu Val Leu 50 55 60 Asp Cys Cys Ser Gly Lys Leu Tyr Arg Ala Leu Leu Ser Gln Ser Ser 65 70 75 80 Leu Leu Gln Leu Leu Gln Asn Thr Cys Leu Asp Cys Glu Lys Met Ala 85 90 95 Ala Leu His Cys Ala Leu Tyr Cys Gly Gln Gly Ala Gln Phe Leu Glu 100 105 110 Ala Gln Ile Ile Gln Trp Ile Ser Glu Asn Val Ser Ala Cys His Ser 115 120 125 Phe Asp Leu Ile Gln Glu Phe Ile Ile Ala Ser Ser Tyr Trp Ser Val 130 135 140 Tyr Ser Glu Thr Ser Asn Met Asp Lys Leu Leu Pro His Ser Ser Val 145 150 155 160 Leu Thr Trp Asn Thr Glu Ile Pro Gly Ile Thr Leu Val Thr Glu Asp 165 170 175 Ile Ala Leu Pro Leu Met Lys Val Leu Lys Asn Val Leu Gly Ser Lys 180 185 190 89 2529 DNA Homo sapiens 89 attttgcctt atgaaaacta agctgaatcg actgctgcca aacatctatt aggcaaaatt 60 ggcctcttgc ccatgatttg actttccagc acagccagtt ctttttctcc tctgcagctg 120 attggctctg gagtgtggcc agaagcctct ctcctgcaat taaaggagtc gggtctctaa 180 ctgttgatct gtttttttcc cttctgagca atggagctta ccatctttat cctgagactg 240 gccatttaca tcctgacatt tcccttgtac ctgctgaact ttctgggctt gtggagctgg 300 atatgcaaaa aatggttccc ctacttcttg gtgaggttca ctgtgatata caacgaacag 360 atggcaagca agaagcggga gctcttcagt aacctgcagg agtttgcggg cccctccggg 420 aaactctccc tgctggaagt gggctgtggc acgggggcca acttcaagtt ctacccacct 480 gggtgcaggg tgacctgtat tgaccccaac cccaactttg agaagttttt gatcaagagc 540 attgcagaga accgacacct gcagtttgag cgctttgtgg tagctgccgg ggagaacatg 600 caccaggtgg ctgatggctc tgtggatgtg gtggtctgca ccctggtgct gtgctctgtg 660 aagaaccagg agcggattct ccgcgaggtg tgcagagtgc tgagaccggg aggggctttc 720 tatttcatgg agcatgtggc agctgagtgt tcgacttgga attacttctg gcaacaagtc 780 ctggatcctg cctggcacct tctgtttgat gggtgcaacc tgaccagaga gagctggaag 840 gccctggagc gggccagctt ctctaagctg aagctgcagc acatccaggc cccactgtcc 900 tgggagttgg tgcgccctca tatctatgga tatgctgtga aatagtgtga gctggcagtt 960 aagagctgaa tggctcaaag aatttaaagc ttcagtttta catttaaaat gctaagtggg 1020 agaagagaaa cctttttttt ggggggcggt ttttttggtt tgttgttggt tttttttttt 1080 tttttggcgg gaagaaagag ttttgctctt gttgcccagg ctggagtgca atggcgtgat 1140 ctccgctcac tgcaacctcc acctcgcggg tttaagcgat tcttctgcct cagcctccct 1200 agtagctggg attacaggtg cccaccacca tgcccagcta atttgtattt ttagttgaga 1260 cagggtttca ctacgttggc caggctggtc ttgaactcct gatctcaggc aatccaccca 1320 cctcagcctc ccaaagtgct gggatgacag gcgtgagcaa ccgcacccag cttaaggttt 1380 ttttgttttg ttttgagacg gagttttcgc tcttgttgcc caggctggag tgcaatgctg 1440 tgatctcagc ttaccacaac ctccacctcc cgggttcaag tgattcacct gcctcagcct 1500 cctgagtagc tggtattaca ggcatgcgtc accacgccgg ctaattttgt acttttagta 1560 gagatggtgt ttccccacgt tggtcagtct ggtctcaaat tcctgacctc aggtgatctg 1620 cctgcctcgg cctcccaaag tgctgtgatt acagacgtca gccaccatgc ctggcctgaa 1680 acctttttta ggtaaagttg aattccatcc ttaaaagttt ctgttatcct atttagccat 1740 tttctattgt ctcccaaaga attcacatca aaaaaacagc tttgaactcc cccttcaaag 1800 gaaacagtcg actttcataa ttagcatcta ccattatccc caaatcttat tttattcatt 1860 gacttgaaat tttttccaat tgcttttttt tttttttttt ttaaggttaa gagcagaggt 1920 ttactaggcc aaagaaagag aatagctctc tgttgcagag aggggtcctg gagaaatggg 1980 ttaccccagt tgtcttattt aaatggttac ccatcagatt ttaattttat cttctctttg 2040 agagcttggt aataagaagc acttaaatca ctccaaagaa gactttaaaa agggagcagt 2100 gaaaaggtct taataattta ttgattgaat taagaaatac tagctaatta agaatctgag 2160 tctaaacagc acagattttt tctttctgct tttaaattgt gttttaaaaa aagagacagg 2220 gggctgggcg tggtgctcac gcctgtaatc ctagcacttt gggaggccga ggcgggtgga 2280 tcacgaggta ggagttaaag accagcctgg ccaacatggc aaaaccctac taaagataca 2340 aaaaaaaaaa aaaattagcc aggcgtggtg gtgggtgcct gtaatcccag gtacttggag 2400 ggctgaggca ggagaatctc ttgaacccag aaggcgaagg ttgcagtgaa ccgagatcat 2460 gccattgtac tctagcctgg gtgacaagag caagactccg tctcgaaaaa aaaaaaaaaa 2520 aaaaaaaaa 2529 90 244 PRT Homo sapiens 90 Met Glu Leu Thr Ile Phe Ile Leu Arg Leu Ala Ile Tyr Ile Leu Thr 1 5 10 15 Phe Pro Leu Tyr Leu Leu Asn Phe Leu Gly Leu Trp Ser Trp Ile Cys 20 25 30 Lys Lys Trp Phe Pro Tyr Phe Leu Val Arg Phe Thr Val Ile Tyr Asn 35 40 45 Glu Gln Met Ala Ser Lys Lys Arg Glu Leu Phe Ser Asn Leu Gln Glu 50 55 60 Phe Ala Gly Pro Ser Gly Lys Leu Ser Leu Leu Glu Val Gly Cys Gly 65 70 75 80 Thr Gly Ala Asn Phe Lys Phe Tyr Pro Pro Gly Cys Arg Val Thr Cys 85 90 95 Ile Asp Pro Asn Pro Asn Phe Glu Lys Phe Leu Ile Lys Ser Ile Ala 100 105 110 Glu Asn Arg His Leu Gln Phe Glu Arg Phe Val Val Ala Ala Gly Glu 115 120 125 Asn Met His Gln Val Ala Asp Gly Ser Val Asp Val Val Val Cys Thr 130 135 140 Leu Val Leu Cys Ser Val Lys Asn Gln Glu Arg Ile Leu Arg Glu Val 145 150 155 160 Cys Arg Val Leu Arg Pro Gly Gly Ala Phe Tyr Phe Met Glu His Val 165 170 175 Ala Ala Glu Cys Ser Thr Trp Asn Tyr Phe Trp Gln Gln Val Leu Asp 180 185 190 Pro Ala Trp His Leu Leu Phe Asp Gly Cys Asn Leu Thr Arg Glu Ser 195 200 205 Trp Lys Ala Leu Glu Arg Ala Ser Phe Ser Lys Leu Lys Leu Gln His 210 215 220 Ile Gln Ala Pro Leu Ser Trp Glu Leu Val Arg Pro His Ile Tyr Gly 225 230 235 240 Tyr Ala Val Lys 91 2390 DNA Homo sapiens 91 tgccttcaaa gaaaaacctc ggtatccacc aagtcaggct caagcagctc ttcaagacag 60 tccccctgaa gagtactcct ataagaaatc aataagaaac ctgtttaaaa acattccttt 120 tgtccttctg ttgatcactt atggtatcat gactggtgcc ttttattcag tctcaacgtt 180 attaaatcaa atgatattga catattatga gggagaagaa gtcaatgctg gaaggattgg 240 gctaacgcta gtagtagctg gaatggtggg ctctattctt tgtggcttat ggctggatta 300 tactaaaaca tacaaacaga ctactctgat agtttatatt ttgtctttta ttggaatggt 360 tatctttact ttcacattgg accttagata tattatcatc gtgtttgtta ctggaggggt 420 gcttggcttc ttcatgactg gttacctccc tttgggtttt gaatttgctg ttgaaatcac 480 ttaccctgaa tctgaaggta cttcatctgg tcttcttaat gcttctgcac agatatttgg 540 aattttgttc acattggctc aaggaaagct cacatcagac tatggtccta aggcagggaa 600 catttttctc tgtgtctgga tgtttatagg catcatatta acagcattaa tcaagtctga 660 tctgcgaaga cacaacataa atataggaat tacaaatgtt gatgttaaag ctataccagc 720 tgacagtccc acagaccaag aaccaaaaac ggttatgttg tccaagcagt cagaatcagc 780 aatttgaaga gaaaggcaaa gttactgtcc tgtagtaatt ggggacaatg tgatcatcct 840 tggagagaga tgtgagcacc aaggctgggt ttgtatgtgg tgggggaata aacacactta 900 cttgaaaatt accatatgaa ctctaaatgc ataattattg ttttgcttaa ttgttaaatt 960 aagggaaatt ttcttaaaat tcttctgttt acatcatgtt aacactactg tttatctaat 1020 tagtatccgg tttttagtct catattgtat ctgaaagtaa gcttcttgac gtttactttt 1080 taaaagtcga tgtttttctt ttttgtagaa aatggaagct tagaatactt tttaaagtga 1140 taatatgggg tgttcagtcc ccataagata taatagttca tgcagtttat atattaaagt 1200 atccagtgga actaaatgta caatatattc ctaattggct gcctttttca ctgtgctgac 1260 cagctgttca agccacttca gtttgagtac aacataccaa catgacacta ctcacccaca 1320 aaggacagca ttgggatcag gctttcagat gacctctaag atttttccca tttattgtac 1380 tcttgttaca aagtactttt taacacatgc agtcaatggc tataaaaact attctgtgta 1440 cagattctac ccagactttg gtcttagaat tatgttctaa ttaaggagcc tggttacagg 1500 ttcattctgt cttgagttct tttctgtgct gcctttctat catggataaa tgctaacgct 1560 gtattttttc actccaactt gagatagagt agttttgtac ccattgcctt ttttttcttt 1620 taaactctct tttttttttt ttcctgatgt gtaactttct agtaagataa tttcatcatg 1680 tatgttactg gctatttcat gatttcatgt atcacatcgt atattttgcc ttgaagattc 1740 ctgaaataag gaaatctata ataacttcag atagcctaca tgtccccatt tagtggagac 1800 ctcttgaatg ctatttgaat tctgcagtat catttttatg accattctcc tttgaggaat 1860 actatgccca ggtacatgct ctatcagtgt gccgggagag tggattcttt tcttcactgc 1920 agagtcatca cactgttaga atagtctgct cttttacatg ctcaggtagg gaaaatagga 1980 ccaaatatat ttccacagtg cctaccactg tgtcatgttt acagtgagag tttaaatatt 2040 gttgatgtcc tgactctgtg agctcatagg gagtatcttc atagtaatga catttgatca 2100 gccataaaat ttacattatg ttcatatgca cccaaaaaag ctagtcaggt aatgaatacc 2160 cttgaagtga atagcaattt tgatttaggc agtgtgttag gccatccttg cattgctata 2220 aagaaatatt taggctgggc gtggtggctc acgcctgtaa tcccagcact ttgggaggct 2280 gaagcgtgtg gatcacctga ggtcaggagt tcaagaccag cctggccaac atggtaaaac 2340 cccatctcta ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2390 92 212 PRT Homo sapiens 92 Met Thr Gly Ala Phe Tyr Ser Val Ser Thr Leu Leu Asn Gln Met Ile 1 5 10 15 Leu Thr Tyr Tyr Glu Gly Glu Glu Val Asn Ala Gly Arg Ile Gly Leu 20 25 30 Thr Leu Val Val Ala Gly Met Val Gly Ser Ile Leu Cys Gly Leu Trp 35 40 45 Leu Asp Tyr Thr Lys Thr Tyr Lys Gln Thr Thr Leu Ile Val Tyr Ile 50 55 60 Leu Ser Phe Ile Gly Met Val Ile Phe Thr Phe Thr Leu Asp Leu Arg 65 70 75 80 Tyr Ile Ile Ile Val Phe Val Thr Gly Gly Val Leu Gly Phe Phe Met 85 90 95 Thr Gly Tyr Leu Pro Leu Gly Phe Glu Phe Ala Val Glu Ile Thr Tyr 100 105 110 Pro Glu Ser Glu Gly Thr Ser Ser Gly Leu Leu Asn Ala Ser Ala Gln 115 120 125 Ile Phe Gly Ile Leu Phe Thr Leu Ala Gln Gly Lys Leu Thr Ser Asp 130 135 140 Tyr Gly Pro Lys Ala Gly Asn Ile Phe Leu Cys Val Trp Met Phe Ile 145 150 155 160 Gly Ile Ile Leu Thr Ala Leu Ile Lys Ser Asp Leu Arg Arg His Asn 165 170 175 Ile Asn Ile Gly Ile Thr Asn Val Asp Val Lys Ala Ile Pro Ala Asp 180 185 190 Ser Pro Thr Asp Gln Glu Pro Lys Thr Val Met Leu Ser Lys Gln Ser 195 200 205 Glu Ser Ala Ile 210 93 2922 DNA Homo sapiens 93 gaggcgggtt aaggtctgag ggtcttgtgg ggccacggcg ctgatcacca ggtgtttggc 60 ttggtcggtt cttatttctc gcctggcaat ggcgacgtac acctgcataa cttgccgggt 120 ggcgttccgc gacgcggaca tgcagcgggc ccactataag acggactggc accgctacaa 180 cctgcggcgg aaggtggcca gcatggcccc agtgaccgcc gagggcttcc aggagcgagt 240 gcgggcgcag cgggccgtcg cggaggagga gagcaagggc tcggccacct actgcaccgt 300 ttgcagtaag aagtttgcct ctttcaacgc ctacgagaac cacctcaagt cccggcgtca 360 cgttgagctg gagaagaagg ccgtgcaggc agtgaatcgg aaagtggaga tgatgaatga 420 aaagaacttg gagaaaggac tgggcgtgga cagtgtggac aaggatgcca tgaacgcggc 480 catccagcag gccatcaagg cccagccgtc catgtctccc aagaaggcgc ccccagcgcc 540 tgcaaaggag gccaggaatg tcgtggccgt gggtactggt ggccgtggga cccacgaccg 600 agacccgagt gagaaaccac cccggctcca gtggtttgaa cagcaggcga agaagttggc 660 aaagcagcag gaggaggaca gcgaggagga ggaagaggac ctggatggag acgattggga 720 agatattgat tctgatgaag aattggaatg tgaggatact gaagcaatgg acgatgtggt 780 ggagcaggat gcagaggagg aagaggctga ggaaggccca ccccttggtg ccatccctat 840 cacggactgc ttattttgtt cccatcattc cagctcgctg atgaagaatg tggctcacat 900 gaccaaagac cacagtttct ttattcctga tatagaatat ctttcagata ttaagggact 960 gattaaatac ttgggagaga aagttggtgt tggcaagatt tgcttgtggt gcaacgagaa 1020 agggaagtcc ttctactcca cagaagctgt acaggcacat atgaatgaca aaagccactg 1080 taagctcttc acagatggcg atgctgcttt ggaatttgca gacttctatg attttaggag 1140 tagctatcca gatcacaagg aaggggagga ccccaataag gctgaggagt tgccctcaga 1200 aaagaacttg gaatatgatg atgaaaccat ggaattgatt ctgccttctg gtgccagagt 1260 gggtcatcgc tccttgatga gatactacaa acagcgattt ggcttgtcaa gagctgtggc 1320 agttgccaaa aatcggaagg ccgtgggccg agtacttcag cagtacagag ccctgggatg 1380 gactggcagc acaggtacat tgatctttac aactacagac cagtctgaga acttgtattt 1440 ctagaagggg tctggggaaa gttgtttcca tttatgttgt ccatgtggat tctctctagg 1500 ggaaacgtaa cgtcttggct ccagggactt ccattaccac ttgatatgtt taaggcaata 1560 agcccaaagt gctatgactt agaaatttca tattcctggc acagtgattt tatataccat 1620 taactttttc agaagataat agttacaaaa agaattattt agtaatcacc aaaggttgaa 1680 attatcctgg aggttatgca gaggaattag atagtatcct agtggttaat agcttgagct 1740 gtggagtcag acgtgactta tgtgatgtac ttagaggttc ttatatgatg aacatgagta 1800 atttaattaa tataagcttc tgtttcctca tttataaaac agagatgata gtaataagac 1860 ctacctctta gagttgagtg ggttgaatgt catgcatgtg tgatatagtg catgcccata 1920 gtcgaggtta gctatcagtc cccttttttg taattttccc atagaaaatt tagcaaaagt 1980 tagaagagta aagcatgcca ctgcaattgt tgagttttga aacctcatca gtatggtact 2040 ctttacatct attctgatgt gtcttctgga tgaagctggt tatatcctta gatcttcagg 2100 gaaagcatct atccaactga ggactgtgga gaaaataaga ggcgggctgc cttctgatgg 2160 cctgggaagc tctaggcaac taaaatccat ttgaaaaggc actgtgttta tatgtggttt 2220 ccttcactgt ggctgcttgt gagctgtgtg gccacttgaa tctggcagag acttgacttc 2280 atcttactct tatcaggaag tattgtctga ctcgatatat agcttctgcc tttctgatta 2340 atggggcttt accttttggg cttataaact cttccagatg atgaaaacta aagctactaa 2400 tcccagataa gtgtatatat acaaaagttc tggtatgcaa ttctggagtc cacagagacc 2460 cctgaggcgc atggcttaga gaccccaagt tagcaactct gttttaaata caagaaccta 2520 gttaccccaa actaaccttt tgaattctct gccaaggttg gattttctct gatcacaaat 2580 aacagaactt tgcctaattt cttaactgcc ttccaatcat aggagcggct cttatgcgag 2640 agcgagacat gcagtatgtc caaaggatga aatcaaaatg gatgctgaag acaggaatga 2700 agaacaatgc caccaagcag atgcactttc gggtccaagt gagattctga gagtctgctg 2760 ggattgagca atcatctcct gcccaagttt cctccttgcc ctgaggacca gtgaaagaca 2820 gatcatagga gagacccttt tgctgctact tcattcgttc tgacctaata ataaaagtta 2880 gaaccataaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2922 94 451 PRT Homo sapiens 94 Met Ala Thr Tyr Thr Cys Ile Thr Cys Arg Val Ala Phe Arg Asp Ala 1 5 10 15 Asp Met Gln Arg Ala His Tyr Lys Thr Asp Trp His Arg Tyr Asn Leu 20 25 30 Arg Arg Lys Val Ala Ser Met Ala Pro Val Thr Ala Glu Gly Phe Gln 35 40 45 Glu Arg Val Arg Ala Gln Arg Ala Val Ala Glu Glu Glu Ser Lys Gly 50 55 60 Ser Ala Thr Tyr Cys Thr Val Cys Ser Lys Lys Phe Ala Ser Phe Asn 65 70 75 80 Ala Tyr Glu Asn His Leu Lys Ser Arg Arg His Val Glu Leu Glu Lys 85 90 95 Lys Ala Val Gln Ala Val Asn Arg Lys Val Glu Met Met Asn Glu Lys 100 105 110 Asn Leu Glu Lys Gly Leu Gly Val Asp Ser Val Asp Lys Asp Ala Met 115 120 125 Asn Ala Ala Ile Gln Gln Ala Ile Lys Ala Gln Pro Ser Met Ser Pro 130 135 140 Lys Lys Ala Pro Pro Ala Pro Ala Lys Glu Ala Arg Asn Val Val Ala 145 150 155 160 Val Gly Thr Gly Gly Arg Gly Thr His Asp Arg Asp Pro Ser Glu Lys 165 170 175 Pro Pro Arg Leu Gln Trp Phe Glu Gln Gln Ala Lys Lys Leu Ala Lys 180 185 190 Gln Gln Glu Glu Asp Ser Glu Glu Glu Glu Glu Asp Leu Asp Gly Asp 195 200 205 Asp Trp Glu Asp Ile Asp Ser Asp Glu Glu Leu Glu Cys Glu Asp Thr 210 215 220 Glu Ala Met Asp Asp Val Val Glu Gln Asp Ala Glu Glu Glu Glu Ala 225 230 235 240 Glu Glu Gly Pro Pro Leu Gly Ala Ile Pro Ile Thr Asp Cys Leu Phe 245 250 255 Cys Ser His His Ser Ser Ser Leu Met Lys Asn Val Ala His Met Thr 260 265 270 Lys Asp His Ser Phe Phe Ile Pro Asp Ile Glu Tyr Leu Ser Asp Ile 275 280 285 Lys Gly Leu Ile Lys Tyr Leu Gly Glu Lys Val Gly Val Gly Lys Ile 290 295 300 Cys Leu Trp Cys Asn Glu Lys Gly Lys Ser Phe Tyr Ser Thr Glu Ala 305 310 315 320 Val Gln Ala His Met Asn Asp Lys Ser His Cys Lys Leu Phe Thr Asp 325 330 335 Gly Asp Ala Ala Leu Glu Phe Ala Asp Phe Tyr Asp Phe Arg Ser Ser 340 345 350 Tyr Pro Asp His Lys Glu Gly Glu Asp Pro Asn Lys Ala Glu Glu Leu 355 360 365 Pro Ser Glu Lys Asn Leu Glu Tyr Asp Asp Glu Thr Met Glu Leu Ile 370 375 380 Leu Pro Ser Gly Ala Arg Val Gly His Arg Ser Leu Met Arg Tyr Tyr 385 390 395 400 Lys Gln Arg Phe Gly Leu Ser Arg Ala Val Ala Val Ala Lys Asn Arg 405 410 415 Lys Ala Val Gly Arg Val Leu Gln Gln Tyr Arg Ala Leu Gly Trp Thr 420 425 430 Gly Ser Thr Gly Thr Leu Ile Phe Thr Thr Thr Asp Gln Ser Glu Asn 435 440 445 Leu Tyr Phe 450 95 1395 DNA Homo sapiens 95 ctgcagtctg tctgagggcg gccgaagtgg ctggctcatt taagatgagg cttctgctgc 60 ttctcctagt ggcggcgtct gcgatggtcc ggagcgaggc ctcggccaat ctgggcggcg 120 tgcccagcaa gagattaaag atgcagtacg ccacggggcc gctgctcaag ttccagattt 180 gtgtttcctg aggttatagg cgggtgtttg aggagtacat gcgggttatt agccagcggt 240 acccagacat ccgcattgaa ggagagaatt acctccctca accaatatat agacacatag 300 catctttcct gtcagtcttc aaactagtat taataggctt aataattgtt ggcaaggatc 360 cttttgcttt ctttggcatg caagctccta gcatctggca gtggggccaa gaaaataagg 420 tttatgcatg tatgatggtt ttcttcttga gcaacatgat tgagaaccag tgtatgtcaa 480 caggtgcatt tgagataact ttaaatgatg tacctgtgtg gtctaagctg gaatctggtc 540 accttccatc catgcaacaa cttgttcaaa ttcttgacaa tgaaatgaag ctcaatgtgc 600 atatggattc aatcccacac catcgatcat agcaccacct atcagcactg aaaactcttt 660 tgcattaagg gatcattgca agagcagcgt gactgacatt atgaaggcct gtactgaaga 720 cagcaagctg ttagtacaga ccagatgctt tcttggcagg ctcgttgtac ctcttggaaa 780 acctcaatgc aagatagtgt ttcagtgctg gcatattttg gaattctgca cattcatgga 840 gtgcaataat actgtatagc tttccccacc tcccacaaag tcacccagtt aatgtgtgtg 900 tgtgtttttt ttttaaggta aacattacta cttgtaactt tttttcttag tcatatttga 960 aaaagtagaa aattgagtta caatttgatt ttttttccaa agatgtctgt taaatctgtt 1020 gtgcttttat atgaatattt gttttttata gtttaaaatt gatcctttgg gaatccagtt 1080 gaagttccca aatactttat aagagtttat cagacatctc taatttggcc atgtccagtt 1140 tatacagttt acaaaatata gcagatgcaa gattatgggg gaaatcctat attcagagta 1200 ctctataaat ttttgtgtat gtgtgtatgt gcgtgtgatt accagagaac tactaaaaaa 1260 accaactgct ttttaaatcc tattgtgtag ttaaagtgtc atgccttgac caatctaatg 1320 aattgattaa ttaactgggc ctttatactt aactaaataa aaaactaagc agatatgaaa 1380 aaaaaaaaaa aaaaa 1395 96 137 PRT Homo sapiens 96 Met Arg Val Ile Ser Gln Arg Tyr Pro Asp Ile Arg Ile Glu Gly Glu 1 5 10 15 Asn Tyr Leu Pro Gln Pro Ile Tyr Arg His Ile Ala Ser Phe Leu Ser 20 25 30 Val Phe Lys Leu Val Leu Ile Gly Leu Ile Ile Val Gly Lys Asp Pro 35 40 45 Phe Ala Phe Phe Gly Met Gln Ala Pro Ser Ile Trp Gln Trp Gly Gln 50 55 60 Glu Asn Lys Val Tyr Ala Cys Met Met Val Phe Phe Leu Ser Asn Met 65 70 75 80 Ile Glu Asn Gln Cys Met Ser Thr Gly Ala Phe Glu Ile Thr Leu Asn 85 90 95 Asp Val Pro Val Trp Ser Lys Leu Glu Ser Gly His Leu Pro Ser Met 100 105 110 Gln Gln Leu Val Gln Ile Leu Asp Asn Glu Met Lys Leu Asn Val His 115 120 125 Met Asp Ser Ile Pro His His Arg Ser 130 135 97 1299 DNA Homo sapiens 97 aggatatcga attcaatcgg gaccaaaggt cagaaagaaa agttatctga gtagactgat 60 gctctcaaac aggcttccgt tctctgcagc gaagagcctc ataaattccc cttcacaagg 120 ggctttttca tccttaagag acctgagtcc tcaagaaaat ccttttctgg aagtatctgc 180 tccttcagaa cattttatag aaaacaataa tacaaaagac acaactgcaa gaaatgcctt 240 tgaagaaaat gtttttatgg aaaacactaa catgccagaa ggaaccatct ctgaaaacac 300 aaactacaat catcctcctg aggcagattc cgctgggact gcattcaact tagggccaac 360 tgttaaacaa actgagacaa aatgggaata caacaacgtg ggcactgacc tgtcccccga 420 gcccaaaagc ttcaattacc cattgctctc gtcccaggtg atcagtttga aattcagcta 480 acccagcagc tgcagtccgt tatccccaac aacaatgtga gaaggctcat tgctcatgtt 540 atccggacct tgaagatgga ctgctctggg gcccatgtgc aagtgacctg tgccaagctc 600 gtctccagga caggccacct gatgaagctt ctcagtgggc agcaggaagt aaaggcatcc 660 aagatagaat gggatacgga ccaatggaag actgagaact acattaatga gagcacagaa 720 gcccagagtg aacagaaaga gaagtcgctt gagttcacaa aagaacttcc aggatatggc 780 tataccaaaa aactcatctt ggcgttaatt gtgactggaa tactaacgat tttgattata 840 cttctctgcc tcattgagat ctgttgtcac cgaaggtcat tacaagaaga tgaagaagga 900 ttctcaaggg acagcgaagc cccaacggag gaggagagtg aagccctgcc ataggaggag 960 aacccagccc acctcaggcc tcctgcaaaa atacatagcg taaacaacgg ccatcaaaaa 1020 agcaggactg aagccagcgg cccacacatc cacagaggca gcgggcagag caagcacagg 1080 gccatcgttc ctgcccttgt ttcccagtct aattagtcac ccagacctga aaacatatgc 1140 tcagggggtg gagattttac aattaaataa cattgttttt ggtgccctcc aaaaaaaaaa 1200 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1299 98 132 PRT Homo sapiens 98 Met Asp Cys Ser Gly Ala His Val Gln Val Thr Cys Ala Lys Leu Val 1 5 10 15 Ser Arg Thr Gly His Leu Met Lys Leu Leu Ser Gly Gln Gln Glu Val 20 25 30 Lys Ala Ser Lys Ile Glu Trp Asp Thr Asp Gln Trp Lys Thr Glu Asn 35 40 45 Tyr Ile Asn Glu Ser Thr Glu Ala Gln Ser Glu Gln Lys Glu Lys Ser 50 55 60 Leu Glu Phe Thr Lys Glu Leu Pro Gly Tyr Gly Tyr Thr Lys Lys Leu 65 70 75 80 Ile Leu Ala Leu Ile Val Thr Gly Ile Leu Thr Ile Leu Ile Ile Leu 85 90 95 Leu Cys Leu Ile Glu Ile Cys Cys His Arg Arg Ser Leu Gln Glu Asp 100 105 110 Glu Glu Gly Phe Ser Arg Asp Ser Glu Ala Pro Thr Glu Glu Glu Ser 115 120 125 Glu Ala Leu Pro 130 99 915 DNA Homo sapiens 99 cgagcatccc gctgccccgg accctcccgc gggcgcgcac caggctcaac tcaggctcag 60 gactgcaggt agacatctcc actgcccagg aatcactgag cgtgcagaca gcacagcctc 120 ctctgaaggc cggccatacc agagtcctgc ctcggcatgg gcctcaccat tgaggcagct 180 ccactgtctg tgctggtctg agggtgctgc ctgtcatggg ggcagccatc tcccaggggg 240 ccctcatcgc catcgtctgc aacggtctcg tgggcttctt gctgctgctg ctctgggtca 300 tcctctgctg ggcctgccat tctcgctctg ccgacgttga ctctctctct gaatccagtc 360 ccaactccag ccctggcccc tgtcctgaga aggccccacc accccagaag cccagccatg 420 aaggcagcta cctgctgcag ccctgaaggc ccctggccta gcctggagcc caggacctaa 480 gtccacctca cctagagcct ggaattagga tcccagagtt cagccagcct ggggtccaga 540 actcaagagt ccgcctgctt ggagctggac ccagcggccc agagtctagc cagcttggct 600 ccaataggag ctcagtggcc ctaaggagat gggcctgggg tgggggctta tgagttggtg 660 ctagagccag ggccatctgg actatgctcc atcccaaggg ccaagggtca ggggccgggt 720 ccactctttc cctaggctga gcacctctag gccctctagg ttggggaagc aaactggaac 780 ccatggcaat aataggaggg tgtccaggct gggcccctcc cctggtcctc ccagtgtttg 840 ctggataata aatggaacta tggctctaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900 aaaaaaaaaa aaaaa 915 100 76 PRT Homo sapiens 100 Met Gly Ala Ala Ile Ser Gln Gly Ala Leu Ile Ala Ile Val Cys Asn 1 5 10 15 Gly Leu Val Gly Phe Leu Leu Leu Leu Leu Trp Val Ile Leu Cys Trp 20 25 30 Ala Cys His Ser Arg Ser Ala Asp Val Asp Ser Leu Ser Glu Ser Ser 35 40 45 Pro Asn Ser Ser Pro Gly Pro Cys Pro Glu Lys Ala Pro Pro Pro Gln 50 55 60 Lys Pro Ser His Glu Gly Ser Tyr Leu Leu Gln Pro 65 70 75 101 2915 DNA Homo sapiens 101 caaacttgga gggaaacttc attcatttgg tttattttta tttttatttt tatttatctt 60 tttgagacag aatctcactc tggtttgaga cagaatctca ctgtgtcccc caggttggag 120 tgcggtggtg cgatctcggc tcactgaaac ctctgcctcc tgggttcaag cgattctcct 180 gcttcaccct ccgagtagct gggattacag gtgtgcacca ccacacccgg ctaatttttg 240 tatttttggt agagacggtt tcgccacatt ggctaggttg gtgtcaaact cctggcctca 300 aagtgatccg cccaccttgg cctcccaaag tggagccccc gtgccccttg tttgtgacct 360 gtcaatataa atatgctcag tagcgggggg aggggtgggg ggtgaaaaag gaaatatgtt 420 taatattaag actttggcct tttagtgtaa actgatattc aaaaatttct tcatagaaca 480 tttgcttctt tgcttgatca tttttctaat tctgtacatc taaaatgccc agaatttgag 540 ttgctgttat agtctactaa catagaactt tggagtaata agatgggaat ttgtctctct 600 tttgccaaga caagtattcg taatctaaca cagtattgtt gccacgagta cgagtatgtg 660 atagactgtt gagaataaag aaagcaggca cagttggtca gtcctaagat aaaggagatg 720 ttttttctta tatgtttgtg cattaaagaa aaaaaaatct tgaatctgac caatgatgtt 780 ttttttcctt gtaagaaaat ttaacaaatg tttggcaagc ttctggaatc taaatttgaa 840 attatacatt tgtcattttc tttaaatatt tcttcacctt agctttgatt atgagaaatc 900 actgtcctct gctgttcttt tttttttttt ttcttttgag gcggagtctc actctgtgcc 960 aggctggagt gcagtggtgc aatctcggct cactgcaacc tccacttcct gggttcaaat 1020 gattctcctg ccgcagcctc ccgagtagct gggactacag gtgcatgcca ccacacccag 1080 ctaatttttg tatttttggt agagacaggg tttcaccacg ttgtccatgg ccaggatggt 1140 cttgatcttg accttgtgat ccgcccgcct cggcctccca aagtgctggg attgcaggca 1200 tgagccaccg tgcccggcct gtcctctgtg gttttctggg cttatgttaa aattataact 1260 caatcaccag tctttatata tttgcttttt tatatttaaa ccaaacctaa tgctaattgt 1320 gatatgttat ttattctcac ctgatttgaa tcattggatt caattaaatg agtttaatta 1380 tcattaaata attctaagag aaataatgtc tattcggatg gtgggaattt tctttctaca 1440 tgcagcccca ttctgaatga atgaaatcaa atcatgtgaa gatcagggtc ctagagtaac 1500 ctaatatttt gtacattggt tatttgactc ctcattttta tattaaatgt tatatcaagg 1560 gagggggtat aaaagaaata caaaaattgc agaggtatct ggaatgtacc tatttgttaa 1620 ttctatttgt catttctttt gtttcatctt ttgagtaata agctgcttgg aaaagtttct 1680 gttctttagc tgatttttta gctataaaaa tgtatttgaa aagctcataa atttcaggat 1740 tgaaaagata attggaagtt taaaaaaaac ctaattcatt gaagtaataa ccaaataatt 1800 ttcaatcttg attcaactgt gattcaaatc ttacaccatt tgcccacttc tatgaatttt 1860 atgtataaaa ttttttaaga gtcagagttt ttttttcttg attaattgga tgtatttcac 1920 agaatttcca actgctcacg ttagttttct tccttttaga gttgatctct ctaatgtatt 1980 agatcttcat gcctttgata gtctctctgg aataagttgt ttttagtttg cagaaaaaac 2040 ttcagcatgt gccaggaaca caacctcacc ttgatcagag tattgttaca atcacatttg 2100 aagtaccagg aaatgcaaag gaagaacatc ttaatatgtt tattcagaat ctcctgtggg 2160 aaaagaatgt gagaaacaag gacaatcact gcatggaggt cataaggctg aagggattgg 2220 tgtcaatcaa agacaaatca caacaagtga ttgtccaggg tgtccatgag ctctatgatc 2280 tggaggagac tccagtgagc tggaaggatg acactgagag aacaaatcga ttggtcctca 2340 ttggcagaaa tttagataag gatatcctta aacagctgtt tatagctact gtgacagaaa 2400 cagaaaagca gtggacaaca catttcaaag aagatcaagt ttgtacataa cactagtggc 2460 atttcttatc aaaaggattg gataataaaa ataagtttct actgggtata tttcaagcat 2520 ttatttatta ctttagttac gaattccaat atactttaaa atggtatttg ttttacagca 2580 tacataaaat gtagcaaatc agtactgtaa aacatttaac attcatacaa ttatatataa 2640 tatccttttt tttaaagaat ggtatttcac aaaaatatct tttgaaattg gctttggagt 2700 ttacatatac tgaacatgaa agtttataat aatgatgata caactttcaa cattgtcatt 2760 ttttcttaga acttcagctg attgcagaga tataatgatt acattgttat taaatttttt 2820 taacacaagt aagtgtcacc attttatgac atgaaataaa aggttatgac tgttaaaaaa 2880 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 2915 102 104 PRT Homo sapiens 102 Met Phe Ile Gln Asn Leu Leu Trp Glu Lys Asn Val Arg Asn Lys Asp 1 5 10 15 Asn His Cys Met Glu Val Ile Arg Leu Lys Gly Leu Val Ser Ile Lys 20 25 30 Asp Lys Ser Gln Gln Val Ile Val Gln Gly Val His Glu Leu Tyr Asp 35 40 45 Leu Glu Glu Thr Pro Val Ser Trp Lys Asp Asp Thr Glu Arg Thr Asn 50 55 60 Arg Leu Val Leu Ile Gly Arg Asn Leu Asp Lys Asp Ile Leu Lys Gln 65 70 75 80 Leu Phe Ile Ala Thr Val Thr Glu Thr Glu Lys Gln Trp Thr Thr His 85 90 95 Phe Lys Glu Asp Gln Val Cys Thr 100 103 1530 DNA Homo sapiens 103 atcgggagat atacctaatg ctagatgatg agttagtggg tgcagcgcac cagcacggca 60 catgtataca tatgtaacta acctgcacaa tgtgcacatg taccctaaaa cttaaagtat 120 atatatataa aaaaagacat cgctagtgag cacgctgtat acgacatcgc taatgaggac 180 accatacaag gcatcgctaa cgatgacgct gtacacaaca tcactaatga tgacaccgta 240 taagacatcg ctaattatga cgctgtatac gacatcgcta atgacaccgt acaaggcacg 300 ctaacgagga tgctgtacac gacatcacta atgaggacag tgtacaagcc atcactaatg 360 aggacactgt atatggcatc gctaacgagg acactgtaca aggcattgct aacgaggacg 420 ctgtacacaa catcgctaat gaggacacca tataagacat caccaatgag gatgctgtat 480 atgacatcgc taatggcacc cacaaggcat gctaacgagg acgctgtaga cgacattgct 540 tataaggaca ccgtacaaga catcgctaac gaggacgctg tatacgacat cgctaatgag 600 gacgttgtat atgacatcgc taatgaggat gctttacaag acatagctaa tgaggttgct 660 gtatatgaca tcgctaatga ggacattgta tatgacatcg ctaatgagga cgctctatac 720 gacatcacta atgaggacgc tgtatacaac atcgctaatg aggacgctgt atatggcatc 780 gctaatgagg atgctgtata cgaattcgct aataaggacg ctgtatatga cattgctaat 840 gaggacactg tacaagacat ctgtaaaaaa gaagatgctg ccaatgagcc attgacactg 900 gagaatgata cgtaccctga aataactcac ttcctgagga aaaagcgcca tctctagggg 960 atctcccggg gtgagtgagg aggcgggatc ggaccctggc agtctgacgg cagcacctgt 1020 gttcctctgc actgggccgt ggatgacatt acacaccttg ccactcccac ggtcctgtgt 1080 gttccggata ttttaaaata atggctataa ggttgagcac ttcaggatac gctgttttgc 1140 tgtgtgcaga tggaggcagt ggctggagtg aatgaacggc aacacttgct ggcaaccggc 1200 agaagctgag agacagggaa caggctctcc tccagagcct ccaggagcca ggcctttgga 1260 caccttgaat gtgggcttct gggagaccat gcgtttctgt tataagcagc ccagtctctg 1320 gcagttttta cggctgcccc ggaacactca tctatacctg tctgacaagg tcaagctcca 1380 aggaagggac tctctacata tctacattgt ttgcagattt tacaataatc atttattctt 1440 gcatggctga tcattgttaa ccaatacaaa taaaataata aagaaatgac ccacatttta 1500 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1530 104 215 PRT Homo sapiens 104 Met Leu Tyr Thr Thr Ser Leu Met Arg Thr Val Tyr Lys Pro Ser Leu 1 5 10 15 Met Arg Thr Leu Tyr Met Ala Ser Leu Thr Arg Thr Leu Tyr Lys Ala 20 25 30 Leu Leu Thr Arg Thr Leu Tyr Thr Thr Ser Leu Met Arg Thr Pro Tyr 35 40 45 Lys Thr Ser Pro Met Arg Met Leu Tyr Met Thr Ser Leu Met Ala Pro 50 55 60 Thr Arg His Ala Asn Glu Asp Ala Val Asp Asp Ile Ala Tyr Lys Asp 65 70 75 80 Thr Val Gln Asp Ile Ala Asn Glu Asp Ala Val Tyr Asp Ile Ala Asn 85 90 95 Glu Asp Val Val Tyr Asp Ile Ala Asn Glu Asp Ala Leu Gln Asp Ile 100 105 110 Ala Asn Glu Val Ala Val Tyr Asp Ile Ala Asn Glu Asp Ile Val Tyr 115 120 125 Asp Ile Ala Asn Glu Asp Ala Leu Tyr Asp Ile Thr Asn Glu Asp Ala 130 135 140 Val Tyr Asn Ile Ala Asn Glu Asp Ala Val Tyr Gly Ile Ala Asn Glu 145 150 155 160 Asp Ala Val Tyr Glu Phe Ala Asn Lys Asp Ala Val Tyr Asp Ile Ala 165 170 175 Asn Glu Asp Thr Val Gln Asp Ile Cys Lys Lys Glu Asp Ala Ala Asn 180 185 190 Glu Pro Leu Thr Leu Glu Asn Asp Thr Tyr Pro Glu Ile Thr His Phe 195 200 205 Leu Arg Lys Lys Arg His Leu 210 215 105 2423 DNA Homo sapiens 105 gactgcaccg tgactaacat gcagtgacag cttaattaat gttaaccctt atcattatca 60 tataagaatg tgagttacat aagagaggag tcctgtcagt tcgttctctg ctgtgtcccc 120 aagaccatga atcatggctg gcatgtagta ggcatttaat aatatatgtt caacaagtat 180 ttggcagtct tggagggcag aaaaggaggt ggggaagatt tttaaataac attttttaaa 240 aagtcacatt gtcctacaat actgattttt cttgcatatt taggaaattg agggtttttt 300 tctaaaacat gcggacatat gggaaatagg atgcaacatt tgcactaatg tttcagacac 360 agttagaggt ttccaagaga ttttgcgctg gggaggctgc ttgctacaag ctcccaaagc 420 tctgggagga catagtattc attcctccct cagcagaagc ggtgaggcaa gaagctctgg 480 ggagcaccca gcgttggact tttagcatag tgtgtcaggt cttcatagtt tgggcccagg 540 gcacagagaa gtcacagctc tccggcatcc tgtgaccttt accctctttg ccaagggaaa 600 atgtggccca ccaaagcaag aaacttgagg gcatgggtca ccccagccct ggcatctgcc 660 cagagcccga gaaggaagga acaatgatcc tccagctacc tcacggggct ggcacaggtg 720 accactgccc tggcatcacc cagctgtgtc cggcagcctg aaccccatct gtggggatgc 780 gaggaggaaa atacaaaagt ccttaggtga acactgagaa ggcagatgca gcagaaacct 840 ccaggccaga actacccagt cttggaccta tggtggagat agagcatagc tggcgatcat 900 gtgtacttac actctaaggt cacctggttg cactatggcc tcatctgtgg ctctgaaaat 960 gaagatttgg aaggagatca tcacagctaa tgtttaacaa gcccctcctg tgtgccaaat 1020 cattcacccc tcaccacaac cgaatgagct aaggattctc attatatata gtttatggag 1080 agggaagtgc agacataaag aggtgaatta tcttacccag atcacacagc tgataagtgg 1140 tggaggcaga atagaatcta aacagtgtgg ctccggagcc cacatgcatt gattcgacaa 1200 gtgtttattg agcacctgcc gcggacaagg ccttgtgtga ttaaataggg ttataattag 1260 taatataaaa atgagaaatc actaatgctt tttagactta acattttgtt tttttgtagg 1320 tttcaggcac agaactgtat atccaataat agtgaaatgg atcccactaa ttatgacaga 1380 aatgatgata catttaaatg acttggatgt tttataggta tgatctcgtg aaatcttgag 1440 agaaactgaa tgacgaatga aactattgtt cctgtttcac acagaagaaa actgaggtta 1500 aaaggggtaa agtaattttg catggcatga agtagaaatt caaagtacag gaatttgaac 1560 ttggttctgt ccttttctga agcccttgac cactatagac tcaaacatca ccttgttttt 1620 ccactcattc aacacttttt tttttaaatt atctaatagg ttggcactca tcatgagccc 1680 ctgttctcat tctgcaaatg gtgaagctct ctattgtcct gaccccacag ttcctgtccc 1740 atgaccaggg ccagctcacc aaggagctgc agcagcatgt aaagtcagtg acatgcccat 1800 gcgagtacct gaggaaggtg agtgagtgca gacagatggg gcctggtgcc cttgagcagt 1860 tcccgggtct cagctgccac acatctcata gccggtgatg ctgggggaag cttacgcagt 1920 cacagtactg gcttcttcct ctttttcttt ccatacaagt ggcttaggga tggggtagag 1980 tagttgactt atttggatga aaaccactat cttctgtcag aaactcaaaa ggaatcattg 2040 ctggcatggt aacctaaaga aaaacaacca gacaagtgcc caacgacact taaaaaggtg 2100 atttattatc ttgccaagtt tgggctgggc atggtgactc atgcctctaa tcccagcatt 2160 ttgggaggct gaggctggtg gatcaccgga ggccaggact ttgagaccag cctgaccaat 2220 atggcgaaac ctcgtccctg ctgggaatgc aaaggttagc cgggcatggt ggtgtgagcc 2280 tgtagtccca gctactcagg aggctgagac aggagaattg cttggattcg ggaggtgggg 2340 gttttggtgg gccgagatca cgccattgca ctccagactg tgcgacagag cgagactctg 2400 tcaaaaaaaa aaaaaaaaaa aaa 2423 106 66 PRT Homo sapiens 106 Met Val Lys Leu Ser Ile Val Leu Thr Pro Gln Phe Leu Ser His Asp 1 5 10 15 Gln Gly Gln Leu Thr Lys Glu Leu Gln Gln His Val Lys Ser Val Thr 20 25 30 Cys Pro Cys Glu Tyr Leu Arg Lys Val Ser Glu Cys Arg Gln Met Gly 35 40 45 Pro Gly Ala Leu Glu Gln Phe Pro Gly Leu Ser Cys His Thr Ser His 50 55 60 Ser Arg 65 107 1418 DNA Homo sapiens 107 cttttgggca gtttgatcac tgatcgagta aggaatgacc tttagattgt gcgacttttg 60 tttttgtttt tttaaatttt tttaaaccaa gaatgatttc tcctgcttcc ttctcctcac 120 catcttccca gacggagttc aaaggccact tctcaagcag cttttggcac cttcagcctc 180 agagtggaat cttttaaaga caggacccct atgtccagga aaggggaaaa ggaactttgc 240 caatgatagt gaccacagca aaagcaaata ataataatat taataataat aaagagaaat 300 aaaataataa aataaaaaac aatagcacag cccttgttga ggtcagcagg gaggaggggc 360 tgcccggagt tgggtccttg cctggatttt gacacagcaa cttcctgtag tgagcacttt 420 gtatgaatcg tggacttcct gttctcaagg cgcaggtatt tattctgtat ctgtctagag 480 cacacaccaa aatccaacct tctaataaac atgatggcgc agtcccactc cctgcctcgc 540 ctgttcccct atccccccca ggcctgggat cttcaggcgt cggtgtgggg aggggcccct 600 gccctccttg ccttgatttt gctcccctgg gtccagctgg ttccaggcct gtgaatgtca 660 gttcgtcggg cactgactcc gtctgctctt ggccttgggt tcatttgaca aatatttgcc 720 cagggcctcc caggcccagc cccatgccac ctgggccccg gcatctcttt gaggttctgc 780 caatgtgctc ttagctgagg acgaaggagg aacacctttc tatgagtctt gcaaagttta 840 cctccttcag gccacaaata tttgagtgca cactacgtgc caggcactgt gcagggctgc 900 aggcatagag acagaatgta atctagctgg gccttggacc ccatagggag aggggaccac 960 tcaggtccat acttcctttg gacttggggc tttggccttg ggaggggtgg aggtggggtg 1020 gcaagatgaa aaagacatcc tgcccccatc cacttcggca gagcttctca aagtctcaag 1080 catgtcttgg gagcttgtta aaagggctga ttccttgctg tggctcacgc ctgtaatcct 1140 gacattttgg gaggccaagg caaattgcct gagctcaggg gtttgagacc agcctgggca 1200 acatgtcgga accctgtttc tacaaaaaat acaagaatta gttgggcgtg gtggggcaca 1260 ccacacctgt ggtcccagct actctgggac tgaggtggga gaactgcttg agcctgggag 1320 gcagaggttg cagtaggtct agatcaggtc actgcactcc agcctgtgca acaaaacaac 1380 agagcaggac cctgtctcaa aaaaaaaaaa aaaaaaaa 1418 108 123 PRT Homo sapiens 108 Met Asn Arg Gly Leu Pro Val Leu Lys Ala Gln Val Phe Ile Leu Tyr 1 5 10 15 Leu Ser Arg Ala His Thr Lys Ile Gln Pro Ser Asn Lys His Asp Gly 20 25 30 Ala Val Pro Leu Pro Ala Ser Pro Val Pro Leu Ser Pro Pro Gly Leu 35 40 45 Gly Ser Ser Gly Val Gly Val Gly Arg Gly Pro Cys Pro Pro Cys Leu 50 55 60 Asp Phe Ala Pro Leu Gly Pro Ala Gly Ser Arg Pro Val Asn Val Ser 65 70 75 80 Ser Ser Gly Thr Asp Ser Val Cys Ser Trp Pro Trp Val His Leu Thr 85 90 95 Asn Ile Cys Pro Gly Pro Pro Arg Pro Ser Pro Met Pro Pro Gly Pro 100 105 110 Arg His Leu Phe Glu Val Leu Pro Met Cys Ser 115 120 109 1199 DNA Homo sapiens 109 gtcggttggc gaggtcactg caggtcagag gtcacgagat caaggatctg gaaccctgag 60 cctcgaagcg gaggatccct gtgtcccagc cgggcatggc cgacccccac cagcttttcg 120 atgacacaag ttcagcccag agccggggct atggggccca gcgggcacct ggtggcctga 180 gttatcctgc agcctctccc acgccccatg cagccttcct ggctgacccg gtgtccaaca 240 tggccatggc ctatgggagc agcctggccg cgcagggcaa ggagctggtg gataagaaca 300 tcgaccgctt catccccatc accaagctca agtattactt tgctgtggac accatgtatg 360 tgggcagaaa gctgggcctg ctgttcttcc cctacctaca ccaggactgg gaagtgcagt 420 accaacagga caccccggtg gccccccgct ttgacgtcaa tgccccggac ctctacattc 480 cagcaatggc tttcatcacc tacgttttgg tggctggtct tgcgctgggg acccaggata 540 ggttctcccc agacctcctg gggctgcaag cgagctcagc cctggcctgg ctgaccctgg 600 aggtgctggc catcctgctc agcctctatc tggtcactgt caacaccgac ctcaccacca 660 tcgacctggt ggccttcttg ggctacaaat atgtcgggat gattggcggg gtcctcatgg 720 gcctgctctt cgggaagatt ggctactacc tggtgctggg ctggtgctgc gtagccatct 780 ttgtgttcat gatccggacg ctgcggctga agatcttggc agacgcagca gctgaggggg 840 tcccggtgcg tggggcccgg aaccagctgc gcatgtacct gaccatggcg gtggcggcgg 900 cgcagcctat gctcatgtac tggctcacct tccacctggt gcggtgagcg cgcccgctga 960 acctcccgct gctgctgctg ctgctggggg ccactgtggc cgccgaactc atctcctgcc 1020 tgcaggcccc aaggtccacc ctgtctggcc acaggcaccg cctccatccc atgtcccgcc 1080 cagccccgcc cccaacccaa ggtgctgaga gatctccagc tgcacaggcc accgccccag 1140 ggcgtggccg ctgttacaga aacaataaac cctgatgggc atggaaaaaa aaaaaaaaa 1199 110 283 PRT Homo sapiens 110 Met Ala Asp Pro His Gln Leu Phe Asp Asp Thr Ser Ser Ala Gln Ser 1 5 10 15 Arg Gly Tyr Gly Ala Gln Arg Ala Pro Gly Gly Leu Ser Tyr Pro Ala 20 25 30 Ala Ser Pro Thr Pro His Ala Ala Phe Leu Ala Asp Pro Val Ser Asn 35 40 45 Met Ala Met Ala Tyr Gly Ser Ser Leu Ala Ala Gln Gly Lys Glu Leu 50 55 60 Val Asp Lys Asn Ile Asp Arg Phe Ile Pro Ile Thr Lys Leu Lys Tyr 65 70 75 80 Tyr Phe Ala Val Asp Thr Met Tyr Val Gly Arg Lys Leu Gly Leu Leu 85 90 95 Phe Phe Pro Tyr Leu His Gln Asp Trp Glu Val Gln Tyr Gln Gln Asp 100 105 110 Thr Pro Val Ala Pro Arg Phe Asp Val Asn Ala Pro Asp Leu Tyr Ile 115 120 125 Pro Ala Met Ala Phe Ile Thr Tyr Val Leu Val Ala Gly Leu Ala Leu 130 135 140 Gly Thr Gln Asp Arg Phe Ser Pro Asp Leu Leu Gly Leu Gln Ala Ser 145 150 155 160 Ser Ala Leu Ala Trp Leu Thr Leu Glu Val Leu Ala Ile Leu Leu Ser 165 170 175 Leu Tyr Leu Val Thr Val Asn Thr Asp Leu Thr Thr Ile Asp Leu Val 180 185 190 Ala Phe Leu Gly Tyr Lys Tyr Val Gly Met Ile Gly Gly Val Leu Met 195 200 205 Gly Leu Leu Phe Gly Lys Ile Gly Tyr Tyr Leu Val Leu Gly Trp Cys 210 215 220 Cys Val Ala Ile Phe Val Phe Met Ile Arg Thr Leu Arg Leu Lys Ile 225 230 235 240 Leu Ala Asp Ala Ala Ala Glu Gly Val Pro Val Arg Gly Ala Arg Asn 245 250 255 Gln Leu Arg Met Tyr Leu Thr Met Ala Val Ala Ala Ala Gln Pro Met 260 265 270 Leu Met Tyr Trp Leu Thr Phe His Leu Val Arg 275 280 111 2024 DNA Homo sapiens 111 gatatcttaa gcccgggtac gtcgacaaaa tttgctaagt taatccttct gtatttttgt 60 ctcctagagc tgcttatcat ccagactttc caacagttct gacagcttta gaaatagata 120 atgcggttgt ggcaaatagc ctaattgaca tgagaggcat agagacagtg ctactaatca 180 aaaataattc tgtagctcgt gcagtaatgc agtcccaaaa gccacccaaa aattgtagag 240 aagcttttac tgctgatggt gatcaagttt ttgcaggacg ttattattca tctgaaaata 300 caagacctaa gttcctaagc agagatgtgg attctgaaat aagtgacttg gagaatgagg 360 ttgaaaataa gacggcccag atattaaatc ttcagcaaca tttatctgcc cttgaaaaag 420 atattaaaca caatgaggaa cttcttaaaa ggtgccaact acattataaa gaactaaaga 480 tgaaaataag aaaaaatatt tctgaaattc gggaacttga gaacatagaa gaacaccagt 540 ctgtagatat tgcaactttg gaagatgaag ctcaggaaaa taaaagcaaa atgaaaatgg 600 ttgaggaaca tatggagcaa caaaaagaaa atatggagca tcttaaaagt ctgaaaatag 660 aagcagaaaa taagtatgat gcaattaaat tcaaaattaa tcaactatcg gagctagcag 720 acccacttaa ggatgaatta aaccttgctg attctgaagt ggataaccaa aaacgaggga 780 aacgacatta tgaagaaaaa caaaaagaac acttggatac cttaaataaa aagaaacgag 840 aactggatat gaaagagaaa gaactagagg agaaaatgtc acaagcaaga caaatctgcc 900 cagagcgtat agaagtagaa aaatctgcat caattytgga caaagaaatt aatcgattaa 960 ggcagaagat acaggcagaa catgctagtc atggagatcg agaggaaata atgaggcagt 1020 accaagaagc aagagagacc tatcttgatc tggatagtaa agtgaggact ttaaaaaagt 1080 ttattaaatt actgggagaa atcatggagc acagattcaa gacatatcaa caatttagaa 1140 ggtgtttgac tttacgatgc aaattatact ttgacaactt actatctcag cgggcctatt 1200 gtggaaaaat gaattttgac cacaagaatg aaactctaag tatatcagtt cagcctggag 1260 aaggaaataa agctgctttc aatgacatga gagccttgtc tggaggtgaa cgttctttct 1320 ccacagtgtg ttttattctt tccctgtggt ccatcgcaga atctcctttc agatgcctgg 1380 atgaatttga tgtctacatg gatatggtta ataggagaat tgccatggac ttgatactga 1440 agatggcaga ttcccagcgt tttagacagt ttatcttgct cacacctcaa agcatgagtt 1500 cacttccatc cagtaaactg ataagaattc tccgaatgtc tgatcctgaa agaggacaaa 1560 ctacattgcc tttcagacct gtgactcaag aagaagatga tgaccaaagg tgatttgtaa 1620 cttaacatgc cttgtcctga tgttgaagga tttgtgaagg gaaaaaaaat tctggactct 1680 ttgatataat aaaatgagac tggaggcatt ctgaaatgaa agaaactcct ttatatatcc 1740 aaccacaatc aaacatataa ataagcctgg aaaaccaact acaaccagca atttaagatt 1800 actattactt taagaaaatc aatttcatag tattggtttt aaatcttttt aagttttttt 1860 aatacgatct atttttatag gttctttttc agaagtaaaa ttttgtacat atatacatgt 1920 acatatctgt ttagtttggg ttcatttcta taacattttg taagaaaata aaagtttgag 1980 cacctgatta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2024 112 487 PRT Homo sapiens 112 Met Arg Gly Ile Glu Thr Val Leu Leu Ile Lys Asn Asn Ser Val Ala 1 5 10 15 Arg Ala Val Met Gln Ser Gln Lys Pro Pro Lys Asn Cys Arg Glu Ala 20 25 30 Phe Thr Ala Asp Gly Asp Gln Val Phe Ala Gly Arg Tyr Tyr Ser Ser 35 40 45 Glu Asn Thr Arg Pro Lys Phe Leu Ser Arg Asp Val Asp Ser Glu Ile 50 55 60 Ser Asp Leu Glu Asn Glu Val Glu Asn Lys Thr Ala Gln Ile Leu Asn 65 70 75 80 Leu Gln Gln His Leu Ser Ala Leu Glu Lys Asp Ile Lys His Asn Glu 85 90 95 Glu Leu Leu Lys Arg Cys Gln Leu His Tyr Lys Glu Leu Lys Met Lys 100 105 110 Ile Arg Lys Asn Ile Ser Glu Ile Arg Glu Leu Glu Asn Ile Glu Glu 115 120 125 His Gln Ser Val Asp Ile Ala Thr Leu Glu Asp Glu Ala Gln Glu Asn 130 135 140 Lys Ser Lys Met Lys Met Val Glu Glu His Met Glu Gln Gln Lys Glu 145 150 155 160 Asn Met Glu His Leu Lys Ser Leu Lys Ile Glu Ala Glu Asn Lys Tyr 165 170 175 Asp Ala Ile Lys Phe Lys Ile Asn Gln Leu Ser Glu Leu Ala Asp Pro 180 185 190 Leu Lys Asp Glu Leu Asn Leu Ala Asp Ser Glu Val Asp Asn Gln Lys 195 200 205 Arg Gly Lys Arg His Tyr Glu Glu Lys Gln Lys Glu His Leu Asp Thr 210 215 220 Leu Asn Lys Lys Lys Arg Glu Leu Asp Met Lys Glu Lys Glu Leu Glu 225 230 235 240 Glu Lys Met Ser Gln Ala Arg Gln Ile Cys Pro Glu Arg Ile Glu Val 245 250 255 Glu Lys Ser Ala Ser Ile Leu Asp Lys Glu Ile Asn Arg Leu Arg Gln 260 265 270 Lys Ile Gln Ala Glu His Ala Ser His Gly Asp Arg Glu Glu Ile Met 275 280 285 Arg Gln Tyr Gln Glu Ala Arg Glu Thr Tyr Leu Asp Leu Asp Ser Lys 290 295 300 Val Arg Thr Leu Lys Lys Phe Ile Lys Leu Leu Gly Glu Ile Met Glu 305 310 315 320 His Arg Phe Lys Thr Tyr Gln Gln Phe Arg Arg Cys Leu Thr Leu Arg 325 330 335 Cys Lys Leu Tyr Phe Asp Asn Leu Leu Ser Gln Arg Ala Tyr Cys Gly 340 345 350 Lys Met Asn Phe Asp His Lys Asn Glu Thr Leu Ser Ile Ser Val Gln 355 360 365 Pro Gly Glu Gly Asn Lys Ala Ala Phe Asn Asp Met Arg Ala Leu Ser 370 375 380 Gly Gly Glu Arg Ser Phe Ser Thr Val Cys Phe Ile Leu Ser Leu Trp 385 390 395 400 Ser Ile Ala Glu Ser Pro Phe Arg Cys Leu Asp Glu Phe Asp Val Tyr 405 410 415 Met Asp Met Val Asn Arg Arg Ile Ala Met Asp Leu Ile Leu Lys Met 420 425 430 Ala Asp Ser Gln Arg Phe Arg Gln Phe Ile Leu Leu Thr Pro Gln Ser 435 440 445 Met Ser Ser Leu Pro Ser Ser Lys Leu Ile Arg Ile Leu Arg Met Ser 450 455 460 Asp Pro Glu Arg Gly Gln Thr Thr Leu Pro Phe Arg Pro Val Thr Gln 465 470 475 480 Glu Glu Asp Asp Asp Gln Arg 485 113 1424 DNA Homo sapiens 113 ggagcaagaa gggcgccgcg gcgtgcggcc cgcgcagccc ccggagccat gggcaagtgc 60 agcgggcgct gcacgctggt cgccttctgc tgcctgcagc tggtggctgc gctggagcgg 120 cagatctttg acttcctggg ctaccagtgg gctcccatcc tagccaactt cctgcacatc 180 atggcagtca tcctgggcat ctttggcacc gtgcagtacc gctcccggta cctcatcctg 240 tatgcagcct ggctggtgct ctgggttggc tggaatgcat ttatcatctg cttctacttg 300 gaggttggac agctgtccca ggaccgggac ttcatcatga ccttcaacac atccctgcac 360 cgctcctggt ggatggagaa tgggccaggc tgcctggtga cacctgttct gaactcccgc 420 ctggctctgg aggaccacca tgtcatctct gtcactggct gcctgcttga ctacccctac 480 attgaagccc tcagcagcgc cctgcagatc ttcctggcac tgttcggctt cgtgttcgcc 540 tgctacgtga gcaaagtgtt cctggaggag gaggacagct ttgacttcat cggcggcttt 600 gactcctacg gataccaggc gccccagaag acgtcgcatt tacagctgca gcctctgtac 660 acgtcggggt agcctctgcc ccgcgcccac cccggcgcct cgccctgggc tgaccgcagc 720 tgccgcgagc tcgggccaag gcgcaggcgt gtccccctgg tggcccgcgc gctcactgca 780 gcctgtgccc aaccccgcgt ctgcatctgg agatgcggac ttggacgtgg acttggactt 840 ggacttggat ttgagcttgg ctcttcgcag cccggacttc ggaggagtgg ggcggggcgg 900 gggaggggca ccacggcttt tttgtttttt gtttgtttgt ttttaatctc agccttggcg 960 tgagctgggg ccttcctctc ttctccagcc tctccctttc actcttcacc cagcatcctg 1020 cccccctgtc caaaaacagc aggacatcag acccatccca tcccaccaca ctcactcacc 1080 agctctgggg aaagctactg tgaactagga gcaggattcc tgggttctaa tcgcaggtcc 1140 atcactgact gtgacgtcta gcaaagccct tgccctctct gagcctcggt ttccgcacct 1200 caagtaatta atcccttagc aaatggactc tttcagactt ctcatttaac tcaattccct 1260 gagctagact gggattaaaa ttctcatttt gcagtacatt aaaactgagg cccagagatg 1320 tgatttgctt gaggccacac agctagattt ttggtggaag tgggccttga acacagtgta 1380 ctttctgcag tttctgactg taaaaaaaaa aaaaaaaaaa aaaa 1424 114 207 PRT Homo sapiens 114 Met Gly Lys Cys Ser Gly Arg Cys Thr Leu Val Ala Phe Cys Cys Leu 1 5 10 15 Gln Leu Val Ala Ala Leu Glu Arg Gln Ile Phe Asp Phe Leu Gly Tyr 20 25 30 Gln Trp Ala Pro Ile Leu Ala Asn Phe Leu His Ile Met Ala Val Ile 35 40 45 Leu Gly Ile Phe Gly Thr Val Gln Tyr Arg Ser Arg Tyr Leu Ile Leu 50 55 60 Tyr Ala Ala Trp Leu Val Leu Trp Val Gly Trp Asn Ala Phe Ile Ile 65 70 75 80 Cys Phe Tyr Leu Glu Val Gly Gln Leu Ser Gln Asp Arg Asp Phe Ile 85 90 95 Met Thr Phe Asn Thr Ser Leu His Arg Ser Trp Trp Met Glu Asn Gly 100 105 110 Pro Gly Cys Leu Val Thr Pro Val Leu Asn Ser Arg Leu Ala Leu Glu 115 120 125 Asp His His Val Ile Ser Val Thr Gly Cys Leu Leu Asp Tyr Pro Tyr 130 135 140 Ile Glu Ala Leu Ser Ser Ala Leu Gln Ile Phe Leu Ala Leu Phe Gly 145 150 155 160 Phe Val Phe Ala Cys Tyr Val Ser Lys Val Phe Leu Glu Glu Glu Asp 165 170 175 Ser Phe Asp Phe Ile Gly Gly Phe Asp Ser Tyr Gly Tyr Gln Ala Pro 180 185 190 Gln Lys Thr Ser His Leu Gln Leu Gln Pro Leu Tyr Thr Ser Gly 195 200 205 115 843 DNA Homo sapiens 115 ccagaatctg gcacgctgac ggggacctag ggacagacga ccgcacaaca cgccacgttg 60 caggcgctgc caggccgggt gcctcaccta gctccttcat gtattcatca aagcctttgc 120 tgtccaccag gcgccatctt ccttccagct gctgaactgt ggccatgggt acgcgacggc 180 ctctcgggcg cctcctgcaa gcagggactc gcccggcgcg ccccacgcct catggacgcc 240 ggcgcctgca cgtttcggcg cctctgcagg cccaggaagc cagaggggtc acctggaggc 300 ctggccccgc ctctcctgca cccctccgtt tgacaacata tccaccgccg tttttccttt 360 caaaataccc ggaccaatcg attagccctc gccggactcg gactgcagga agtgattgat 420 cggctgtttg gtttattgat tcattaacta cggtgcctcc ctgaccttct gctcctcgcc 480 agcgcacaag ctcacaatcc acaccctcct aagagaacct gctctcgcca tccgcaggtc 540 tccctggccc aatagtgggg atatacctga gttgagctag aggattttat ccctgttggg 600 atgggggacg tctcgggaag tgtggtttct aaactaaaag actgcaggaa gtgtcaactt 660 tagtgactgt cattgccatt caagaatgtt tgattagttt atattccctt cgtagtgcac 720 ccttcaccgt ttcttctcag acaccagcgg gtttcttctc agacaccagc gggttccctc 780 tttctcttga actataataa taccctacac atgtgcgtaa aaaaaaaaaa aaaaaaaaaa 840 aaa 843 116 84 PRT Homo sapiens 116 Met Gly Thr Arg Arg Pro Leu Gly Arg Leu Leu Gln Ala Gly Thr Arg 1 5 10 15 Pro Ala Arg Pro Thr Pro His Gly Arg Arg Arg Leu His Val Ser Ala 20 25 30 Pro Leu Gln Ala Gln Glu Ala Arg Gly Val Thr Trp Arg Pro Gly Pro 35 40 45 Ala Ser Pro Ala Pro Leu Arg Leu Thr Thr Tyr Pro Pro Pro Phe Phe 50 55 60 Leu Ser Lys Tyr Pro Asp Gln Ser Ile Ser Pro Arg Arg Thr Arg Thr 65 70 75 80 Ala Gly Ser Asp 117 2232 DNA Homo sapiens unsure (225) 117 ataagctggg aggttcctgg cctgtctcct gctctctgct gagttgcttg gggcagggat 60 ggtgaaaaga gcccccagga agtctctgga agtgaggagg gtccttgggc actaactgtg 120 tgaccttggg caagtgactc cccatctctg ggcctcagga ggttgggcag gtccgggcca 180 aggctgaaat actgagtgga ggaatggtgg gggaggagga ggaancgcct aataccccca 240 accctcatct ttcccaacca cactcattcc aaattcttgc tctgggggtt ctgatccatg 300 ggcaggtcac ggtgtgggag gcggaggctc cactccaggg aggatttgga gctccacaga 360 gtacacctgg ggcaaaagga gcctgggcgt gggaggccag gactgggaag gttctgggac 420 tctctccctc accccggact cctccccaga gcctggggct cagcaactct catgaccggg 480 cactggtgaa gcgcaagttg aaggagatgg cagcagctgc cgagaaggag cgcaaggccc 540 aggagaaggc tgcgcggcag cgggagaagc tccggcgccg agagcaggag gccaagaaga 600 gctaggggag ggtgcacagg cgctggcacc cggcaggggc agccactggc tccgcgggca 660 caggcctcac cagggaggct ggacctgggc gctgcacttg ggctagcctg gtcccacgct 720 ctcagggggg acatgctctc tcttaccctg tcacttggtc tagacccaga gaccccagaa 780 agggagaccc cagggagagg gcctagtaat aaatcctatt ttgaggactt gtttggcaca 840 gagttcctgg gggaggagca gatgaagggg agagggcaga gaggccaggg ctgaggcaag 900 tctgggagcc tgggtcaggc tgtcccattg ccctcaggcc atcgtggggc tggggtggag 960 gggagctagg aggcctgcct gcctgcttgc ctgccagagg ccctgaggcc gggccccagg 1020 gctcagagct gggctgggca tttcagcagg agcccatgtg ggagcggctc ctctccactc 1080 ttccaggggg ctgtgtggtg ggagagctct gtcctgctcc cccaagaggc cagtgggcgc 1140 tgcagcaagt cgcactcagg gtagactccc agccaaactc ctcaacagga gcgcagagaa 1200 agcagcctgg ggcgagtgca gtctttgcca ggactcaaga ggggaggatg aacatcccct 1260 tctccctctc ccctcctctg tcctgtgggt cccagggggc gagatgacac cacacaggtc 1320 tgcctctcag ggcccattca agacctggtc tttgacccat tctccaagcc aggactccct 1380 tcacttcctg ctgcttcctc agagggcacc taagtcctct ttgggagctg agcaaacagg 1440 aactgatagg gacagaggac accacttcca ccagccaagg cctaggagct gctgacctgg 1500 tcagccctca ccccagccag gcagagaggc aaaacctggg ggtccccggc agctacgaga 1560 ttggaaaggt tcatcagccc tcccccatct gccccaggca ttgtcaggga atcagtgggc 1620 tcagaactgg caggcggtgc aagctctgct tccctgggcc acactgaggg ctggggccag 1680 ctccctggat gggggtggag tttaccagca gcctggggac agcatgtgtc ctttttagga 1740 aatgtccttg gaggaagtgt tcatgtgtgg cgctggtcag cagctagtcc cgcttccagg 1800 acactggtca gagttaccga tgaggcctgg gggctcccgc ttggaaaccc ctccagctcc 1860 tcccatctgc ccagacagag cggcagatgg caccaatgca tgctggctcc ctcattcctg 1920 cccaggggct gtggcttacg gccagcaccc tgtacctggg actcagccct tatcccccct 1980 ctgctatctg tgctgggaga ggggcttcgg agggaaacag atatgaggac actggcacca 2040 tctgggcctg gtggcagggc catgggaggt tggaaggcac ccacatcctt aaagccatca 2100 gtagctctag tgggtgccca cctgcatgtg aaggggaggc agttctcaat ttatttcaat 2160 aaatccttat gatgtgccag tgaccagaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220 aaaaaaaaaa aa 2232 118 133 PRT Homo sapiens UNSURE (8) 118 Met Val Gly Glu Glu Glu Glu Xaa Pro Asn Thr Pro Asn Pro His Leu 1 5 10 15 Ser Gln Pro His Ser Phe Gln Ile Leu Ala Leu Gly Val Leu Ile His 20 25 30 Gly Gln Val Thr Val Trp Glu Ala Glu Ala Pro Leu Gln Gly Gly Phe 35 40 45 Gly Ala Pro Gln Ser Thr Pro Gly Ala Lys Gly Ala Trp Ala Trp Glu 50 55 60 Ala Arg Thr Gly Lys Val Leu Gly Leu Ser Pro Ser Pro Arg Thr Pro 65 70 75 80 Pro Gln Ser Leu Gly Leu Ser Asn Ser His Asp Arg Ala Leu Val Lys 85 90 95 Arg Lys Leu Lys Glu Met Ala Ala Ala Ala Glu Lys Glu Arg Lys Ala 100 105 110 Gln Glu Lys Ala Ala Arg Gln Arg Glu Lys Leu Arg Arg Arg Glu Gln 115 120 125 Glu Ala Lys Lys Ser 130 119 4086 DNA Homo sapiens 119 aaaatagcgg gtactgtggt accggaggct ggcggtacca gtgtggattc caagtgatca 60 tcacaggtac atatagtgat cttccttgtc cgtctcgtcc cactgggtac caggcgaatc 120 ctactgggta ggtcgggtac gcggcatatg tggggtatgt ttggtatcca ggtatttgag 180 gtacgaattc agtgtacgtt gccaggtgtg cttggtcttc taaatttgga atacataggc 240 gaggatactg attctggata gtaaaattgt ttggagctcg gcaatcataa gaaacttgca 300 gtttccaccc cctcttcacc tggagaactt gggctccatt aggtgcaatc gttggagtaa 360 ttagcccatc ttttacattt cttgccacaa aatctcgaag agctgccatt tcaggttcgg 420 acagtgaata cacatgtcca ctgggaatac tgtgtgctcc aggtatcatt tctatgtgag 480 ggtcaaccag gcggtgatct gggtagacgt gctcatctac tggagtgtac acattctgga 540 catagtaata cctcactggt tggtaaactc tgtatccatc tactggataa tagagtggcg 600 gttgtggtgc tggtggtggg agcgatggtg gtattggaga atacatccgg cagtggtagc 660 ggcagtattc agaatcaaag acgatagatc gagtgctcca tgtgatattg ggatcatgtg 720 tgctcagcca gcgaacccct aggacgacag ggaagaatgg agactgagtc acatcaaatg 780 acagcacctc tcggtgatct cccaggtcaa ctatcaggtc gtgagtttcg tggacaactg 840 ggcccgatgc tatggggcgc ccatcaattg cttccacaag tattggccag tccttgattc 900 ttagaggaat tccattttga gcaacatatt cgtgatcaat gaagttgcca gaagcaccag 960 aatcgatcat ggctcggacg aacagggtgt gtctgcccgg aagatgaatc tggagcatca 1020 cttgcaagtg tggagatgag gcatcatctt gtggggacct tattatttct ggcccggtcg 1080 ctgaaggtcc ctctacagcg gggccgggga gtttcccgcc ggcgaagact ttgaggcctt 1140 ggcaggacaa ttgtcagcgt agtgacctcc tgttccacag tagaggcaca ggttcagctt 1200 tctgcgtctt tctttttctt cctgcgtcag gcgcatgcgg gcacctccca ccggctcggt 1260 tggatctacc tggtggtggc ttgcaatgtg aggcaacacc agcgcccggg gtggcgagcg 1320 tggcttgcga gctgcagcag ccctggccag ccttctctca atgtgaatgc actgcccaat 1380 cagagcagac agcgacttgg cgacctcgag caacattaac tgaggaaaaa attgaaaaag 1440 gggcgccctt gcttgggggc ttcctattgt ggaactgtta tggaaaggag ccccatccat 1500 tgcttcctcc ttgaatggca aatgccttta tgatccctat aacttgtccc attatgttta 1560 gacccttggt ggtcagaagg gttctattta gggcagtgtc ccctgcccct ccttgtcctc 1620 caaaaatttt gggaggcact gacgtggatg tcatggggtc agcacaggca tcaacatccc 1680 cagagggatg gaaccaagca gcctattgcc caggcattca ctaacaggca gcccatcctc 1740 agcctcatag ctggccgggg agaagaaagg ctattttggg tcccagatct tttttttttt 1800 ttttgagaca gagtctcgct ctgtcaccca ggctgaagtg caatggtgcg gtctcagctc 1860 actacaacct ccgcctcccg agttcaagag attctcctgc ctcagcctcc tgagtagctg 1920 ggactacagg tgcgtaccac caagcctggc taatttttgt gcttttagta gggacgtggt 1980 ttcaccatgt tgcccaggtt ggtctcaaac tcctgggctc atgcagtccg cctacctcag 2040 cctcccaaag tgctgggatt acaggcatga gccactgcac ccggtctctg tttacaaatt 2100 tatcaccagc ttcatcccct aaggttataa gctccatgag ggtgggaagt ctgtattgtt 2160 cacctctgta tcctaagcat ctagaacata gcccggcaca cagtaggtgc tgaagaattg 2220 aatctgttaa tgtagaaagg atgtttcatc tagctgaagt gtcttgtaca gaataaactc 2280 tcaataaatg aactgtggac acatggaagg gtgagctaga gctctgctca ggggttgagt 2340 gctcctcttg tgcccttgtg gttgtctggt tacctgaact aattggagtg cgatgcagac 2400 atagtcatgg agtgagacag cagaactttg ctgtcttgtt tgtgagccca catcaggggt 2460 tctagactgg ctggttgaca tggtggcccc agcctgtctc ttcagcagct cggcttataa 2520 aaaataacca cctcctattt tggcctcttt ggccgaattc ggccaaagag gcctagcctc 2580 cgattactaa accccttgcc ccacaaacgt ccacattgac gagcctcttt ttagtaactg 2640 cttccccgta attccttcag aggttgctgt acccttcgct gatgtgctgc cctcctgtaa 2700 aacctccaga tgccttccca cgtaatgccc ctttcagatg ctttaagctg agagcttaaa 2760 ccacaggtac catggctgac gcctgccagg tttctgctgc agataatcta tgatgggagg 2820 ggcatatttt ttacttcatt acttatgtaa actcttgttc cagaaagctt taatgtgtgt 2880 gggagtgttc tgggtctatt aggtctgtgc gcatgggtgt gggcatttgc ctgtgtccac 2940 cgggtgggtc tcattatgaa atgtatgttt atgtagggct ttaatggctg aaaatggcaa 3000 agagatgaat agaccacttg gccccatgtg taattgccag gccccttctg tgctcaaatg 3060 aggtgtccga gtgaaggtca gcccttccct tctgtatttg gggcctattt atgccaccag 3120 taattttata agaaatctga atagttctcc cctttgagtg catttaactc tttagtatct 3180 tctctcttac ctatttgagc ccctctagct acagtctggc ttaaatgaaa ggggaattat 3240 atgcttaaga aaaagtagga cacggttgag gcagtttgct gactgaatac gcgaagaagg 3300 acctgatggg ctcatatgca ccactgccat cacagtcccc atcgtgatgc aagcttatat 3360 gattcttgag gtaactctac cagatacttc cagatttaga aatgtgtcaa aggaaaaatt 3420 ggtgatactc ttctttccct gccagaaaca gcccagatct cctcttaagc ggaaaagaga 3480 ttgaccttct agcagaggca aaggtaaact cctgtaagtt acttctgtta ccaaagggag 3540 gggggcggct tttgtgaatg tatgaggagc ttttgccaga gagatattcg gaggaggggt 3600 gtgcccatat gcacacatat attttcccgc ataaccgtat ccaatgctag catttagagg 3660 aaggcattta gccaccaaaa gtccatccat ctatgctgct tccacagaga aaacattttc 3720 tctttcctcc tcttgaactt acataatatc ctcctcccat tccaacctta gaatggagtc 3780 ttctgggggc agctgcaaag cgttctccct aggacagatg gagcctccct ttcctcatct 3840 actctgtggg tggtttcagg gcccacgagt caacatgagg agttgtgctg gtggtatgtg 3900 tgttggaggc tgggctggct gattcacagt gacgaggatg tcaataataa caagaatgag 3960 aatgatggta cctaataaag actttttttc ccaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4020 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4080 aaaaaa 4086 120 102 PRT Homo sapiens 120 Met Ser Thr Gly Asn Thr Val Cys Ser Arg Tyr His Phe Tyr Val Arg 1 5 10 15 Val Asn Gln Ala Val Ile Trp Val Asp Val Leu Ile Tyr Trp Ser Val 20 25 30 His Ile Leu Asp Ile Val Ile Pro His Trp Leu Val Asn Ser Val Ser 35 40 45 Ile Tyr Trp Ile Ile Glu Trp Arg Leu Trp Cys Trp Trp Trp Glu Arg 50 55 60 Trp Trp Tyr Trp Arg Ile His Pro Ala Val Val Ala Ala Val Phe Arg 65 70 75 80 Ile Lys Asp Asp Arg Ser Ser Ala Pro Cys Asp Ile Gly Ile Met Cys 85 90 95 Ala Gln Pro Ala Asn Pro 100 121 1293 DNA Homo sapiens 121 ggtccagaag aaatgtggct tcagctctgc tgctactgtg cctcccttct cctgccccac 60 tcagcccaca aaataggctg gacactcaaa aaacgttgcg tttatctacc ttttagagag 120 ggtgaatagc agagaactgg aggtgggaat ggtaaggaac tcccagcagg gtagtggagg 180 gaatgggctg acgcatctaa ggctgatgcc aggtctgctc cctatctggg tggcctcagc 240 aaatgacgtc cagcacatcc aggggcaggc tcaagggaga acagccccca aagctaagat 300 cctgccaagc taaatacagt agttctaatg aaatgtgaga ggctataatc ccatttggga 360 aattcctaaa aagtcatgag gcaggggatt ggtttatgtt attatcatga cctgagagtc 420 atggctcaga gccaaatgtt caggattgaa ttcaacagca tttaaatgtc tttagagcag 480 gatggaaata tgttagcaat gcctgcagag tgccaagtaa acgcaaaagc caatgagatc 540 ataaaggaag ttgttagcta acctagtgga gtcgccaact tccttctact ctaataatta 600 aaataaaaat aatacttggg aggtaactgg aataaaggtt ctaaaatcaa aaccctctga 660 agggtgaaaa ctgggagcct cctgttccca tagtaaccac agcactcagg gcactgtctc 720 ccagcgctgg agtactgtct tatgaccaga gatcctaagc aacctctgct catctgagtt 780 gtccaccata ttgtgggcat gagtccttga caatagtaaa tagcacctct gttcccttat 840 tgggtaaatg attttccaac tctgggaatg tgtagaattc attatggaaa taatgcaata 900 attcaaatcc ataatattga tactttcatg ttaagtttag gactaatctt gtgtatgctc 960 cttaagtgat ttgaatcttt aaaaagctta tgattccaat ttgaaatgtg aaattgattt 1020 tacgtttgtg atttgaagtt gaaaggtata agaatattta acttagctca tgaaaagtat 1080 tagactagat ttactataag tttaatgtat tagatttaca agagatgctt aaatatatga 1140 gaatgttttg tcttaattgg ttataatctt gtcatatcaa tgatttgaag tgctaaaata 1200 gaaaattaaa tatgataaat tacacaagaa gtttagaatg tttaaaagat tttaataaac 1260 aaagcctata actaagaaaa aaaaaaaaaa aaa 1293 122 54 PRT Homo sapiens 122 Met Val Arg Asn Ser Gln Gln Gly Ser Gly Gly Asn Gly Leu Thr His 1 5 10 15 Leu Arg Leu Met Pro Gly Leu Leu Pro Ile Trp Val Ala Ser Ala Asn 20 25 30 Asp Val Gln His Ile Gln Gly Gln Ala Gln Gly Arg Thr Ala Pro Lys 35 40 45 Ala Lys Ile Leu Pro Ser 50 123 2509 DNA Homo sapiens 123 gagctgcatc gcgggaggcg catggcgggg atggcgctgg cgcgggcctg gaagcagatg 60 tcctggttct actaccagta cctgctggtc acggcgctct acatgctgga gccctgggag 120 cggacggtgt tcagctggtt tccattgtgg ggatggcact atacacagga tacgtcttca 180 tgccccagca catcatggcg atattgcact actttgaaat cgtacaatga ccaagatgcg 240 accaggatca gaggttcctt ggggaagacc caccctacga agttggaatg agaccatcag 300 atgtgataag aaactcttct agatgtcaac ataaccaacc ttataaagac taaaattcat 360 gagtagaaca ggaaaatcat cctgactcat gtgttgtgtt ctttattttt aattttcaaa 420 gaggctcttg tatagcagtt tttgtctatt ttaacattgt agtcatttgt actttgatat 480 cagtattttc ttaacctttg tgactgtttc aatattaccc ccgtgaaagc ttttcttaat 540 gtaactttga gtacatttta attgccttct atttttaaaa ctcaaaatca ttagttgggc 600 tttactgttc ttgctattgt atggcatata catctgcctg gatatatttc tactcttgac 660 caaagttttg taaagaacaa tataagattt cgggtagggg tatggggagg gaagatattt 720 tattgagaac tacttaacaa aagatttatc tgtaagcttg aactcaggag tacagtttta 780 gctatctaga ctctaacagc ttttgcttta aaattattaa agtgtttctt aatgaaaaag 840 aaaagatctt gctaaagtta aaataaggaa catttcacct tttaaatatt taattcttat 900 gtggacttat ttccagaaaa ctttggtgat aattcttgag acaaaaggtg gttaagtagc 960 attattatgt aatgcttata taccatagag tttttaatag aagagaaatc catttcctcc 1020 gagggtcact attaacaatg tacttcctta aatttagttt aatgattgta atgggtgctg 1080 catttgcaca ttgcattaag ttatgatgag acgaattgtt gttaaaaatt atagcaaaaa 1140 gaaatgtaaa cttggttaaa atcctttcac tctttgtatt gtttttttta aggtttttat 1200 tccttaaatg taaaatgact acctaatttt ttgatgtaaa tacattaaat tcaaagagaa 1260 aaaaaatcag ctgatgtagc agtatatctt ttccttgatg gttaaatatt gatctagtat 1320 ttatattgct gaattatttt ctgtggagga ccagataagc agtaagtatg tcttatccta 1380 tatgttttgc aacataaaaa tattgctaat tgaaaagaat taggcaatta tgtgtgttgc 1440 tgggttgttt ttttgttttt tttttttgag acggagtctt gccctgtcgc ccaggatgga 1500 gtgcaacagc atgatctcgg ttcactgcaa cctccatctc ctgggatcaa gtgattctcc 1560 tgcctcagcc tcctgaatag ctgggattac aggcacctgc caccatgcct ggctaatttt 1620 ttgtatctgt agtagagacg gggtttcact gtgttggcca ggatggtctc aaactcctga 1680 cctcctgatc cacctgcctc ggcctcccaa agtgctgggt ttacaggcgt gagccaccgc 1740 gcccggccaa aattgaggta ttttttgccc tacgttttaa ggactagact tttgaagtat 1800 tttatagtct agaggtctca agtaatatat atgtgtttaa tatttttaga gccaattgat 1860 accacaatta gataggagta gtgagaataa tatggaatta cttggtttga agtagttaaa 1920 aattggatat ggttatatct gagctgtagt catattatct caagaaaaat aatacgagga 1980 tttaacataa gatttgttct attaatgccc aaatttggct ttcctctact atcccccata 2040 gagaaccact aacaagtgga tgtctaatat tcctctggtg agttgaaggc aggagaagtt 2100 gagaatcatt agtttcaatg agtatccagg tgacctatcc tggccctcta ctcagaaacc 2160 ggcaatttgt cttcactctg agattcatta aattgctgtt gtataactga tggttattat 2220 gaacactgac ctgtgagaca tatggaagat aaagtttggt cttacaggaa atcttgagga 2280 gagtcaaaag agaaatggga gatgtctctt gagaggtgat cagagaagtt tatgctcact 2340 gtctgatgca aatgtctggt ctatttgtta gtaaataaca gggaaatcat tttcactttt 2400 tgttaaaaat aaggtattta caagcatacc ttgtagttat tgtgggttca gtttcagacc 2460 actgcaataa agtgaatatc tcaataaaaa aaaaaaaaaa aaaaaaaaa 2509 124 89 PRT Homo sapiens 124 Met Ala Gly Met Ala Leu Ala Arg Ala Trp Lys Gln Met Ser Trp Phe 1 5 10 15 Tyr Tyr Gln Tyr Leu Leu Val Thr Ala Leu Tyr Met Leu Glu Pro Trp 20 25 30 Glu Arg Thr Val Phe Ser Trp Phe Pro Leu Trp Gly Trp His Tyr Thr 35 40 45 Gln Asp Thr Ser Ser Cys Pro Ser Thr Ser Trp Arg Tyr Cys Thr Thr 50 55 60 Leu Lys Ser Tyr Asn Asp Gln Asp Ala Thr Arg Ile Arg Gly Ser Leu 65 70 75 80 Gly Lys Thr His Pro Thr Lys Leu Glu 85 125 2672 DNA Homo sapiens 125 ggaggagaga agaggaggtg gagaaggctt gggctcgcgc cgctgaagtc ggcttacccg 60 ctggccgcct cctgacaagc gggagggatc cgcggtggac ccagggaagc ggaggagcct 120 ggcggccacc ccctcttcct cacttccctg tactctcatc gctctcggcc tccgacacga 180 aaaggaagca aatgagctga tggaagatct gtttgaaact ttccaagatg agatgggatt 240 ctccaacatg gaagatgatg gcccagaaga ggaggagcgt gtggctgagc ctcaagctaa 300 ctttaacacc cctcaagctc tacggtttga ggaactactg gccaacctac taaatgaaca 360 acatcagata gcgaaggaac tatttgaaca gctgaagatg aagaaacctt cagccaaaca 420 gcagaaggag gtagagaagg ttaaacccca gtgtaaggaa gttcatcaga ccctgattct 480 ggacccagca caaaggaaga gactccagca gcagatgcag cagcatgttc agctcttgac 540 acaaatccac cttcttgcca cctgcaaccc caatctcaat ccggaggcca gtagcaccag 600 gatatgtctt aaagagctgg gaacctttgc tcaaagctcc atcgcccttc accatcagta 660 caaccccaag tttcagaccc tgttccaacc ctgtaacttg atgggagcta tgcagctgat 720 tgaagacttc agcacacatg tcagcattga ctgcagccct cataaaactg tcaagaagac 780 tgccaatgaa tttccctgtt tgccaaagca agtggcttgg atcctggcca caagcaaggt 840 tttcatgtat ccagagttac ttccagtgtg ttccctgaag gcaaagaatc cccaggataa 900 gatcctcttc accaaggctg aggacaattt gttagcttta ggactgaagc attttgaagg 960 gactgagttt cttaaccctc taatcagcaa gtaccttcta acctgcaaga ctgcccgcca 1020 actgacagtg agaatcaaga acctcaacat gaacagagct cctgacaaca tcattaaatt 1080 ttataagaag accaaacagc tgccagtcct aggaaaatgc tgtgaagaga tccagccaca 1140 tcagtggaag ccacctatag agagagaaga acaccggctc ccattctggt taaaggccag 1200 tctgccatcc atccaggaag aactgcggca catggctgat ggtgctagag aggtaggaaa 1260 tatgactgga accactgaga tcaactcaga tcaaggccta gaaaaagaca actcagagtt 1320 ggggagtgaa actcggtacc cactgctatt gcctaagggt gtagtcctga aactgaagcc 1380 agttgccgac cgtttcccca agaaggcttg gagacagaag cgttcatcag tcctgaaacc 1440 cctccttatc caacccagcc cctctctcca gcccagcttc aaccctggga aaacaccagc 1500 ccaatcaact cattcagaag cccctccgag caaaatggtg ctccggattc ctcacccaat 1560 acagccagcc actgttttac agacagttcc aggtgtccct ccactggggg tcagtggagg 1620 tgagagtttt gagtctcctg cagcactgcc tgctatgccc cctgaggcca ggacaagctt 1680 ccctctgtct gagtcccaga ctttgctctc ttctgcccct gtgcccaagg taatgatgcc 1740 ctcccctgcc tcttccatgt ttcgaaagcc atatgtgaga cggagaccct caaaaagaag 1800 gggagccagg gcctttcgct gtatcaaacc tgcccctgtt atccaccctg catctgttat 1860 cttcactgtt cctgctacca ctgtgaagat tgtgagcctt ggcggtggct gtaacatgat 1920 ccagcctgtc aatgcggctg tggcccagag tccccagact attcccatcg ccaccctctt 1980 ggttaaccct acttccttcc cctgtccatt gaaccagccc cttgtggcct cctctgtctc 2040 acccttaatt gtttctggca attctgtgaa tcttcctata ccatccaccc ctgaagataa 2100 ggcccacatg aatgtggaca ttgcttgtgc tgtggctgat ggggaaaatg cctttcaggg 2160 cctagaaccc aaattagagc cccaggaact atctcctctc tctgctactg ttttccccaa 2220 agtggaacat agcccagggc ctccaccagt cgataaacag tgccaagaag gattgtcaga 2280 gaacagtgcc tatcgctgga ccgttgtgaa aacagaggag ggaaggcaag ctctggagcc 2340 gctccctcag ggcatccagg agtctctaaa caactcttcc cctggggatt tagaggaagt 2400 tgtcaagatg gaacctgaag atgctacaga ggaaatcagt ggatttcttt gagctaggag 2460 aataagagtc tggagactgg gagccttcac ttcggcctcc gattggtggc gcatagggtg 2520 taaccaatag gaaaccccta aagggtactt aaaccccaga ttttgcaact ggggctcttg 2580 agcagcttgc tttagcctgc tcccactctg tggaatatac ttttgcttca ataaatctgt 2640 gcttttattg cttcaaaaaa aaaaaaaaaa aa 2672 126 750 PRT Homo sapiens 126 Met Glu Asp Leu Phe Glu Thr Phe Gln Asp Glu Met Gly Phe Ser Asn 1 5 10 15 Met Glu Asp Asp Gly Pro Glu Glu Glu Glu Arg Val Ala Glu Pro Gln 20 25 30 Ala Asn Phe Asn Thr Pro Gln Ala Leu Arg Phe Glu Glu Leu Leu Ala 35 40 45 Asn Leu Leu Asn Glu Gln His Gln Ile Ala Lys Glu Leu Phe Glu Gln 50 55 60 Leu Lys Met Lys Lys Pro Ser Ala Lys Gln Gln Lys Glu Val Glu Lys 65 70 75 80 Val Lys Pro Gln Cys Lys Glu Val His Gln Thr Leu Ile Leu Asp Pro 85 90 95 Ala Gln Arg Lys Arg Leu Gln Gln Gln Met Gln Gln His Val Gln Leu 100 105 110 Leu Thr Gln Ile His Leu Leu Ala Thr Cys Asn Pro Asn Leu Asn Pro 115 120 125 Glu Ala Ser Ser Thr Arg Ile Cys Leu Lys Glu Leu Gly Thr Phe Ala 130 135 140 Gln Ser Ser Ile Ala Leu His His Gln Tyr Asn Pro Lys Phe Gln Thr 145 150 155 160 Leu Phe Gln Pro Cys Asn Leu Met Gly Ala Met Gln Leu Ile Glu Asp 165 170 175 Phe Ser Thr His Val Ser Ile Asp Cys Ser Pro His Lys Thr Val Lys 180 185 190 Lys Thr Ala Asn Glu Phe Pro Cys Leu Pro Lys Gln Val Ala Trp Ile 195 200 205 Leu Ala Thr Ser Lys Val Phe Met Tyr Pro Glu Leu Leu Pro Val Cys 210 215 220 Ser Leu Lys Ala Lys Asn Pro Gln Asp Lys Ile Leu Phe Thr Lys Ala 225 230 235 240 Glu Asp Asn Leu Leu Ala Leu Gly Leu Lys His Phe Glu Gly Thr Glu 245 250 255 Phe Leu Asn Pro Leu Ile Ser Lys Tyr Leu Leu Thr Cys Lys Thr Ala 260 265 270 Arg Gln Leu Thr Val Arg Ile Lys Asn Leu Asn Met Asn Arg Ala Pro 275 280 285 Asp Asn Ile Ile Lys Phe Tyr Lys Lys Thr Lys Gln Leu Pro Val Leu 290 295 300 Gly Lys Cys Cys Glu Glu Ile Gln Pro His Gln Trp Lys Pro Pro Ile 305 310 315 320 Glu Arg Glu Glu His Arg Leu Pro Phe Trp Leu Lys Ala Ser Leu Pro 325 330 335 Ser Ile Gln Glu Glu Leu Arg His Met Ala Asp Gly Ala Arg Glu Val 340 345 350 Gly Asn Met Thr Gly Thr Thr Glu Ile Asn Ser Asp Gln Gly Leu Glu 355 360 365 Lys Asp Asn Ser Glu Leu Gly Ser Glu Thr Arg Tyr Pro Leu Leu Leu 370 375 380 Pro Lys Gly Val Val Leu Lys Leu Lys Pro Val Ala Asp Arg Phe Pro 385 390 395 400 Lys Lys Ala Trp Arg Gln Lys Arg Ser Ser Val Leu Lys Pro Leu Leu 405 410 415 Ile Gln Pro Ser Pro Ser Leu Gln Pro Ser Phe Asn Pro Gly Lys Thr 420 425 430 Pro Ala Gln Ser Thr His Ser Glu Ala Pro Pro Ser Lys Met Val Leu 435 440 445 Arg Ile Pro His Pro Ile Gln Pro Ala Thr Val Leu Gln Thr Val Pro 450 455 460 Gly Val Pro Pro Leu Gly Val Ser Gly Gly Glu Ser Phe Glu Ser Pro 465 470 475 480 Ala Ala Leu Pro Ala Met Pro Pro Glu Ala Arg Thr Ser Phe Pro Leu 485 490 495 Ser Glu Ser Gln Thr Leu Leu Ser Ser Ala Pro Val Pro Lys Val Met 500 505 510 Met Pro Ser Pro Ala Ser Ser Met Phe Arg Lys Pro Tyr Val Arg Arg 515 520 525 Arg Pro Ser Lys Arg Arg Gly Ala Arg Ala Phe Arg Cys Ile Lys Pro 530 535 540 Ala Pro Val Ile His Pro Ala Ser Val Ile Phe Thr Val Pro Ala Thr 545 550 555 560 Thr Val Lys Ile Val Ser Leu Gly Gly Gly Cys Asn Met Ile Gln Pro 565 570 575 Val Asn Ala Ala Val Ala Gln Ser Pro Gln Thr Ile Pro Ile Ala Thr 580 585 590 Leu Leu Val Asn Pro Thr Ser Phe Pro Cys Pro Leu Asn Gln Pro Leu 595 600 605 Val Ala Ser Ser Val Ser Pro Leu Ile Val Ser Gly Asn Ser Val Asn 610 615 620 Leu Pro Ile Pro Ser Thr Pro Glu Asp Lys Ala His Met Asn Val Asp 625 630 635 640 Ile Ala Cys Ala Val Ala Asp Gly Glu Asn Ala Phe Gln Gly Leu Glu 645 650 655 Pro Lys Leu Glu Pro Gln Glu Leu Ser Pro Leu Ser Ala Thr Val Phe 660 665 670 Pro Lys Val Glu His Ser Pro Gly Pro Pro Pro Val Asp Lys Gln Cys 675 680 685 Gln Glu Gly Leu Ser Glu Asn Ser Ala Tyr Arg Trp Thr Val Val Lys 690 695 700 Thr Glu Glu Gly Arg Gln Ala Leu Glu Pro Leu Pro Gln Gly Ile Gln 705 710 715 720 Glu Ser Leu Asn Asn Ser Ser Pro Gly Asp Leu Glu Glu Val Val Lys 725 730 735 Met Glu Pro Glu Asp Ala Thr Glu Glu Ile Ser Gly Phe Leu 740 745 750 127 2673 DNA Homo sapiens 127 aggtctagaa ttcaatcggg acgcctcgcg ctgattctca cgggcccggc tgccggcccc 60 cgctctgccc tgcataataa aatggctaat caggtgaatg gtaatgcggt acagttaaaa 120 gaagaggaag aaccaatgga tacttccagt gtaactcaca cagaacacta caagacactg 180 atagaggcag gcctcccaca gaaggtggca gaaagacttg atgaaatatt tcagacagga 240 ttggtagctt atgtcgatct tgatgaaaga gcaattgatg ctctcaggga atttaatgaa 300 gaaggagctc tgtctgtact acagcagttc aaggaaagtg acttatcaca tgttcagaac 360 aaaagtgcat ttttatgtgg agttatgaag acctacaggc agagagagaa acaggggagc 420 aaggtgcaag agtccacaaa gggacctgat gaagcgaaga tcaaggcctt gcttgagaga 480 actggttata ctctggatgt aaccacagga cagaggaagt atggtggtcc tccaccagac 540 agtgtgtact ctggcgtgca acctggaatt ggaacggagg tatttgtagg caaaatacca 600 agggatttat atgaggatga gttggtgccc ctttttgaga aggccggacc catttgggat 660 ctacgtctta tgatggatcc actgtccggt cagaatagag ggtatgcatt tatcaccttc 720 tgtggaaagg aagctgcaca ggaagccgtg aaactgtgtg acagctatga aattcgccct 780 ggtaaacacc ttggagtgtg catttctgtg gcaaacaaca gactttttgt tggatccatt 840 ccgaagaata agactaaaga aaacattttg gaagaattca gtaaagtcac agagggtttg 900 gtggacgtta ttctctatca tcaacccgat gacaaaaaga agaatcgggg gttctgcttc 960 cttgaatatg aggatcacaa gtcagcagca caagccagac gccggctgat gagtggaaaa 1020 gtaaaagtgt ggggaaatgt agttacagtt gaatgggctg accctgtgga agaaccagat 1080 ccagaagtca tggctaaggt aaaagttttg tttgtgagaa acttggctac tacggtgaca 1140 gaagaaatat tggaaaagtc attttctgaa tttggaaaac tcgaaagagt aaagaagttg 1200 aaagattatg catttgttca ttttgaagac agaggagcag ctgttaaggc tatggatgaa 1260 atgaatggca aagaaataga aggggaagaa attgaaatag tcttagccaa gccaccagac 1320 aagaaaagga aagagcgcca agctgctaga caggcctcca gaagcactgc gtatgaagat 1380 tattactacc accctcctcc tcgcatgcca cctccaatta gaggtcgggg tcgtggtggg 1440 gggagaggtg gatatggcta ccctccagat tactacggct atgaagatta ctatgatgat 1500 tactatggtt atgattatca cgactatcgt ggaggctatg aagatcccta ctacggctat 1560 gatgatggct atgcagtaag aggaagagga ggaggaaggg gagggcgagg tgctccacca 1620 ccaccaaggg ggaggggagc accacctcca agaggtagag ctggctattc acagaggggg 1680 gcacctttgg gaccaccaag aggctctagg ggtggcagag ggggtcctgc tcaacagcag 1740 agaggccgtg gttcccgtgg atctcggggc aatcgtgggg gcaatgtagg aggcaagaga 1800 aaggcagatg ggtacaacca gcctgattcc aagcgtcgtc agaccaacaa ccaacagaac 1860 tggggttccc aacccatcgc tcagcagccg cttcagcaag gtggtgacta ttctggtaac 1920 tatggttaca ataatgacaa ccaggaattt tatcaggata cttatgggca acagtggaag 1980 tagacaagta agggcttgaa aatgatactg gcaagatacg attggctcta gatctacatt 2040 cttcaaaaaa aaaaattggc ttaactgttt catctttaag tagcattttg ctgccatttg 2100 tattgggctg aagaaatcac tattgtgtat atactcaagt ctttttattt ttcctctttt 2160 cataaatgct cttggacatt attgggcttg cagagttccc ttattctggg gattacaatg 2220 cttttatcgt ttcaggcttc attttagctt caaaacaagc tgggcacact gttaaatcat 2280 gattttgcag aacctttggt tttggacagt ttcatttttt tggatttggg atagattaca 2340 taggagtatg gagtatgctg taaataaaaa tacaagctag tgctttgtct tagtagtttt 2400 aagaaattaa agcaaacaaa tttaagtttt cttgtattga aaataaccta tgattgtatg 2460 ttttgcattc ctagaagtag gttaactgtg tttttaaatt gttataactt cacacctttt 2520 tgaaatctgc cctacaaaat ttgtttggct taaacgtcaa aagccgtgac aatttgttct 2580 ttgatgtgat tgtatttcca atttcttgtt catgtaagat ttcaataaaa ctaaaaaatc 2640 tattcaaaac aaaaaaaaaa aaaaaaaaaa aaa 2673 128 633 PRT Homo sapiens 128 Met Ala Asn Gln Val Asn Gly Asn Ala Val Gln Leu Lys Glu Glu Glu 1 5 10 15 Glu Pro Met Asp Thr Ser Ser Val Thr His Thr Glu His Tyr Lys Thr 20 25 30 Leu Ile Glu Ala Gly Leu Pro Gln Lys Val Ala Glu Arg Leu Asp Glu 35 40 45 Ile Phe Gln Thr Gly Leu Val Ala Tyr Val Asp Leu Asp Glu Arg Ala 50 55 60 Ile Asp Ala Leu Arg Glu Phe Asn Glu Glu Gly Ala Leu Ser Val Leu 65 70 75 80 Gln Gln Phe Lys Glu Ser Asp Leu Ser His Val Gln Asn Lys Ser Ala 85 90 95 Phe Leu Cys Gly Val Met Lys Thr Tyr Arg Gln Arg Glu Lys Gln Gly 100 105 110 Ser Lys Val Gln Glu Ser Thr Lys Gly Pro Asp Glu Ala Lys Ile Lys 115 120 125 Ala Leu Leu Glu Arg Thr Gly Tyr Thr Leu Asp Val Thr Thr Gly Gln 130 135 140 Arg Lys Tyr Gly Gly Pro Pro Pro Asp Ser Val Tyr Ser Gly Val Gln 145 150 155 160 Pro Gly Ile Gly Thr Glu Val Phe Val Gly Lys Ile Pro Arg Asp Leu 165 170 175 Tyr Glu Asp Glu Leu Val Pro Leu Phe Glu Lys Ala Gly Pro Ile Trp 180 185 190 Asp Leu Arg Leu Met Met Asp Pro Leu Ser Gly Gln Asn Arg Gly Tyr 195 200 205 Ala Phe Ile Thr Phe Cys Gly Lys Glu Ala Ala Gln Glu Ala Val Lys 210 215 220 Leu Cys Asp Ser Tyr Glu Ile Arg Pro Gly Lys His Leu Gly Val Cys 225 230 235 240 Ile Ser Val Ala Asn Asn Arg Leu Phe Val Gly Ser Ile Pro Lys Asn 245 250 255 Lys Thr Lys Glu Asn Ile Leu Glu Glu Phe Ser Lys Val Thr Glu Gly 260 265 270 Leu Val Asp Val Ile Leu Tyr His Gln Pro Asp Asp Lys Lys Lys Asn 275 280 285 Arg Gly Phe Cys Phe Leu Glu Tyr Glu Asp His Lys Ser Ala Ala Gln 290 295 300 Ala Arg Arg Arg Leu Met Ser Gly Lys Val Lys Val Trp Gly Asn Val 305 310 315 320 Val Thr Val Glu Trp Ala Asp Pro Val Glu Glu Pro Asp Pro Glu Val 325 330 335 Met Ala Lys Val Lys Val Leu Phe Val Arg Asn Leu Ala Thr Thr Val 340 345 350 Thr Glu Glu Ile Leu Glu Lys Ser Phe Ser Glu Phe Gly Lys Leu Glu 355 360 365 Arg Val Lys Lys Leu Lys Asp Tyr Ala Phe Val His Phe Glu Asp Arg 370 375 380 Gly Ala Ala Val Lys Ala Met Asp Glu Met Asn Gly Lys Glu Ile Glu 385 390 395 400 Gly Glu Glu Ile Glu Ile Val Leu Ala Lys Pro Pro Asp Lys Lys Arg 405 410 415 Lys Glu Arg Gln Ala Ala Arg Gln Ala Ser Arg Ser Thr Ala Tyr Glu 420 425 430 Asp Tyr Tyr Tyr His Pro Pro Pro Arg Met Pro Pro Pro Ile Arg Gly 435 440 445 Arg Gly Arg Gly Gly Gly Arg Gly Gly Tyr Gly Tyr Pro Pro Asp Tyr 450 455 460 Tyr Gly Tyr Glu Asp Tyr Tyr Asp Asp Tyr Tyr Gly Tyr Asp Tyr His 465 470 475 480 Asp Tyr Arg Gly Gly Tyr Glu Asp Pro Tyr Tyr Gly Tyr Asp Asp Gly 485 490 495 Tyr Ala Val Arg Gly Arg Gly Gly Gly Arg Gly Gly Arg Gly Ala Pro 500 505 510 Pro Pro Pro Arg Gly Arg Gly Ala Pro Pro Pro Arg Gly Arg Ala Gly 515 520 525 Tyr Ser Gln Arg Gly Ala Pro Leu Gly Pro Pro Arg Gly Ser Arg Gly 530 535 540 Gly Arg Gly Gly Pro Ala Gln Gln Gln Arg Gly Arg Gly Ser Arg Gly 545 550 555 560 Ser Arg Gly Asn Arg Gly Gly Asn Val Gly Gly Lys Arg Lys Ala Asp 565 570 575 Gly Tyr Asn Gln Pro Asp Ser Lys Arg Arg Gln Thr Asn Asn Gln Gln 580 585 590 Asn Trp Gly Ser Gln Pro Ile Ala Gln Gln Pro Leu Gln Gln Gly Gly 595 600 605 Asp Tyr Ser Gly Asn Tyr Gly Tyr Asn Asn Asp Asn Gln Glu Phe Tyr 610 615 620 Gln Asp Thr Tyr Gly Gln Gln Trp Lys 625 630 129 938 DNA Homo sapiens 129 gcaagtccat gcctctacca tgagggtgga ggagttaaga tcaacagatc cacatgtacc 60 ttgaggtgac agactggctc tgaacaagtt gaaatcatcg cagaaggata aagttcgtca 120 gtttatgatc ttcacacaat ctagtgaaaa aacagcagta agttgtcttt ctcaaaatga 180 ctggaagtta gatgttgcaa cagataattt tttccaaaat cctgaacttt atatacgaga 240 gagtgtaaaa ggatcattgg acaggaagaa gttagaacag ctgtacaata gataccaaga 300 ccctcaagat gagaataaaa ttggaataga tggcatacag cagttctgtg atgacctggc 360 actcgatcca gccagcatta gtgtgttgat tattgcatgg aagttcagag cagcaacaca 420 gtgcgagttc tccaaacagg agttcatgga tggcatgaca gaattaggat gtgacagcat 480 agaaaaacta aaggcccaga tacccaagat ggaacaagaa ttgaaagaac caggacgatt 540 taaggatttt taccagttta cttttaattt tgcaaagaat ccaggacaaa aaggattaga 600 tctagaaatg gccattgcct actggaactt agtgcttaat ggaagattta aattcttaga 660 cttatggaat aaatttttgt tggaacatca taaacgatca ataccaaaag acacttggaa 720 tcttctttta gacttcagta cgatgattgc agatgacatg tctaattatg atgaagaagg 780 agcatggcct gtttttattg atgactttgt ggaatttgca cgccctcaaa ttgctgggac 840 aaaaagtaca acagtgtagc actaaaggaa ccttctagaa tgtacatagt ctgtacaata 900 aatacaacag aaaattgcaa aaaaaaaaaa aaaaaaaa 938 130 244 PRT Homo sapiens 130 Met Ile Phe Thr Gln Ser Ser Glu Lys Thr Ala Val Ser Cys Leu Ser 1 5 10 15 Gln Asn Asp Trp Lys Leu Asp Val Ala Thr Asp Asn Phe Phe Gln Asn 20 25 30 Pro Glu Leu Tyr Ile Arg Glu Ser Val Lys Gly Ser Leu Asp Arg Lys 35 40 45 Lys Leu Glu Gln Leu Tyr Asn Arg Tyr Gln Asp Pro Gln Asp Glu Asn 50 55 60 Lys Ile Gly Ile Asp Gly Ile Gln Gln Phe Cys Asp Asp Leu Ala Leu 65 70 75 80 Asp Pro Ala Ser Ile Ser Val Leu Ile Ile Ala Trp Lys Phe Arg Ala 85 90 95 Ala Thr Gln Cys Glu Phe Ser Lys Gln Glu Phe Met Asp Gly Met Thr 100 105 110 Glu Leu Gly Cys Asp Ser Ile Glu Lys Leu Lys Ala Gln Ile Pro Lys 115 120 125 Met Glu Gln Glu Leu Lys Glu Pro Gly Arg Phe Lys Asp Phe Tyr Gln 130 135 140 Phe Thr Phe Asn Phe Ala Lys Asn Pro Gly Gln Lys Gly Leu Asp Leu 145 150 155 160 Glu Met Ala Ile Ala Tyr Trp Asn Leu Val Leu Asn Gly Arg Phe Lys 165 170 175 Phe Leu Asp Leu Trp Asn Lys Phe Leu Leu Glu His His Lys Arg Ser 180 185 190 Ile Pro Lys Asp Thr Trp Asn Leu Leu Leu Asp Phe Ser Thr Met Ile 195 200 205 Ala Asp Asp Met Ser Asn Tyr Asp Glu Glu Gly Ala Trp Pro Val Phe 210 215 220 Ile Asp Asp Phe Val Glu Phe Ala Arg Pro Gln Ile Ala Gly Thr Lys 225 230 235 240 Ser Thr Thr Val 131 5170 DNA Homo sapiens 131 ccgggtcgac ccacgcgtcc gcgtaattcc gaaagagcag aagaaagaga aggagaacag 60 gaaaagaaga gctagtaagc gagagcgaga gcacagaaaa gaaaaaaaaa agccttaaga 120 ggaccgaagg ggaggaaagg aaaaggatgg acaaccacaa aacgcagcga ttgcggaaat 180 tttccagcgc cattggctgg gcagcgtgag tccttcggtc gggcgtgatt tcagcaccgg 240 gggaactgga cagcacctcg gggggacttc tgggcaaccc gcaaccacag caagaactcc 300 accagcagcc tcaacaacag aagccgcgga aaaccctgct ttgtatcaga gaggcaaggt 360 cagtccgacg cacagccatg cacaggcagt gcgcctgtac tacgctgcaa accctctgct 420 tgtttctcta acatgcactt gcttctaatt actagcattg tttcatttct gatcagtgaa 480 gatcagtaga tgagattctg taagggtgta cttttaattt atatgtatat atttaacttc 540 tttttctgtt atttttaaag tgttgtgggg gagtggggtt tttttcctac tttttttttt 600 tttttttttt tctttgcttg ccttgcacta cgtgcctgga tagtttgtgg atataattat 660 tgactggcgt ctgggctatt gcagtgcggg ggggttaggg aggaaggaat ccacccccac 720 ccccccaaac ccttttcttc tcctttcctg gcttcggaca ttggagcact aaatgaactt 780 gaattgtgtc tgtggcgagc aggatggtcg ctgttacttt gtgatgagat cggggatgaa 840 ttgctcgctt taaaaatgct gctttggatt ctgttgctgg agacgtctct ttgttttgcc 900 gctggaaacg ttacagggga cgtttgcaaa gagaagatct gttcctgcaa tgagatagaa 960 ggggacctac acgtagactg tgaaaaaaag ggcttcacaa gtctgcagcg tttcactgcc 1020 ccgacttccc agttttacca tttatttctg catggcaatt ccctcactcg acttttccct 1080 aatgagttcg ctaactttta taatgcggtt agtttgcaca tggaaaacaa tggcttgcat 1140 gaaatcgttc cgggggcttt tctggggctg cagctggtga aaaggctgca catcaacaac 1200 aacaagatca agtcttttcg aaagcagact tttctggggc tggacgatct ggaatatctc 1260 caggctgatt ttaatttatt acgagatata gacccggggg ccttccagga cttgaacaag 1320 ctggaggtgc tcattttaaa tgacaatctc atcagcaccc tacctgccaa cgtgttccag 1380 tatgtgccca tcacccacct cgacctccgg ggtaacaggc tgaaacgctg ccctatgagg 1440 agtcttggag caaatccctg gtattgcgga gatcctgcta gagataaccc ttgggactgc 1500 acctgtgatc tgctctccct gaaagaatgg ctggaaaaca ttcccaagaa tgccctgatc 1560 ggccgagtgg tctgcgaagc ccccaccaga ctgcagggta aagacctcaa tgaaaccacc 1620 gaacaggact tgtgtccttt gaaaaaccga gtggattcta gtctcccggc gccccctgcc 1680 caagaagaga cctttgctcc tggacccctg ccaactcctt tcaagacaaa tgggcaagag 1740 gatcatgcca caccagggtc tgctccaaac ggaggtacaa agatcccagg caactggcag 1800 atcaaaatca gacccacagc agcgatagcg acgggtagct ccaggaacaa acccttagct 1860 aacagtttac cctgccctgg gggctgcagc tgcgaccaca tcccagggtc gggtttaaag 1920 atgaactgca acaacaggaa cgtgagcagc ttggctgatt tgaagcccaa gctctctaac 1980 gtgcaggagc ttttcctacg agataacaag atccacagca tccgaaaatc gcactttgtg 2040 gattacaaga acctcattct gttggatctg ggcaacaata acatcgctac tgtagagaac 2100 aacactttca agaacctttt ggacctcagg tggctataca tggatagcaa ttacctggac 2160 acgctgtccc gggagaaatt cgcggggctg caaaacctag agtacctgaa cgtggagtac 2220 aacgctatcc agctcatcct cccgggcact ttcaatgcca tgcccaaact gaggatcctc 2280 attctcaaca acaacctgct gaggtccctg cctgtggacg tgttcgctgg ggtctcgctc 2340 tctaaactca gcctgcacaa caattacttc atgtacctcc cggtggcagg ggtgctggac 2400 cagttaacct ccatcatcca gatagacctc cacggaaacc cctgggagtg ctcctgcaca 2460 attgtgcctt tcaagcagtg ggcagaacgc ttgggttccg aagtgctgat gagcgacctc 2520 aagtgtgaga cgccggtgaa cttctttaga aaggatttca tgctcctctc caatgacgag 2580 atctgccctc agctgtacgc taggatctcg cccacgttaa cttcgcacag taaaaacagc 2640 actgggttgg cggagaccgg gacgcactcc aactcctacc tagacaccag cagggtgtcc 2700 atctcggtgt tggtcccggg actgctgctg gtgtttgtca cctccgcctt caccgtggtg 2760 ggcatgctcg tgtttatcct gaggaaccga aagcggtcca agagacgaga tgccaactcc 2820 tccgcgtccg agattaattc cctacagaca gtctgtgact cttcctactg gcacaatggg 2880 ccttacaacg cagatggggc ccacagagtg tatgactgtg gctctcactc gctctcagac 2940 taagacccca accccaatag gggagggcag agggaaggcg atacatcctt ccccaccgca 3000 ggcaccccgg gggctggagg ggcgtgtacc caaatccccg cgccatcagc ctggatgggc 3060 ataagtagat aaataactgt gagctcgcac aaccgaaagg gcctgacccc ttacttagct 3120 ccctccttga aacaaagagc agactgtgga gagctgggag agcgcagcca gctcgctctt 3180 tgctgagagc cccttttgac agaaagccca gcacgaccct gctggaagaa ctgacagtgc 3240 cctcgccctc ggccccgggg cctgtggggt tggatgccgc ggttctatac atatatacat 3300 atatccacat ctatatagag agatagatat ctatttttcc cctgtggatt agccccgtga 3360 tggctccctg ttggctacgc agggatgggc agttgcacga aggcatgaat gtattgtaaa 3420 taagtaactt tgacttctga caaaaaacaa aaagtgctgc atggctcgca tggaatccac 3480 gcgctccagg gactctgccc gcccccgcga ctggagacgg catctcgttc acagcaccca 3540 ccctcttacc tgataagttc catcgtatca aactttctat aaacaaaata cagtataatc 3600 agaaagtgcc atttcgccat tatttgtgat cggtaggcag ttcagagcat aagttaactg 3660 tgaaaaaaat gtaaaggttt tatttaggac atttgcatgg ctagtcatca gtccatttta 3720 tgagttaaca atgtattttg ttgagggaag tttttagggg ttgttttggg ttcttttatt 3780 ttgatggtga tgttttattt tattttattt ttttcagggg gtcttttttt taatacatat 3840 ccaataatgc cttccatctg aatgtaaaat aagtacccat gatttctatt atagtatcag 3900 tgtaattatt taaaaaatga ttttgaggca gttaagcatg accaattaat gtcactctag 3960 tgcttaggct gcgatcctat ggtagcaatt ctgtgctggt ataaatctta cttataaagt 4020 aggaaaagag aaccgaggaa gcacgtgaaa cttactaatt ctattcgagg attttataat 4080 ggcatatttt ttcagtatta aagcgaaaat gttttcaact ctgggtcctt acctttttcc 4140 agcttcatat ttgcaagtgg taaattggat ttgcggtgga agagacaggg gagggaaacg 4200 gttggggtta gatcccttcc tgagctacat taaggctctt tctctaatcg ccttacttag 4260 ctttttaccc tttaagtagc tcctcttccc tcgcccccac cctctacccc acccccacct 4320 tcgctcagac tttaccggct ttccccagtc cataaaggtc ttgccccaac actcacccct 4380 tctttttttc ccctctccaa atgcagcagt gaatcccttt attaatactg gaaatccctc 4440 tctgctgctt ttgttggtgc tgcccacact gcagatatat taaggatgtt aggagagatt 4500 tgatttaatt gactctgcct agataggtct cattaaacag agtggagatt tcattggtca 4560 gcactcctca atgaaagaca gacctaatga ctggcatttg agatgctgct ggcattttga 4620 attcaacatc tgctgaaaac ggtaaaacta attagtgccc acccaccctc cccgccccag 4680 caactgcata ttgaaatttg ttaaagcact catctttatg gaaattaatc attatcctaa 4740 agaagtgttt ctctcccatc atccggattt ctggttgtgg cccagcaatt aacaaaaaca 4800 gcttcaactg ttcgaatttt attgaaccaa tgtaactctg gcctcaatca tattcctctg 4860 ggatttctaa acagcagtta agctacaaaa agcaaacaaa accacacata ttgatggagt 4920 ctgcattcca ccacatatcc acccttgaga agtatgtcaa aagactgcag actatagatt 4980 tttttttaat ataggattat aaatcagcta gtgaaagacc tcagagcagt tgtaagtaga 5040 tctgccatct agaactcata ttctaaaggg aagtgatttc tcagaacagt gatgttctgg 5100 aatatgtatt atttatttta acactttttt aataaaatct ttattataaa ccatgaaaaa 5160 aaaaaaaaaa 5170 132 695 PRT Homo sapiens 132 Met Leu Leu Trp Ile Leu Leu Leu Glu Thr Ser Leu Cys Phe Ala Ala 1 5 10 15 Gly Asn Val Thr Gly Asp Val Cys Lys Glu Lys Ile Cys Ser Cys Asn 20 25 30 Glu Ile Glu Gly Asp Leu His Val Asp Cys Glu Lys Lys Gly Phe Thr 35 40 45 Ser Leu Gln Arg Phe Thr Ala Pro Thr Ser Gln Phe Tyr His Leu Phe 50 55 60 Leu His Gly Asn Ser Leu Thr Arg Leu Phe Pro Asn Glu Phe Ala Asn 65 70 75 80 Phe Tyr Asn Ala Val Ser Leu His Met Glu Asn Asn Gly Leu His Glu 85 90 95 Ile Val Pro Gly Ala Phe Leu Gly Leu Gln Leu Val Lys Arg Leu His 100 105 110 Ile Asn Asn Asn Lys Ile Lys Ser Phe Arg Lys Gln Thr Phe Leu Gly 115 120 125 Leu Asp Asp Leu Glu Tyr Leu Gln Ala Asp Phe Asn Leu Leu Arg Asp 130 135 140 Ile Asp Pro Gly Ala Phe Gln Asp Leu Asn Lys Leu Glu Val Leu Ile 145 150 155 160 Leu Asn Asp Asn Leu Ile Ser Thr Leu Pro Ala Asn Val Phe Gln Tyr 165 170 175 Val Pro Ile Thr His Leu Asp Leu Arg Gly Asn Arg Leu Lys Arg Cys 180 185 190 Pro Met Arg Ser Leu Gly Ala Asn Pro Trp Tyr Cys Gly Asp Pro Ala 195 200 205 Arg Asp Asn Pro Trp Asp Cys Thr Cys Asp Leu Leu Ser Leu Lys Glu 210 215 220 Trp Leu Glu Asn Ile Pro Lys Asn Ala Leu Ile Gly Arg Val Val Cys 225 230 235 240 Glu Ala Pro Thr Arg Leu Gln Gly Lys Asp Leu Asn Glu Thr Thr Glu 245 250 255 Gln Asp Leu Cys Pro Leu Lys Asn Arg Val Asp Ser Ser Leu Pro Ala 260 265 270 Pro Pro Ala Gln Glu Glu Thr Phe Ala Pro Gly Pro Leu Pro Thr Pro 275 280 285 Phe Lys Thr Asn Gly Gln Glu Asp His Ala Thr Pro Gly Ser Ala Pro 290 295 300 Asn Gly Gly Thr Lys Ile Pro Gly Asn Trp Gln Ile Lys Ile Arg Pro 305 310 315 320 Thr Ala Ala Ile Ala Thr Gly Ser Ser Arg Asn Lys Pro Leu Ala Asn 325 330 335 Ser Leu Pro Cys Pro Gly Gly Cys Ser Cys Asp His Ile Pro Gly Ser 340 345 350 Gly Leu Lys Met Asn Cys Asn Asn Arg Asn Val Ser Ser Leu Ala Asp 355 360 365 Leu Lys Pro Lys Leu Ser Asn Val Gln Glu Leu Phe Leu Arg Asp Asn 370 375 380 Lys Ile His Ser Ile Arg Lys Ser His Phe Val Asp Tyr Lys Asn Leu 385 390 395 400 Ile Leu Leu Asp Leu Gly Asn Asn Asn Ile Ala Thr Val Glu Asn Asn 405 410 415 Thr Phe Lys Asn Leu Leu Asp Leu Arg Trp Leu Tyr Met Asp Ser Asn 420 425 430 Tyr Leu Asp Thr Leu Ser Arg Glu Lys Phe Ala Gly Leu Gln Asn Leu 435 440 445 Glu Tyr Leu Asn Val Glu Tyr Asn Ala Ile Gln Leu Ile Leu Pro Gly 450 455 460 Thr Phe Asn Ala Met Pro Lys Leu Arg Ile Leu Ile Leu Asn Asn Asn 465 470 475 480 Leu Leu Arg Ser Leu Pro Val Asp Val Phe Ala Gly Val Ser Leu Ser 485 490 495 Lys Leu Ser Leu His Asn Asn Tyr Phe Met Tyr Leu Pro Val Ala Gly 500 505 510 Val Leu Asp Gln Leu Thr Ser Ile Ile Gln Ile Asp Leu His Gly Asn 515 520 525 Pro Trp Glu Cys Ser Cys Thr Ile Val Pro Phe Lys Gln Trp Ala Glu 530 535 540 Arg Leu Gly Ser Glu Val Leu Met Ser Asp Leu Lys Cys Glu Thr Pro 545 550 555 560 Val Asn Phe Phe Arg Lys Asp Phe Met Leu Leu Ser Asn Asp Glu Ile 565 570 575 Cys Pro Gln Leu Tyr Ala Arg Ile Ser Pro Thr Leu Thr Ser His Ser 580 585 590 Lys Asn Ser Thr Gly Leu Ala Glu Thr Gly Thr His Ser Asn Ser Tyr 595 600 605 Leu Asp Thr Ser Arg Val Ser Ile Ser Val Leu Val Pro Gly Leu Leu 610 615 620 Leu Val Phe Val Thr Ser Ala Phe Thr Val Val Gly Met Leu Val Phe 625 630 635 640 Ile Leu Arg Asn Arg Lys Arg Ser Lys Arg Arg Asp Ala Asn Ser Ser 645 650 655 Ala Ser Glu Ile Asn Ser Leu Gln Thr Val Cys Asp Ser Ser Tyr Trp 660 665 670 His Asn Gly Pro Tyr Asn Ala Asp Gly Ala His Arg Val Tyr Asp Cys 675 680 685 Gly Ser His Ser Leu Ser Asp 690 695 133 1564 DNA Homo sapiens 133 attctagacc tcggcctccc aaagtgctgt gattataggt gtaagccacc gtgtctggcc 60 tctgaacaac tttttcagca actaaaaaag ccacaggagt tgaactgcta ggattctgac 120 tatgctgtgg tggctagtgc tcctactcct acctacatta aaatctgttt tttgttctct 180 tgtaactagc ctttaccttc ctaacacaga ggatctgtca ctgtggctct ggcccaaacc 240 tgaccttcac tctggaacga gaacagaggt ttctacccac accgtcccct cgaagccggg 300 gacagcctca ccttgctggc ctctcgctgg agcagtgccc tcaccaactg tctcacgtct 360 ggaggcactg actcgggcag tgcaggtagc tgagcctctt ggtagctgcg gctttcaagg 420 tgggccttgc cctggccgta gaagggattg acaagcccga agatttcata ggcgatggct 480 cccactgccc aggcatcagc cttgctgtag tcaatcactg ccctggggcc aggacgggcc 540 gtggacacct gctcagaagc agtgggtgag acatcacgct gcccgcccat ctaacctttt 600 catgtcctgc acatcacctg atccatgggc taatctgaac tctgtcccaa ggaacccaga 660 gcttgagtga gctgtggctc agacccagaa ggggtctgct tagaccacct ggtttatgtg 720 acaggacttg cattctcctg gaacatgagg gaacgccgga ggaaagcaaa gtggcaggga 780 aggaacttgt gccaaattat gggtcagaaa agatggaggt gttgggttat cacaaggcat 840 cgagtctcct gcattcagtg gacatgtggg ggaagggctg ccgatggcgc atgacacact 900 cgggactcac ctctggggcc atcagacagc cgtttccgcc ccgatccacg taccagctgc 960 tgaagggcaa ctgcaggccg atgctctcat cagccaggca gcagccaaaa tctgcgatca 1020 ccagccaggg gcagccgtct gggaaggagc aagcaaagtg accatttctc ctcccctcct 1080 tccctctgag aggccctcct atgtccctac taaagccacc agcaagacat agctgacagg 1140 ggctaatggc tcagtgttgg cccaggaggt cagcaaggcc tgagagctga tcagaagggc 1200 ctgctgtgcg aacacggaaa tgcctccagt aagtacaggc tgcaaaatcc ccaggcaaag 1260 gactgtgtgg ctcaatttaa atcatgttct agtaattgga gctgtcccca agaccaaagg 1320 agctagagct tggttcaaat gatctccaag ggcccttata ccccaggaga ctttgatttg 1380 aatttgaaac cccaaatcca aacctaagaa ccaggtgcat taagaatcag ttattgccgg 1440 gtgtggtggc ctgtaatgcc aacattttgg gaggccgagg cgggtagatc acctgaggtc 1500 aggagttcaa gaccagcctg gccaacatgg tgaaacccct gtctctacta aaaaaaaaaa 1560 aaaa 1564 134 109 PRT Homo sapiens 134 Met Leu Trp Trp Leu Val Leu Leu Leu Leu Pro Thr Leu Lys Ser Val 1 5 10 15 Phe Cys Ser Leu Val Thr Ser Leu Tyr Leu Pro Asn Thr Glu Asp Leu 20 25 30 Ser Leu Trp Leu Trp Pro Lys Pro Asp Leu His Ser Gly Thr Arg Thr 35 40 45 Glu Val Ser Thr His Thr Val Pro Ser Lys Pro Gly Thr Ala Ser Pro 50 55 60 Cys Trp Pro Leu Ala Gly Ala Val Pro Ser Pro Thr Val Ser Arg Leu 65 70 75 80 Glu Ala Leu Thr Arg Ala Val Gln Val Ala Glu Pro Leu Gly Ser Cys 85 90 95 Gly Phe Gln Gly Gly Pro Cys Pro Gly Arg Arg Arg Asp 100 105 135 839 DNA Homo sapiens 135 aacgcgtttt gccagttatg cgaaaacatg gctgcggccg gtttggccct tctttgtagg 60 agagtttcat ccgccctgaa atcttcccga tcgttaataa ctcctcaggt ccctgcctgc 120 acagggtttt ttcttagttt gttgcctaag agtacaccaa atgtgacatc ctttcaccaa 180 tatagattac ttcataccac attgtcaagg aaaggactag aagaattttt tgatgaccca 240 aaaaactggg ggcaagaaaa agtaaaatct ggagcagcat ggacctgtca gcaactaagg 300 aacaaaagta atgaagattt acacaaactt tggtatgtct tactgaaaga aagaaacatg 360 cttctaaccc tagagcagga ggccaagcgg cagagattgc caatgccaag tccagagcgg 420 ttagataagg tagtagattc catggatgca ttagataaag ttgtccagga aagagaagat 480 gccctaaggc ttcttcagac tggtcaagaa agagctagac ctggtgcttg gagaagagac 540 atctttggaa gaatcatctg gcacaagttc aagcagtggg ttataccttg gcacctaaat 600 aaaagataca ataggaaacg attctttgcc ttgccttatg tggaccattt tctcagactg 660 gaacgtgaga aacgagcccg catcaaagca cggaaggaaa atttagagag aaagaaagca 720 aaaattcttt taaaaaagtt tccacatctt gctgaagccc aaaagtcaag tcttgtctaa 780 gatgtctgaa ctattaaatt taccattttg tttttcttga aaaaaaaaaa aaaaaaaaa 839 136 250 PRT Homo sapiens 136 Met Ala Ala Ala Gly Leu Ala Leu Leu Cys Arg Arg Val Ser Ser Ala 1 5 10 15 Leu Lys Ser Ser Arg Ser Leu Ile Thr Pro Gln Val Pro Ala Cys Thr 20 25 30 Gly Phe Phe Leu Ser Leu Leu Pro Lys Ser Thr Pro Asn Val Thr Ser 35 40 45 Phe His Gln Tyr Arg Leu Leu His Thr Thr Leu Ser Arg Lys Gly Leu 50 55 60 Glu Glu Phe Phe Asp Asp Pro Lys Asn Trp Gly Gln Glu Lys Val Lys 65 70 75 80 Ser Gly Ala Ala Trp Thr Cys Gln Gln Leu Arg Asn Lys Ser Asn Glu 85 90 95 Asp Leu His Lys Leu Trp Tyr Val Leu Leu Lys Glu Arg Asn Met Leu 100 105 110 Leu Thr Leu Glu Gln Glu Ala Lys Arg Gln Arg Leu Pro Met Pro Ser 115 120 125 Pro Glu Arg Leu Asp Lys Val Val Asp Ser Met Asp Ala Leu Asp Lys 130 135 140 Val Val Gln Glu Arg Glu Asp Ala Leu Arg Leu Leu Gln Thr Gly Gln 145 150 155 160 Glu Arg Ala Arg Pro Gly Ala Trp Arg Arg Asp Ile Phe Gly Arg Ile 165 170 175 Ile Trp His Lys Phe Lys Gln Trp Val Ile Pro Trp His Leu Asn Lys 180 185 190 Arg Tyr Asn Arg Lys Arg Phe Phe Ala Leu Pro Tyr Val Asp His Phe 195 200 205 Leu Arg Leu Glu Arg Glu Lys Arg Ala Arg Ile Lys Ala Arg Lys Glu 210 215 220 Asn Leu Glu Arg Lys Lys Ala Lys Ile Leu Leu Lys Lys Phe Pro His 225 230 235 240 Leu Ala Glu Ala Gln Lys Ser Ser Leu Val 245 250 137 1067 DNA Homo sapiens 137 gacaaaggga gaaaaacaac aggaagcagc ttacaaactc ggtgaacaac tgagggaacc 60 aaaccagaga cgcgctgaac agagagaatc aggctcaaag caagtggaag tgggcagaga 120 ttccaccagg actggtgcaa ggcgcagagc cagccagatt tgagaagaag gcaaaaagat 180 gctggggagc agagctgtaa tgctgctgtt gctgctgccc tggacagctc agggcagagc 240 tgtgcctggg ggcagcagcc ctgcctggac tcagtgccag cagctttcac agaagctctg 300 cacactggcc tggagtgcac atccactagt gggacacatg gatctaagag aagagggaga 360 tgaagagact acaaatgatg ttccccatat ccagtgtgga gatggctgtg acccccaagg 420 actcagggac aacagtcagt tctgcttgca aaggatccac cagggtctga ttttttatga 480 gaagctgcta ggatcggata ttttcacagg ggagccttct ctgctccctg atagccctgt 540 gggccagctt catgcctccc tactgggcct cagccaactc ctgcagcctg agggtcacca 600 ctgggagact cagcagattc caagcctcag tcccagccag ccatggcagc gtctccttct 660 ccgcttcaaa atccttcgca gcctccaggc ctttgtggct gtagccgccc gggtctttgc 720 ccatggagca gcaaccctga gtccctaaag gcagcagctc aaggatggca ctcagatctc 780 catggcccag caaggccaag ataaatctac caccccaggc acctgtgagc caacaggtta 840 attagtccat taattttagt gggacctgca tatgttgaaa attaccaata ctgactgaca 900 tgtgatgctg acctatgata aggttgagta tttattagat gggaagggaa atttggggat 960 tatttatcct cctggggaca gtttggggag gattatttat tgtatttata ttgaattatg 1020 tacttttttc aataaagtct tatttttgtg gcaaaaaaaa aaaaaaa 1067 138 189 PRT Homo sapiens 138 Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr 1 5 10 15 Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln 20 25 30 Cys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His 35 40 45 Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr 50 55 60 Thr Asn Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln 65 70 75 80 Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly 85 90 95 Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu 100 105 110 Pro Ser Leu Leu Pro Asp Ser Pro Val Gly Gln Leu His Ala Ser Leu 115 120 125 Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr 130 135 140 Gln Gln Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu 145 150 155 160 Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala 165 170 175 Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro 180 185 139 1785 DNA Homo sapiens 139 gcccaggaga ctcccctccc accagcctgg cccccagagt gctgactggc aacaatattc 60 caagttaaaa tagtttgcta aatagttata caattagttt acaattcaaa tatatcagag 120 gaaaagacag ggaaaaaaat tctaagatac atgaatccca gaccattgct ctccaaatat 180 tttcaagtga ttcatctcct ttatttaaaa aatgaattaa ccaccagatg ggacactcat 240 acattcctga tggttgtagg aatcagtaga ccctgtatgg aaagcaatag gataatattt 300 cataggatca aattaaaatg ttcacagcat tggttccagg aaattggctt ctggagaatt 360 tatactccag aaacaattca acaaaagaac acagctctgt gcatgcagat gctcattagc 420 ccatcaccta gagtaaggga aagtggagat cccaatgaac aacaatgaga tgggttagcg 480 aactgtgacc tatcagccca atggacattt aagcaatcac tgaaaagtag aaacatgaag 540 atattacaca acatggaaac tgtttatgga gtatatttag gtaaaaagga aaaaaaggca 600 gaactgtata tctgtggttg gatatacttt ttttttttaa tattaagcac caaccaaaag 660 aagaaaggag gatagaaaaa ataaaatgga agatgtaggg tgggcagatt agggctgcgt 720 ttgttgcttg ctttcatgtt accatcatag cgtttttgcc acttacaaag gaggaaaaaa 780 atcaattctg tgccaaccca gacaacagag acctgagtgg gggttgggaa gagagatttt 840 tcagcacaga atcagactcc ttctccaaag agctgtgtgg ccttcacctg caaggcgacc 900 tcttccacaa gcagaggcca ggacaaaaag aggcacctgt gagcgacaaa gacggtttcc 960 ttggtttccc tcacggcgcc aagcggagtg gccgcctccc accacagggc cccctaatgg 1020 gcgcttttgt cctgcggggc agagggacct cattagaagg cgctggtgct aaagggaaat 1080 gcatttccag aacaggaggt ttcatcattc ctagcgttag cgacagaatg gtgacagaag 1140 ctctgtggac gtattttcca gcgttcagtt cacatcaagg atgggtatgc actggcggaa 1200 aaggccctca ggaggaagca ctcatcttta acaagacctg ctttctcagg actgcaaaca 1260 agagaaaagc ccaataagag gaaagtgaag tgtgaaaatc catttcaaag aactttactg 1320 agaactcacc atgtcagaga gcttccatta atacagttgc ttcaaaacca ataggcagaa 1380 cccaaagtaa tggatgactc accaggactt ttagcagcta atggagtact ctgagaaatg 1440 ctgtaaatcc aatatttttg ctgaaaaatt aatgtgttat gggagggagc ctcttttcta 1500 atcacttacc cacccccacc ctctacttct agttcaccat cagcatcttt agctcttcta 1560 atttttgcca aagctgaatg cagttctttc ccaattttct tatatcattt taagtattat 1620 atatgctatc ttaccaggcc cactcagaga aacagcactt atctttaaaa ttatttttta 1680 actactcccc acagcctacg gccaataaaa actctgtaaa ctatgttaaa tataccaaag 1740 taaagtttcc agaattcaca gaaaaaaaaa aaaaaaaaaa aaaaa 1785 140 86 PRT Homo sapiens 140 Met Gly Ala Phe Val Leu Arg Gly Arg Gly Thr Ser Leu Glu Gly Ala 1 5 10 15 Gly Ala Lys Gly Lys Cys Ile Ser Arg Thr Gly Gly Phe Ile Ile Pro 20 25 30 Ser Val Ser Asp Arg Met Val Thr Glu Ala Leu Trp Thr Tyr Phe Pro 35 40 45 Ala Phe Ser Ser His Gln Gly Trp Val Cys Thr Gly Gly Lys Gly Pro 50 55 60 Gln Glu Glu Ala Leu Ile Phe Asn Lys Thr Cys Phe Leu Arg Thr Ala 65 70 75 80 Asn Lys Arg Lys Ala Gln 85 141 947 DNA Homo sapiens 141 caaactgaag gtaggatgtc tatataccct tcatttcagg ggcccctaga gaatatacct 60 tagctttccc tcttccggca tcctggaaag tggatacctg tggccttcct ttcactttga 120 aagcttacac cctcattttg actacaacta atactaaaag cttggcatct tgcttgagat 180 tagtgtttgc tatgccaaac accttctcct ctttctattg aaagcaaaac ataggaaaat 240 aatttgaaat acttttaagg catcttaaaa acatgacttt ttcatcttat ggaaaagcag 300 accaattttg cttttttttc ccaacttgtt ctccagactg tgccaataaa atgtgttcat 360 agcaggaaaa tttggaaaat acagaaaagc actatgaaga aaacaaaatg tacccaaaat 420 cccatcactc agataacatc actgttaatg ttttgatatg tatttccagt cttttctatt 480 gtgttaattt ttcattttgt ttttgaataa ataactttca ggaaagaaat tgagcctttt 540 ctgccacctc tgaagcctga ttactgtgtg aagcaggcca tgaaggccat cctcactgac 600 cagcccatga tctgcactcc ccgcctcatg tacatcgtga ccttcatgaa gagcatccta 660 ccatttgaag cagttgtgtg catgtatcgg ttcctaggag cggacaagtg tatgtacccc 720 tttattgctc aaagaaagca agccacaaac aataatgaag caaaaaatgg aatctaagaa 780 tctttttgta tggaatatta cttctatcag aagatgatca agatgtttca gtccagtgca 840 catcagcatt gctgacattt tatggattct aaacttgtgt tgtttctttt ttaaatcaac 900 tttttaaaaa aataaagtgt aaattaaccg acaaaaaaaa aaaaaaa 947 142 65 PRT Homo sapiens 142 Met Lys Ala Ile Leu Thr Asp Gln Pro Met Ile Cys Thr Pro Arg Leu 1 5 10 15 Met Tyr Ile Val Thr Phe Met Lys Ser Ile Leu Pro Phe Glu Ala Val 20 25 30 Val Cys Met Tyr Arg Phe Leu Gly Ala Asp Lys Cys Met Tyr Pro Phe 35 40 45 Ile Ala Gln Arg Lys Gln Ala Thr Asn Asn Asn Glu Ala Lys Asn Gly 50 55 60 Ile 65 143 1148 DNA Homo sapiens 143 gcgagatccc taccgcagta tccgcctctg ccgccgcgga gcttcccgaa cctcttcagc 60 cgcccggagc cgctcccgga gcccggccgt agaggctgca atcgcagccg ggagcccgca 120 gcccgcgccc cgagcccgcc gccgcccttc gagggcgccc caggccgcgc catggtgaag 180 gtgacgttca actccgctct ggcccagaag gaggccaaga aggacgagcc caagagcggc 240 gaggaggcgc tcatcatccc ccccgacgcc gtcgcggtgg actgcaagga cccagatgat 300 gtggtaccag ttggccaaag aagagcctgg tgttggtgca tgtgctttgg actagcattt 360 atgcttgcag gtgttattct aggaggagca tacttgtaca aatattttgc acttcaacca 420 gatgacgtgt actactgtgg aataaagtac atcaaagatg atgtcatctt aaatgagccc 480 tctgcagatg ccccagctgc tctctaccag acaattgaag aaaatattaa aatctttgaa 540 gaagaagaag ttgaatttat cagtgtgcct gtcccagagt ttgcagatag tgatcctgcc 600 aacattgttc atgactttaa caagaaactt acagcctatt tagatcttaa cctggataag 660 tgctatgtga tccctctgaa cacttccatt gttatgccac ccagaaacct actggagtta 720 cttattaaca tcaaggctgg aacctatttg cctcagtcct atctgattca tgagcacatg 780 gttattactg atcgcattga aaacattgat cacctgggtt tctttattta tcgactgtgt 840 catgacaagg aaacttacaa actgcaacgc agagaaacta ttaaaggtat tcagaaacgt 900 gaagccagca attgtttcgc aattcggcat tttgaaaaca aatttgccgt ggaaacttta 960 atttgttctt gaacagtcaa gaaaaacatt attgaggaaa attaatatca cagcataacc 1020 ccacccttta cattttgtgc agtgattatt ttttaaagtc ttctttcatg taagtagcaa 1080 acagggcttt actatcttct catctcatta attcaattaa aaccattacc ttaaaaaaaa 1140 aaaaaaaa 1148 144 266 PRT Homo sapiens 144 Met Val Lys Val Thr Phe Asn Ser Ala Leu Ala Gln Lys Glu Ala Lys 1 5 10 15 Lys Asp Glu Pro Lys Ser Gly Glu Glu Ala Leu Ile Ile Pro Pro Asp 20 25 30 Ala Val Ala Val Asp Cys Lys Asp Pro Asp Asp Val Val Pro Val Gly 35 40 45 Gln Arg Arg Ala Trp Cys Trp Cys Met Cys Phe Gly Leu Ala Phe Met 50 55 60 Leu Ala Gly Val Ile Leu Gly Gly Ala Tyr Leu Tyr Lys Tyr Phe Ala 65 70 75 80 Leu Gln Pro Asp Asp Val Tyr Tyr Cys Gly Ile Lys Tyr Ile Lys Asp 85 90 95 Asp Val Ile Leu Asn Glu Pro Ser Ala Asp Ala Pro Ala Ala Leu Tyr 100 105 110 Gln Thr Ile Glu Glu Asn Ile Lys Ile Phe Glu Glu Glu Glu Val Glu 115 120 125 Phe Ile Ser Val Pro Val Pro Glu Phe Ala Asp Ser Asp Pro Ala Asn 130 135 140 Ile Val His Asp Phe Asn Lys Lys Leu Thr Ala Tyr Leu Asp Leu Asn 145 150 155 160 Leu Asp Lys Cys Tyr Val Ile Pro Leu Asn Thr Ser Ile Val Met Pro 165 170 175 Pro Arg Asn Leu Leu Glu Leu Leu Ile Asn Ile Lys Ala Gly Thr Tyr 180 185 190 Leu Pro Gln Ser Tyr Leu Ile His Glu His Met Val Ile Thr Asp Arg 195 200 205 Ile Glu Asn Ile Asp His Leu Gly Phe Phe Ile Tyr Arg Leu Cys His 210 215 220 Asp Lys Glu Thr Tyr Lys Leu Gln Arg Arg Glu Thr Ile Lys Gly Ile 225 230 235 240 Gln Lys Arg Glu Ala Ser Asn Cys Phe Ala Ile Arg His Phe Glu Asn 245 250 255 Lys Phe Ala Val Glu Thr Leu Ile Cys Ser 260 265 145 1353 DNA Homo sapiens 145 aggtctagaa ttcaatcggc cgcttttttt tttttttttt ttgctaacac ccagttctgc 60 ctgctacacc acctgggaat tgaccatcca gctgtgttct ctctgcctct ggcccagtag 120 caactgacct gccctattcc tggctgatct catgctgctg aagttcaagg cgctggacac 180 actaccctga tttttgttgc acctggccta gcctcattaa cttggcaatt agttggtggt 240 tttctttctt tcttcttctt ttttttttta attcatttca tttctgtcac cccttaattt 300 tcatctttct tttttaagta gttgttccat gctgttgttt tttgttttat ctttcattgc 360 ctttccctct gcagtcaaca ttatgacctg gggactccag catccttcaa gcaagccatt 420 tccgaagaag gtgaaaagaa gccaggatga ttggcacctc ctcctcctcc tcctcttctt 480 cctcttccct tgcccagccc cctcctgtgc gtgtgtttca gacaacacag gagccagcac 540 aggagtggaa aatcctgcag cgcaactcag ctcagcccac agaagccttg ggaatggcct 600 cagtttgtgc aataagaaga tttttttttt ctttttaaat cttcattata ttttctttga 660 ttgtctgtga gaaagtaccc aggtccgcct ggaattactc tacagtagaa ataactgaac 720 acaaacaaac tgatggaaaa aaagagttaa ctattttatt tatttcaata tttaaaagga 780 aaaaagtgct gacatggcac agtatttttg tttaaagtac ctcctacttc aaaagttaag 840 cgcaattttg tgaagacatg aaatcataag agtacttaat gtaaaataaa agactgcata 900 ttaactctaa agaaaaatgc cccacatttt aaataagaaa ataaagatca actctgctct 960 ctcaggcttt ttaaaaagcc attcatgtat gtgctttagg tatttttatt tctgcgagtt 1020 ggatgtggta agtgaggagt gctcagtttt tttttcctcc ttcaaaagtc tattgaaagt 1080 gttggtgatg ttaaatgatt gtgtgttaag atttgactga aataacttag ccacaaatca 1140 gcagtttccc ccaccctcat tgccccctca ccccaggcaa gcccctttta tctgaatgtc 1200 agaagcagcc tgcctcctag ttatcatgtc tgatgaggtc tagctcagga aggaattcca 1260 tctattgatg gaatatatcc cctcaagttc aatagattcg aacacagaga gctttgttta 1320 aaataatgca gcaaaaaaaa aaaaaaaaaa aaa 1353 146 113 PRT Homo sapiens 146 Met Leu Leu Phe Phe Val Leu Ser Phe Ile Ala Phe Pro Ser Ala Val 1 5 10 15 Asn Ile Met Thr Trp Gly Leu Gln His Pro Ser Ser Lys Pro Phe Pro 20 25 30 Lys Lys Val Lys Arg Ser Gln Asp Asp Trp His Leu Leu Leu Leu Leu 35 40 45 Leu Phe Phe Leu Phe Pro Cys Pro Ala Pro Ser Cys Ala Cys Val Ser 50 55 60 Asp Asn Thr Gly Ala Ser Thr Gly Val Glu Asn Pro Ala Ala Gln Leu 65 70 75 80 Ser Ser Ala His Arg Ser Leu Gly Asn Gly Leu Ser Leu Cys Asn Lys 85 90 95 Lys Ile Phe Phe Phe Phe Leu Asn Leu His Tyr Ile Phe Phe Asp Cys 100 105 110 Leu 147 2312 DNA Homo sapiens unsure (2224) unsure (2236) 147 gtttcggcct ggcctgggca ggcgcttgtg ctgccagggc gccgggcccg gggaggccgg 60 ggtctcgggt ggccgccggc ccaggcgctg gacggcagca ggatggggaa ggcgaaggtc 120 cccgcctcca agcgcgcccc gagcagcccc gtggctaagc cgggtcctgt caagacgctc 180 actcggaaga aaaacaagaa gaaaaaaagg ttttggaaaa gcaaggcgcg ggaagtaagc 240 aagaagccag caagcggccc cggtgctgtg gtgcgacctc caaaggcacc agaagacttt 300 tctcaaaact ggaaggcgct gcaagagtgg ctgctgaaac aaaaatctca ggccccagaa 360 aagcctcttg tcatctctca gatgggttcc aaaaagaagc ccaaaattat ccagcaaaac 420 aaaaaagaga cctcgcctca agtgaaggga gaggagatgc cggcaggaaa agaccaggag 480 gccagcaggg gctctgttcc ttcaggttcc aagatggaca ggagggcgcc agtacctcgc 540 accaaggcca gtggaacaga gcacaataag aaaggaacca aggaaaggac aaatggtgat 600 attgttccag aacgagggga catcgagcat aagaagcgga aagctaagga ggcagcccca 660 gccccaccca ccgaggaaga catctggttt gacgacgtgg acccagcgga tatcgaagct 720 gccataggtc cagaggcggc caagatagcg aggaaacagt tgggtcagag cgagggcagc 780 gtcagcctca gcctcgtgaa agagcaggcc ttcggcggcc tgacaagagc cttagccttg 840 gactgtgaga tggtgggcgt gggccctaag ggggaggaga gcatggccgc ccgtgtgtcc 900 atcgtgaacc agtatgggaa gtgcgtttat gacaagtacg tcaaaccaac cgagcccgtg 960 acggactata ggacagcggt cagtgggatt cggcctgaga acctcaagca gggagaagag 1020 cttgaagttg ttcagaagga agtggcagag atgctgaagg gcagaattct agtggggcac 1080 gctctgcata atgacctaaa ggtactattt cttgatcatc caaaaaagaa gattcgggac 1140 acacagaaat ataaaccttt caagagtcaa gtaaagagtg gaaggccgtc tctgagacta 1200 ctttcagaga agatccttgg gctccaggtc cagcaggcgg agcactgttc aattcaggat 1260 gcccaggcag caatgaggct gtacgtcatg gtgaagaagg agtgggagag catggcccga 1320 gacaggcgcc ccctgctgac tgctccagac cactgcagtg acgacgccta gcagtcctgc 1380 cctgctgctg ctgccgcccc gctacagagg caatgtgacc agtcacaggg acagatcaca 1440 tctccccaga gtggcaactc tggtgaaacc ttttcagaat catggcagag gggcgtggcg 1500 tggtgctact gagaaggtcc tccttcctct tgactttgtg gtctgaaacc tggtcttact 1560 gtccatgtgt gtttgggccc ggatggtcag ggtggggagc agggacggcc atgggcacgc 1620 ctggccacgc tttaccgact gctgaccccc tgggccaggt gaggttgggg cctgtgggcc 1680 gccagtccat acggtgctgt cactgcccat cttcggtgac accctggggt gaggtgctca 1740 gcaccttcct ctcgaggagc cacattttcc tcctttgtgt taggggacat aacaagctct 1800 gctgggcttg agggacccag accaggtgtc tgcagtcagc tcctgagaca cagctggccg 1860 gcacaacagg tgttacatca ggggtttcct gtggccgttt gaactttgag catttatcta 1920 aattaaattg gcccagggtt ggctggtggg tcacccagca gaggcttctc cccatagcac 1980 gaggatgtgt tgcctgggca cggtgactgc ggttattcct ggaggtcggc agacatgcca 2040 accttgggct atttgagctg gagaagctat gtgatgctag ccggtggctt tctgggctag 2100 gccccagttt gaggctcccc tgggaactag agccaggaac agccagtggc actgacaagg 2160 ggacggagtc caaggcgtta ttgggccacc tgacagctgg acagaaaagg ggcagacaca 2220 ccgnggatgc gatttnaaat aaatgcagat gtttacttgg aaaaaaaaaa aaaaaaaaaa 2280 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2312 148 422 PRT Homo sapiens 148 Met Gly Lys Ala Lys Val Pro Ala Ser Lys Arg Ala Pro Ser Ser Pro 1 5 10 15 Val Ala Lys Pro Gly Pro Val Lys Thr Leu Thr Arg Lys Lys Asn Lys 20 25 30 Lys Lys Lys Arg Phe Trp Lys Ser Lys Ala Arg Glu Val Ser Lys Lys 35 40 45 Pro Ala Ser Gly Pro Gly Ala Val Val Arg Pro Pro Lys Ala Pro Glu 50 55 60 Asp Phe Ser Gln Asn Trp Lys Ala Leu Gln Glu Trp Leu Leu Lys Gln 65 70 75 80 Lys Ser Gln Ala Pro Glu Lys Pro Leu Val Ile Ser Gln Met Gly Ser 85 90 95 Lys Lys Lys Pro Lys Ile Ile Gln Gln Asn Lys Lys Glu Thr Ser Pro 100 105 110 Gln Val Lys Gly Glu Glu Met Pro Ala Gly Lys Asp Gln Glu Ala Ser 115 120 125 Arg Gly Ser Val Pro Ser Gly Ser Lys Met Asp Arg Arg Ala Pro Val 130 135 140 Pro Arg Thr Lys Ala Ser Gly Thr Glu His Asn Lys Lys Gly Thr Lys 145 150 155 160 Glu Arg Thr Asn Gly Asp Ile Val Pro Glu Arg Gly Asp Ile Glu His 165 170 175 Lys Lys Arg Lys Ala Lys Glu Ala Ala Pro Ala Pro Pro Thr Glu Glu 180 185 190 Asp Ile Trp Phe Asp Asp Val Asp Pro Ala Asp Ile Glu Ala Ala Ile 195 200 205 Gly Pro Glu Ala Ala Lys Ile Ala Arg Lys Gln Leu Gly Gln Ser Glu 210 215 220 Gly Ser Val Ser Leu Ser Leu Val Lys Glu Gln Ala Phe Gly Gly Leu 225 230 235 240 Thr Arg Ala Leu Ala Leu Asp Cys Glu Met Val Gly Val Gly Pro Lys 245 250 255 Gly Glu Glu Ser Met Ala Ala Arg Val Ser Ile Val Asn Gln Tyr Gly 260 265 270 Lys Cys Val Tyr Asp Lys Tyr Val Lys Pro Thr Glu Pro Val Thr Asp 275 280 285 Tyr Arg Thr Ala Val Ser Gly Ile Arg Pro Glu Asn Leu Lys Gln Gly 290 295 300 Glu Glu Leu Glu Val Val Gln Lys Glu Val Ala Glu Met Leu Lys Gly 305 310 315 320 Arg Ile Leu Val Gly His Ala Leu His Asn Asp Leu Lys Val Leu Phe 325 330 335 Leu Asp His Pro Lys Lys Lys Ile Arg Asp Thr Gln Lys Tyr Lys Pro 340 345 350 Phe Lys Ser Gln Val Lys Ser Gly Arg Pro Ser Leu Arg Leu Leu Ser 355 360 365 Glu Lys Ile Leu Gly Leu Gln Val Gln Gln Ala Glu His Cys Ser Ile 370 375 380 Gln Asp Ala Gln Ala Ala Met Arg Leu Tyr Val Met Val Lys Lys Glu 385 390 395 400 Trp Glu Ser Met Ala Arg Asp Arg Arg Pro Leu Leu Thr Ala Pro Asp 405 410 415 His Cys Ser Asp Asp Ala 420 149 2103 DNA Homo sapiens 149 gggaggaacg tatcccttct ggaggctgtc tcagggggca gagggaccgg accggaagtg 60 acgtgagcgg gttccggttg tctggagccc agctgcgggt gtgagagtcc gtaaggagca 120 gcttccagga tcctgagatc cggagcagcc ggggtcggag cggctcctca agagttactg 180 atctatgaaa tggcagagaa tggaaaaaat tgtgaccaga gacgtgtagc aatgaacaag 240 gaacatcata atggaaattt cacagacccc tcttcagtga atgaaaagaa gaggagggag 300 cgggaagaaa ggcagaatat tgtcctgtgg agacagccgc tcattacctt gcagtatttt 360 tctctggaaa tccttgtaat cttgaaggaa tggacctcaa aattatggca tcgtcaaagc 420 attgtggtgt cttttttact gctgcttgct gtgcttatag ctacgtatta tgttgaagga 480 gtgcatcaac agtatgtgca acgtatagag aaacagtttc ttttgtatgc ctactggata 540 ggcttaggaa ttttgtcttc tgttgggctt ggaacagggc tgcacacctt tctgctttat 600 ctgggtccac atatagcctc agttacatta gctgcttatg aatgcaattc agttaatttt 660 cccgaaccac cctatcctga tcagattatt tgtccagatg aagagggcac tgaaggaacc 720 atttctttgt ggagtatcat ctcaaaagtt aggattgaag cctgcatgtg gggtatcggt 780 acagcaatcg gagagctgcc tccatatttc atggccagag cagctcgcct ctcaggtgct 840 gaaccagatg atgaagagta tcaggaattt gaagagatgc tggaacatgc agagtctgca 900 caagactttg cctcccgggc caaactggca gttcaaaaac tagtacagaa agttggattt 960 tttggaattt tggcctgtgc ttcaattcca aatcctttat ttgatctggc tggaataacg 1020 tgtggacact ttctggtacc tttttggacc ttctttggtg caaccctaat tggaaaagca 1080 ataataaaaa tgcatatcca gaaaattttt gttataataa cattcagcaa gcacatagtg 1140 gagcaaatgg tggctttcat tggtgctgtc cccggcatag gtccatctct gcagaagcca 1200 tttcaggagt acctggaggc tcaacggcag aagcttcacc acaaaagcga aatgggcaca 1260 ccacagggag aaaactggtt gtcctggatg tttgaaaagt tggtcgttgt catggtgtgt 1320 tacttcatcc tatctatcat taactccatg gcacaaagtt atgccaaacg aatccagcag 1380 cggttgaact cagaggagaa aactaaataa gtagagaaag ttttaaactg cagaaattgg 1440 agtggatggg ttctgcctta aattgggagg actccaagcc gggaaggaaa attccctttt 1500 ccaacctgta tcaattttta caactttttt cctgaaagca gtttagtcca tactttgcac 1560 tgacatactt tttccttctg tgctaaggta aggtatccac cctcgatgca atccaccttg 1620 tgttttctta gggtggaatg tgatgttcag cagcaaactt gcaacagact ggccttctgt 1680 ttgttacttt caaaaggccc acatgataca attagagaat tcccaccgca caaaaaaagt 1740 tcctaagtat gttaaatatg tcaagctttt taggcttgtc acaaatgatt gctttgtttt 1800 cctaagtcat caaaatgtat ataaattatc tagattggat aacagtcttg catgtttatc 1860 atgttacaat ttaatattcc atcctgccca acccttcctc tcccatcctc aaaaaagggc 1920 cattttatga tgcattgcac accctctggg gaaattgatc tttaaatttt gagacagtat 1980 aaggaaaatc tggttggtgt cttacaagtg agctgacacc attttttatt ctgtgtattt 2040 agaatgaagt cttgaaaaaa actttataaa gacatcttta atcattccaa aaaaaaaaaa 2100 aaa 2103 150 406 PRT Homo sapiens 150 Met Ala Glu Asn Gly Lys Asn Cys Asp Gln Arg Arg Val Ala Met Asn 1 5 10 15 Lys Glu His His Asn Gly Asn Phe Thr Asp Pro Ser Ser Val Asn Glu 20 25 30 Lys Lys Arg Arg Glu Arg Glu Glu Arg Gln Asn Ile Val Leu Trp Arg 35 40 45 Gln Pro Leu Ile Thr Leu Gln Tyr Phe Ser Leu Glu Ile Leu Val Ile 50 55 60 Leu Lys Glu Trp Thr Ser Lys Leu Trp His Arg Gln Ser Ile Val Val 65 70 75 80 Ser Phe Leu Leu Leu Leu Ala Val Leu Ile Ala Thr Tyr Tyr Val Glu 85 90 95 Gly Val His Gln Gln Tyr Val Gln Arg Ile Glu Lys Gln Phe Leu Leu 100 105 110 Tyr Ala Tyr Trp Ile Gly Leu Gly Ile Leu Ser Ser Val Gly Leu Gly 115 120 125 Thr Gly Leu His Thr Phe Leu Leu Tyr Leu Gly Pro His Ile Ala Ser 130 135 140 Val Thr Leu Ala Ala Tyr Glu Cys Asn Ser Val Asn Phe Pro Glu Pro 145 150 155 160 Pro Tyr Pro Asp Gln Ile Ile Cys Pro Asp Glu Glu Gly Thr Glu Gly 165 170 175 Thr Ile Ser Leu Trp Ser Ile Ile Ser Lys Val Arg Ile Glu Ala Cys 180 185 190 Met Trp Gly Ile Gly Thr Ala Ile Gly Glu Leu Pro Pro Tyr Phe Met 195 200 205 Ala Arg Ala Ala Arg Leu Ser Gly Ala Glu Pro Asp Asp Glu Glu Tyr 210 215 220 Gln Glu Phe Glu Glu Met Leu Glu His Ala Glu Ser Ala Gln Asp Phe 225 230 235 240 Ala Ser Arg Ala Lys Leu Ala Val Gln Lys Leu Val Gln Lys Val Gly 245 250 255 Phe Phe Gly Ile Leu Ala Cys Ala Ser Ile Pro Asn Pro Leu Phe Asp 260 265 270 Leu Ala Gly Ile Thr Cys Gly His Phe Leu Val Pro Phe Trp Thr Phe 275 280 285 Phe Gly Ala Thr Leu Ile Gly Lys Ala Ile Ile Lys Met His Ile Gln 290 295 300 Lys Ile Phe Val Ile Ile Thr Phe Ser Lys His Ile Val Glu Gln Met 305 310 315 320 Val Ala Phe Ile Gly Ala Val Pro Gly Ile Gly Pro Ser Leu Gln Lys 325 330 335 Pro Phe Gln Glu Tyr Leu Glu Ala Gln Arg Gln Lys Leu His His Lys 340 345 350 Ser Glu Met Gly Thr Pro Gln Gly Glu Asn Trp Leu Ser Trp Met Phe 355 360 365 Glu Lys Leu Val Val Val Met Val Cys Tyr Phe Ile Leu Ser Ile Ile 370 375 380 Asn Ser Met Ala Gln Ser Tyr Ala Lys Arg Ile Gln Gln Arg Leu Asn 385 390 395 400 Ser Glu Glu Lys Thr Lys 405 151 1330 DNA Homo sapiens 151 gatgtgagtc ttgccaaagc tcctggcgga ataaagccct tccttcttta actcggtgtc 60 tgaggggttt tgtctgtggc ttgtcctgct acatttcttg gttccctgac caggaaacaa 120 ggtgattaat ggatggtcga gacagctcct taggtggctt aggcctgccc tgtggagcat 180 acctgagggg gactccagcc agcttgagtg aagcagatcc tgagagcact cccaggtagg 240 caattgcccc agtggaatgc ctcatcagag cagtgcacag caggcccctg tggaggatca 300 atgcagtggc tgaacaccat gaaggaactg gcacttggag tccggacatc taaaacttgc 360 accttttctg ctgccatgac aaccatgcaa ggaatggaac aggccatgcc aggggctggc 420 cctggtgtgc cccagctggg aaacatggct gtcatacatt cacatctgtg gaaaggattg 480 caagagaagt tcttgaaggg agaacccaaa gtccttgggg ttgtgcagat tctgactgcc 540 ctgatgagcc ttagcatggg aataacaatg atgtgtatgg catctaatac ttatggaagt 600 aaccctattt ccgtgtatat cgggtacaca atttgggggt cagtaatgtt tattatttca 660 ggatccttgt caattgcagc aggaattaga actacaaaag gcctggtccg aggtagtcta 720 ggaatgaata tcaccagctc tgtactggct gcatcaggga tcttaatcaa cacatttagc 780 ttggcgtttt attcattcca tcacccttac tgtaactact atggcaactc aaataattgt 840 catgggacta tgtccatctt aatgggtctg gatggcatgg tgctcctctt aagtgtgctg 900 gaattctgca ttgctgtgtc cctctctgcc tttggatgta aagtgctctg ttgtacccct 960 ggtggggttg tgttaattct gccatcacat tctcacatgg cagaaacagc atctcccaca 1020 ccacttaatg aggtttgagg ccaccaaaag atcaacagac aaatgctcca gaaatctatg 1080 ctgactgtga cacaagagcc tcacatgaga aattaccagt atccaacttc gatactgata 1140 gacttgttga tattattatt atatgtaatc caattatgaa ctgtgtgtgt atagagagat 1200 aataaattca aaattatgtt ctcatttttt tccctggaac tcaataactc atttcactgg 1260 ctctttatcg agagtactag aagttaaatt aataaataat gcatttaatg aggcaaaaaa 1320 aaaaaaaaaa 1330 152 245 PRT Homo sapiens 152 Met Gln Trp Leu Asn Thr Met Lys Glu Leu Ala Leu Gly Val Arg Thr 1 5 10 15 Ser Lys Thr Cys Thr Phe Ser Ala Ala Met Thr Thr Met Gln Gly Met 20 25 30 Glu Gln Ala Met Pro Gly Ala Gly Pro Gly Val Pro Gln Leu Gly Asn 35 40 45 Met Ala Val Ile His Ser His Leu Trp Lys Gly Leu Gln Glu Lys Phe 50 55 60 Leu Lys Gly Glu Pro Lys Val Leu Gly Val Val Gln Ile Leu Thr Ala 65 70 75 80 Leu Met Ser Leu Ser Met Gly Ile Thr Met Met Cys Met Ala Ser Asn 85 90 95 Thr Tyr Gly Ser Asn Pro Ile Ser Val Tyr Ile Gly Tyr Thr Ile Trp 100 105 110 Gly Ser Val Met Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala Ala Gly 115 120 125 Ile Arg Thr Thr Lys Gly Leu Val Arg Gly Ser Leu Gly Met Asn Ile 130 135 140 Thr Ser Ser Val Leu Ala Ala Ser Gly Ile Leu Ile Asn Thr Phe Ser 145 150 155 160 Leu Ala Phe Tyr Ser Phe His His Pro Tyr Cys Asn Tyr Tyr Gly Asn 165 170 175 Ser Asn Asn Cys His Gly Thr Met Ser Ile Leu Met Gly Leu Asp Gly 180 185 190 Met Val Leu Leu Leu Ser Val Leu Glu Phe Cys Ile Ala Val Ser Leu 195 200 205 Ser Ala Phe Gly Cys Lys Val Leu Cys Cys Thr Pro Gly Gly Val Val 210 215 220 Leu Ile Leu Pro Ser His Ser His Met Ala Glu Thr Ala Ser Pro Thr 225 230 235 240 Pro Leu Asn Glu Val 245 153 1724 DNA Homo sapiens 153 cgttctctcc tccttcctcc ccgcctccag ctgccggcag gacctttctc tcgctgccgc 60 tgggaccccg tgtcatcgcc caggccgagc acgatgcccc ctaaaaaggg aggtgatgga 120 attaaaccac ccccaatcat tggaagattt ggaacctcac tgaaaattgg tattgttgga 180 ttgccaaatg ttgggaaatc tactttcttc aatgtgttaa ccaatagtca ggcttcagca 240 gaaaacttcc cgttctgcac tattgatcct aatgagagca gagtacctgt gccagatgaa 300 aggtttgact ttctttgtca ataccacaaa ccagcaagca aaattcctgc ctttctaaat 360 gtggtggata ttgctggcct tgtgaaagga gctcacaatg ggcagggcct ggggaatgct 420 tttttatctc atattagtgc ctgtgatggc atctttcatc taacacgtgc ttttgaagat 480 gatgatatca cgcacgttga aggaagtgta gatcctattc gagatataga aataatacat 540 gaagagcttc agcttaaaga tgaggaaatg attgggccca ttatagataa actagaaaag 600 gtggctgtga gaggaggaga taaaaaacta aaacctgaat atgatataat gtgcaaagta 660 aaatcctggg ttatagatca aaagacacct gttcgcttct atcatgattg gaatgacaaa 720 gagattgaag tgttgaatac acacttattt ttgacttcaa aaccaatggt ctacttggtt 780 aatctttctg aaaaagacta cattagaaag aaaaacaaat ggttgataaa aattaaagag 840 tgggtggaca agtatgaccc aggtgctttg gtcattcctt ttagtggggc cttggaactc 900 aagttgcaag aattgagtgc tgaggagaga cagaagtatc tggaagcgaa catgacacaa 960 agtgctttgc caaagatcat taaggctggg tttgcagcac tccaactaga atactttttc 1020 actgcaggcc cagatgaagt gcgtgcatgg accatcagga aagggactaa ggctcctcag 1080 gctgcaggaa agattcacac agattttgaa aagggattca ttatggctga agtaatgaaa 1140 tacgaagatt ttaaagagga aggttctgaa aatgcagtca aggctgctgg aaagtacaga 1200 caacaaggca gaaattatat tgttgaagat ggagatatta tcttcttcaa atttaacaca 1260 cctcaacaac cgaagaagaa ataaaattta gttattgctc agataaacat acaacttcca 1320 aaaggcatct gatttttaaa aaattaaaat ttctgaaaac caatgcgaca aataaagttg 1380 gggagatggg aatctttgac aaacaaatta tttttatttg ttttaaaatt aaaatactgt 1440 gtaccccccc cccccccatg aaatgcaggt tcactaaatg tgaacagctt tgcttttcac 1500 gtgattaaga ccctactcca aattgtagaa gcttttcagg aaccatatta ctctcatgat 1560 acttcattaa tctccatcat gtatgccaag cctgacacat ttgacagtga ggacaatgtg 1620 gcttgctcct ttttgaatct acagataatg catgttttac agtactccag atgtctacac 1680 tcaataaaac atttgacaaa accaaaaaaa aaaaaaaaaa aaaa 1724 154 396 PRT Homo sapiens 154 Met Pro Pro Lys Lys Gly Gly Asp Gly Ile Lys Pro Pro Pro Ile Ile 1 5 10 15 Gly Arg Phe Gly Thr Ser Leu Lys Ile Gly Ile Val Gly Leu Pro Asn 20 25 30 Val Gly Lys Ser Thr Phe Phe Asn Val Leu Thr Asn Ser Gln Ala Ser 35 40 45 Ala Glu Asn Phe Pro Phe Cys Thr Ile Asp Pro Asn Glu Ser Arg Val 50 55 60 Pro Val Pro Asp Glu Arg Phe Asp Phe Leu Cys Gln Tyr His Lys Pro 65 70 75 80 Ala Ser Lys Ile Pro Ala Phe Leu Asn Val Val Asp Ile Ala Gly Leu 85 90 95 Val Lys Gly Ala His Asn Gly Gln Gly Leu Gly Asn Ala Phe Leu Ser 100 105 110 His Ile Ser Ala Cys Asp Gly Ile Phe His Leu Thr Arg Ala Phe Glu 115 120 125 Asp Asp Asp Ile Thr His Val Glu Gly Ser Val Asp Pro Ile Arg Asp 130 135 140 Ile Glu Ile Ile His Glu Glu Leu Gln Leu Lys Asp Glu Glu Met Ile 145 150 155 160 Gly Pro Ile Ile Asp Lys Leu Glu Lys Val Ala Val Arg Gly Gly Asp 165 170 175 Lys Lys Leu Lys Pro Glu Tyr Asp Ile Met Cys Lys Val Lys Ser Trp 180 185 190 Val Ile Asp Gln Lys Thr Pro Val Arg Phe Tyr His Asp Trp Asn Asp 195 200 205 Lys Glu Ile Glu Val Leu Asn Thr His Leu Phe Leu Thr Ser Lys Pro 210 215 220 Met Val Tyr Leu Val Asn Leu Ser Glu Lys Asp Tyr Ile Arg Lys Lys 225 230 235 240 Asn Lys Trp Leu Ile Lys Ile Lys Glu Trp Val Asp Lys Tyr Asp Pro 245 250 255 Gly Ala Leu Val Ile Pro Phe Ser Gly Ala Leu Glu Leu Lys Leu Gln 260 265 270 Glu Leu Ser Ala Glu Glu Arg Gln Lys Tyr Leu Glu Ala Asn Met Thr 275 280 285 Gln Ser Ala Leu Pro Lys Ile Ile Lys Ala Gly Phe Ala Ala Leu Gln 290 295 300 Leu Glu Tyr Phe Phe Thr Ala Gly Pro Asp Glu Val Arg Ala Trp Thr 305 310 315 320 Ile Arg Lys Gly Thr Lys Ala Pro Gln Ala Ala Gly Lys Ile His Thr 325 330 335 Asp Phe Glu Lys Gly Phe Ile Met Ala Glu Val Met Lys Tyr Glu Asp 340 345 350 Phe Lys Glu Glu Gly Ser Glu Asn Ala Val Lys Ala Ala Gly Lys Tyr 355 360 365 Arg Gln Gln Gly Arg Asn Tyr Ile Val Glu Asp Gly Asp Ile Ile Phe 370 375 380 Phe Lys Phe Asn Thr Pro Gln Gln Pro Lys Lys Lys 385 390 395 155 2291 DNA Homo sapiens 155 gaacttgtct gaagcccttg tccgtaagcc ttgaactacg ttcttaaatc tatgaagtcg 60 agggaccttt cgctgctttt gtagggactt ctttccttgc ttcagcaaca tgaggctttt 120 cttgtggaac gcggtcttga ctctgttcgt cacttctttg attggggctt tgatccctga 180 accagaagtg aaaattgaag ttctccagaa gccattcatc tgccatcgca agaccaaagg 240 aggggatttg atgttggtcc actatgaagg ctacttagaa aaggacggct ccttatttca 300 ctccactcac aaacataaca atggtcagcc catttggttt accctgggca tcctggaggc 360 tctcaaaggt tgggaccagg gcttgaaagg aatgtgtgta ggagagaaga gaaagctcat 420 cattcctcct gctctgggct atggaaaaga aggaaaaggt aaaattcccc cagaaagtac 480 actgatattt aatattgatc tcctggagat tcgaaatgga ccaagatccc atgaatcatt 540 ccaagaaatg gatcttaatg atgactggaa actctctaaa gatgaggtta aagcatattt 600 aaagaaggag tttgaaaaac atggtgcggt ggtgaatgaa agtcatcatg atgctttggt 660 ggaggatatt tttgataaag aagatgaaga caaagatggg tttatatctg ccagagaatt 720 tacatataaa cacgatgagt tatagagata catctaccct tttaatatag cactcatctt 780 tcaagagagg gcagtcatct ttaaagaaca ttttattttt atacaatgct ctttcttgct 840 ttgcttttta tttttatata ttttttctga ctcctattta aagaacccct taggtttcta 900 agtacccatt tctttctgat aagttattgg gaagaaaaag ctaattggtc tttgaataga 960 agacttctgg acaatttttc actttcacag atatgaagct ttgttttact ttctcactta 1020 taaatttaaa atgttgcaac tgggaatata ccacgacatg agaccaggtt atagcacaaa 1080 ttagcaccct atatttctgc ttccctctat tttctccaag ttagaggtca acatttgaaa 1140 agccttttgc aatagcccaa ggcttgctat tttcatgtta taatgaaata gtttatgtgt 1200 aactggctct gagtctctgc ttgaggacca gaggaaaatg gttgttggac ctgacttgtt 1260 aatggctact gctttactaa ggagatgtgc aatgctgaag ttagaaacaa ggttaatagc 1320 caggcatggt ggctcatgcc tgtaatccca gcactttggg aggctgaggc gggcggatca 1380 cctgaggttg ggagttcgag accagcctga ccaacacgga gaaaccctat ctctactaaa 1440 aatacaaaag tagccgggcg tggtgatgcg tgcctgtaat cccagctacc caggaaggct 1500 gaggcggcag aatcacttga acccggaggc ggaggttgcg gtaagccgag atcacctcca 1560 gcctggacac tctgtctcga aaaaaagaaa agaaacacgg ttaataacat ataaatatgt 1620 atgcattgag acatgctacc taggacttaa gctgatgaag cttggctcct agtgattggt 1680 ggcctattat gataaatagg acaaatcatt tatgtgtgag tttctttgta ataaaatgta 1740 tcaatatgtt atagatgagg tagaaagtta tatttatatt caatatttac ttcttaaggc 1800 tagcggaata tccttcctgg ttctttaatg ggtagtctat agtatattat actacaataa 1860 cattgtatca taagataaag tagtaaacca gtctacattt tcccatttct gtctcatcaa 1920 aaactgaagt tagctgggtg tggtggctca tgcctgtaat cccagcactt tgggggccaa 1980 ggagggtgga tcacttgaga tcaggagttc aagaccagcc tggccaacat ggtgaaacct 2040 tgtctctact aaaaatacaa aaattagcca ggcgtggtgg tgcacacctg tagtcccagc 2100 tactcgggag gctgagacag gagatttgct tgaacccggg aggcggaggt tgcagtgagc 2160 caagattgtg ccactgcact ccagcctggg tgacagagca agactccatc tcaaaaaaaa 2220 aaaaaagaag cagacctaca gcagctacta ttgaataaat acctatcctg gattttaaaa 2280 aaaaaaaaaa a 2291 156 211 PRT Homo sapiens 156 Met Arg Leu Phe Leu Trp Asn Ala Val Leu Thr Leu Phe Val Thr Ser 1 5 10 15 Leu Ile Gly Ala Leu Ile Pro Glu Pro Glu Val Lys Ile Glu Val Leu 20 25 30 Gln Lys Pro Phe Ile Cys His Arg Lys Thr Lys Gly Gly Asp Leu Met 35 40 45 Leu Val His Tyr Glu Gly Tyr Leu Glu Lys Asp Gly Ser Leu Phe His 50 55 60 Ser Thr His Lys His Asn Asn Gly Gln Pro Ile Trp Phe Thr Leu Gly 65 70 75 80 Ile Leu Glu Ala Leu Lys Gly Trp Asp Gln Gly Leu Lys Gly Met Cys 85 90 95 Val Gly Glu Lys Arg Lys Leu Ile Ile Pro Pro Ala Leu Gly Tyr Gly 100 105 110 Lys Glu Gly Lys Gly Lys Ile Pro Pro Glu Ser Thr Leu Ile Phe Asn 115 120 125 Ile Asp Leu Leu Glu Ile Arg Asn Gly Pro Arg Ser His Glu Ser Phe 130 135 140 Gln Glu Met Asp Leu Asn Asp Asp Trp Lys Leu Ser Lys Asp Glu Val 145 150 155 160 Lys Ala Tyr Leu Lys Lys Glu Phe Glu Lys His Gly Ala Val Val Asn 165 170 175 Glu Ser His His Asp Ala Leu Val Glu Asp Ile Phe Asp Lys Glu Asp 180 185 190 Glu Asp Lys Asp Gly Phe Ile Ser Ala Arg Glu Phe Thr Tyr Lys His 195 200 205 Asp Glu Leu 210 157 2229 DNA Homo sapiens 157 gaagacgttg acacacttgg agccaacaag aacattagtc atgacaagca tgccatctga 60 aaagcagaat gtcgtcatcc aggttgtgga taaattgaaa ggcttttcaa ttgcaccaga 120 cgtctgtgag accacgactc acgtgctttc cgggaagcca cttcgcaccc tgaatgtgct 180 gctgggaatt gcgcgtggct gctgggttct ctcttatgat tgggtgctat ggtctttaga 240 attgggtcac tggatttctg aggagccgtt cgaactgtct caccacttcc ctgcagctcc 300 cctgtgccga agcgagtgcc acttgtctgc agggccgtac cgcggaaccc tctttgccga 360 ccagccagcg atgtttgtct cgcctgccag cagcccccca gtggccaagc tctgtgaact 420 agtccacctg tgcggaggcc gggtcagcca agtcccccgc caggccagca tcgtcatcgg 480 gccctacagc ggaaagaaga aagccacagt caagtatctg tctgagaaat gggtcttagg 540 taagaatcca ggcacacaga cgctgtggtg tggtccagat ctgtggacag gtttccaggg 600 agggcggcgt caggctcaca cccccttcca cgcagctggg gcacctgggt tgatgtctca 660 gcctccagca tctgccctgg cagcgtcgtg tggtcaccct cggcattccc gctccttgct 720 gttagcagac gtacagttca cgaggaaatg ggaactctaa ctggacttcc ccacttgact 780 tccctggctc gtgtgaaaaa tccaggctac ccaaagccac cccgggccac ccctgtgggc 840 acagactctc cgggcacccc tcttagaccc tccctcccca gtgcctcctt gtcctgcttc 900 aggagtccct ggcagcgccc ggcactgggg cccaagcccc cgtccctgtc atctcctctc 960 ccaggtacat ctcatgatca ctccgtctgc tcatgtgctc aaagggtgtt aaaagacgtc 1020 aaacgactcc atcttttatt tgacaaagtg agcacagtgt gaccgtaatg tcccactctg 1080 gcgttcatgg agctgcgcca ggcgccgtgt gcgattctgg ggaggaagag gtggtaggag 1140 ctgagctgag atcggaggag gctggaaccc cacgccgtgc taacacacgg gctccaggag 1200 acttgcaggt gatccccgga gaagagggtt aaggaagagt gtgaagcaag gacggcctgg 1260 ggaatgcgga ggaagcaggg cagcgtctgt gctagaaatt acctgccctg tggtggagtc 1320 atatgtggcg ggacaagcct agggctccac tgtggggaaa tcccacaccc tcctccatgg 1380 ggttgtgata aacatgttag tttgcttggg ctgccatcgc aaaatactac aggctgggtg 1440 gcttcaaaca acacgcattg tctctcagtt ctggaggctg gaagtctaag atggggtatc 1500 ggcagcgttg gtttcccctg aggcctctct cctgggcttg cagacagctg ccttcttcct 1560 gtgacctcac gtggcctttc ctccatgcac acacatccct ggtatctctg tgtgtgtcca 1620 aatgttctct tctctaagga taccagtcag attggattag ggctcaccca gtggcatcat 1680 tttaacttgt ctttttcaag gccccatctc caaatacagt ctcatcctga gttactgagg 1740 gttaagacat cgacatacga attttgggca gacacaattc agcccataac aatgaatcac 1800 tctagtttca gcccctgggg ccaagatcct tacccgactt tagaggtaca tcccctctct 1860 ctctctcaat ctctctctct ctctcccgtt ctctcattct ttttctctct ctttgcttcc 1920 atctccttcc atgtttccta ttcagtctcc tttcttagta cttttgcatg tctctaaatc 1980 ctaaacttct ggcttttctc atcatctgct caacattatc ccttaataga caagtagata 2040 ctgtgtttgt tcaagttaca ttcgtatcta actacggaca ttttacaagt atcttttaca 2100 tgactgatgg tcatcctttc atatatttta gaagtgtggc aatcaaaagt aattttttac 2160 tctggtgcag agtaattcat cttttgcctg gaaaccaact tccaaaaaaa aaaaaaaaaa 2220 aaaaaaaaa 2229 158 239 PRT Homo sapiens 158 Met Thr Ser Met Pro Ser Glu Lys Gln Asn Val Val Ile Gln Val Val 1 5 10 15 Asp Lys Leu Lys Gly Phe Ser Ile Ala Pro Asp Val Cys Glu Thr Thr 20 25 30 Thr His Val Leu Ser Gly Lys Pro Leu Arg Thr Leu Asn Val Leu Leu 35 40 45 Gly Ile Ala Arg Gly Cys Trp Val Leu Ser Tyr Asp Trp Val Leu Trp 50 55 60 Ser Leu Glu Leu Gly His Trp Ile Ser Glu Glu Pro Phe Glu Leu Ser 65 70 75 80 His His Phe Pro Ala Ala Pro Leu Cys Arg Ser Glu Cys His Leu Ser 85 90 95 Ala Gly Pro Tyr Arg Gly Thr Leu Phe Ala Asp Gln Pro Ala Met Phe 100 105 110 Val Ser Pro Ala Ser Ser Pro Pro Val Ala Lys Leu Cys Glu Leu Val 115 120 125 His Leu Cys Gly Gly Arg Val Ser Gln Val Pro Arg Gln Ala Ser Ile 130 135 140 Val Ile Gly Pro Tyr Ser Gly Lys Lys Lys Ala Thr Val Lys Tyr Leu 145 150 155 160 Ser Glu Lys Trp Val Leu Gly Lys Asn Pro Gly Thr Gln Thr Leu Trp 165 170 175 Cys Gly Pro Asp Leu Trp Thr Gly Phe Gln Gly Gly Arg Arg Gln Ala 180 185 190 His Thr Pro Phe His Ala Ala Gly Ala Pro Gly Leu Met Ser Gln Pro 195 200 205 Pro Ala Ser Ala Leu Ala Ala Ser Cys Gly His Pro Arg His Ser Arg 210 215 220 Ser Leu Leu Leu Ala Asp Val Gln Phe Thr Arg Lys Trp Glu Leu 225 230 235 159 3580 DNA Homo sapiens 159 aggtctagaa gtgccccaag ccccatcatg gaagagggct tccgagaccg ggcagctttc 60 atccgtgggg ccaaagacat tgctaaggaa gtcaaaaagc atgcggccaa gaaggtggtg 120 aagggcctgg acagagtcca ggacgaatat tcccgaagat cgtactcccg ctttgaggag 180 gaggatgatg atgatgactt ccctgctccc agtgatggtt attacccagg agaagggacc 240 caggatgagg aggaaggtgg tgcatccagt gatgctactg agggccatga cgaggatgat 300 gacatctatg aaggggaata tcagggcatt ccccgggcag agtctggggg caaaggcgag 360 cggatggcag atggggcgcc cctggctgga gtaagggggg gcttgagtga tggggagggt 420 ccccctgggg gccgggggga ggcacaacga cggaaagaac gagaagaact ggcccaacag 480 tatgaagcca tcctacggga gtgtggccac ggccgcttcc agtggacact gtattttgtg 540 cttggtctgg cgctgatggc tgacggtgtg gaggtctttg tggtgggctt cgtgctgccc 600 agcgctgaga aagacatgtg cctgtccgac tccaacaaag gcatgctagg cctcatcgtc 660 tacctgggca tgatggtggg agccttcctc tggggaggtc tggctgaccg gctgggtcgg 720 aggcagtgtc tgctcatctc gctctcagtc aacagcgtct tcgccttctt ctcatctttt 780 gtccagggtt acggcacttt cctcttctgc cgcctacttt ctggggttgg gattggaggg 840 tccatcccca ttgtcttctc ctatttctcc gagtttctgg cccaggagaa acgaggggag 900 catttgagct ggctctgcat gttttggatg attggtggcg tgtacgcagc tgctatggcc 960 tgggccatca tcccccacta tgggtggagt tttcagatgg gttctgccta ccagttccac 1020 agctggaggg tcttcgtcct cgtctgcgcc tttccttctg tgtttgccat tggggctctg 1080 accacgcagc ctgagagccc ccgtttcttc ctagagaatg gaaagcatga tgaggcctgg 1140 atggtgctga agcaggtcca tgataccaac atgcgagcca aaggacatcc tgagcgagtg 1200 ttctcagtaa cccacattaa gacgattcat caggaggatg aattgattga gatccagtcg 1260 gacacaggga cctggtacca gcgctggggg gtccgggcct tgagcctagg ggggcaggtt 1320 tgggggaatt ttctctcctg ttttggtccc gaatatcggc gcatcactct gatgatgatg 1380 ggtgtgtggt tcaccatgtc attcagctac tatggcctga ccgtctggtt tcctgacatg 1440 atccgccatc tccaggcagt ggactacgca tcccgcacca aagtgttccc cggggagcgc 1500 gtagagcatg taacttttaa cttcacgttg gagaatcaga tccaccgagg cgggcagtac 1560 ttcaatgaca agttcattgg gctgcggctc aagtcagtgt cctttgagga ttccctgttt 1620 gaagagtgtt attttgagga tgtcacatcc agcaacacgt ttttccgcaa ctgcacattc 1680 atcaacactg tgttctataa cactgacctg ttcgagtaca agtttgtgaa cagccgtctg 1740 ataaacagta cattcctgca caacaaggag ggctgcccgc tagacgtgac agggacgggc 1800 gaaggtgcct acatggtata ctttgtgagc ttcctgggga cactggcagt gcttcctggg 1860 aatatcgtgt ctgccctgct catggacaag atcggcaggc tcagaatgct tgctggctcc 1920 agcgtgatgt cctgtgtctc ctgcttcttc ctgtcttttg ggaacagtga gtcggccatg 1980 atcgctctgc tctgcctttt tggcggggtc agcattgcat cctggaatgc gctggacgtg 2040 ttgactgttg aactttaccc ctcagacaag aggaccacag cttttggctt cctgaatgcc 2100 ctgtgtaagc tggcagctgt gctggggatc agcatcttca catccttcgt gggaatcacc 2160 aaggctgcac ccatcctctt tgcctcagct gcccttgccc ttggcagctc tctggccctg 2220 aagctgcctg agacccgggg gcaggtgctg cagtgaaggg gtctctaggg ctttgggatt 2280 ggcaggcaca ctgtgagacc aacaactcct tccttcccct ccctgccctg ccatcctgac 2340 ctccagagcc ctcactcccc actccccgtg tttggtgtct tagctgtgtg tgcgtgtgcg 2400 tgtgcatgtg tgtaaacccc gtgggcaggg actacaggga aggctccttc atcccagttt 2460 tgagatgaag ctgtactccc catttcccac tgcccttgac tttgcacaag agaaggctga 2520 gccccatcct tctccccctg ttagagaggg gcccttgctt ccctgttcca ggggttccag 2580 aataggcttc ctgccttccc catcattccc tctgcctagg ccctggtgaa accacaggta 2640 tgcaattatg ctaggggctg gggctctggt gtagaccatg gaccaaaaga acttcttaga 2700 gtctgaagag tgggcctcgg gtgccctctc acatctcctg ttggatgctg ggggagaagc 2760 aataaacctc agccctctgg cctccacttt cctctcaatt tgggctgcaa atatgaagcc 2820 tgaattttat gaaattagct ttctgattct tatttattaa tagattaagt tctgaggcag 2880 ctccgcagga ctgtgtgtga atgtgtatgt atacttacat atgtgtgtgc atgtgccatg 2940 gggcgggggg tatcactata ctgtcctcaa atataagcca agggtaattt cagcggatgc 3000 acacacaacc ctgcctccca cagttcctcc cctaatctgg tttctgtgtt gagcctggga 3060 tggaggagcc ctaggccagc ctgggataag agtcccacag tctagggaga tctgagggca 3120 tccgacaagg cccatctcct tccctcctca agaagcagag gcctcctctg gagtgagagg 3180 ctccacccac tacagcacag gcgggaatag cacagctgcc ctcccatgct ccctacctgt 3240 cccctcacag ggaggggagc aggggaggga aagaaaccag gcatctggtc aaaccagcag 3300 atcaaaaagc acaaagagct ggggcagagg caggaagcag gggccctcct ggcagctcct 3360 ctgagtgggg agaggttggg cagtgagtga gggaccccta atgcagggac tagaagcctc 3420 agtttcccca ttttaccctt ccacacaata gcctctgtag gttaggctgc cccatcccac 3480 cctactctgt gtggctgctt tctttggtgc cctcccctca ccccactgta gctgtgacgt 3540 gttgtagttt ttagatgttt gtaaaatgtt taaaaaaatg 3580 160 742 PRT Homo sapiens 160 Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys 1 5 10 15 Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys Val Val Lys 20 25 30 Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg 35 40 45 Phe Glu Glu Glu Asp Asp Asp Asp Asp Phe Pro Ala Pro Ser Asp Gly 50 55 60 Tyr Tyr Pro Gly Glu Gly Thr Gln Asp Glu Glu Glu Gly Gly Ala Ser 65 70 75 80 Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Asp Ile Tyr Glu Gly 85 90 95 Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg 100 105 110 Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Ser Asp 115 120 125 Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Glu 130 135 140 Arg Glu Glu Leu Ala Gln Gln Tyr Glu Ala Ile Leu Arg Glu Cys Gly 145 150 155 160 His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu 165 170 175 Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser 180 185 190 Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly 195 200 205 Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly 210 215 220 Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser 225 230 235 240 Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly 245 250 255 Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser 260 265 270 Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys 275 280 285 Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly 290 295 300 Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp 305 310 315 320 Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe 325 330 335 Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr 340 345 350 Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp 355 360 365 Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala 370 375 380 Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile 385 390 395 400 His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp 405 410 415 Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp 420 425 430 Gly Asn Phe Leu Ser Cys Phe Gly Pro Glu Tyr Arg Arg Ile Thr Leu 435 440 445 Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu 450 455 460 Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr 465 470 475 480 Ala Ser Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr 485 490 495 Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe 500 505 510 Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp 515 520 525 Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr 530 535 540 Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp 545 550 555 560 Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Ile Asn Ser Thr Phe 565 570 575 Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu 580 585 590 Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val 595 600 605 Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg 610 615 620 Leu Arg Met Leu Ala Gly Ser Ser Val Met Ser Cys Val Ser Cys Phe 625 630 635 640 Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys 645 650 655 Leu Phe Gly Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu 660 665 670 Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe 675 680 685 Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe 690 695 700 Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser 705 710 715 720 Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr 725 730 735 Arg Gly Gln Val Leu Gln 740 161 29 DNA Artificial Sequence oligonucleotide 161 cnccaagcag gggaacggtg agagaaaca 29 162 29 DNA Artificial Sequence oligonucleotide 162 cnagcacaaa acacaaagct gcaaaagcc 29 163 29 DNA Artificial Sequence oligonucleotide 163 gntgagttag tgaccacaaa gatgcgctt 29 164 29 DNA Artificial Sequence oligonucleotide 164 gncatcgtcc tcctccttca acatcccag 29 165 29 DNA Artificial Sequence oligonucleotide 165 gngtttcaga aaattccata cagacctca 29 166 29 DNA Artificial Sequence oligonucleotide 166 angacattga gatgttcctt gagtccagc 29 167 29 DNA Artificial Sequence oligonucleotide 167 tngtggttcc aaagtacggg ccatcctga 29 168 29 DNA Artificial Sequence oligonucleotide 168 tncagcatcc gtagcacaaa tctccattg 29 169 29 DNA Artificial Sequence oligonucleotide 169 gngcacagag gccagcacgt taagaagga 29 170 29 DNA Artificial Sequence oligonucleotide 170 cntcatgagg gggaccacac agttggcta 29 171 29 DNA Artificial Sequence oligonucleotide 171 gnattctcta tgtttgcaga tgccgccat 29 172 29 DNA Artificial Sequence oligonucleotide 172 tncgcttgtg acaaggaacc aagcaattt 29 173 29 DNA Artificial Sequence oligonucleotide 173 gngctaaata ccgccatata tccaaagta 29 174 29 DNA Artificial Sequence oligonucleotide 174 tncagagttc taaccaggct ccccaatgc 29 175 29 DNA Artificial Sequence oligonucleotide 175 cnactaaagg gaccataaca accaaaact 29 176 29 DNA Artificial Sequence oligonucleotide 176 cnagacacca acactgctac catgcgcag 29 177 29 DNA Artificial Sequence oligonucleotide 177 gntcacaatg gagaacacac ggagaaggc 29 178 29 DNA Artificial Sequence oligonucleotide 178 cnggctgtcc tcgccgtttt ctaaccatg 29 179 29 DNA Artificial Sequence oligonucleotide 179 tnctgtaggg ctgcctggct cttgtcgct 29 180 29 DNA Artificial Sequence oligonucleotide 180 antcccttag aaagagatga ctggatgtc 29 181 29 DNA Artificial Sequence oligonucleotide 181 gngcataatc ctccagatcc atgtaaacc 29 182 29 DNA Artificial Sequence oligonucleotide 182 tncttccaat cactatatca ccacgctca 29 183 29 DNA Artificial Sequence oligonucleotide 183 gnatagacga agccccctgc cacagatcg 29 184 29 DNA Artificial Sequence oligonucleotide 184 gnccttcctt ccactggact gccacaaca 29 185 29 DNA Artificial Sequence oligonucleotide 185 cnggaacctt cttcgtacac tgcctttgg 29 186 29 DNA Artificial Sequence oligonucleotide 186 gncttgcaat tactgatcca accctctgt 29 187 29 DNA Artificial Sequence oligonucleotide 187 tnctgtctcg tcataaaaca gctctgggg 29 188 29 DNA Artificial Sequence oligonucleotide 188 gngaaacatg tggtgatgat ggcagaagc 29 189 29 DNA Artificial Sequence oligonucleotide 189 angagtccac tgttgaatga tgactaaca 29 190 29 DNA Artificial Sequence oligonucleotide 190 gnccagagat acacaggaga atagacatt 29 191 29 DNA Artificial Sequence oligonucleotide 191 cntgtagcat ctttctcctg actatctaa 29 192 29 DNA Artificial Sequence oligonucleotide 192 gnaacttgaa ttccgcacat ggcatagcc 29 193 29 DNA Artificial Sequence oligonucleotide 193 tnctccacag ggcatacatg gtggttcat 29 194 29 DNA Artificial Sequence oligonucleotide 194 cntctgcatt tttttctgtg atcggtctt 29 195 29 DNA Artificial Sequence oligonucleotide 195 tngtcttttt gtgagtgttt tctgactgc 29 196 29 DNA Artificial Sequence oligonucleotide 196 gncactaact ctaaaatccc accctgcct 29 197 23 DNA Artificial Sequence oligonucleotide 197 cactatgagg tttaattgga aac 23 198 21 DNA Artificial Sequence oligonucleotide 198 tcctgaattg aaagcaactg c 21 199 21 DNA Artificial Sequence oligonucleotide 199 aactccatga ctgaccgaca c 21 200 20 DNA Artificial Sequence oligonucleotide 200 tcagttcccg tcatattcag 20 201 18 DNA Artificial Sequence oligonucleotide 201 gaccaagctg gtgaaccg 18 202 21 DNA Artificial Sequence oligonucleotide 202 gtgctgttta gactcagatt c 21 203 21 DNA Artificial Sequence oligonucleotide 203 agctcacaga gtcaggacat c 21 204 29 DNA Artificial Sequence oligonucleotide 204 cnacgcccag tcctttctcc aagttcttt 29 205 29 DNA Artificial Sequence oligonucleotide 205 tnattctctc cttcaatgcg gatgtctgg 29 206 29 DNA Artificial Sequence oligonucleotide 206 antctatctt ggatgccttt acttcctgc 29 207 29 DNA Artificial Sequence oligonucleotide 207 anagagagag tcaacgtcgg cagagcgag 29 208 29 DNA Artificial Sequence oligonucleotide 208 tngattgaca ccaatccctt cagccttat 29 209 29 DNA Artificial Sequence oligonucleotide 209 anagcgtcat cgttagcgat gccttgtat 29 210 29 DNA Artificial Sequence oligonucleotide 210 gngacacagc agagaacgaa ctgacagga 29 211 29 DNA Artificial Sequence oligonucleotide 211 cnttgtatga atcgtggact tcctgttct 29 212 29 DNA Artificial Sequence oligonucleotide 212 tnggtgttga cagtgaccag atagaggct 29 213 29 DNA Artificial Sequence oligonucleotide 213 antggtgttc ttctatgttc tcaagttcc 29 214 29 DNA Artificial Sequence oligonucleotide 214 gntgggtctg atgtcctgct gtttttgga 29 215 29 DNA Artificial Sequence oligonucleotide 215 angtcaggga ggcaccgtag ttaatgaat 29 216 29 DNA Artificial Sequence oligonucleotide 216 ancggtaact ctgaccagtg tcctggaag 29 217 29 DNA Artificial Sequence oligonucleotide 217 tnctgtggaa caggaggtca ctacgctga 29 218 29 DNA Artificial Sequence oligonucleotide 218 cnctggtcat aagacagtac tccagcgct 29 219 29 DNA Artificial Sequence oligonucleotide 219 tnataatgct acttaaccac cttttgtct 29 220 29 DNA Artificial Sequence oligonucleotide 220 cntgacacaa atccaccttc ttgccacct 29 221 29 DNA Artificial Sequence oligonucleotide 221 tnagtgtctt gtagtgttct gtgtgagtt 29 222 29 DNA Artificial Sequence oligonucleotide 222 gntcatggat ggcatgacag aattaggat 29 223 29 DNA Artificial Sequence oligonucleotide 223 anattgtcat ttaaaatgag cacctccag 29 224 29 DNA Artificial Sequence oligonucleotide 224 cnctagccac cacagcatag tcagaatcc 29 225 29 DNA Artificial Sequence oligonucleotide 225 gngcagcatg gacctgtcag caactaagg 29 226 29 DNA Artificial Sequence oligonucleotide 226 gntcagcgcg tctctggttt ggttccctc 29 227 29 DNA Artificial Sequence oligonucleotide 227 gnacaccatc agatgtatga aatgtgggt 29 228 29 DNA Artificial Sequence oligonucleotide 228 tnccacctct gaagcctgat tactgtgtg 29 229 29 DNA Artificial Sequence oligonucleotide 229 tnttgggctc gtccttcttg gcctccttc 29 230 29 DNA Artificial Sequence oligonucleotide 230 cntaatgttg actgcagagg gaaaggcaa 29 231 29 DNA Artificial Sequence oligonucleotide 231 tngataattt tgggcttctt tttggaacc 29 232 29 DNA Artificial Sequence oligonucleotide 232 tnagcggctg tctccacagg acaatattc 29 233 29 DNA Artificial Sequence oligonucleotide 233 tncccgatat acacggaaat agggttact 29 234 29 DNA Artificial Sequence oligonucleotide 234 tngatttccc aacatttggc aatccaaca 29 235 29 DNA Artificial Sequence oligonucleotide 235 angcagcgaa aggtccctcg acttcatag 29 236 20 DNA Artificial Sequence oligonucleotide 236 cggaaagaag aaagccacag 20 237 29 DNA Artificial Sequence oligonucleotide 237 tngtcagagc cccaatggca aacacagaa 29 238 86 PRT Homo sapiens 238 Met Ser Gly His Ser Leu Ala Arg Thr Leu Leu Leu Tyr Leu Arg Asn 1 5 10 15 Met Thr Phe Leu Phe Gln Arg Met Met Met Met Met Thr Asn Arg Asn 20 25 30 Tyr Arg Lys Glu Lys Ala Leu Thr Glu Glu Met Val Met Leu Ser Val 35 40 45 Ser Leu Pro Ser Leu Ser Ala Glu Arg Leu Gly Glu Gly Pro Gln Pro 50 55 60 Pro Ser Leu Val Lys Leu Pro Val Trp Ser Met Thr Val Phe His Pro 65 70 75 80 Arg Leu Trp Glu Ala Pro 85 239 48 PRT Homo sapiens 239 Met Arg Leu Leu Leu Leu Leu Leu Val Ala Ala Ser Ala Met Val Arg 1 5 10 15 Ser Glu Ala Ser Ala Asn Leu Gly Gly Val Pro Ser Lys Arg Leu Lys 20 25 30 Met Gln Tyr Ala Thr Gly Pro Leu Leu Lys Phe Gln Ile Cys Val Ser 35 40 45 240 140 PRT Homo sapiens 240 Met Leu Ser Asn Arg Leu Pro Phe Ser Ala Ala Lys Ser Leu Ile Asn 1 5 10 15 Ser Pro Ser Gln Gly Ala Phe Ser Ser Leu Arg Asp Leu Ser Pro Gln 20 25 30 Glu Asn Pro Phe Leu Glu Val Ser Ala Pro Ser Glu His Phe Ile Glu 35 40 45 Asn Asn Asn Thr Lys Asp Thr Thr Ala Arg Asn Ala Phe Glu Glu Asn 50 55 60 Val Phe Met Glu Asn Thr Asn Met Pro Glu Gly Thr Ile Ser Glu Asn 65 70 75 80 Thr Asn Tyr Asn His Pro Pro Glu Ala Asp Ser Ala Gly Thr Ala Phe 85 90 95 Asn Leu Gly Pro Thr Val Lys Gln Thr Glu Thr Lys Trp Glu Tyr Asn 100 105 110 Asn Val Gly Thr Asp Leu Ser Pro Glu Pro Lys Ser Phe Asn Tyr Pro 115 120 125 Leu Leu Ser Ser Gln Val Ile Ser Leu Lys Phe Ser 130 135 140

Claims

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:41;

(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348;

(c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348;

(d) the nucleotide sequence of the full-length protein coding sequence of clone dd504_—18 deposited under accession number ATCC 98850;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone dd504_—18 deposited under accession number ATCC 98850;

(f) the nucleotide sequence of a mature protein coding sequence of clone dd504_—18 deposited under accession number ATCC 98850;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone dd504_—18 deposited under accession number ATCC 98850;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 65 degrees C., or 4×SSC at 42 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 50 degrees C., or 6×SSC at 40 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:41.

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.

5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2; and

(b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.

7. An isolated polynucleotide encoding the protein of claim 6.

8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone dd504_—18 deposited under accession number ATCC 98850.

9. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;

(c) the amino acid sequence encoded by the cDNA insert of clone dd504_—18 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins.

10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:42.

11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.

12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:51;

(b) the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783;

(c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783;

(d) the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938;

(e) the nucleotide sequence of the full-length protein coding sequence of clone qs14_—3 deposited under accession number ATCC 98850;

(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone qs14_—3 deposited under accession number ATCC 98850;

(g) the nucleotide sequence of a mature protein coding sequence of clone qs14_—3 deposited under accession number ATCC 98850;

(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone qs14_—3 deposited under accession number ATCC 98850;

(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;

(j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 65 degrees C., or 4×SSC at 42 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and

(l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 50 degrees C., or 6×SSC at 40 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:51.

13. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:52;

(d) the amino acid sequence encoded by the cDNA insert of clone qs14_—3 deposited under accession number ATCC 98850;

the protein being substantially free from other mammalian proteins.